Patent Publication Number: US-2023146195-A1

Title: Bcma binding molecules and methods of use thereof

Description:
CROSS REFERENCE TO RELATED APPLICATIONS 
     This application is a continuation of U.S. application Ser. No. 16/569,341, filed Sep. 12, 2019, now U.S. Pat. No. 11,505,613, which is a continuation of U.S. application Ser. No. 15/476,309, filed Mar. 31, 2017, now U.S. Pat. No. 10,689,450, and claims the benefit of U.S. Provisional Patent Application No. 62/317,334, filed Apr. 1, 2016, all of which are hereby incorporated by reference in their entireties. 
    
    
     REFERENCE TO AN ELECTRONIC SEQUENCE LISTING 
     The contents of the electronic sequence listing (76NT-353593-US3.xml; Size: 670,804 bytes; and Date of Creation: Jan. 12, 2023) is herein incorporated by reference in its entirety. 
     FIELD OF THE INVENTION 
     This invention relates to chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule which binds to B-cell maturation antigen (BCMA), polynucleotides encoding the same, and methods of treating a cancer or other disease or disorder in a patient using the same. 
     BACKGROUND OF THE INVENTION 
     Human cancers are by their nature comprised of normal cells that have undergone a genetic or epigenetic conversion to become abnormal cancer cells. In doing so, cancer cells begin to express proteins and other antigens that are distinct from those expressed by normal cells. These aberrant tumor antigens can be used by the body&#39;s innate immune system to specifically target and kill cancer cells. However, cancer cells employ various mechanisms to prevent immune cells, such as T and B lymphocytes, from successfully targeting cancer cells. 
     Human T cell therapies rely on enriched or modified human T cells to target and kill cancer cells in a patient. To increase the ability of T cells to target and kill a particular cancer cell, methods have been developed to engineer T cells to express constructs which direct T cells to a particular target cancer cell. Chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs), which comprise binding domains capable of interacting with a particular tumor antigen, allow T cells to target and kill cancer cells that express the particular tumor antigen. 
     Current therapies for hematologic malignancies have shown varying levels of effectiveness with undesired side effects. Therefore, a need exists to identify novel and improved therapies for treating BCMA related diseases and disorders. 
     SUMMARY OF THE INVENTION 
     The present invention is directed to an isolated polynucleotide encoding a chimeric antigen receptor (CAR) or T cell receptor (TCR) comprising a binding molecule that specifically binds to B-cell maturation antigen (BCMA), wherein the binding molecule comprises: (a) a heavy chain variable region (VH) complementarity determining region (CDR) 1 comprising, consisting of, or consisting essentially of the amino acid sequence GX 2 X 3 X 4 X 5 X 6 X 7 SY (SEQ ID NO: 145) wherein: X 2  is not present or G; X 3  is not present or S; X 4  is F, G, I, or Y; X 5  is S or T; X 6  is F or S; and X 7  is S or T; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 11 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 YX 12 X 13 X 14 X 15 X 16 X 17  (SEQ ID NO: 146), wherein: X 1  is A, G, I, S, T, or V; X 3  is I, N, or S; X 4  is G, P, S, or Y; X 5  is D, G, I, or S; X 6  is F, G, or S; X 7  is not present or G or S; X 8  is N, S, or T; X 9  is A, I, K, or T; X 10  is N, S, or Y; X 12  is A or N; X 13  is D, P, or Q; X 14  is K or S; X 15  is F, L, or V; X 16  is K or Q; and X 17  is G or S; and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 DX 19  (SEQ ID NO: 147), wherein: X 1  is A or V; X 2  is K or R; X 3  is not present or D, G, or T; X 4  is not present or A, D, G, P, R, or S; X 5  is not present or E, F, G, L, Q, or T; X 6  is not present or E, M, Q, W, or Y; X 7  is not present or A, E, L, or S; X 8  is not present or G, P, S, or T; X 9  is not present or G, P, or S; X 10  is not present or I, L, P, or Y; X 11  is not present or W; X 12  is not present or H; X 13  is not present or E or Y; X 14  is not present or D, G, H, P, S, W, or Y; X 15  is A, G, L, W, or Y; X 16  is not present or A, G, I, P, or V; X 17  is F, L, or M; and X 19  is I, L, V, or Y; and/or (d) a light chain variable region (VL) CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SQX 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 LX 17  (SEQ ID NO: 148), wherein X 1  is K or R; X 2  is A or S; X 5  is G or S; X 6  is I, L, or V; X 7  is L or S; X 8  is not present or H or Y; X 9  is not present or S; X 10  is not present or N or S; X 11  is not present or G or N; X 12  is not present or N; X 13  is not present or K or Y; X 14  is N, R, or S; X 15  is N, W, or Y; and X 17  is A or D; (e) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SX 4 X 5 X 6 X 7 (SEQ ID NO: 149), wherein X 1  is D, G, L, S, or W; X 2  is A or G; X 4  is N, S, or T; X 5  is L or R; X 6  is A, E, or Q; and X 7  is S or T; and/or (f) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 QX 3 X 4 X 5 X 6 PX 8 T (SEQ ID NO: 150), wherein X 1  is M or Q; X 3  is F, G, H, I, R, or Y; X 4  is A, F, H, I, L, or Y; X 5  is A, G, H, S, T, V, or Y; X 6  is F, L, T, W, or Y; and X 8  is not present or F, L, P, or W. 
     In another embodiment, the invention is directed to an isolated polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, wherein the antibody or the antigen binding molecule thereof comprises: (a) a heavy chain variable region (VH) complementarity determining region (CDR) 1 comprising, consisting of, or consisting essentially of the amino acid sequence GX 2 X 3 X 4 X 5 X 6 X 7 SY (SEQ ID NO: 145), wherein: X 2  is not present or G; X 3  is not present or S; X 4  is F, G, I, or Y; X 5  is S or T; X 6  is F or S; and X 7  is S or T; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 YX 12 X 13 X 14 X 15 X 16 X 17  (SEQ ID NO: 146), wherein: X 1  is A, G, I, S, T, or V; X 3  is I, N, or S; X 4  is G, P, S, or Y; X 5  is D, G, I, or S; X 6  is F, G, or S; X 7  is not present or G or S; X 8  is N, S, or T; X 9  is A, I, K, or T; X 10  is N, S, or Y; X 12  is A or N; X 13  is D, P, or Q; X 14  is K or S; X 15  is F, L, or V; X 16  is K or Q; and X 17  is G or S; and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 DX 19  (SEQ ID NO: 147), wherein: X 1  is A or V; X 2  is K or R; X 3  is not present or D, G, or T; X 4  is not present or A, D, G, P, R, or S; X 5  is not present or E, F, G, L, Q, or T; X 6  is not present or E, M, Q, W, or Y; X 7  is not present or A, E, L, or S; X 8  is not present or G, P, S, or T; X 9  is not present or G, P, or S; X 10  is not present or I, L, P, or Y; X 11  is not present or W; X 12  is not present or H; X 13  is not present or E or Y; X 14  is not present or D, G, H, P, S, W, or Y; X 15  is A, G, L, W, or Y; X 16  is not present or A, G, I, P, or V; X 17  is F, L, or M; and X 19  is I, L, V, or Y; and/or (d) a light chain variable region (VL) CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SQX 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 LX 17  (SEQ ID NO: 148), wherein X 1  is K or R; X 2  is A or S; X 5  is G or S; X 6  is I, L, or V; X 7  is L or S; X 8  is not present or H or Y; X 9  is not present or S; X 10  is not present or N or S; X 11  is not present or G or N; X 12  is not present or N; X 13  is not present or K or Y; X 14  is N, R, or S; X 15  is N, W, or Y; and X 17  is A or D; (e) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SX 4 X 5 X 6 X 7  (SEQ ID NO: 149), wherein X 1  is D, G, L, S, or W; X 2  is A or G; X 4  is N, S, or T; X 5  is L or R; X 6  is A, E, or Q; and X 7  is S or T; and/or (f) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 QX 3 X 4 X 5 X 6 PX 8 T (SEQ ID NO: 150), wherein X 1  is M or Q; X 3  is F, G, H, I, R, or Y; X 4  is A, F, H, I, L, or Y; X 5  is A, G, H, S, T, V, or Y; X 6  is F, L, T, W, or Y; and X 8  is not present or F, L, P, or W. 
     In some embodiments, the VH CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 9-16. In some embodiments, the VH CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 25-32. In some embodiments, the VL CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 81-88. In some embodiments, the VL CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 97-104. In some embodiments, the VL CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 113-120. 
     In some embodiments, the binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 9; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 25; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 41; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 81; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 97; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 113; (b) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 10; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 26; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 42; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 82; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 98; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 114; (c) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 27; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 43; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 83; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 99; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 115; (d) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 12; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 28; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 44; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 84; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 100; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 116; (e) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 13; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 29; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 45; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 85; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 101; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 117; (f) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 14; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 30; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 46; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 86; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 102; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 118; (g) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 15; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 31; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 47; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 87; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 103; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 119; or (h) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 16; a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 32; a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 48; a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 88; a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 104; and a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 120. 
     In some embodiments, the binding molecule is single chained. In some embodiments, the binding molecule comprises an scFv. 
     In some embodiments, the CAR comprises a transmembrane domain. In some embodiments, the transmembrane domain is a transmembrane domain of CD28, 4-1BB/CD137, CD8 (e.g., CD8 alpha, CD4, CD19, CD3 epsilon, CD45, CD5, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137, CD154, an alpha chain of a T cell receptor, a beta chain of a T cell receptor, a zeta chain of a T cell receptor, or any combination thereof. In some embodiments, the CAR comprises a hinge region between the transmembrane domain and the binding molecule. In some embodiments, the hinge region is of IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, IgM, CD28, or CD8 alpha. In some embodiments, the CAR or TCR comprises a costimulatory region. In some embodiments, the costimulatory region is a signaling region of CD28, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, programmed death-1 (PD-1), inducible T cell costimulator (ICOS), lymphocyte function-associated antigen-1 (LFA-1 (CD11a/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD247, CD276 (B7-H3), LIGHT (tumor necrosis factor superfamily member 14; TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class I molecule, TNF receptor proteins, Immunoglobulin-like proteins, cytokine receptors, integrins, signaling lymphocytic activation molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, a ligand that specifically binds with CD83, or any combination thereof. In some embodiments, the CAR or TCR comprises an activation domain. In some embodiments, the activation domain is a CD3 zeta domain. 
     In other embodiments, the invention is directed to a vector comprising the polynucleotide or a polypeptide encoded by the polynucleotide. 
     In certain embodiments, the invention is directed to a cell comprising the polynucleotide, the vector, the polypeptide, or any combination thereof. In other embodiments, the invention is directed to a cell, e.g., an immune cell, e.g., a tumor-infiltrating lymphocyte (TIL), autologous T cell, engineered autologous T cell (eACT), an allogeneic T cell, or any combination thereof. 
     In other embodiments, the invention is directed to a method of inducing an immunity against a tumor comprising administering to a subject an effective amount of a cell comprising the polynucleotide, the vector, the polypeptide, or any combination thereof. Other aspects of the invention include a method of treating a cancer in a subject in need thereof comprising administering to the subject the polynucleotide, the vector, the polypeptide, the cell, or the composition. The cancer treatable by the method can be a hematologic cancer. 
    
    
     
       BRIEF DESCRIPTION OF THE FIGURES 
         FIG.  1 A- 1 F  show CLUTSTAL W (1.83) multiple sequence alignments of eight example anti-BCMA binding molecules disclosed herein.  FIG.  1 A  shows a sequence alignment of example anti-BCMA binding molecules comprising a VH domain. Complementarity determining regions (CDRs) and framework regions (FRs) are shown, as determined by Chothia.  FIG.  1 B  is a table providing the SEQ ID NO for each VH, CDR, and FR sequence illustrated in  FIG.  1 A .  FIG.  1 C  shows a sequence alignment of example anti-BCMA binding molecules comprising a VH domain, with alternate CDRs and FRs shown.  FIG.  1 D  is a table providing the SEQ ID NO for each VH, CDR, and FR sequence illustrated in  FIG.  1 C .  FIG.  1 E  shows a sequence alignment of example anti-BCMA binding molecules comprising a VL domain. CDRs and FRs are shown, as determined by Chothia.  FIG.  1 F  is a table providing the SEQ ID NO for each VH, CDR, and FR sequence illustrated in  FIG.  1 E . 
         FIGS.  2 A- 2 F  show BCMA expression in various cells.  FIG.  2 A  shows multiple myeloma cell expression of BCMA, CD138, CS-1, CD38, and CD19. Box-plot analysis shows the distribution of gene expression levels in the various multiple myeloma cell lines tested ( FIG.  2 A ).  FIGS.  2 B- 2 D  show BCMA expression in EoL1 ( FIG.  2 B ), MM1S ( FIG.  2 C ), and NCI-H929 ( FIG.  2 D ) cancer cell lines as measured by flow cytometric analysis of BCMA cell surface expression on the respective cell lines.  FIG.  2 E  shows the expression of BCMA, CS-1, CLL-1, DLL3, CD70, and FLT3 in alternatively activated macrophages; CD14-positive, CD16-negative cells; CD38-negative naïve B cells; CD4-positive, alpha-beta T cells; central memory CD4-positive cells; central memory CD8-positive cells; class switched memory B cells; cytotoxic CD56-dim natural killer cell; effector memory CD4-positive cells; effector memory CD8-positive cells; inflammatory macrophages; macrophages; mature neutrophils; memory B cells; monocytes; myeloid cells; and regulatory T cells.  FIG.  2 F  shows the expression of BCMA, CD138, CS-1, CD38, and CD19 in the same cell types as in  FIG.  2 E . Gene expression is shown as fragments per kilobase of exon per million reads mapped (FPKM) ( FIG.  2 A ,  FIG.  2 E , and  FIG.  2 F ). 
         FIG.  3 A  and  FIG.  3 B  show CAR expression in lentivirus transduced primary human T cells from a first healthy donor ( FIG.  3 A ) and a second healthy donor ( FIG.  3 B ). 
         FIGS.  4 A- 4 F  shows IFNγ, TNFα, and IL-2 production by lentivirus transduced CAR T cells from two healthy donors following 16 hours of co-cultured with EoL-1 (Black), NCI-H929 (light grey), or MM1S (grey) target cell lines.  FIGS.  4 A and  4 B  show the IFNγ (pg/ml; y-axis) production in lentivirus transduced CAR T cells from a first donor ( FIG.  4 A ) and a second donor ( FIG.  4 B ).  FIGS.  4 C and  4 D  show the TNFα (pg/ml; y-axis) production in lentivirus transduced CAR T cells from a first donor ( FIG.  4 C ) and a second donor ( FIG.  4 D ).  FIGS.  4 E and  4 F  show the IL-2 production (pg/ml; y-axis) in lentivirus transduced CAR T cells from a first donor ( FIG.  4 E ) and a second donor ( FIG.  4 F ). 
         FIGS.  5 A- 5 F  show the average cytolytic activity (as a percentage of viable target cells remaining; y-axis) over time from two healthy donors expressing the indicated CARs co-cultured with EoL1 ( FIGS.  5 A and  5 B ), NCI-H929 ( FIGS.  5 C and  5 D ), or MM1S ( FIGS.  5 E and  5 F ) target cells for 16 hours, 40 hours, 64 hours, 88 hours, or 112 hours.  FIGS.  5 A and  5 B  show the average cytolytic activity of transduced CART cells from a first donor ( FIG.  5 A ) and a second donor ( FIG.  5 B ) co-cultured with EoL1 target cells for 16 hours, 40 hours, 64 hours, 88 hours, or 112 hours.  FIGS.  5 C and  5 D  show the average cytolytic activity of transduced CAR T cells from a first donor ( FIG.  5 C ) and a second donor ( FIG.  5 D ) co-cultured with NCI-H929 target cells for 16 hours, 40 hours, 64 hours, 88 hours, or 112 hours.  FIGS.  5 E and  5 F  show the average cytolytic activity of transduced CART cells from a first donor ( FIG.  5 E ) and a second donor ( FIG.  5 F ) co-cultured with MM1S target cells for 16 hours, 40 hours, 64 hours, 88 hours, or 112 hours. 
         FIGS.  6 A and  6 B  show proliferation of CFSE-labeled lentivirus transduced CART cells from a first healthy donor ( FIG.  6 A ) and a second healthy donor ( FIG.  6 B ) following 5 days of co-culture with CD3-CD28 beads (top row), EoL-1 (second row), NCI-H929 (third row), or MM1S (bottom row) target cell lines. 
       In the Figure descriptions below, underlined sequences denote CDR regions calculated using Chothia. 
         FIG.  7 A  shows Clone FS-26528 HC DNA sequence (SEQ ID NO: 271) 
         FIG.  7 B  shows Clone FS-26528 HC AA sequence (SEQ ID NO: 272) 
         FIG.  7 C  shows HC CDR sequences for clone FS-26528. 
         FIG.  7 D  shows Clone FS-26528 LC DNA sequence (SEQ ID NO: 276). 
         FIG.  7 E  shows Clone FS-26528 LC AA sequence (SEQ ID NO: 277). 
         FIG.  7 F  shows LC CDR sequences for clone FS-26528. 
         FIG.  7 G  shows Clone FS-26528 CAR DNA H×L sequences (SEQ ID NO: 281) 
         FIG.  7 H  shows Clone FS-26528 CAR H×L AA sequences (SEQ ID NO: 282) 
         FIG.  7 I  shows Clone FS-26528 CAR DNA L×H sequences (SEQ ID NO: 283). 
         FIG.  7 J  shows Clone FS-26528 CAR L×H sequences (SEQ ID NO: 284). 
         FIG.  8 A  shows Clone PC-26534 HC DNA sequence (SEQ ID NO: 285). 
         FIG.  8 B  shows Clone PC-26534 HC sequence (SEQ ID NO: 286). 
         FIG.  8 C  shows HC CDR sequences for clone FS-26528. 
         FIG.  8 D  shows Clone PC-26534 LC DNA sequences (SEQ ID NO: 290). 
         FIG.  8 E  shows the Clone PC-26534 LC sequence (SEQ ID NO: 291). 
         FIG.  8 F  shows LC CDR sequences for Clone PC-26534. 
         FIG.  8 G  shows the Clone PC-26534 CAR DNA H×L sequence (SEQ ID NO: 295). 
         FIG.  8 H  shows the Clone PC-26534 CAR H×L AA sequence (SEQ ID NO: 296) 
         FIG.  8 I  shows the Clone PC-26534 CAR DNA L×H sequence (SEQ ID NO: 297). 
         FIG.  8 J  shows Clone PC-26534 CAR L×H sequence (SEQ ID NO: 298). 
         FIG.  9 A  shows Clone AJ-26545 HC DNA sequence (SEQ ID NO: 299). 
         FIG.  9 B  shows Clone AJ-26545 variable HC sequence (SEQ ID NO: 300). 
         FIG.  9 C  shows HC CDR sequences for Clone AJ-26545. 
         FIG.  9 D  shows Clone AJ-26545 variable LC DNA sequence (SEQ ID NO: 304). 
         FIG.  9 E  shows Clone AJ-26545 variable LC AA sequence (SEQ ID NO: 305) 
         FIG.  9 F  shows Clone AJ-26545 LC CDR sequences. 
         FIG.  9 G  shows Clone AJ-26545 CAR DNA H×L sequence (SEQ ID NO: 309). 
         FIG.  9 H  shows Clone AJ-26545 CAR H×L AA sequence (SEQ ID NO: 310) 
         FIG.  9 I  shows Clone AJ-26545 CAR DNA L×H sequence (SEQ ID NO: 311) 
         FIG.  9 J  shows Clone AJ-26545 CAR L×H sequence (SEQ ID NO: 312). 
         FIG.  10 A  shows Clone AJ-26554 HC DNA sequence (SEQ ID NO: 313) 
         FIG.  10 B  shows Clone AJ-26554 HC AA sequence (SEQ ID NO: 314). 
         FIG.  10 C  shows Clone AJ-26554 HC CDR sequences 
         FIG.  10 D  shows Clone AJ-26554 LC DNA sequence (SEQ ID NO: 318). 
         FIG.  10 E  shows Clone AJ-26554 LC AA sequence (SEQ ID NO: 319). 
         FIG.  10 F  shows Clone AJ-26554 LC CDR sequences. 
         FIG.  10 G  shows Clone AJ-26554 CAR DNA H×L chain sequences (SEQ ID NO: 323). 
         FIG.  10 H  shows Clone AJ-26554 CAR H×L chain AA sequences (SEQ ID NO: 324). 
         FIG.  10 I  shows Clone AJ-26554 CAR DNA L×H chain sequences (SEQ ID NO: 325). 
         FIG.  10 J  shows Clone AJ-26554 CAR L×H AA sequences (SEQ ID NO: 326). 
         FIG.  11 A  shows Clone NM-26562 HC DNA sequence (SEQ ID NO: 327). 
         FIG.  11 B  shows Clone NM-26562 HC AA sequence (SEQ ID NO: 328). 
         FIG.  11 C  shows Clone NM-26562 HC CDR sequences. 
         FIG.  11 D  shows Clone NM-26562 LC DNA sequence (SEQ ID NO: 332). 
         FIG.  11 E  shows Clone NM-26562 LC AA sequence (SEQ ID NO: 333). 
         FIG.  11 F  shows the Clone NM-26562 LC CDR sequences. 
         FIG.  11 G  shows the Clone NM-26562 CAR DNA H×L sequences (SEQ ID NO: 337) 
         FIG.  11 H  shows Clone NM-26562 CAR H×L AA sequences (SEQ ID NO: 338). 
         FIG.  11 I  shows Clone NM-26562 CAR DNA L×H sequences (SEQ ID NO: 339). 
         FIG.  11 J  shows Clone NM-26562 CAR L×H AA sequences (SEQ ID NO: 340). 
         FIG.  12 A  shows Clone TS-26564 HC DNA sequence (SEQ ID NO: 341). 
         FIG.  12 B  shows Clone TS-26564 HC AA sequence (SEQ ID NO: 342). 
         FIG.  12 C  shows the Clone TS-26564 HC CDR sequences. 
         FIG.  12 D  shows the Clone TS-26564 LC DNA sequence (SEQ ID NO: 346). 
         FIG.  12 E  shows the Clone TS-26564 LC AA sequence (SEQ ID NO: 347). 
         FIG.  12 F  shows the Clone TS-26564 LC CDR sequences. 
         FIG.  12 G  shows the Clone TS-26564 CAR DNA H×L sequences (SEQ ID NO: 351). 
         FIG.  12 H  shows the Clone TS-26564 CAR H×L chain AA sequences (SEQ ID NO: 352). 
         FIG.  12 I  shows the Clone TS-26564 CAR DNA L×H sequences (SEQ ID NO: 353) 
         FIG.  12 J  shows the Clone TS-26564 CAR L×H AA sequences (SEQ ID NO: 354) 
         FIG.  13 A  shows the Clone RY-26568 HC DNA sequence (SEQ ID NO: 355) 
         FIG.  13 B  shows the Clone RY-26568 HC AA sequence (SEQ ID NO: 356). 
         FIG.  13 C  shows the Clone RY-26568 HC CDR sequences. 
         FIG.  13 D  shows the Clone RY-26568 LC DNA sequence (SEQ ID NO: 360). 
         FIG.  13 E  shows the Clone RY-26568 LC AA sequence (SEQ ID NO: 361). 
         FIG.  13 F  shows the Clone RY-26568 LC CDR AA sequences. 
         FIG.  13 G  shows the Clone RY-26568 CAR DNA H×L sequences (SEQ ID NO: 365) 
         FIG.  13 H  shows the Clone RY-26568 CAR H×L AA sequences (SEQ ID NO: 366). 
         FIG.  13 I  shows the Clone RY-26568 CAR DNA L×H sequences (SEQ ID NO: 367). 
         FIG.  13 J  shows the Clone RY-26568 CAR L×H AA sequences (SEQ ID NO: 368). 
         FIG.  14 A  shows the Clone PP-26575 HC DNA sequence (SEQ ID NO: 369). 
         FIG.  14 B  shows the Clone PP-26575 HC AA sequence (SEQ ID NO: 370). 
         FIG.  14 C  shows the Clone PP-26575 HC CDR AA sequences. 
         FIG.  14 D  shows the Clone PP-26575 LC DNA sequence (SEQ ID NO: 374). 
         FIG.  14 E  shows the Clone PP-26575 LC AA sequence (SEQ ID NO: 375). 
         FIG.  14 F  shows the Clone PP-26575 LC CDR AA sequences. 
         FIG.  14 G  shows the Clone PP-26575 CAR DNA H×L sequences (SEQ ID NO: 379). 
         FIG.  14 H  shows Clone PP-26575 CAR H×L AA sequences (SEQ ID NO: 380). 
         FIG.  14 I  shows Clone PP-26575 CAR DNA L×H sequence (SEQ ID NO: 381). 
         FIG.  14 J  shows the Clone PP-26575 CAR L×H AA sequence (SEQ ID NO: 382). 
         FIG.  15 A  shows the Clone RD-26576 HC DNA sequence (SEQ ID NO: 383) 
         FIG.  15 B  shows Clone RD-26576 HC AA sequence (SEQ ID NO: 384). 
         FIG.  15 C  shows the Clone RD-26576 HC CDR sequences. 
         FIG.  15 D  shows the Clone RD-26576 LC DNA sequence (SEQ ID NO: 388) 
         FIG.  15 E  shows the Clone RD-26576 LC AA sequence (SEQ ID NO: 389). 
         FIG.  15 F  shows the Clone RD-26576 LC CDR sequences. 
         FIG.  15 G  shoes the Clone RD-26576 CAR DNA H×L sequences (SEQ ID NO: 393). 
         FIG.  15 H  shows the Clone RD-26576 CAR H×L chain AA sequences (SEQ ID NO: 394). 
         FIG.  15 I  shows the Clone RD-26576 CAR DNA L×H sequences (SEQ ID NO: 395). 
         FIG.  15 J  shows the Clone RD-26576 CAR L×H AA sequences (SEQ ID NO: 396). 
         FIG.  16 A  shows the Clone RD-26578 HC DNA sequences (SEQ ID NO: 397). 
         FIG.  16 B  shows the Clone RD-26578 HC AA sequence (SEQ ID NO: 398). 
         FIG.  16 C  shows the Clone RD-26578 HC CDR AA sequences. 
         FIG.  16 D  shows the Clone RD-26578 LC DNA sequence (SEQ ID NO: 402). 
         FIG.  16 E  shows the Clone RD-26578 LC AA sequence (SEQ ID NO: 403) 
         FIG.  16 F  shows the Clone RD-26578 LC CDR sequences. 
         FIG.  16 G  shows the Clone RD-26578 CAR DNA H×L chain sequence (SEQ ID NO: 407). 
         FIG.  16 H  shows the Clone RD-26578 CAR H×L AA sequence (SEQ ID NO: 408). 
         FIG.  16 I  shows the Clone RD-26578 CAR DNA L×H sequences (SEQ ID NO: 409). 
         FIG.  16 J  shows the Clone RD-26578 CAR L×H AA sequence (SEQ ID NO: 410). 
         FIG.  17    shows the outcome of an in vivo study examining the efficacy of clone RD-21530 in a subcutaneous RPMI-8226 mouse model. Cohorts of 10 mice each were tested for the CAR (dashed lines) and mock transduced (bolded lines) T cells. 
         FIG.  18 A  and  FIG.  18 B  show the outcome of an in vitro cytotoxicity assay using the optimized BCMA scFv variants cocultured with NCI-H929 and MM.1S cells, respectively. CAR T cells using these optimized scFvs were incubated overnight with luciferase labeled target cells in 3:1 and 1:1 effector to target cell ratios. 
         FIG.  19    shows the pGAR vector map. 
     
    
    
     DETAILED DESCRIPTION OF THE INVENTION 
     The present invention relates to antibodies, antigen binding molecules thereof, chimeric antigen receptors (CARs), and engineered T cell receptors, which bind BCMA, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered CAR T cell therapy, e.g., an autologous cell therapy (eACT™), for the treatment of a patient suffering from a cancer. In particular, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma. 
     I. Definitions 
     In order that the present disclosure may be more readily understood, certain terms are first defined. As used in this application, except as otherwise expressly provided herein, each of the following terms shall have the meaning set forth below. Additional definitions are set forth throughout the application. 
     The term “and/or” where used herein is to be taken as specific disclosure of each of the two specified features or components with or without the other. Thus, the term “and/or” as used in a phrase such as “A and/or B” herein is intended to include “A and B,” “A or B,” “A” (alone), and “B” (alone). Likewise, the term “and/or” as used in a phrase such as “A, B, and/or C” is intended to encompass each of the following aspects: A, B, and C; A, B, or C; A or C; A or B; B or C; A and C; A and B; B and C; A (alone); B (alone); and C (alone). 
     It is understood that wherever aspects are described herein with the language “comprising,” otherwise analogous aspects described in terms of “consisting of” and/or “consisting essentially of” are also provided. 
     Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure is related. For example, the Concise Dictionary of Biomedicine and Molecular Biology, Juo, Pei-Show, 2nd ed., 2002, CRC Press; The Dictionary of Cell and Molecular Biology, 3rd ed., 1999, Academic Press; and the Oxford Dictionary Of Biochemistry And Molecular Biology, Revised, 2000, Oxford University Press, provide one of skill with a general dictionary of many of the terms used in this disclosure. 
     Units, prefixes, and symbols are denoted in their Système International de Unites (SI) accepted form. Numeric ranges are inclusive of the numbers defining the range. The headings provided herein are not limitations of the various aspects of the disclosure, which can be had by reference to the specification as a whole. Accordingly, the terms defined immediately below are more fully defined by reference to the specification in its entirety. 
     “Administering” refers to the physical introduction of an agent to a subject, using any of the various methods and delivery systems known to those skilled in the art. Exemplary routes of administration for the formulations disclosed herein include intravenous, intramuscular, subcutaneous, intraperitoneal, spinal or other parenteral routes of administration, for example by injection or infusion. The phrase “parenteral administration” as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intralymphatic, intralesional, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid, intraspinal, epidural and intrasternal injection and infusion, as well as in vivo electroporation. In some embodiments, the formulation is administered via a non-parenteral route, e.g., orally. Other non-parenteral routes include a topical, epidermal or mucosal route of administration, for example, intranasally, vaginally, rectally, sublingually or topically. Administering can also be performed, for example, once, a plurality of times, and/or over one or more extended periods. 
     The term “antibody” (Ab) includes, without limitation, a glycoprotein immunoglobulin which binds specifically to an antigen. In general, and antibody can comprise at least two heavy (H) chains and two light (L) chains interconnected by disulfide bonds, or an antigen binding molecule thereof. Each H chain comprises a heavy chain variable region (abbreviated herein as VH) and a heavy chain constant region. The heavy chain constant region comprises three constant domains, CH1, CH2 and CH3. Each light chain comprises a light chain variable region (abbreviated herein as VL) and a light chain constant region. The light chain constant region is comprises one constant domain, CL. The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL comprises three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the Abs may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. 
     Antibodies can include, for example, monoclonal antibodies, recombinantly produced antibodies, monospecific antibodies, multispecific antibodies (including bispecific antibodies), human antibodies, humanized antibodies, chimeric antibodies, immunoglobulins, synthetic antibodies, tetrameric antibodies comprising two heavy chain and two light chain molecules, an antibody light chain monomer, an antibody heavy chain monomer, an antibody light chain dimer, an antibody heavy chain dimer, an antibody light chain-antibody heavy chain pair, intrabodies, antibody fusions (sometimes referred to herein as “antibody conjugates”), heteroconjugate antibodies, single domain antibodies, monovalent antibodies, single chain antibodies or single-chain Fvs (scFv), camelized antibodies, affybodies, Fab fragments, F(ab′) 2  fragments, disulfide-linked Fvs (sdFv), anti-idiotypic (anti-Id) antibodies (including, e.g., anti-anti-Id antibodies), minibodies, domain antibodies, synthetic antibodies (sometimes referred to herein as “antibody mimetics”), and antigen-binding fragments of any of the above. In certain embodiments, antibodies described herein refer to polyclonal antibody populations. 
     An immunoglobulin may derive from any of the commonly known isotypes, including but not limited to IgA, secretory IgA, IgG and IgM. IgG subclasses are also well known to those in the art and include but are not limited to human IgG1, IgG2, IgG3 and IgG4. “Isotype” refers to the Ab class or subclass (e.g., IgM or IgG1) that is encoded by the heavy chain constant region genes. The term “antibody” includes, by way of example, both naturally occurring and non-naturally occurring Abs; monoclonal and polyclonal Abs; chimeric and humanized Abs; human or nonhuman Abs; wholly synthetic Abs; and single chain Abs. A nonhuman Ab may be humanized by recombinant methods to reduce its immunogenicity in man. Where not expressly stated, and unless the context indicates otherwise, the term “antibody” also includes an antigen-binding fragment or an antigen binding molecule of any of the aforementioned immunoglobulins, and includes a monovalent and a divalent fragment or portion, and a single chain Ab. 
     An “antigen binding molecule,” “antigen binding portion,” or “antibody fragment” refers to any molecule that comprises the antigen binding parts (e.g., CDRs) of the antibody from which the molecule is derived. An antigen binding molecule can include the antigenic complementarity determining regions (CDRs). Examples of antibody fragments include, but are not limited to, Fab, Fab′, F(ab′)2, and Fv fragments, dAb, linear antibodies, scFv antibodies, and multispecific antibodies formed from antigen binding molecules. Peptibodies (i.e., Fc fusion molecules comprising peptide binding domains) are another example of suitable antigen binding molecules. In some embodiments, the antigen binding molecule binds to an antigen on a tumor cell. In some embodiments, the antigen binding molecule binds to an antigen on a cell involved in a hyperproliferative disease or to a viral or bacterial antigen. In certain embodiments, the antigen binding molecule binds to BCMA. In further embodiments, the antigen binding molecule is an antibody of fragment thereof, including one or more of the complementarity determining regions (CDRs) thereof. In further embodiments, the antigen binding molecule is a single chain variable fragment (scFv). In some embodiments, the antigen binding molecule comprises or consists of avimers. 
     As used herein, the terms “variable region” or “variable domain” are used interchangeably and are common in the art. The variable region typically refers to a portion of an antibody, generally, a portion of a light or heavy chain, typically about the amino-terminal 110 to 120 amino acids in the mature heavy chain and about 90 to 115 amino acids in the mature light chain, which differ extensively in sequence among antibodies and are used in the binding and specificity of a particular antibody for its particular antigen. The variability in sequence is concentrated in those regions called complementarity determining regions (CDRs) while the more highly conserved regions in the variable domain are called framework regions (FR). Without wishing to be bound by any particular mechanism or theory, it is believed that the CDRs of the light and heavy chains are primarily responsible for the interaction and specificity of the antibody with antigen. In certain embodiments, the variable region is a human variable region. In certain embodiments, the variable region comprises rodent or murine CDRs and human framework regions (FRs). In particular embodiments, the variable region is a primate (e.g., non-human primate) variable region. In certain embodiments, the variable region comprises rodent or murine CDRs and primate (e.g., non-human primate) framework regions (FRs). 
     The terms “VL” and “VL domain” are used interchangeably to refer to the light chain variable region of an antibody or an antigen-binding fragment thereof. 
     The terms “VH” and “VH domain” are used interchangeably to refer to the heavy chain variable region of an antibody or an antigen-binding fragment thereof. 
     A number of definitions of the CDRs are commonly in use: Kabat numbering, Chothia numbering, AbM numbering, or contact numbering. The AbM definition is a compromise between the two used by Oxford Molecular&#39;s AbM antibody modelling software. The contact definition is based on an analysis of the available complex crystal structures. 
     
       
         
           
               
             
               
                 TABLE 1 
               
             
            
               
                   
               
               
                 CDR Numbering 
               
            
           
           
               
               
               
               
               
            
               
                 Loop 
                 Kabat 
                 AbM 
                 Chothia 
                 Contact 
               
               
                   
               
               
                 L1 
                 L24 - - - L34 
                 L24 - - - L34 
                 L24 - - - L34 
                 L30 - - - L36 
               
               
                 L2 
                 L50 - - - L56 
                 L50 - - - L56 
                 L50 - - - L56 
                 L46 - - - L55 
               
               
                 L3 
                 L89 - - - L97 
                 L89 - - - L97 
                 L89 - - - L97 
                 L89 - - - L96 
               
               
                 H1 
                 H31 - - - H35B 
                 H26 - - - H35B 
                 H26 - - - H32 . . . 34 
                 H30 - - - H35B 
               
               
                   
                 (Kabat Numbering) 
                   
                   
                   
               
               
                 H1 
                 H31 - - - H35 
                 H26 - - - H35 
                 H26 - - - H32 
                 H30 - - - H35 
               
               
                   
                 (Chothia Numbering) 
                   
                   
                   
               
               
                 H2 
                 H50 - - - H65 
                 H50 - - - H58 
                 H52 - - - H56 
                 H47 - - - H58 
               
               
                 H3 
                 H95 - - - H102 
                 H95 - - - H102 
                 H95 - - - H102 
                 H93 - - - H101 
               
               
                   
               
            
           
         
       
     
     The term “Kabat numbering” and like terms are recognized in the art and refer to a system of numbering amino acid residues in the heavy and light chain variable regions of an antibody, or an antigen binding molecule thereof. In certain aspects, the CDRs of an antibody can be determined according to the Kabat numbering system (see, e.g., Kabat EA &amp; Wu TT (1971) Ann NY Acad Sci 190: 382-391 and Kabat E A et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No. 91-3242). Using the Kabat numbering system, CDRs within an antibody heavy chain molecule are typically present at amino acid positions 31 to 35, which optionally can include one or two additional amino acids, following 35 (referred to in the Kabat numbering scheme as 35A and 35B) (CDR1), amino acid positions 50 to 65 (CDR2), and amino acid positions 95 to 102 (CDR3). Using the Kabat numbering system, CDRs within an antibody light chain molecule are typically present at amino acid positions 24 to 34 (CDR1), amino acid positions 50 to 56 (CDR2), and amino acid positions 89 to 97 (CDR3). In a specific embodiment, the CDRs of the antibodies described herein have been determined according to the Kabat numbering scheme. 
     In certain aspects, the CDRs of an antibody can be determined according to the Chothia numbering scheme, which refers to the location of immunoglobulin structural loops (see, e.g., Chothia C &amp; Lesk AM, (1987), J Mol Biol 196: 901-917; Al-Lazikani B et al., (1997) J Mol Biol 273: 927-948; Chothia C et al., (1992) J Mol Biol 227: 799-817; Tramontano A et al., (1990) J Mol Biol 215(1): 175-82; and U.S. Pat. No. 7,709,226). Typically, when using the Kabat numbering convention, the Chothia CDR-H1 loop is present at heavy chain amino acids 26 to 32, 33, or 34, the Chothia CDR-H2 loop is present at heavy chain amino acids 52 to 56, and the Chothia CDR-H3 loop is present at heavy chain amino acids 95 to 102, while the Chothia CDR-L1 loop is present at light chain amino acids 24 to 34, the Chothia CDR-L2 loop is present at light chain amino acids 50 to 56, and the Chothia CDR-L3 loop is present at light chain amino acids 89 to 97. The end of the Chothia CDR-HI loop when numbered using the Kabat numbering convention varies between H32 and H34 depending on the length of the loop (this is because the Kabat numbering scheme places the insertions at H35A and H35B; if neither 35A nor 35B is present, the loop ends at 32; if only 35A is present, the loop ends at 33; if both 35A and 35B are present, the loop ends at 34). In a specific embodiment, the CDRs of the antibodies described herein have been determined according to the Chothia numbering scheme. 
     As used herein, the terms “constant region” and “constant domain” are interchangeable and have a meaning common in the art. The constant region is an antibody portion, e.g., a carboxyl terminal portion of a light and/or heavy chain which is not directly involved in binding of an antibody to antigen but which can exhibit various effector functions, such as interaction with the Fc receptor. The constant region of an immunoglobulin molecule generally has a more conserved amino acid sequence relative to an immunoglobulin variable domain. 
     As used herein, the term “heavy chain” when used in reference to an antibody can refer to any distinct type, e.g., alpha (α), delta (δ), epsilon (ε), gamma (γ) and mu (μ), based on the amino acid sequence of the constant domain, which give rise to IgA, IgD, IgE, IgG and IgM classes of antibodies, respectively, including subclasses of IgG, e.g., IgG 1 , IgG 2 , IgG 3  and IgG 4 . 
     As used herein, the term “light chain” when used in reference to an antibody can refer to any distinct type, e.g., kappa (κ) or lambda (λ) based on the amino acid sequence of the constant domains. Light chain amino acid sequences are well known in the art. In specific embodiments, the light chain is a human light chain. 
     “Binding affinity” generally refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair (e.g., antibody and antigen). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (K D ). Affinity can be measured and/or expressed in a number of ways known in the art, including, but not limited to, equilibrium dissociation constant (K D ), and equilibrium association constant (K A ). The K D  is calculated from the quotient of k off /k on , whereas K A  is calculated from the quotient of k on /k off . k on  refers to the association rate constant of, e.g., an antibody to an antigen, and k off  refers to the dissociation of, e.g., an antibody to an antigen. The k on  and k off  can be determined by techniques known to one of ordinary skill in the art, such as BIAcore® or KinExA. 
     As used herein, a “conservative amino acid substitution” is one in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). In certain embodiments, one or more amino acid residues within a CDR(s) or within a framework region(s) of an antibody or antigen-binding fragment thereof can be replaced with an amino acid residue with a similar side chain. 
     As used herein, an “epitope” is a term in the art and refers to a localized region of an antigen to which an antibody can specifically bind. An epitope can be, for example, contiguous amino acids of a polypeptide (linear or contiguous epitope) or an epitope can, for example, come together from two or more non-contiguous regions of a polypeptide or polypeptides (conformational, non-linear, discontinuous, or non-contiguous epitope). In certain embodiments, the epitope to which an antibody binds can be determined by, e.g., NMR spectroscopy, X-ray diffraction crystallography studies, ELISA assays, hydrogen/deuterium exchange coupled with mass spectrometry (e.g., liquid chromatography electrospray mass spectrometry), array-based oligo-peptide scanning assays, and/or mutagenesis mapping (e.g., site-directed mutagenesis mapping). For X-ray crystallography, crystallization may be accomplished using any of the known methods in the art (e.g., Giegé R et al., (1994) Acta Crystallogr D Biol Crystallogr 50(Pt 4): 339-350; McPherson A (1990) Eur J Biochem 189: 1-23; Chayen N E (1997) Structure 5: 1269-1274; McPherson A (1976) J Biol Chem 251: 6300-6303). Antibody:antigen crystals may be studied using well known X-ray diffraction techniques and may be refined using computer software such as X-PLOR (Yale University, 1992, distributed by Molecular Simulations, Inc.; see e.g. Meth Enzymol (1985) volumes 114 &amp; 115, eds Wyckoff H W et al.; U.S. 2004/0014194), and BUSTER (Bricogne G (1993) Acta Crystallogr D Biol Crystallogr 49(Pt 1): 37-60; Bricogne G (1997) Meth Enzymol 276A: 361-423, ed Carter C W; Roversi P et al., (2000) Acta Crystallogr D Biol Crystallogr 56(Pt 10): 1316-1323). Mutagenesis mapping studies may be accomplished using any method known to one of skill in the art. See, e.g., Champe M et al., (1995) J Biol Chem 270: 1388-1394 and Cunningham B C &amp; Wells J A (1989) Science 244: 1081-1085 for a description of mutagenesis techniques, including alanine scanning mutagenesis techniques. 
     As used herein, an antigen binding molecule, an antibody, or an antigen binding molecule thereof “cross competes” with a reference antibody or an antigen binding molecule thereof if the interaction between an antigen and the first binding molecule, an antibody, or an antigen binding molecule thereof blocks, limits, inhibits, or otherwise reduces the ability of the reference binding molecule, reference antibody, or an antigen binding molecule thereof to interact with the antigen. Cross competition can be complete, e.g., binding of the binding molecule to the antigen completely blocks the ability of the reference binding molecule to bind the antigen, or it can be partial, e.g., binding of the binding molecule to the antigen reduces the ability of the reference binding molecule to bind the antigen. In certain embodiments, an antigen binding molecule that cross competes with a reference antigen binding molecule binds the same or an overlapping epitope as the reference antigen binding molecule. In other embodiments, the antigen binding molecule that cross competes with a reference antigen binding molecule binds a different epitope as the reference antigen binding molecule. Numerous types of competitive binding assays can be used to determine if one antigen binding molecule competes with another, for example: solid phase direct or indirect radioimmunoassay (RIA); solid phase direct or indirect enzyme immunoassay (EIA); sandwich competition assay (Stahli et al., 1983, Methods in Enzymology 9:242-253); solid phase direct biotin-avidin EIA (Kirkland et al., 1986, J. Immunol. 137:3614-3619); solid phase direct labeled assay, solid phase direct labeled sandwich assay (Harlow and Lane, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Press); solid phase direct label RIA using 1-125 label (Morel et al., 1988, Molec. Immunol. 25:7-15); solid phase direct biotin-avidin EIA (Cheung, et al., 1990, Virology 176:546-552); and direct labeled RIA (Moldenhauer et al., 1990, Scand. J. Immunol. 32:77-82). 
     As used herein, the terms “immunospecifically binds,” “immunospecifically recognizes,” “specifically binds,” and “specifically recognizes” are analogous terms in the context of antibodies and refer to molecules that bind to an antigen (e.g., epitope or immune complex) as such binding is understood by one skilled in the art. For example, a molecule that specifically binds to an antigen may bind to other peptides or polypeptides, generally with lower affinity as determined by, e.g., immunoassays, BIAcore®, KinExA 3000 instrument (Sapidyne Instruments, Boise, Id.), or other assays known in the art. In a specific embodiment, molecules that specifically bind to an antigen bind to the antigen with a K A  that is at least 2 logs, 2.5 logs, 3 logs, 4 logs or greater than the K A  when the molecules bind to another antigen. 
     In another embodiment, specific embodiment, molecules that specifically bind to an antigen bind with a dissociation constant (K d ) of about 1×10 −7  M. In some embodiments, the antigen binding molecule specifically binds an antigen with “high affinity” when the K d  is about 1×10 −9  M to about 5×10 −9  M. In some embodiments, the antigen binding molecule specifically binds an antigen with “very high affinity” when the K d  is 1×10 −10  M to about 5×10 −10  M. In one embodiment, the antigen binding molecule has a K d  of 10 −9  M. In one embodiment, the off-rate is less than about 1×10 −5 . In other embodiments, the antigen binding molecule binds human BCMA with a K d  of between about 1×10 −7  M and about 1×10 −13  M. In yet another embodiment, the antigen binding molecule binds human BCMA with a K d  of about 1×10 −10  M to about 5×10 −10  M. 
     In another specific embodiment, molecules that specifically bind to an antigen do not cross react with other proteins under similar binding conditions. In another specific embodiment, molecules that specifically bind to an antigen do not cross react with other non-BCMA proteins. In a specific embodiment, provided herein is an antibody or fragment thereof that binds to BCMA with higher affinity than to another unrelated antigen. In certain embodiments, provided herein is an antibody or fragment thereof that binds to BCMA (e.g., human BCMA) with a 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or higher affinity than to another, unrelated antigen as measured by, e.g., a radioimmunoassay, surface plasmon resonance, or kinetic exclusion assay. In a specific embodiment, the extent of binding of an anti-BCMA antibody or antigen-binding fragment thereof described herein to an unrelated, non-BCMA protein is less than 10%, 15%, or 20% of the binding of the antibody to BCMA protein as measured by, e.g., a radioimmunoassay. 
     In a specific embodiment, provided herein is an antibody or fragment thereof that binds to human BCMA with higher affinity than to another species of BCMA. In certain embodiments, provided herein is an antibody or fragment thereof that binds to human BCMA with a 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70% or higher affinity than to another species of BCMA as measured by, e.g., a radioimmunoassay, surface plasmon resonance, or kinetic exclusion assay. In a specific embodiment, an antibody or fragment thereof described herein, which binds to human BCMA, will bind to another species of BCMA protein with less than 10%, 15%, or 20% of the binding of the antibody or fragment thereof to the human BCMA protein as measured by, e.g., a radioimmunoassay, surface plasmon resonance, or kinetic exclusion assay. 
     An “antigen” refers to any molecule that provokes an immune response or is capable of being bound by an antibody or an antigen binding molecule. The immune response may involve either antibody production, or the activation of specific immunologically-competent cells, or both. A person of skill in the art would readily understand that any macromolecule, including virtually all proteins or peptides, can serve as an antigen. An antigen can be endogenously expressed, i.e. expressed by genomic DNA, or can be recombinantly expressed. An antigen can be specific to a certain tissue, such as a cancer cell, or it can be broadly expressed. In addition, fragments of larger molecules can act as antigens. In one embodiment, antigens are tumor antigens. In one particular embodiment, the antigen is BCMA. 
     The term “neutralizing” refers to an antigen binding molecule, scFv, antibody, or a fragment thereof that binds to a ligand and prevents or reduces the biological effect of that ligand. In some embodiments, the antigen binding molecule, scFv, antibody, or a fragment thereof, directly blocking a binding site on the ligand or otherwise alters the ligand&#39;s ability to bind through indirect means (such as structural or energetic alterations in the ligand). In some embodiments, the antigen binding molecule, scFv, antibody, or a fragment thereof prevents the protein to which it is bound from performing a biological function. 
     As used herein, the term “BCMA” refers to B cell maturation antigen, which can include, but is not limited to, native BCMA, an isoform of BCMA, or an interspecies BCMA homolog of BCMA. BCMA (also known as TNFRSF17, CD269, and TNFRSF13A) is a member of the tumor necrosis factor (TNF)-receptor superfamily. BCMA is expressed on the surface of multiple myeloma cells, while highly restricted to plasma cells and a subset of mature B cells in healthy tissue ( FIG.  2 A  and  FIG.  2 C ). The amino acid sequence of human BCMA (hBCMA) is provided in NCBI Accession Q02223.2 (GI:313104029) (SEQ ID NO: 163). As used herein, BCMA includes human BCMA and non-human BCMA homologs, as well as variants, fragments, or post-transnationally modified forms thereof, including, but not limited to, N- and O-linked glycosylated forms of BCMA. BCMA proteins may further include fragments comprising all or a portion of the extracellular domain of BCMA (e.g., all or a portion of amino acids 1-54 of hBCMA). 
     The term “autologous” refers to any material derived from the same individual to which it is later to be re-introduced. For example, the engineered autologous cell therapy (eACT™) method described herein involves collection of lymphocytes from a patient, which are then engineered to express, e.g., a CAR construct, and then administered back to the same patient. 
     The term “allogeneic” refers to any material derived from one individual which is then introduced to another individual of the same species, e.g., allogeneic T cell transplantation. 
     The terms “transduction” and “transduced” refer to the process whereby foreign DNA is introduced into a cell via viral vector (see Jones et al., “Genetics: principles and analysis,” Boston: Jones &amp; Bartlett Publ. (1998)). In some embodiments, the vector is a retroviral vector, a DNA vector, a RNA vector, an adenoviral vector, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector, a herpes simplex viral vector, an adenovirus associated vector, a lentiviral vector, or any combination thereof. 
     A “cancer” refers to a broad group of various diseases characterized by the uncontrolled growth of abnormal cells in the body. Unregulated cell division and growth results in the formation of malignant tumors that invade neighboring tissues and may also metastasize to distant parts of the body through the lymphatic system or bloodstream. A “cancer” or “cancer tissue” can include a tumor. Examples of cancers that can be treated by the methods of the present invention include, but are not limited to, cancers of the immune system including lymphoma, leukemia, myeloma, and other leukocyte malignancies. In some embodiments, the methods of the present invention can be used to reduce the tumor size of a tumor derived from, for example, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular malignant melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, testicular cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, multiple myeloma, Hodgkin&#39;s Disease, non-Hodgkin&#39;s lymphoma (NHL), primary mediastinal large B cell lymphoma (PMBC), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), transformed follicular lymphoma, splenic marginal zone lymphoma (SMZL), cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, chronic or acute leukemia, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia (ALL) (including non T cell ALL), chronic lymphocytic leukemia (CLL), solid tumors of childhood, lymphocytic lymphoma, cancer of the bladder, cancer of the kidney or ureter, carcinoma of the renal pelvis, neoplasm of the central nervous system (CNS), primary CNS lymphoma, tumor angiogenesis, spinal axis tumor, brain stem glioma, pituitary adenoma, Kaposi&#39;s sarcoma, epidermoid cancer, squamous cell cancer, T-cell lymphoma, environmentally induced cancers including those induced by asbestos, other B cell malignancies, and combinations of said cancers. In one particular embodiment, the cancer is multiple myeloma. The particular cancer can be responsive to chemo- or radiation therapy or the cancer can be refractory. A refractor cancer refers to a cancer that is not amendable to surgical intervention and the cancer is either initially unresponsive to chemo- or radiation therapy or the cancer becomes unresponsive over time. 
     An “anti-tumor effect” as used herein, refers to a biological effect that can present as a decrease in tumor volume, a decrease in the number of tumor cells, a decrease in tumor cell proliferation, a decrease in the number of metastases, an increase in overall or progression-free survival, an increase in life expectancy, or amelioration of various physiological symptoms associated with the tumor. An anti-tumor effect can also refer to the prevention of the occurrence of a tumor, e.g., a vaccine. 
     A “cytokine,” as used herein, refers to a non-antibody protein that is released by one cell in response to contact with a specific antigen, wherein the cytokine interacts with a second cell to mediate a response in the second cell. A cytokine can be endogenously expressed by a cell or administered to a subject. Cytokines may be released by immune cells, including macrophages, B cells, T cells, and mast cells to propagate an immune response. Cytokines can induce various responses in the recipient cell. Cytokines can include homeostatic cytokines, chemokines, pro-inflammatory cytokines, effectors, and acute-phase proteins. For example, homeostatic cytokines, including interleukin (IL) 7 and IL-15, promote immune cell survival and proliferation, and pro-inflammatory cytokines can promote an inflammatory response. Examples of homeostatic cytokines include, but are not limited to, IL-2, IL-4, IL-5, IL-7, IL-10, IL-12p40, IL-12p70, IL-15, and interferon (IFN) gamma. Examples of pro-inflammatory cytokines include, but are not limited to, IL-1a, IL-1b, IL-6, IL-13, IL-17a, tumor necrosis factor (TNF)-alpha, TNF-beta, fibroblast growth factor (FGF) 2, granulocyte macrophage colony-stimulating factor (GM-CSF), soluble intercellular adhesion molecule 1 (sICAM-1), soluble vascular adhesion molecule 1 (sVCAM-1), vascular endothelial growth factor (VEGF), VEGF-C, VEGF-D, and placental growth factor (PLGF). Examples of effectors include, but are not limited to, granzyme A, granzyme B, soluble Fas ligand (sFasL), and perforin. Examples of acute phase-proteins include, but are not limited to, C-reactive protein (CRP) and serum amyloid A (SAA). 
     “Chemokines” are a type of cytokine that mediates cell chemotaxis, or directional movement. Examples of chemokines include, but are not limited to, IL-8, IL-16, eotaxin, eotaxin-3, macrophage-derived chemokine (MDC or CCL22), monocyte chemotactic protein 1 (MCP-1 or CCL2), MCP-4, macrophage inflammatory protein 1α (MIP-1α, MIP-1α), MIP-1β (MIP-1b), gamma-induced protein 10 (IP-10), and thymus and activation regulated chemokine (TARC or CCL17). 
     A “therapeutically effective amount,” “effective dose,” “effective amount,” or “therapeutically effective dosage” of a therapeutic agent, e.g., engineered CAR T cells, is any amount that, when used alone or in combination with another therapeutic agent, protects a subject against the onset of a disease or promotes disease regression evidenced by a decrease in severity of disease symptoms, an increase in frequency and duration of disease symptom-free periods, or a prevention of impairment or disability due to the disease affliction. The ability of a therapeutic agent to promote disease regression can be evaluated using a variety of methods known to the skilled practitioner, such as in human subjects during clinical trials, in animal model systems predictive of efficacy in humans, or by assaying the activity of the agent in in vitro assays. 
     The term “lymphocyte” as used herein includes natural killer (NK) cells, T cells, or B cells. NK cells are a type of cytotoxic (cell toxic) lymphocyte that represent a major component of the inherent immune system. NK cells reject tumors and cells infected by viruses. It works through the process of apoptosis or programmed cell death. They were termed “natural killers” because they do not require activation in order to kill cells. T-cells play a major role in cell-mediated-immunity (no antibody involvement). Its T-cell receptors (TCR) differentiate themselves from other lymphocyte types. The thymus, a specialized organ of the immune system, is primarily responsible for the T cell&#39;s maturation. There are six types of T-cells, namely: Helper T-cells (e.g., CD4+ cells), Cytotoxic T-cells (also known as TC, cytotoxic T lymphocyte, CTL, T-killer cell, cytolytic T cell, CD8+ T-cells or killer T cell), Memory T-cells ((i) stem memory T SCM  cells, like naive cells, are CD45RO−, CCR7+, CD45RA+, CD62L+(L-selectin), CD27+, CD28+ and IL-7Rα+, but they also express large amounts of CD95, IL-2Rβ, CXCR3, and LFA-1, and show numerous functional attributes distinctive of memory cells); (ii) central memory T CM  cells express L-selectin and the CCR7, they secrete IL-2, but not IFNγ or IL-4, and (iii) effector memory TEM cells, however, do not express L-selectin or CCR7 but produce effector cytokines like IFNγ and IL-4), Regulatory T-cells (Tregs, suppressor T cells, or CD4+CD25+ regulatory T cells), Natural Killer T-cells (NKT) and Gamma Delta T-cells. B-cells, on the other hand, play a principal role in humoral immunity (with antibody involvement). It makes antibodies and antigens and performs the role of antigen-presenting cells (APCs) and turns into memory B-cells after activation by antigen interaction. In mammals, immature B-cells are formed in the bone marrow, where its name is derived from. 
     The term “genetically engineered” or “engineered” refers to a method of modifying the genome of a cell, including, but not limited to, deleting a coding or non-coding region or a portion thereof or inserting a coding region or a portion thereof. In some embodiments, the cell that is modified is a lymphocyte, e.g., a T cell, which can either be obtained from a patient or a donor. The cell can be modified to express an exogenous construct, such as, e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR), which is incorporated into the cell&#39;s genome. 
     An “immune response” refers to the action of a cell of the immune system (for example, T lymphocytes, B lymphocytes, natural killer (NK) cells, macrophages, eosinophils, mast cells, dendritic cells and neutrophils) and soluble macromolecules produced by any of these cells or the liver (including Abs, cytokines, and complement) that results in selective targeting, binding to, damage to, destruction of, and/or elimination from a vertebrate&#39;s body of invading pathogens, cells or tissues infected with pathogens, cancerous or other abnormal cells, or, in cases of autoimmunity or pathological inflammation, normal human cells or tissues. 
     The term “immunotherapy” refers to the treatment of a subject afflicted with, or at risk of contracting or suffering a recurrence of, a disease by a method comprising inducing, enhancing, suppressing or otherwise modifying an immune response. Examples of immunotherapy include, but are not limited to, T cell therapies. T cell therapy can include adoptive T cell therapy, tumor-infiltrating lymphocyte (TIL) immunotherapy, autologous cell therapy, engineered autologous cell therapy (eACT), and allogeneic T cell transplantation. However, one of skill in the art would recognize that the conditioning methods disclosed herein would enhance the effectiveness of any transplanted T cell therapy. Examples of T cell therapies are described in U.S. Patent Publication Nos. 2014/0154228 and 2002/0006409, U.S. Pat. No. 5,728,388, and International Publication No. WO 2008/081035. 
     The T cells of the immunotherapy can come from any source known in the art. For example, T cells can be differentiated in vitro from a hematopoietic stem cell population, or T cells can be obtained from a subject. T cells can be obtained from, e.g., peripheral blood mononuclear cells (PBMCs), bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In addition, the T cells can be derived from one or more T cell lines available in the art. T cells can also be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled artisan, such as FICOLL™ separation and/or apheresis. Additional methods of isolating T cells for a T cell therapy are disclosed in U.S. Patent Publication No. 2013/0287748, which is herein incorporated by references in its entirety. 
     The term “engineered Autologous Cell Therapy,” which can be abbreviated as “eACT™,” also known as adoptive cell transfer, is a process by which a patient&#39;s own T cells are collected and subsequently genetically altered to recognize and target one or more antigens expressed on the cell surface of one or more specific tumor cells or malignancies. T cells can be engineered to express, for example, chimeric antigen receptors (CAR) or T cell receptor (TCR). CAR positive (+) T cells are engineered to express an extracellular single chain variable fragment (scFv) with specificity for a particular tumor antigen linked to an intracellular signaling part comprising at least one costimulatory domain and at least one activating domain. The costimulatory domain can be derived from, e.g., CD28, and the activating domain can be derived from, e.g., CD3-zeta. In certain embodiments, the CAR is designed to have two, three, four, or more costimulatory domains. The CAR scFv can be designed to target, for example, CD19, which is a transmembrane protein expressed by cells in the B cell lineage, including all normal B cells and B cell malignances, including but not limited to NHL, CLL, and non-T cell ALL. In some embodiments, the CAR is engineered such that the costimulatory domain is expressed as a separate polypeptide chain. Example CAR T cell therapies and constructs are described in U.S. Patent Publication Nos. 2013/0287748, 2014/0227237, 2014/0099309, and 2014/0050708, and these references are incorporated by reference in their entirety. 
     A “patient” as used herein includes any human who is afflicted with a cancer (e.g., a lymphoma or a leukemia). The terms “subject” and “patient” are used interchangeably herein. 
     As used herein, the term “in vitro cell” refers to any cell which is cultured ex vivo. In particular, an in vitro cell can include a T cell. 
     The terms “peptide,” “polypeptide,” and “protein” are used interchangeably, and refer to a compound comprised of amino acid residues covalently linked by peptide bonds. A protein or peptide must contain at least two amino acids, and no limitation is placed on the maximum number of amino acids that can comprise a protein&#39;s or peptide&#39;s sequence. Polypeptides include any peptide or protein comprising two or more amino acids joined to each other by peptide bonds. As used herein, the term refers to both short chains, which also commonly are referred to in the art as peptides, oligopeptides and oligomers, for example, and to longer chains, which generally are referred to in the art as proteins, of which there are many types. “Polypeptides” include, for example, biologically active fragments, substantially homologous polypeptides, oligopeptides, homodimers, heterodimers, variants of polypeptides, modified polypeptides, derivatives, analogs, fusion proteins, among others. The polypeptides include natural peptides, recombinant peptides, synthetic peptides, or a combination thereof. 
     In some aspects, the polypeptides and/or proteins have deletions from, additions to, and/or substitutions of one or more amino acid of antigen-binding protein, and in some embodiments preferably no more than 8 amino acid substitutions therein. Useful polypeptide fragments may include immunologically functional fragments of antigen binding molecules, including not limited to one or more CDR regions, variable domains of a heavy and/or light chain, a portion of other portions of an antibody chain, and the like. Additionally, polypeptide fragments of activating and/or costimulatory molecules and the like are within the scope of the invention. 
     “Activation” or “Stimulation” as used herein, refers to a primary response induced by binding of an activating molecule with its cognate ligand, wherein the binding mediates a signal transduction event. An “activating molecule” or “stimulating molecule” refers to a molecule on a T cell, e.g., the TCR/CD3 complex that specifically binds with a cognate stimulatory ligand present on an antigen present cell. Suitable activating molecules are described herein. 
     A “stimulatory ligand” is a ligand that when present on an antigen presenting cell (e.g., an aAPC, a dendritic cell, a B-cell, and the like) can specifically bind with a stimulatory molecule on a T cell, thereby mediating a primary response by the T cell, including, but not limited to, activation, initiation of an immune response, proliferation, and the like. Stimulatory ligands include, but are not limited to, an MHC Class I molecule loaded with a peptide, an anti-CD3 antibody, a superagonist anti-CD28 antibody, and a superagonist anti-CD2 antibody. 
     A “costimulatory signal,” as used herein, refers to a signal, which in combination with a primary signal, such as TCR/CD3 ligation, leads to a T cell response, such as, but not limited to, proliferation and/or upregulation or down regulation of key molecules. 
     A “costimulatory ligand” as used herein, includes a molecule on an antigen presenting cell that specifically binds a cognate co-stimulatory molecule on a T cell. Binding of the costimulatory ligand provides a signal that mediates a T cell response, including, but not limited to, proliferation, activation, differentiation, and the like. A costimulatory ligand induces a signal that is in addition to the primary signal provided by a stimulatory molecule, for instance, by binding of a T cell receptor (TCR)/CD3 complex with a major histocompatibility complex (MHC) molecule loaded with peptide. A co-stimulatory ligand can include, but is not limited to, CD7, B7-1 (CD80), B7-2 (CD86), programmed death (PD) L1, PD-L2, 4-1BB ligand, OX40 ligand, inducible costimulatory ligand (ICOS-L), intercellular adhesion molecule (ICAM), CD30 ligand, CD40, CD70, CD83, human leukocyte antigen G (HLA-G), MHC class I chain-related protein A (MICA), MHC class I chain-related protein B (MICB), herpes virus entry mediator (HVEM), lymphotoxin beta receptor, 3/TR6, immunoglobulin-like transcript (ILT) 3, ILT4, an agonist or antibody that binds Toll ligand receptor and a ligand that specifically binds with B7-H3. A co-stimulatory ligand includes, without limitation, an antibody that specifically binds with a co-stimulatory molecule present on a T cell, such as, but not limited to, CD27, CD28, 4-1BB, OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1), CD2, CD7, tumor necrosis factor superfamily member 14 (TNFSF14 or LIGHT), natural killer cell receptor C (NKG2C), B7-H3, and a ligand that specifically binds with CD83. 
     A “costimulatory molecule” is a cognate binding partner on a T cell that specifically binds with a costimulatory ligand, thereby mediating a costimulatory response by the T cell, such as, but not limited to, proliferation. Costimulatory molecules include, but are not limited to, CD28, CD28T, OX40, 4-1BB/CD137, CD2, CD3 (alpha, beta, delta, epsilon, gamma, zeta), CD4, CD5, CD7, CD9, CD16, CD22, CD27, CD30, CD 33, CD37, CD40, CD 45, CD64, CD80, CD86, CD134, CD137, CD154, PD-1, ICOS, lymphocyte function-associated antigen-1 (LFA-1 (CD11a/CD18), CD247, CD276 (B7-H3), LIGHT (tumor necrosis factor superfamily member 14; TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class I molecule, TNF, TNFr, integrin, signaling lymphocytic activation molecule, BTLA, Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, CD83 ligand, or fragments or combinations thereof. 
     The terms “reducing” and “decreasing” are used interchangeably herein and indicate any change that is less than the original. “Reducing” and “decreasing” are relative terms, requiring a comparison between pre- and post-measurements. “Reducing” and “decreasing” include complete depletions. 
     “Treatment” or “treating” of a subject refers to any type of intervention or process performed on, or the administration of an active agent to, the subject with the objective of reversing, alleviating, ameliorating, inhibiting, slowing down or preventing the onset, progression, development, severity or recurrence of a symptom, complication or condition, or biochemical indicia associated with a disease. In one embodiment, “treatment” or “treating” includes a partial remission. In another embodiment, “treatment” or “treating” includes a complete remission. 
     To calculate percent identity, the sequences being compared are typically aligned in a way that gives the largest match between the sequences. One example of a computer program that can be used to determine percent identity is the GCG program package, which includes GAP (Devereux et al., 1984, Nucl. Acid Res. 12:387; Genetics Computer Group, University of Wisconsin, Madison, Wis.). The computer algorithm GAP is used to align the two polypeptides or polynucleotides for which the percent sequence identity is to be determined. The sequences are aligned for optimal matching of their respective amino acid or nucleotide (the “matched span”, as determined by the algorithm). In certain embodiments, a standard comparison matrix (see, Dayhoff et al., 1978, Atlas of Protein Sequence and Structure 5:345-352 for the PAM 250 comparison matrix; Henikoff et al., 1992, Proc. Natl. Acad. Sci. U.S.A. 89:10915-10919 for the BLOSUM 62 comparison matrix) is also used by the algorithm. 
     The use of the alternative (e.g., “or”) should be understood to mean either one, both, or any combination thereof of the alternatives. As used herein, the indefinite articles “a” or “an” should be understood to refer to “one or more” of any recited or enumerated component. 
     The terms “about” or “comprising essentially of” refer to a value or composition that is within an acceptable error range for the particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined, i.e., the limitations of the measurement system. For example, “about” or “comprising essentially of” can mean within 1 or more than 1 standard deviation per the practice in the art. Alternatively, “about” or “comprising essentially of” can mean a range of up to 10% (i.e., ±10%). For example, about 3 mg can include any number between 2.7 mg and 3.3 mg (for 10%). Furthermore, particularly with respect to biological systems or processes, the terms can mean up to an order of magnitude or up to 5-fold of a value. When particular values or compositions are provided in the application and claims, unless otherwise stated, the meaning of “about” or “comprising essentially of” should be assumed to be within an acceptable error range for that particular value or composition. 
     As described herein, any concentration range, percentage range, ratio range or integer range is to be understood to include the value of any integer within the recited range and, when appropriate, fractions thereof (such as one-tenth and one-hundredth of an integer), unless otherwise indicated. 
     Various aspects of the invention are described in further detail in the following subsections. 
     II. Binding Molecules and Polynucleotides Encoding the Same 
     The present invention is directed to a polynucleotide encoding an anti-BCMA antibody or antigen binding molecule thereof which cross competes with one or more antibodies described herein (i.e., one or more described in  FIG.  1   ) or an antibody or antigen binding molecule thereof encoded by the polynucleotide. In one embodiment, the invention is directed to a polynucleotide encoding an anti-BCMA antibody or antigen binding molecule thereof which binds to the same epitope as one or more antibodies described in  FIG.  1    or an antibody or antigen binding molecule thereof encoded by the polynucleotide. In some embodiments, the polynucleotide encodes an antibody or antigen binding molecule thereof that specifically binds to BCMA, wherein the antibody or binding molecule comprises a heavy chain VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GX 2 X 3 X 4 X 5 X 6 X 7 SY (SEQ ID NO: 145), wherein: X 2  is not present or G; X 3  is not present or S; X 4  is F, G, I, or Y; X 5  is S or T; X 6  is F or S; and X 7  is S or T; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 YX 12 X 13 X 14 X 15 X 16 X 17  (SEQ ID NO: 146), wherein: X 1  is A, G, I, S, T, or V; X 3  is I, N, or S; X 4  is G, P, S, or Y; X 5  is D, G, I, or S; X 6  is F, G, or S; X 7  is not present or G or S; X 8  is N, S, or T; X 9  is A, I, K, or T; X 10  is N, S, or Y; X 12  is A or N; X 13  is D, P, or Q; X 14  is K or S; X 15  is F, L, or V; X 16  is K or Q; and X 17  is G or S; and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 DX 19  (SEQ ID NO: 147), wherein: X 1  is A or V; X 2  is K or R; X 3  is not present or D, G, or T; X 4  is not present or A, D, G, P, R, or S; X 5  is not present or E, F, G, L, Q, or T; X 6  is not present or E, M, Q, W, or Y; X 7  is not present or A, E, L, or S; X 8  is not present or G, P, S, or T; X 9  is not present or G, P, or S; X 10  is not present or I, L, P, or Y; X 11  is not present or W; X 12  is not present or H; X 13  is not present or E or Y; X 14  is not present or D, G, H, P, S, W, or Y; X 15  is A, G, L, W, or Y; X 16  is not present or A, G, I, P, or V; X 17  is F, L, or M; and X 19  is I, L, V, or Y. 
     In one particular embodiment, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 SYX 9 X 10 X 11  (SEQ ID NO: 263), wherein: X 1  is not present or G; X 2  is not present or S X 3  is F, G, I, or Y; X 4  is S or T; X 5  is F or S; X 6  is S or T; X 9  is A, G, S, or Y; X 10  is I, M, or W; and X 11  is G, H, N, or S; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 YX 12 X 13 X 14 X 15 X 16 X 17  (SEQ ID NO: 146), wherein: X 1  is A, G, I, S, T, or V; X 3  is I, N, or S; X 4  is G, P, S, or Y; X 5  is D, G, I, or S; X 6  is F, G, or S; X 7  is G or S; X 8  is not present or N, S, or T; X 9  is A, I, K, or T; X 10  is N, S, or Y; X 12  is A or N; X 13  is D, P, or Q; X 14  is K or S; X 15  is F, L, or V; X 16  is K or Q; and X 17  is G or S; and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 DX 21  (SEQ ID NO: 264), wherein: X 1  is A or V; X 2  is K or R; X 3  is not present or D, G, or T; X 4  is not present or D, G, or P; X 5  is not present or F, L, or T; X 6  is not present or P, Q, R, W, or Y; X 7  is not present or E, G, L, or S; X 8  is not present or A, G, P, S, or Y; X 9  is not present or A, E, G, P, Q, or S; X 10  is not present or E, L, M, PS, T, or Y; X 11  is not present or D, G, H, P, S or W; X 12  is not present or A, G, I, L, or Y; X 13  is not present or A, G, I, V, or W; X 14  is not present or H; X 15  is not present or Y; X 16  is not present or Y; X 17  is not present or W or Y; X 18  is not present or P or G; X 19  is F, L, or M; and X 21  is I, L, V, or Y. 
     In another embodiment, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VL comprising: (a) a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SQX 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 LX 17  (SEQ ID NO: 148), wherein X 1  is K or R; X 2  is A or S; X 5  is G or S; X 6  is I, L, or V; X 7  is L or S; X 8  is not present or H or Y; X 9  is not present or S; X 10  is not present or N or S; X 11  is not present or G or N; X 12  is not present or N; X 13  is not present or K or Y; X 14  is N, R, or S; X 15  is N, W, or Y; and X 17  is A or D; and/or (b) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SX 4 X 5 X 6 X 7  (SEQ ID NO: 149), wherein X 1  is D, G, L, S, or W; X 2  is A or G; X 4  is N, S, or T; X 5  is L or R; X 6  is A, E, or Q; and X 7  is S or T; and/or (c) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 QX 3 X 4 X 5 X 6 PX 8 T (SEQ ID NO: 150), wherein X 1  is M or Q; X 3  is F, G, H, I, R, or Y; X 4  is A, F, H, I, L, or Y; X 5  is A, G, H, S, T, V, or Y; X 6  is F, L, T, W, or Y; and X 8  is not present or F, L, P, or W. 
     In one particular embodiment, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GX 2 X 3 X 4 X 5 X 6 X 7 SY (SEQ ID NO: 145), wherein: X 2  is not present or G; X 3  is not present or S; X 4  is F, G, I, or Y; X 5  is S or T; X 6  is F or S; and X 7  is S or T; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 YX 12 X 13 X 14 X 15 X 16 X 17  (SEQ ID NO: 146), wherein: X 1  is A, G, I, S, T, or V; X 3  is I, N, or S; X 4  is G, P, S, or Y; X 5  is D, G, I, or S; X 6  is F, G, or S; X 7  is not present or G or S; X 8  is N, S, or T; X 9  is A, I, K, or T; X 10  is N, S, or Y; X 12  is A or N; X 13  is D, P, or Q; X 14  is K or S; X 15  is F, L, or V; X 16  is K or Q; and X 17  is G or S; and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 DX 19  (SEQ ID NO: 147), wherein: X 1  is A or V; X 2  is K or R; X 3  is not present or D, G, or T; X 4  is not present or A, D, G, P, R, or S; X 5  is not present or E, F, G, L, Q, or T; X 6  is not present or E, M, Q, W, or Y; X 7  is not present or A, E, L, or S; X 8  is not present or G, P, S, or T; X 9  is not present or G, P, or S; X 10  is not present or I, L, P, or Y; X 11  is not present or W; X 12  is not present or H; X 13  is not present or E or Y; X 14  is not present or D, G, H, P, S, W, or Y; X 15  is A, G, L, W, or Y; X 16  is not present or A, G, I, P, or V; X 17  is F, L, or M; and X 19  is I, L, V, or Y; and/or (d) a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SQX 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 LX 17  (SEQ ID NO: 148), wherein X 1  is K or R; X 2  is A or S; X 5  is G or S; X 6  is I, L, or V; X 7  is L or S; X 8  is not present or H or Y; X 9  is not present or S; X 10  is not present or N or S; X 11  is not present or G or N; X 12  is not present or N; X 13  is not present or K or Y; X 14  is N, R, or S; X 15  is N, W, or Y; and X 17  is A or D; and/or (e) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SX 4 X 5 X 6 X 7  (SEQ ID NO: 149), wherein X 1  is D, G, L, S, or W; X 2  is A or G; X 4  is N, S, or T; X 5  is L or R; X 6  is A, E, or Q; and X 7  is S or T; and/or (f) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 QX 3 X 4 X 5 X 6 PX 8 T (SEQ ID NO: 150), wherein X 1  is M or Q; X 3  is F, G, H, I, R, or Y; X 4  is A, F, H, I, L, or Y; X 5  is A, G, H, S, T, V, or Y; X 6  is F, L, T, W, or Y; and X 8  is not present or F, L, P, or W. 
     In one particular embodiment, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH comprising: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 SYX 9 X 10 X 11  (SEQ ID NO: 263), wherein: X 1  is not present or G; X 2  is not present or S X 3  is F, G, I, or Y; X 4  is S or T; X 5  is F or S; X 6  is S or T; X 9  is A, G, S, or Y; X 10  is I, M, or W; and X 11  is G, H, N, or S; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 YX 12 X 13 X 14 X 15 X 16 X 17  (SEQ ID NO: 146), wherein: X 1  is A, G, I, S, T, or V; X 3  is I, N, or S; X 4  is G, P, S, or Y; X 5  is D, G, I, or S; X 6  is F, G, or S; X 7  is G or S; X 8  is not present or N, S, or T; X 9  is A, I, K, or T; X 10  is N, S, or Y; X 12  is A or N; X 13  is D, P, or Q; X 14  is K or S; X 15  is F, L, or V; X 16  is K or Q; and X 17  is G or S; and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 DX 21  (SEQ ID NO: 264), wherein: X 1  is A or V; X 2  is K or R; X 3  is not present or D, G, or T; X 4  is not present or D, G, or P; X 5  is not present or F, L, or T; X 6  is not present or P, Q, R, W, or Y; X 7  is not present or E, G, L, or S; X 8  is not present or A, G, P, S, or Y; X 9  is not present or A, E, G, P, Q, or S; X 10  is not present or E, L, M, PS, T, or Y; X 11  is not present or D, G, H, P, S or W; X 12  is not present or A, G, I, L, or Y; X 13  is not present or A, G, I, V, or W; X 14  is not present or H; X 15  is not present or Y; X 16  is not present or Y; X 17  is not present or W or Y; X 18  is not present or P or G; X 19  is F, L, or M; and X 21  is I, L, V, or Y; and/or (d) a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SQX 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 LX 17  (SEQ ID NO: 148), wherein X 1  is K or R; X 2  is A or S; X 5  is G or S; X 6  is I, L, or V; X 7  is L or S; X 8  is not present or H or Y; X 9  is not present or S; X 10  is not present or N or S; X 11  is not present or G or N; X 12  is not present or N; X 13  is not present or K or Y; X 14  is N, R, or S; X 15  is N, W, or Y; and X 17  is A or D; and/or (e) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SX 4 X 5 X 6 X 7  (SEQ ID NO: 149), wherein X 1  is D, G, L, S, or W; X 2  is A or G; X 4  is N, S, or T; X 5  is L or R; X 6  is A, E, or Q; and X 7  is S or T; and/or (f) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 QX 3 X 4 X 5 X 6 PX 8 T (SEQ ID NO: 150), wherein X 1  is M or Q; X 3  is F, G, H, I, R, or Y; X 4  is A, F, H, I, L, or Y; X 5  is A, G, H, S, T, V, or Y; X 6  is F, L, T, W, or Y; and X 8  is not present or F, L, P, or W. 
     In another embodiment, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH and a VL, wherein: (i) the VH comprises: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GX 2 X 3 X 4 X 5 X 6 X 7 SY (SEQ ID NO: 145), wherein: X 2  is not present or G; X 3  is not present or S; X 4  is F, G, I, or Y; X 5  is S or T; X 6  is F or S; and X 7  is S or T; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 YX 12 X 13 X 14 X 15 X 16 X 17  (SEQ ID NO: 146), wherein: X 1  is A, G, I, S, T, or V; X 3  is I, N, or S; X 4  is G, P, S, or Y; X 5  is D, G, I, or S; X 6  is F, G, or S; X 7  is not present or G or S; X 8  is N, S, or T; X 9  is A, I, K, or T; X 10  is N, S, or Y; X 12  is A or N; X 13  is D, P, or Q; X 14  is K or S; X 15  is F, L, or V; X 16  is K or Q; and X 17  is G or S; and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 DX 19  (SEQ ID NO: 147), wherein: X 1  is A or V; X 2  is K or R; X 3  is not present or D, G, or T; X 4  is not present or A, D, G, P, R, or S; X 5  is not present or E, F, G, L, Q, or T; X 6  is not present or E, M, Q, W, or Y; X 7  is not present or A, E, L, or S; X 8  is not present or G, P, S, or T; X 9  is not present or G, P, or S; X 10  is not present or I, L, P, or Y; X 11  is not present or W; X 12  is not present or H; X 13  is not present or E or Y; X 14  is not present or D, G, H, P, S, W, or Y; X 15  is A, G, L, W, or Y; X 16  is not present or A, G, I, P, or V; X 17  is F, L, or M; and X 19  is I, L, V, or Y; and (ii) the VL comprises: (a) a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SQX 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 LX 17  (SEQ ID NO: 148), wherein X 1  is K or R; X 2  is A or S; X 5  is G or S; X 6  is I, L, or V; X 7  is L or S; X 8  is not present or H or Y; X 9  is not present or S; X 10  is not present or N or S; X 11  is not present or G or N; X 12  is not present or N; X 13  is not present or K or Y; X 14  is N, R, or S; X 15  is N, W, or Y; and X 17  is A or D; and/or (b) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SX 4 X 5 X 6 X 7  (SEQ ID NO: 149), wherein X 1  is D, G, L, S, or W; X 2  is A or G; X 4  is N, S, or T; X 5  is L or R; X 6  is A, E, or Q; and X 7  is S or T; and/or (c) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 QX 3 X 4 X 5 X 6 PX 8 T (SEQ ID NO: 150), wherein X 1  is M or Q; X 3  is F, G, H, I, R, or Y; X 4  is A, F, H, I, L, or Y; X 5  is A, G, H, S, T, V, or Y; X 6  is F, L, T, W, or Y; and X 8  is not present or F, L, P, or W. 
     In another embodiment, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH and a VL, wherein: (i) the VH comprises: (a) a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 SYX 9 X 10 X 11  (SEQ ID NO: 263), wherein: X 1  is not present or G; X 2  is not present or S X 3  is F, G, I, or Y; X 4  is S or T; X 5  is F or S; X 6  is S or T; X 9  is A, G, S, or Y; X 10  is I, M, or W; and X 11  is G, H, N, or S; and/or (b) a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 YX 12 X 13 X 14 X 15 X 16 X 17  (SEQ ID NO: 146), wherein: X 1  is A, G, I, S, T, or V; X 3  is I, N, or S; X 4  is G, P, S, or Y; X 5  is D, G, I, or S; X 6  is F, G, or S; X 7  is G or S; X 8  is not present or N, S, or T; X 9  is A, I, K, or T; X 10  is N, S, or Y; X 12  is A or N; X 13  is D, P, or Q; X 14  is K or S; X 15  is F, L, or V; X 16  is K or Q; and X 17  is G or S; and/or (c) a VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 DX 21  (SEQ ID NO: 264), wherein: X 1  is A or V; X 2  is K or R; X 3  is not present or D, G, or T; X 4  is not present or D, G, or P; X 5  is not present or F, L, or T; X 6  is not present or P, Q, R, W, or Y; X 7  is not present or E, G, L, or S; X 8  is not present or A, G, P, S, or Y; X 9  is not present or A, E, G, P, Q, or S; X 10  is not present or E, L, M, P, S, T, or Y; X 11  is not present or D, G, H, P, S or W; X 12  is not present or A, G, I, L, or Y; X 13  is not present or A, G, I, V, or W; X 14  is not present or H; X 15  is not present or Y; X 16  is not present or Y; X 17  is not present or W or Y; X 18  is not present or P or G; X 19  is F, L, or M; and X 21  is I, L, V, or Y; and (ii) the VL comprises: (a) a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SQX 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 LX 17  (SEQ ID NO: 148), wherein X 1  is K or R; X 2  is A or S; X 5  is G or S; X 6  is I, L, or V; X 7  is L or S; X 8  is not present or H or Y; X 9  is not present or S; X 10  is not present or N or S; X 11  is not present or G or N; X 12  is not present or N; X 13  is not present or K or Y; X 14  is N, R, or S; X 15  is N, W, or Y; and X 17  is A or D; and/or (b) a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SX 4 X 5 X 6 X 7  (SEQ ID NO: 149), wherein X 1  is D, G, L, S, or W; X 2  is A or G; X 4  is N, S, or T; X 5  is L or R; X 6  is A, E, or Q; and X 7  is S or T; and/or (c) a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 QX 3 X 4 X 5 X 6 PX 8 T (SEQ ID NO: 150), wherein X 1  is M or Q; X 3  is F, G, H, I, R, or Y; X 4  is A, F, H, I, L, or Y; X 5  is A, G, H, S, T, V, or Y; X 6  is F, L, T, W, or Y; and X 8  is not present or F, L, P, or W. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GX 2 X 3 X 4 X 5 X 6 X 7 SY (SEQ ID NO: 145), wherein: X 2  is not present or G; X 3  is not present or S; X 4  is F, G, I, or Y; X 5  is S or T; X 6  is F or S; and X 7  is S or T. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GX 2 TFSSY (SEQ ID NO: 151), wherein: X 2  is F or G. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence GX 2 X 3 X 4 X 5 X 6 SSY (SEQ ID NO: 152), wherein: X 2  is not present or G; X 3  is not present or S; X 4  is F, G, or I; X 5  is S or T; and X 6  is F or S. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 SYX 9 X 10 X 11  (SEQ ID NO: 263), wherein: X 1  is not present or G; X 2  is not present or S X 3  is F, G, I, or Y; X 4  is S or T; X 5  is F or S; X 6  is S or T; X 9  is A, G, S, or Y; X 10  is I, M, or W; and X 11  is G, H, N, or S. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 TFX 4 SYX 7 X 8 X 9  (SEQ ID NO: 265), wherein: X 1  is F, G, or Y; X 4  is S or T; X 7  is A, G, S, or Y; X 8  is I or M; and X 9  is H, N, or S. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence FTFSSYX 7 MX 9  (SEQ ID NO: 266), wherein: X 7  is A, G, or S; and X 9  is H, N, or S. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 YX 12 X 13 X 14 X 15 X 16 X 17  (SEQ ID NO: 146), wherein: X 1  is A, G, I, S, T, or V; X 3  is I, N, or S; X 4  is G, P, S, or Y; X 5  is D, G, I, or S; X 6  is F, G, or S; X 7  is G or S; X 8  is not present or N, S, or T; X 9  is A, I, K, or T; X 10  is N, S, or Y; X 12  is A or N; X 13  is D, P, or Q; X 14  is K or S; X 15  is F, L, or V; X 16  is K or Q; and X 17  is G or S. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 YAX 13 X 14 X 15 X 16 G (SEQ ID NO: 153), wherein: X 1  is A, G, I, T, or V; X 3  is I, N, or S; X 4  is G, P, S, or Y; X 5  is D, G, I, or S; X 6  is F, G, or S; X 7  is G or S; X 8  is N, S, or T; X 9  is A, I, K, or T; X 10  is N, S, or Y; X 13  is D or Q; X 14  is K or S; X 15  is F or V; and X 16  is K or Q. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 ISX 4 X 5 X 6 X 7 X 8 X 9 YYADSVKG (SEQ ID NO: 154), wherein: X 1  is A, T, or V; X 4  is G, S, or Y; X 5  is D or S; X 6  is G or S; X 7  is G or S; X 8  is N, S, or T; and X 9  is I, K, or T. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VH CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 IX 3 PX 5 X 6 GX 8 X 9 X 10 YAQKFQG (SEQ ID NO: 155), wherein: X 1  is G or I; X 3  is I or N; X 5  is G or I; X 6  is F or G; X 8  is S or T; X 9  is A or T; and X 10  is N or S. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises three VH CDRs and three VL CDRs, wherein the VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 DX 19  (SEQ ID NO: 147) and wherein: X 1  is A or V; X 2  is K or R; X 3  is not present or D, G, or T; X 4  is not present or A, D, G, P, R, or S; X 5  is not present or E, F, G, L, Q, or T; X 6  is not present or E, M, Q, W, or Y; X 7  is not present or A, E, L, or S; X 8  is not present or G, P, S, or T; X 9  is not present or G, P, or S; X 10  is not present or I, L, P, or Y; X 11  is not present or W; X 12  is not present or H; X 13  is not present or E or Y; X 14  is not present or D, G, H, P, S, W, or Y; X 15  is A, G, L, W, or Y; X 16  is not present or A, G, I, P, or V; X 17  is F, L, or M; and X 19  is I, L, V, or Y. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises three VH CDRs and three VL CDRs, wherein the VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence ARX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 DX 19  (SEQ ID NO: 156) and wherein: X 3  is not present or D, G, or T; X 4  is not present or A, D, G, P, R, or S; X 5  is not present or E, F, G, Q, or T; X 6  is not present or E, M, W, or Y; X 7  is not present or A, L, or S; X 8  is not present or G, S, or T; X 9  is not present or G or S; X 10  is not present or I, L, or P; X 11  is not present or W; X 12  is not present or H; X 13  is not present or E or Y; X 14  is not present or G, H, P, S, W, or Y; X 15  is A, G, L, W, or Y; X 16  is not present or A, G, I, P, or V; X 17  is F, L, or M; and X 19  is I, L, V, or Y. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises three VH CDRs and three VL CDRs, wherein the VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 DX 21  (SEQ ID NO: 264) and wherein: X 1  is A or V; X 2  is K or R; X 3  is not present or D, G, or T; X 4  is not present or D, G, or P; X 5  is not present or F, L, or T; X 6  is not present or P, Q, R, W, or Y; X 7  is not present or E, G, L, or S; X 8  is not present or A, G, P, S, or Y; X 9  is A, E, G, P, Q, or S; X 10  is E, L, M, P, S, T, or Y; X 11  is not present or D, G, H, P, S or W; X 12  is not present or A, G, I, L, or Y; X 13  is not present or A, G, I, V, or W; X 14  is not present or H; X 15  is not present or Y; X 16  is not present or Y; X 17  is not present or W or Y; X 18  is not present or P or G; X 19  is F, L, or M; and X 21  is I, L, V, or Y. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises three VH CDRs and three VL CDRs, wherein the VH CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence ARX 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 X 18 X 19 DX 21  (SEQ ID NO: 267), wherein: X 3  is not present or D or T; X 4  is not present or D or G; X 5  is not present or F or T; X 6  is not present or P, R, W, or Y; X 7  is not present or E, G, L, or S; X 8  is not present or A, G, S, or Y; X 9  is A, E, G, Q, or S; X 10  is E, L, M, P, S, or T; X 11  is not present or G, H, P, S or W; X 12  is not present or A, G, I, L, or Y; X 13  is not present or A, I, V, or W; X 14  is not present or H; X 15  is not present or Y; X 16  is not present or Y; X 17  is not present or W or Y; X 18  is not present or P or G; X 19  is F, L, or M; and X 21  is I, L, V, or Y. 
     In some embodiments, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises one, two, or all three of any of the VH CDRs listed above or described in  FIG.  1 A  or  FIG.  1 B . In some embodiments, the antibody or antigen binding molecule comprises the VH framework regions (FRs) described herein. In specific embodiments, the antibody or antigen binding molecule comprises the VH FRs of an antibody set forth in  FIG.  1 A  or  FIG.  1 B  (e.g., one, two, three, or four of the FRs in one sequence of  FIG.  1 A ). 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SQX 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 LX 17  (SEQ ID NO: 148), wherein: X 1  is K or R; X 2  is A or S; X 5  is G or S; X 6  is I, L, or V; X 7  is L or S; X 8  is not present or H or Y; X 9  is not present or S; X 10  is not present or N or S; X 11  is not present or G or N; X 12  is not present or N; X 13  is not present or K or Y; X 14  is N, R, or S; X 15  is N, W, or Y; and X 17  is A or D. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence RASQX 5 X 6 SX 8 X 9 LA (SEQ ID NO: 157), wherein: X 5  is G or S; X 6  is I or V; X 8  is R or S; and X 9  is N, W, or Y. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR1 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 SSQSX 6 LX 8 SX 10 X 11 X 12 X 13 NYLX 17  (SEQ ID NO: 158), wherein: X 1  is K or R; X 6  is L or V; X 8  is H or Y; X 10  is N or S; X 11  is G or N; X 12  is not present or N; X 13  is K or Y; and X 17  is A or D. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SX 4 X 5 X 6 X 7  (SEQ ID NO: 149), wherein: X 1  is D, G, L, S, or W; X 2  is A or G; X 4  is N, S, or T; X 5  is L or R; X 6  is A, E, or Q; and X 7  is S or T. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 ASX 4 RAT (SEQ ID NO: 159), wherein: X 1  is D, G, or S; and X 4  is N or T. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 ASX 4 X 5 X 6 X 7  (SEQ ID NO: 160), wherein: X 1  is D, G, or S; X 4  is N, S, or T; X 5  is L or R; X 6  is A or Q; and X 7  is S or T. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR2 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 X 2 SX 4 RX 6 S (SEQ ID NO: 161), wherein X 1  is L or W; X 2  is A or G; X 4  is N or T; and X 6  is A or E. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence X 1 QX 3 X 4 X 5 X 6 PX 8 T (SEQ ID NO: 150), wherein: X 1  is M or Q; X 3  is F, G, H, I, R, or Y; X 4  is A, F, H, I, L, or Y; X 5  is A, G, H, S, T, V, or Y; X 6  is F, L, T, W, or Y; and X 8  is not present or F, L, P, or W. 
     In one embodiment, the antibody or antigen binding molecule, which specifically binds to BCMA (e.g., hBCMA), comprises a VL CDR3 comprising, consisting of, or consisting essentially of the amino acid sequence QQX 3 X 4 X 5 X 6 PX 8 T (SEQ ID NO: 162), wherein: X 3  is H, I, R, or Y; X 4  is A, F, H, I, or Y; X 5  is A, S, T, V, or Y; X 6  is F, W, or Y; and X 8  is not present or F, L, P, or W. 
     In some embodiments, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises one, two, or all three of any of the VL CDRs listed above or described in  FIG.  2   . In some embodiments, the antibody or antigen binding molecule comprises the VL framework regions (FRs) described herein. In specific embodiments, the antibody or antigen binding molecule comprises the VL FRs of an antibody set forth in  FIG.  4    (e.g., one, two, three, or four of the FRs in one row of  FIG.  4   ). 
     In some embodiments, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH CDR1, wherein the VH CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 9-16. In other embodiments, the antibody or antigen binding molecule comprises a VH CDR1, wherein the VH CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 215-222. In some embodiments, the antibody or antigen binding molecule comprises a VH CDR2, wherein the VH CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 25-32. In some embodiments, the antibody or antigen binding molecule comprises a VH CDR2, wherein the VH CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 231-238. In some embodiments, the antibody or antigen binding molecule comprises a VH CDR3, wherein the VH CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 41-48. In some embodiments, the antibody or antigen binding molecule comprises a VH CDR3, wherein the VH CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 247-254. 
     In some embodiments, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH CDR1, a VH CDR2, and VH CDR3, wherein the VH CDR1, VH CDR2, and VH CDR3 comprise the amino acid sequence of the VH CDR1, VH CDR2, and VH CDR3 of an antibody in  FIG.  1 A  or  FIG.  1 B , respectively. 
     In some embodiments, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VL CDR1, wherein the VL CDR1 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 81-88. In some embodiments, the antibody or antigen binding molecule comprises a VL CDR2, wherein the VL CDR2 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 97-104. In some embodiments, the antibody or antigen binding molecule comprises a VL CDR3, wherein the VL CDR3 comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 113-120. 
     In some embodiments, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VL CDR1, a VL CDR2, and VL CDR3, wherein the VL CDR1, VL CDR2, and VL CDR3 comprise the amino acid sequence of the VL CDR1, VL CDR2, and VL CDR3 of an antibody in  FIG.  1 C , respectively. 
     In some embodiments, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises a VH framework region 1 (FR1), wherein the VH FR1 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 1-8 and 207-214. In some embodiments, the antibody or antigen binding molecule comprises a VH FR2, wherein the VH FR2 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 17-24 and 223-23. In some embodiments, the antibody or antigen binding molecule comprises a VH FR3, wherein the VH FR3 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 33-40 and 239-246. In some embodiments, the antibody or antigen binding molecule comprises a VH FR4, wherein the VH FR4 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 49-56 and 255-262. 
     In some embodiments, the antibody or antigen binding molecule or a fragment thereof comprises a VL FR1, wherein the VL FR1 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 73-80. In some embodiments, the antibody or antigen binding molecule or a fragment thereof comprises a VL FR2, wherein the VL FR2 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 89-96. In some embodiments, the antibody or antigen binding molecule or a fragment thereof comprises a VL FR3, wherein the VL FR3 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 105-112. In some embodiments, the antibody or antigen binding molecule or a fragment thereof comprises a VL FR4, wherein the VL FR4 comprises an amino acid sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from SEQ ID NOs: 121-128. 
     In some embodiments, the polynucleotide encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule comprises any one, two, and/or three VH CDR sequences disclosed herein. In certain embodiments, the antibody or antigen binding molecule comprises a VH CDR1, a VH CDR2, and a VH CDR3 having the amino acid sequence of any VH CDR1, VH CDR2, and VH CDR3 disclosed herein, respectively. In some embodiments, the antibody or antigen binding molecule comprises any one, two, and/or three VL CDR sequences disclosed herein. In certain embodiments, the antibody or antigen binding molecule comprises a VL CDR1, a VL CDR2, and a VL CDR3 having the amino acid sequence of any VL CDR1, VL CDR2, and VL CDR3 disclosed herein, respectively. 
     In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 9; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 25; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 41; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 81; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 97; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 113. 
     In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 10; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 26; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 42; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 82; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 98; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 114. 
     In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 11; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 27; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 43; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 83; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 99; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 115. 
     In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 12; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 28; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 44; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 84; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 100; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 116. 
     In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 13; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 29; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 45; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 85; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 101; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 117. 
     In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 14; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 30; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 46; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 86; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 102; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 118. 
     In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 15; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 31; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 47; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 87; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 103; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 119. 
     In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 16; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 32; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 48; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 88; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 104; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 120. 
     In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 215; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 231; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 247; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 81; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 97; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 113. 
     In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 216; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 232; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 248; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 82; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 98; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 114. 
     In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 217; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 233; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 249; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 83; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 99; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 115. 
     In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO:218; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 234; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 250; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 84; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 100; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 116. 
     In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 219; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 235; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 251; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 85; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 101; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 117. 
     In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 220; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 236; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 252; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 86; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 102; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 118. 
     In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 221; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 237; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 253; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 87; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 103; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 119. 
     In one embodiment, the antibody or antigen binding molecule comprises: (a) a VH CDR1 region comprising the amino acid sequence of SEQ ID NO: 222; (b) a VH CDR2 region comprising the amino acid sequence of SEQ ID NO: 238; (c) a VH CDR3 region comprising the amino acid sequence of SEQ ID NO: 254; (d) a VL CDR1 region comprising the amino acid sequence of SEQ ID NO: 88; (e) a VL CDR2 region comprising the amino acid sequence of SEQ ID NO: 104; and (f) a VL CDR3 region comprising the amino acid sequence of SEQ ID NO: 120. 
     In some embodiments, the antibody or antigen binding molecule comprises a heavy chain variable region sequence comprising an amino acid sequence of  FIG.  1 A  or  FIG.  1 B . In some embodiments, the antibody or antigen binding molecule comprises a heavy chain variable region sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 65-72. In some embodiments, the antibody or antigen binding molecule comprises a light chain variable region sequence comprising an amino acid sequence selected from  FIG.  1 C . In some embodiments, the antibody or antigen binding molecule comprises a light chain variable region sequence comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 137-144. 
     In some embodiments, the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 65; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO 137. 
     In some embodiments, the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 66; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 138. 
     In some embodiments, the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 67; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 139. 
     In some embodiments, the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 68; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 140. 
     In some embodiments, the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 69; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 141. 
     In some embodiments, the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 70; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 142. 
     In some embodiments, the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 71; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 143. 
     In some embodiments, the antibody or antigen binding molecule comprises (a) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 72; and (b) a light chain variable region comprising the amino acid sequence of SEQ ID NO: 144. 
     In one particular embodiment, the polynucleotide of the present invention comprises a nucleotide sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a nucleotide sequence selected form the group consisting of SEQ ID NOs: 57-64. In another embodiment, the polynucleotide of the present invention comprises a nucleotide sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to a nucleotide sequence selected form the group consisting of SEQ ID NOs: 129-136. 
     The antibody or antigen binding molecule encoded by the polypeptide of the present invention can be single chained or double chained. In some embodiments, the antibody or antigen binding molecule comprises is single chained. In certain embodiments, the antigen binding molecule is selected from the group consisting of an scFv, an Fab, an Fab′, an Fv, an F(ab′)2, a dAb, and any combination thereof. In one particular embodiment, the antibody or antigen binding molecule comprises an scFv. 
     In certain embodiments, the antibody or antigen binding molecule comprises a single chain, wherein the heavy chain variable region and the light chain variable region are connected by a linker. In some embodiments, the VH is located at the N terminus of the linker and the VL is located at the C terminus of the linker. In other embodiments, the VL is located at the N terminus of the linker and the VH is located at the C terminus of the linker. In some embodiments, the linker comprises at least about 5, at least about 8, at least about 10, at least about 13, at least about 15, at least about 18, at least about 20, at least about 25, at least about 30, at least about 35, at least about 40, at least about 45, at least about 50, at least about 60, at least about 70, at least about 80, at least about 90, or at least about 100 amino acids. In some embodiments, the linker comprises at least about 18 amino acids. In certain embodiments, the linker comprises an amino acid sequence that is at least about 75%, at least about 85%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the amino acid sequence GSTSGSGKPGSGEGSTKG (SEQ ID NO: 174) or a poly-Gly linker such as the amino acid sequence GGGGSGGGGSGGGGS (SEQ ID NO: 268). Or GGGGSGGGGSGGGGSGGGGS (SEQ ID NO: 411). In one embodiment, the linker is a Whitlow linker. In certain embodiments, the antibody or antigen binding molecule comprises a single chain, wherein the heavy chain variable region and the light chain variable region are connected by a linker, wherein the linker comprises the amino acid sequence of SEQ ID NO: 174. 
     In some embodiments, the antibody or antigen binding molecules of the present invention specifically bind BCMA (e.g., hBCMA). In certain embodiments, an anti-BCMA antibody or antigen binding molecule of the present invention binds human BCMA with a K D  of less than 1×10 −6  M, less than 1×10 −7  M, less than 1×10 −8 M, or less than 1×10 −9  M. In one particular embodiment, the anti-BCMA antibody or antigen binding molecules binds human BCMA with a K D  of less than 1×10 −7  M. In another embodiment, the anti-BCMA antibody or antigen binding molecules binds human BCMA with a K D  of less than 1×10 −8  M. In some embodiments, the anti-BCMA antibody or antigen binding molecules binds human BCMA with a K D  of about 1×10 −7  M, about 2×10 −7  M, about 3×10 −7  M, about 4×10 −7  M, about 5×10 −7  M, about 6×10 −7  M, about 7×10 −7  M, about 8×10 −7  M, about 9×10 −7  M, about 1×10 −8  M, about 2×10 −8  M, about 3×10 −8 M, about 4×10 −8 M, about 5×10 −8  M, about 6×10 −8  M, about 7×10 −8  M, about 8×10 −8  M, about 9×10 −8  M, about 1×10 −9 M, about 2×10 −9 M, about 3×10 −9  M, about 4×10 −9 M, about 5×10 −9  M, about 6×10 −9  M, about 7×10 −9  M, about 8×10 −9 M, about 9×10 −9 M, about 1×10 −10  M, or about 5×10 −10  M. In certain embodiments, the K D  is calculated as the quotient of k off /k on , and the k on  and k off  are determined using a monovalent antibody, such as a Fab fragment, as measured by, e.g., BIAcore® surface plasmon resonance technology. In other embodiments, the K D  is calculated as the quotient of k off /k on , and the k on  and k off  are determined using a bivalent antibody, such as a Fab fragment, as measured by, e.g., BIAcore® surface plasmon resonance technology. 
     In other embodiments, the anti-BCMA antibody or antigen binding molecule binds human BCMA-Fc with a K D  of less than 1×10 −9 M, less than 3×10 −9 M, less than 5×10 −9 M, less than 1×10 −10 M, less than 3×10 −10 M, or less than 5×10 −10 M. In other embodiments, the anti-BCMA antibody or antigen binding molecules binds cyno BCMA-Fc with a K D  of less than 1×10 −5 M, less than 1×10 −6  M, less than 1×10 −7 M, less than 1×10 −8  M, less than 1×10 −9 M, or less than 1×10 −10  M. 
     In some embodiments, the anti-BCMA antibody or antigen binding molecule binds human BCMA with an association rate (k on ) of less than 1×10 −4 M −1  s −1 , less than 2×10 −4 M −1  s −1 , less than 3×10 −4  M −1  s −1 , less than 4×10 −4 M −1  s −1 , less than 5×10 −4 M −1  s −1 , less than 6×10 −4  M −1  s −1 , less than 7×10 −4  M −1  s −1 , less than 8×10 −4 M −1  s −1 , less than 9×10 −4  M −1  s −1 , less than 1×10 −5 M −1  s −1 , less than 2×10 −5  M −1  s −1 , less than 3×10 −5 M −1  s −1 , less than 4×10 −5  M −1  s −1 , less than 5×10 −5  M −1  s −1 , less than 6×10 −5 M −1  s −1 , less than 7×10 −5 M −1  s −1 , less than 8×10 −5  M −1  s −1 , less than 9×10 −5  M −1  s −1 , less than 1×10 −6 M −1  s −1 , less than 2×10 −6  M −1  s −1 , less than 3×10 −6 M −1  s −1 , less than 4×10 −6  M −1  s −1 , less than 5×10 −6 M −1  s −1 , less than 6×10 −6  M −1  s −1 , less than 7×10 −6  M −1  s −1 , less than 8×10 −6 M −1  s −1 , less than 9×10 −6 M −1  s −1 , or less than 1×10 −7 M −1 s −1 . In certain embodiments, the k on  is determined using a monovalent antibody, such as a Fab fragment, as measured by, e.g., BIAcore® surface plasmon resonance technology. In other embodiments, the k on  is determined using a bivalent antibody as measured by, e.g., BIAcore® surface plasmon resonance technology. 
     In some embodiments, the anti-BCMA antibody or antigen binding molecule binds human BCMA with an dissociation rate (k off ) of less than 1×10 −2  s −1 , less than 2×10 −2  s −1 , less than 3×10 −2  s −1 , less than 4×10 −2  s −1 , less than 5×10 −2  s −1 , less than 6×10 −2  s −1 , less than 7×10 −2  s −1 , less than 8×10 −2  s −1 , less than 9×10 −2  s −1 , less than 1×10 −3  s −1 , less than 2×10 −3  s −1 , less than 3×10 −3  s −1 , less than 4×10 −3  s −1 , less than 5×10 −3  s −1 , less than 6×10 −3  s −1 , less than 7×10 −3  s −1 , less than 8×10 −3  s −1 , less than 9×10 −3  s −1 , less than 1×10 −4  s −1 , less than 2×10 −4  s −1 , less than 3×10 −4  s −1 , less than 4×10 −4  s −1 , less than 5×10 −4 s −1 , less than 6×10 −4  s −1 , less than 7×10 −4  s −1 , less than 8×10 −4  s −1 , less than 9×10 −4  s −1 , less than 1×10 −4  s −1 , or less than 5×10 −4  s −1 . In certain embodiments, the k off  is determined using a monovalent antibody, such as a Fab fragment, as measured by, e.g., BIAcore® surface plasmon resonance technology. In other embodiments, the k off  is determined using a bivalent antibody as measured by, e.g., BIAcore® surface plasmon resonance technology. 
     In some embodiments, the polynucleotide of the present invention encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule cross competes with a reference antibody disclosed herein. In certain embodiments, the antibody or antigen binding molecule cross competes with a reference antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-56, 65-128, and 137-144. In some embodiments, the antibody or antigen binding molecule cross competes with a reference antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 65-72 and 137-144. In certain embodiments, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VH CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 9-16. In certain embodiments, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VH CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 25-32. In certain embodiments, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VH CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 41-48. In some embodiments, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VL CDR1 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 89-96. In certain embodiments, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VL CDR2 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 105-112. In certain embodiments, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VL CDR3 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 121-128. In one embodiment, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VH comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 65-72. In another embodiment, the antibody or antigen binding molecule cross competes with a reference antibody, wherein the reference antibody comprises a VL comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 137-144. 
     In some embodiments, the polynucleotide of the present invention encodes an antibody or antigen binding molecule that specifically binds to BCMA, wherein the antibody or antigen binding molecule binds the same or an overlapping epitope as a reference antibody disclosed herein (e.g.,  FIG.  1   ). In certain embodiments, the antibody or antigen binding molecule binds the same or an overlapping epitope as a reference antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-56, 65-128, and 137-144. In some embodiments, the antibody or antigen binding molecule binds the same or an overlapping epitope as a reference antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 65-72 and 137-144. 
     III. Polynucleotides Encoding Chimeric Antigen Receptors and T Cell Receptors 
     The present invention is also directed to polynucleotides encoding chimeric antigen receptors (CARs) or T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to BCMA described in Section II, and engineered T cells comprising an antigen binding molecule that specifically binds to BCMA described in Section II. In some embodiments, an anti-BCMA CAR or TCR encoded by the polynucleotide of the present invention comprises an antigen binding molecule that specifically binds to BCMA. In some embodiments, the anti-BCMA CAR or TCR encoded by the polynucleotide further comprises a costimulatory domain. In some embodiments, the costimulatory domain in the anti-BCMA CAR or TCR encoded by the polynucleotide comprises an extracellular domain (i.e., a hinge region), a transmembrane domain, and/or an intracellular (signaling) domain. In some embodiments, the anti-BCMA CAR or TCR encoded by the polynucleotide further comprises a CD3 zeta activating domain. In one particular embodiment, the anti-BCMA CAR or TCR encoded by the polynucleotide comprises an antigen binding molecule that specifically binds BCMA (e.g., hBCMA), a costimulatory domain comprising an extracellular domain, a transmembrane domain, and an intracellular domain, and a CD3 zeta activating domain. 
     In some embodiments, the polynucleotide of the present invention encodes a TCR, wherein the TCR comprises an antigen binding molecule that specifically binds to BCMA, and wherein the TCR further comprises a fourth complementarity determining region (CDR4). In certain embodiments, the polynucleotide encodes a TCR, wherein the TCR comprises an antigen binding molecule that specifically binds to BCMA, and a constant region. In some embodiments, the constant region is selected from a constant region of IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, and IgM. 
     III.A. Costimulatory Domain 
     In some embodiments, the polynucleotide of the present invention encodes a CAR, wherein the CAR comprises an antigen binding molecule that specifically binds to BCMA (one or more antigen binding molecules in Section II), and wherein the CAR further comprises a costimulatory domain. In some embodiments, the costimulatory domain is positioned between the antigen binding molecule and an activating domain. In certain embodiments, the costimulatory domain can comprise an extracellular domain, a transmembrane domain, and an intracellular signaling domain. 
     Extracellular Domain: In one embodiment, the extracellular domain comprises a hinge region (e.g., a spacer region). In another embodiment, the extracellular domain is from or derived from (e.g., comprises) CD28, CD28T, OX40, 4-1BB/CD137, CD2, CD3 (alpha, beta, delta, epsilon, gamma, zeta), CD4, CD5, CD7, CD8, CD9, CD16, CD22, CD27, CD30, CD 33, CD37, CD40, CD 45, CD64, CD80, CD86, CD134, CD137, CD154, programmed death-1 (PD-1), ICOS, April, BAFF, lymphocyte function-associated antigen-1 (LFA-1 (CD11a/CD18), CD247, CD276 (B7-H3), LIGHT (tumor necrosis factor superfamily member 14; TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class I molecule, TNFγ, integrin, signaling lymphocytic activation molecule, BTLA, Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, CD83 ligand, or fragments or combinations thereof. The extracellular domain can be derived either from a natural or from a synthetic source. 
     In some embodiments, the extracellular domain in the costimulatory domain is positioned between the antigen binding molecule and the transmembrane domain. In certain embodiments, the extracellular domain in the costimulatory domain is from or derived from an immunoglobulin. In some embodiments, the extracellular domain in the costimulatory domain is selected from the hinge regions of IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, and IgM, or a fragment thereof. In other embodiments, the extracellular domain in the costimulatory domain is from or derived from the hinge region of CD8 alpha. In one particular embodiment, the extracellular domain in the costimulatory domain is from or derived from the hinge region of CD28. In certain embodiments, the extracellular domain in the costimulatory domain comprises a fragment of the hinge region of CD8 alpha or a fragment of the hinge region of CD28, wherein the fragment is anything less than the whole hinge region. In some embodiments, the fragment of the CD8 alpha hinge region or the fragment of the CD28 hinge region comprises an amino acid sequence that excludes at least 1, at least 2, at least 3, at least 4, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 16, at least 17, at least 18, at least 19, or at least 20 amino acids at the N-terminus or C-Terminus, or both, of the CD8 alpha hinge region of the CD28 hinge region. 
     In certain embodiments, the extracellular domain in the costimulatory domain comprises an amino acid sequence that is at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the amino acid sequence LDNEKSNGTIIHVKGKHLCPSPLFPGPSKP (SEQ ID NO: 167) or a fragment thereof. In some embodiments, the extracellular domain in the costimulatory domain comprises the amino acid sequence of SEQ ID NO: 167 or a fragment thereof. 
     In certain embodiments, the extracellular domain in the costimulatory domain is encoded by a nucleotide sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the nucleotide sequence CTTGATAATGAAAAGTCAAACGGAACAATCATT CACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCA (SEQ ID NO: 166) or a fragment thereof. In some embodiments, the extracellular domain in the costimulatory domain is encoded by a nucleotide sequence that comprises the nucleotide sequence of SEQ ID NO: 166 or a fragment thereof. 
     In some embodiments, the CD28T domain is derived from a human CD28 hinge region. In other embodiments, the CD28T domain is derived from a rodent, murine, or primate (e.g., non-human primate) CD28 hinge region. In some embodiments, the CD28T domain is derived from a chimeric CD28 hinge region. 
     In some embodiments, the extracellular domain comprises some or all of a member of the immunoglobulin family such as IgG1, IgG2, IgG3, IgG4, IgA, IgD, IgE, IgM, or fragment thereof. 
     Transmembrane Domain: The costimulatory domain for the CAR or TCR of the invention can further comprise a transmembrane domain. The transmembrane domain can be designed to be fused to the extracellular domain in the costimulatory domain. It can similarly be fused to the intracellular domain in the costimulatory domain. In one embodiment, the transmembrane domain that naturally is associated with one of the domains in a CAR is used. In some instances, the transmembrane domain can be selected or modified by amino acid substitution to avoid binding of such domains to the transmembrane domains of the same or different surface membrane proteins to minimize interactions with other members of the receptor complex. The transmembrane domain may be derived either from a natural or from a synthetic source. Where the source is natural, the domain can be derived from any membrane-bound or transmembrane protein. In some embodiments, the transmembrane domain is derived from CD28, OX-40, 4-1BB/CD137, CD2, CD3 (alpha, beta, delta, epsilon, zeta), CD4, CD5, CD7, CD8, CD9, CD16, CD22, CD27, CD30, CD 33, CD37, CD40, CD 45, CD64, CD80, CD86, CD134, CD137, CD154, programmed death-1 (PD-1), ICOS, lymphocyte function-associated antigen-1 (LFA-1 (CD11a/CD18), CD3 gamma, CD247, CD276 (B7-H3), LIGHT (tumor necrosis factor superfamily member 14; TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class I molecule, TNFγ, integrin, signaling lymphocytic activation molecule, BTLA, Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, CD83 ligand, or a fragment thereof. 
     Optionally, a short oligo or polypeptide linker, preferably between 2 and 10 amino acids in length may form the linkage between the transmembrane domain and the cytoplasmic signaling domain of the CAR. A glycine-serine doublet provides a particularly suitable linker. 
     In one embodiment, the transmembrane domain in the CAR of the invention comprises the CD8 transmembrane domain. In one embodiment, the CD8 transmembrane domain comprises the transmembrane portion of the nucleic acid sequence of GCTGCAGCATTGAGCAACTCAATAATGTATTTTAGTCACTTTGTACCAGTGTTCTTGCCGGC TAAGCCTACTACCACACCCGCTCCACGGCCACCTACCCCAGCTCCTACCATCGCTTCACAGC CTCTGTCCCTGCGCCCAGAGGCTTGCCGACCGGCCGCAGGGGGCGCTGTTCATACCAGAGGA CTGGATTTCGCCTGCGATATCTATATCTGGGCACCCCTGGCCGGAACCTGCGGCGTACTCCT GCTGTCCCTGGTCATCACGCTCTATTGTAATCACAGGAAC (SEQ ID NO: 269). In one embodiment, the CD8 transmembrane domain comprises the nucleic acid sequence that encodes the transmembrane amino acid sequence contained within 
     
       
         
           
               
            
               
                 (SEQ ID NO: 270) 
               
               
                 AAALSNSIMYFSHEVPVFLPAKPTTTPAPRPPTPAPTIASQPLSLRPEA 
               
               
                 CRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYCNHRN. 
               
            
           
         
       
     
     In another embodiment, the transmembrane domain in the costimulating domain is a CD28 transmembrane domain. In some embodiments, the transmembrane domain comprises an amino acid sequence that is at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the amino acid sequence FWVLVVVGGVLACYSLLVTVAFIIFWV (SEQ ID NO: 169). In some embodiments, the transmembrane domain comprises the amino acid sequence of SEQ ID NO: 169. 
     In some embodiments, the transmembrane domain is encoded by a nucleotide sequence at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the nucleotide sequence TTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGC TTTTATAATCTTCTGGGTT (SEQ ID NO: 168). In some embodiments, the transmembrane domain is encoded by a nucleotide sequence that comprises the nucleotide sequence of SEQ ID NO: 168. 
     Intracellular (signaling) Domain: The intracellular (signaling) domain of the engineered T cells of the invention can provide signaling to an activating domain, which then activates at least one of the normal effector functions of the immune cell. Effector function of a T cell, for example, can be cytolytic activity or helper activity including the secretion of cytokines. 
     In certain embodiments, suitable intracellular signaling domain include (i.e., comprise), but are not limited to CD28, CD28T, OX-40, 4-1BB/CD137, CD2, CD7, CD27, CD30, CD40, programmed death-1 (PD-1), inducible T cell costimulator (ICOS), lymphocyte function-associated antigen-1 (LFA-1, CD11a/CD18), CD3 gamma, CD3 delta, CD3 epsilon, CD247, CD276 (B7-H3), LIGHT, (TNFSF14), NKG2C, Ig alpha (CD79a), DAP-10, Fc gamma receptor, MHC class 1 molecule, TNF receptor proteins, an Immunoglobulin protein, cytokine receptor, integrins, Signaling Lymphocytic Activation Molecules (SLAM proteins), activating NK cell receptors, BTLA, a Toll ligand receptor, ICAM-1, B7-H3, CDS, ICAM-1, GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL-2R beta, IL-2R gamma, IL-7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, LFA-1, ITGB7, NKG2D, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRT AM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, a ligand that specifically binds with CD83, or any combination thereof. 
     An example of a nucleotide sequence encoding the intracellular signaling domain is set forth in SEQ ID NO. 170: 
     
       
         
           
               
            
               
                 AGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTC 
               
               
                 CACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACC 
               
               
                 TAGAGATTTCGCTGCCTATCGGAGC. 
               
            
           
         
       
     
     In one embodiment, the polynucleotide encoding an intracellular signaling domain within a costimulatory domain comprises a nucleotide sequence at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the nucleotide sequence of SEQ ID NO: 170. 
     An example of an intracellular signaling domain is set forth in SEQ ID NO. 171: 
     
       
         
           
               
               
            
               
                   
                 RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS 
               
            
           
         
       
     
     In one particular embodiment, the intracellular signaling domain within a costimulatory domain comprises an amino acid sequence at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence of SEQ ID NO: 171. 
     The intracellular signaling sequences within the CAR of the invention can be linked to each other or to an activating domain in a random or specified order. Optionally, a short oligo- or polypeptide linker, preferably between 2 and 10 amino acids in length may form the linkage. A glycine-serine doublet provides a particularly suitable linker. 
     It will further be appreciated that where desired, the costimulatory regions described herein can be expressed in a separate chain from the antigen binding molecule (e.g., scFv) and activating domains, in so-called “trans” configuration. 
     III.B Activating Domain 
     In some embodiments, intracellular domains for use in the engineered T cell of the invention include cytoplasmic sequences of the T cell receptor (TCR) and co-receptors that act in concert to initiate signal transduction following antigen/receptor engagement, as well as any derivative or variant of these sequences and any synthetic sequence that has the same functional capability. CD3 is an element of the T cell receptor on native T cells, and has been shown to be an important intracellular activating element in CARs. In one embodiment, the activating domain is CD3, e.g., CD3 zeta, the nucleotide sequence of which is set forth in SEQ ID NO. 172: 
     
       
         
           
               
            
               
                 AGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCC 
               
               
                   
               
               
                 AGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGA 
               
               
                   
               
               
                 CGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCA 
               
               
                   
               
               
                 AGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATA 
               
               
                   
               
               
                 AGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAG 
               
               
                   
               
               
                 GGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAG 
               
               
                   
               
               
                 GATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. 
               
            
           
         
       
     
     In some embodiments, the polynucleotide encoding an activating domain comprises a nucleotide sequence at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the nucleotide sequence of SEQ ID NO: 172. 
     The corresponding amino acid of intracellular CD3 zeta is set forth in SEQ ID NO. 173: 
     
       
         
           
               
            
               
                 RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKP 
               
               
                 RRKNPQEGLYNELQK  
               
               
                 DKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR. 
               
            
           
         
       
     
     In some embodiments, the activating domain comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence of SEQ ID NO: 173. 
     Additionally, in certain embodiments the activating domain comprises an amino acid sequence at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to the amino acid sequence of a CD3 zeta variant as set forth in SEQ ID NO: 412: 
     
       
         
           
               
            
               
                 RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKP 
               
               
                 RRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATK 
               
               
                 DTYDALHMQALPPR. 
               
            
           
         
       
     
     III.C. Leader Peptide 
     In some embodiments, the polynucleotide of the present invention encodes a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, and wherein the CAR or the TCR further comprises a leader peptide (also referred to herein as a “signal peptide”). In certain embodiments, the leader peptide comprises an amino acid sequence that is at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to the amino acid sequence MALPVTALLLPLALLLHAARP (SEQ ID NO: 165). In some embodiments, the signal peptide comprises the amino acid sequence of SEQ ID NO: 165. In some embodiments, the leader peptide is encoded by a nucleotide sequence at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or about 100% identical to SEQ ID NO: 164. 
     In some embodiments, the polynucleotide of the present invention encodes a CAR, wherein the CAR comprises a leader peptide (P), an antigen binding molecule (B), a hinge domain (H), a transmembrane domain (T), a costimulatory region (C), and an activation domain (A), wherein the CAR is configured according to the following: P-B-H-T-C-A. In some embodiments, the antigen binding molecule comprises a VH and a VL, wherein the CAR is configured according to the following: P-VH-VL-H-T-C-A or P-VL-VH-H-T-C-A. In some embodiments, the VH and the VL are connected by a linker (L), wherein the anti-BCMA CAR is configured according to the following, from N-terminus to C-terminus: P-VH-L-VL-H-T-C-A or P-VH-L-VL-H-T-C-A. 
     In some embodiments, the polynucleotide of the present invention encodes a CAR, wherein the CAR comprises an amino acid sequence at least about 75%, at least about 85%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from Table 2. In certain embodiments, the polynucleotide of the present invention encodes a CAR, wherein the CAR comprises an amino acid sequence selected from Table 2. 
     
       
         
           
               
             
               
                 TABLE 2 
               
             
            
               
                   
               
               
                 Example CAR Sequences 
               
            
           
           
               
               
               
               
               
            
               
                   
                   
                 SEQ 
                   
                 SEQ 
               
               
                 Anti- 
                   
                 ID 
                   
                 ID 
               
               
                 BCMA CAR 
                 Nucleotide Sequence 
                 NO: 
                 Amino Acid Sequence 
                 NO: 
               
               
                   
               
               
                 FS- 
                 ATGGCACTCCCCGTAACTGCTCTGCTGC 
                 175 
                 MALPVTALLLPLALLLHAARP 
                 176 
               
               
                 21495CAR 
                 TGCCGTTGGCATTGCTCCTGCACGCCGC 
                   
                 EVQLLESGGGLVQPGGSLRLS 
                   
               
               
                 HxL 
                 ACGCCCGGAGGTGCAGCTGTTGGAGTCT 
                   
                 CAASGFTFSSYAMSWVRQAPG 
                   
               
               
                   
                 GGGGGAGGCTTGGTACAGCCTGGGGGGT 
                   
                 KGLEWVSAISGSGGSTYYADS 
                   
               
               
                   
                 CCCTGAGACTCTCCTGTGCAGCCTCTGG 
                   
                 VKGRFTISRDNSKNTLYLQMN 
                   
               
               
                   
                 ATTCACCTTTAGCAGCTATGCCATGAGC 
                   
                 SLRAEDTAVYYCARAEMGAVF 
                   
               
               
                   
                 TGGGTCCGCCAGGCTCCAGGGAAGGGGC 
                   
                 DIWGQGTMVTVSSGSTSGSGK 
                   
               
               
                   
                 TGGAGTGGGTCTCAGCTATTAGTGGTAG 
                   
                 PGSGEGSTKGEIVLTQSPATL 
                   
               
               
                   
                 TGGTGGTAGCACATACTACGCAGACTCC 
                   
                 SLSPGERATLSCRASQSVSRY 
                   
               
               
                   
                 GTGAAGGGCCGGTTCACCATCTCCAGAG 
                   
                 LAWYQQKPGQAPRLLIYDASN 
                   
               
               
                   
                 ACAATTCCAAGAACACGCTGTATCTGCA 
                   
                 RATGIPARFSGSGSGTDFTLT 
                   
               
               
                   
                 AATGAACAGCCTGAGAGCCGAGGACACG 
                   
                 ISSLEPEDFAVYYCQQRISWP 
                   
               
               
                   
                 GCGGTGTACTACTGCGCAAGAGCCGAGA 
                   
                 FTFGGGTKVEIKRAAALDNEK 
                   
               
               
                   
                 TGGGAGCCGTATTCGACATATGGGGTCA 
                   
                 SNGTIIHVKGKHLCPSPLFPG 
                   
               
               
                   
                 GGGTACAATGGTCACCGTCTCCTCAGGG 
                   
                 PSKPFWVLVVVGGVLACYSLL 
                   
               
               
                   
                 TCTACATCCGGCTCCGGGAAGCCCGGAA 
                   
                 VTVAFIIFWVRSKRSRLLHSD 
                   
               
               
                   
                 GTGGCGAAGGTAGTACAAAGGGGGAAAT 
                   
                 YMNMTPRRPGPTRKHYQPYAP 
                   
               
               
                   
                 TGTGTTGACACAGTCTCCAGCCACCCTG 
                   
                 PRDFAAYRSRVKFSRSADAPA 
                   
               
               
                   
                 TCTTTGTCTCCAGGGGAAAGAGCCACCC 
                   
                 YQQGQNQLYNELNLGRREEYD 
                   
               
               
                   
                 TCTCCTGCAGGGCCAGTCAGAGTGTTAG 
                   
                 VLDKRRGRDPEMGGKPRRKNP 
                   
               
               
                   
                 CAGGTACTTAGCCTGGTACCAACAGAAA 
                   
                 QEGLYNELQKDKMAEAYSEIG 
                   
               
               
                   
                 CCTGGCCAGGCTCCCAGGCTCCTCATCT 
                   
                 MKGERRRGKGHDGLYQGLSTA 
                   
               
               
                   
                 ATGATGCATCCAACAGGGCCACTGGCAT 
                   
                 TKDTYDALHMQALPPR 
                   
               
               
                   
                 CCCAGCCAGGTTCAGTGGCAGTGGGTCT 
                   
                   
                   
               
               
                   
                 GGGACAGACTTCACTCTCACCATCAGCA 
                   
                   
                   
               
               
                   
                 GCCTAGAGCCTGAAGATTTTGCAGTTTA 
                   
                   
                   
               
               
                   
                 TTACTGTCAGCAGAGAATCTCCTGGCCT 
                   
                   
                   
               
               
                   
                 TTCACTTTTGGCGGAGGGACCAAGGTTG 
                   
                   
                   
               
               
                   
                 AGATCAAACGGGCCGCTGCCCTTGATAA 
                   
                   
                   
               
               
                   
                 TGAAAAGTCAAACGGAACAATCATTCAC 
                   
                   
                   
               
               
                   
                 GTGAAGGGCAAGCACCTCTGTCCGTCAC 
                   
                   
                   
               
               
                   
                 CCTTGTTCCCTGGTCCATCCAAGCCATT 
                   
                   
                   
               
               
                   
                 CTGGGTGTTGGTCGTAGTGGGTGGAGTC 
                   
                   
                   
               
               
                   
                 CTCGCTTGTTACTCTCTGCTCGTCACCG 
                   
                   
                   
               
               
                   
                 TGGCTTTTATAATCTTCTGGGTTAGATC 
                   
                   
                   
               
               
                   
                 CAAAAGAAGCCGCCTGCTCCATAGCGAT 
                   
                   
                   
               
               
                   
                 TACATGAATATGACTCCACGCCGCCCTG 
                   
                   
                   
               
               
                   
                 GCCCCACAAGGAAACACTACCAGCCTTA 
                   
                   
                   
               
               
                   
                 CGCACCACCTAGAGATTTCGCTGCCTAT 
                   
                   
                   
               
               
                   
                 CGGAGCAGGGTGAAGTTTTCCAGATCTG 
                   
                   
                   
               
               
                   
                 CAGATGCACCAGCGTATCAGCAGGGCCA 
                   
                   
                   
               
               
                   
                 GAACCAACTGTATAACGAGCTCAACCTG 
                   
                   
                   
               
               
                   
                 GGACGCAGGGAAGAGTATGACGTTTTGG 
                   
                   
                   
               
               
                   
                 ACAAGCGCAGAGGACGGGACCCTGAGAT 
                   
                   
                   
               
               
                   
                 GGGTGGCAAACCAAGACGAAAAAACCCC 
                   
                   
                   
               
               
                   
                 CAGGAGGGTCTCTATAATGAGCTGCAGA 
                   
                   
                   
               
               
                   
                 AGGATAAGATGGCTGAAGCCTATTCTGA 
                   
                   
                   
               
               
                   
                 AATAGGCATGAAAGGAGAGCGGAGAAGG 
                   
                   
                   
               
               
                   
                 GGAAAAGGGCACGACGGTTTGTACCAGG 
                   
                   
                   
               
               
                   
                 GACTCAGCACTGCTACGAAGGATACTTA 
                   
                   
                   
               
               
                   
                 TGACGCTCTCCACATGCAAGCCCTGCCA 
                   
                   
                   
               
               
                   
                 CCTAGGTAA 
                   
                   
                   
               
               
                   
               
               
                 FS- 
                 ATGGCACTCCCCGTAACTGCTCTGCTGC 
                 177 
                 MALPVTALLLPLALLLHAARP 
                 178 
               
               
                 21495CAR 
                 TGCCGTTGGCATTGCTCCTGCACGCCGC 
                   
                 EIVLTQSPATLSLSPGERATL 
                   
               
               
                 LxH 
                 ACGCCCGGAAATTGTGTTGACACAGTCT 
                   
                 SCRASQSVSRYLAWYQQKPGQ 
                   
               
               
                   
                 CCAGCCACCCTGTCTTTGTCTCCAGGGG 
                   
                 APRLLIYDASNRATGIPARES 
                   
               
               
                   
                 AAAGAGCCACCCTCTCCTGCAGGGCCAG 
                   
                 GSGSGTDFTLTISSLEPEDFA 
                   
               
               
                   
                 TCAGAGTGTTAGCAGGTACTTAGCCTGG 
                   
                 VYYCQQRISWPFTFGGGTKVE 
                   
               
               
                   
                 TACCAACAGAAACCTGGCCAGGCTCCCA 
                   
                 IKRGSTSGSGKPGSGEGSTKG 
                   
               
               
                   
                 GGCTCCTCATCTATGATGCATCCAACAG 
                   
                 EVQLLESGGGLVQPGGSLRLS 
                   
               
               
                   
                 GGCCACTGGCATCCCAGCCAGGTTCAGT 
                   
                 CAASGFTFSSYAMSWVRQAPG 
                   
               
               
                   
                 GGCAGTGGGTCTGGGACAGACTTCACTC 
                   
                 KGLEWVSAISGSGGSTYYADS 
                   
               
               
                   
                 TCACCATCAGCAGCCTAGAGCCTGAAGA 
                   
                 VKGRFTISRDNSKNTLYLQMN 
                   
               
               
                   
                 TTTTGCAGTTTATTACTGTCAGCAGAGA 
                   
                 SLRAEDTAVYYCARAEMGAVF 
                   
               
               
                   
                 ATCTCCTGGCCTTTCACTTTTGGCGGAG 
                   
                 DIWGQGTMVTVSSAAALDNEK 
                   
               
               
                   
                 GGACCAAGGTTGAGATCAAACGGGGGTC 
                   
                 SNGTIIHVKGKHLCPSPLFPG 
                   
               
               
                   
                 TACATCCGGCTCCGGGAAGCCCGGAAGT 
                   
                 PSKPFWVLVVVGGVLACYSLL 
                   
               
               
                   
                 GGCGAAGGTAGTACAAAGGGGGAGGTGC 
                   
                 VTVAFIIFWVRSKRSRLLHSD 
                   
               
               
                   
                 AGCTGTTGGAGTCTGGGGGAGGCTTGGT 
                   
                 YMNMTPRRPGPTRKHYQPYAP 
                   
               
               
                   
                 ACAGCCTGGGGGGTCCCTGAGACTCTCC 
                   
                 PRDFAAYRSRVKFSRSADAPA 
                   
               
               
                   
                 TGTGCAGCCTCTGGATTCACCTTTAGCA 
                   
                 YQQGQNQLYNELNLGRREEYD 
                   
               
               
                   
                 GCTATGCCATGAGCTGGGTCCGCCAGGC 
                   
                 VLDKRRGRDPEMGGKPRRKNP 
                   
               
               
                   
                 TCCAGGGAAGGGGCTGGAGTGGGTCTCA 
                   
                 QEGLYNELQKDKMAEAYSEIG 
                   
               
               
                   
                 GCTATTAGTGGTAGTGGTGGTAGCACAT 
                   
                 MKGERRRGKGHDGLYQGLSTA 
                   
               
               
                   
                 ACTACGCAGACTCCGTGAAGGGCCGGTT 
                   
                 TKDTYDALHMQALPPR 
                   
               
               
                   
                 CACCATCTCCAGAGACAATTCCAAGAAC 
                   
                   
                   
               
               
                   
                 ACGCTGTATCTGCAAATGAACAGCCTGA 
                   
                   
                   
               
               
                   
                 GAGCCGAGGACACGGCGGTGTACTACTG 
                   
                   
                   
               
               
                   
                 CGCAAGAGCCGAGATGGGAGCCGTATTC 
                   
                   
                   
               
               
                   
                 GACATATGGGGTCAGGGTACAATGGTCA 
                   
                   
                   
               
               
                   
                 CCGTCTCCTCAGCCGCTGCCCTTGATAA 
                   
                   
                   
               
               
                   
                 TGAAAAGTCAAACGGAACAATCATTCAC 
                   
                   
                   
               
               
                   
                 GTGAAGGGCAAGCACCTCTGTCCGTCAC 
                   
                   
                   
               
               
                   
                 CCTTGTTCCCTGGTCCATCCAAGCCATT 
                   
                   
                   
               
               
                   
                 CTGGGTGTTGGTCGTAGTGGGTGGAGTC 
                   
                   
                   
               
               
                   
                 CTCGCTTGTTACTCTCTGCTCGTCACCG 
                   
                   
                   
               
               
                   
                 TGGCTTTTATAATCTTCTGGGTTAGATC 
                   
                   
                   
               
               
                   
                 CAAAAGAAGCCGCCTGCTCCATAGCGAT 
                   
                   
                   
               
               
                   
                 TACATGAATATGACTCCACGCCGCCCTG 
                   
                   
                   
               
               
                   
                 GCCCCACAAGGAAACACTACCAGCCTTA 
                   
                   
                   
               
               
                   
                 CGCACCACCTAGAGATTTCGCTGCCTAT 
                   
                   
                   
               
               
                   
                 CGGAGCAGGGTGAAGTTTTCCAGATCTG 
                   
                   
                   
               
               
                   
                 CAGATGCACCAGCGTATCAGCAGGGCCA 
                   
                   
                   
               
               
                   
                 GAACCAACTGTATAACGAGCTCAACCTG 
                   
                   
                   
               
               
                   
                 GGACGCAGGGAAGAGTATGACGTTTTGG 
                   
                   
                   
               
               
                   
                 ACAAGCGCAGAGGACGGGACCCTGAGAT 
                   
                   
                   
               
               
                   
                 GGGTGGCAAACCAAGACGAAAAAACCCC 
                   
                   
                   
               
               
                   
                 CAGGAGGGTCTCTATAATGAGCTGCAGA 
                   
                   
                   
               
               
                   
                 AGGATAAGATGGCTGAAGCCTATTCTGA 
                   
                   
                   
               
               
                   
                 AATAGGCATGAAAGGAGAGCGGAGAAGG 
                   
                   
                   
               
               
                   
                 GGAAAAGGGCACGACGGTTTGTACCAGG 
                   
                   
                   
               
               
                   
                 GACTCAGCACTGCTACGAAGGATACTTA 
                   
                   
                   
               
               
                   
                 TGACGCTCTCCACATGCAAGCCCTGCCA 
                   
                   
                   
               
               
                   
                 CCTAGGTAA 
                   
                   
                   
               
               
                   
               
               
                 PC- 
                 ATGGCACTCCCCGTAACTGCTCTGCTGC 
                 179 
                 MALPVTALLLPLALLLHAARP 
                 180 
               
               
                 21497CAR 
                 TGCCGTTGGCATTGCTCCTGCACGCCGC 
                   
                 QVQLVESGGGVVQPGRSLRLS 
                   
               
               
                 HxL 
                 ACGCCCGCAGGTGCAGCTGGTGGAGTCT 
                   
                 CAASGFTFSSYGMHWVRQAPG 
                   
               
               
                   
                 GGGGGAGGCGTGGTCCAGCCTGGGAGGT 
                   
                 KGLEWVAVISYDGSNKYYADS 
                   
               
               
                   
                 CCCTGAGACTCTCCTGTGCAGCGTCTGG 
                   
                 VKGRFTISRDNSKNTLYLQMN 
                   
               
               
                   
                 ATTCACCTTCAGTAGCTATGGCATGCAC 
                   
                 SLRAEDTAVYYCARDGTYLGG 
                   
               
               
                   
                 TGGGTCCGCCAGGCTCCAGGCAAGGGGC 
                   
                 LWYFDLWGRGTLVTVSSGSTS 
                   
               
               
                   
                 TGGAGTGGGTGGCAGTTATATCGTATGA 
                   
                 GSGKPGSGEGSTKGDIVMTQS 
                   
               
               
                   
                 TGGAAGTAATAAATACTATGCAGACTCC 
                   
                 PLSLPVTPGEPASISCRSSQS 
                   
               
               
                   
                 GTGAAGGGCCGATTCACCATCTCCAGAG 
                   
                 LLHSNGYNYLDWYLQKPGQSP 
                   
               
               
                   
                 ACAATTCCAAGAACACGCTGTATCTGCA 
                   
                 QLLIYLGSNRASGVPDRFSGS 
                   
               
               
                   
                 AATGAACAGCCTGAGAGCCGAGGACACG 
                   
                 GSGTDFTLKISRVEAEDVGVY 
                   
               
               
                   
                 GCGGTGTACTACTGCGCCAGAGACGGTA 
                   
                 YCMQGLGLPLTFGGGTKVEIK 
                   
               
               
                   
                 CTTATCTAGGTGGTCTCTGGTACTTCGA 
                   
                 RAAALDNEKSNGTIIHVKGKH 
                   
               
               
                   
                 CTTATGGGGGAGAGGTACCTTGGTCACC 
                   
                 LCPSPLFPGPSKPFWVLVVVG 
                   
               
               
                   
                 GTCTCCTCAGGGTCTACATCCGGCTCCG 
                   
                 GVLACYSLLVTVAFIIFWVRS 
                   
               
               
                   
                 GGAAGCCCGGAAGTGGCGAAGGTAGTAC 
                   
                 KRSRLLHSDYMNMTPRRPGPT 
                   
               
               
                   
                 AAAGGGGGATATTGTGATGACTCAGTCT 
                   
                 RKHYQPYAPPRDFAAYRSRVK 
                   
               
               
                   
                 CCACTCTCCCTGCCCGTCACCCCTGGAG 
                   
                 FSRSADAPAYQQGQNQLYNEL 
                   
               
               
                   
                 AGCCGGCCTCCATCTCCTGCAGGTCTAG 
                   
                 NLGRREEYDVLDKRRGRDPEM 
                   
               
               
                   
                 TCAGAGCCTCCTGCATAGTAATGGATAC 
                   
                 GGKPRRKNPQEGLYNELQKDK 
                   
               
               
                   
                 AACTATTTGGATTGGTACCTGCAGAAGC 
                   
                 MAEAYSEIGMKGERRRGKGHD 
                   
               
               
                   
                 CAGGGCAGTCTCCACAGCTCCTGATCTA 
                   
                 GLYQGLSTATKDTYDALHMQA 
                   
               
               
                   
                 TTTGGGTTCTAATCGGGCCTCCGGGGTC 
                   
                 LPPR 
                   
               
               
                   
                 CCTGACAGGTTCAGTGGCAGTGGATCAG 
                   
                   
                   
               
               
                   
                 GCACAGATTTTACACTGAAAATCAGCAG 
                   
                   
                   
               
               
                   
                 AGTGGAGGCTGAGGATGTTGGGGTTTAT 
                   
                   
                   
               
               
                   
                 TACTGCATGCAGGGACTCGGCCTCCCTC 
                   
                   
                   
               
               
                   
                 TCACTTTTGGCGGAGGGACCAAGGTTGA 
                   
                   
                   
               
               
                   
                 GATCAAACGGGCCGCTGCCCTTGATAAT 
                   
                   
                   
               
               
                   
                 GAAAAGTCAAACGGAACAATCATTCACG 
                   
                   
                   
               
               
                   
                 TGAAGGGCAAGCACCTCTGTCCGTCACC 
                   
                   
                   
               
               
                   
                 CTTGTTCCCTGGTCCATCCAAGCCATTC 
                   
                   
                   
               
               
                   
                 TGGGTGTTGGTCGTAGTGGGTGGAGTCC 
                   
                   
                   
               
               
                   
                 TCGCTTGTTACTCTCTGCTCGTCACCGT 
                   
                   
                   
               
               
                   
                 GGCTTTTATAATCTTCTGGGTTAGATCC 
                   
                   
                   
               
               
                   
                 AAAAGAAGCCGCCTGCTCCATAGCGATT 
                   
                   
                   
               
               
                   
                 ACATGAATATGACTCCACGCCGCCCTGG 
                   
                   
                   
               
               
                   
                 CCCCACAAGGAAACACTACCAGCCTTAC 
                   
                   
                   
               
               
                   
                 GCACCACCTAGAGATTTCGCTGCCTATC 
                   
                   
                   
               
               
                   
                 GGAGCAGGGTGAAGTTTTCCAGATCTGC 
                   
                   
                   
               
               
                   
                 AGATGCACCAGCGTATCAGCAGGGCCAG 
                   
                   
                   
               
               
                   
                 AACCAACTGTATAACGAGCTCAACCTGG 
                   
                   
                   
               
               
                   
                 GACGCAGGGAAGAGTATGACGTTTTGGA 
                   
                   
                   
               
               
                   
                 CAAGCGCAGAGGACGGGACCCTGAGATG 
                   
                   
                   
               
               
                   
                 GGTGGCAAACCAAGACGAAAAAACCCCC 
                   
                   
                   
               
               
                   
                 AGGAGGGTCTCTATAATGAGCTGCAGAA 
                   
                   
                   
               
               
                   
                 GGATAAGATGGCTGAAGCCTATTCTGAA 
                   
                   
                   
               
               
                   
                 ATAGGCATGAAAGGAGAGCGGAGAAGGG 
                   
                   
                   
               
               
                   
                 GAAAAGGGCACGACGGTTTGTACCAGGG 
                   
                   
                   
               
               
                   
                 ACTCAGCACTGCTACGAAGGATACTTAT 
                   
                   
                   
               
               
                   
                 GACGCTCTCCACATGCAAGCCCTGCCAC 
                   
                   
                   
               
               
                   
                 CTAGGTAA 
                   
                   
                   
               
               
                   
               
               
                 PC- 
                 ATGGCACTCCCCGTAACTGCTCTGCTGC 
                 181 
                 MALPVTALLLPLALLLHAARP 
                 182 
               
               
                 21497CAR 
                 TGCCGTTGGCATTGCTCCTGCACGCCGC 
                   
                 DIVMTQSPLSLPVTPGEPASI 
                   
               
               
                 HxL 
                 ACGCCCGGATATTGTGATGACTCAGTCT 
                   
                 SCRSSQSLLHSNGYNYLDWYL 
                   
               
               
                   
                 CCACTCTCCCTGCCCGTCACCCCTGGAG 
                   
                 QKPGQSPQLLIYLGSNRASGV 
                   
               
               
                   
                 AGCCGGCCTCCATCTCCTGCAGGTCTAG 
                   
                 PDRFSGSGSGTDFTLKISRVE 
                   
               
               
                   
                 TCAGAGCCTCCTGCATAGTAATGGATAC 
                   
                 AEDVGVYYCMQGLGLPLTFGG 
                   
               
               
                   
                 AACTATTTGGATTGGTACCTGCAGAAGC 
                   
                 GTKVEIKRGSTSGSGKPGSGE 
                   
               
               
                   
                 CAGGGCAGTCTCCACAGCTCCTGATCTA 
                   
                 GSTKGQVQLVESGGGVVQPGR 
                   
               
               
                   
                 TTTGGGTTCTAATCGGGCCTCCGGGGTC 
                   
                 SLRLSCAASGFTFSSYGMHWV 
                   
               
               
                   
                 CCTGACAGGTTCAGTGGCAGTGGATCAG 
                   
                 RQAPGKGLEWVAVISYDGSNK 
                   
               
               
                   
                 GCACAGATTTTACACTGAAAATCAGCAG 
                   
                 YYADSVKGRFTISRDNSKNTL 
                   
               
               
                   
                 AGTGGAGGCTGAGGATGTTGGGGTTTAT 
                   
                 YLQMNSLRAEDTAVYYCARDG 
                   
               
               
                   
                 TACTGCATGCAGGGACTCGGCCTCCCTC 
                   
                 TYLGGLWYFDLWGRGTLVTVS 
                   
               
               
                   
                 TCACTTTTGGCGGAGGGACCAAGGTTGA 
                   
                 SAAALDNEKSNGTIIHVKGKH 
                   
               
               
                   
                 GATCAAACGGGGGTCTACATCCGGCTCC 
                   
                 LCPSPLFPGPSKPFWVLVVVG 
                   
               
               
                   
                 GGGAAGCCCGGAAGTGGCGAAGGTAGTA 
                   
                 GVLACYSLLVTVAFIIFWVRS 
                   
               
               
                   
                 CAAAGGGGCAGGTGCAGCTGGTGGAGTC 
                   
                 KRSRLLHSDYMNMTPRRPGPT 
                   
               
               
                   
                 TGGGGGAGGCGTGGTCCAGCCTGGGAGG 
                   
                 RKHYQPYAPPRDFAAYRSRVK 
                   
               
               
                   
                 TCCCTGAGACTCTCCTGTGCAGCGTCTG 
                   
                 FSRSADAPAYQQGQNQLYNEL 
                   
               
               
                   
                 GATTCACCTTCAGTAGCTATGGCATGCA 
                   
                 NLGRREEYDVLDKRRGRDPEM 
                   
               
               
                   
                 CTGGGTCCGCCAGGCTCCAGGCAAGGGG 
                   
                 GGKPRRKNPQEGLYNELQKDK 
                   
               
               
                   
                 CTGGAGTGGGTGGCAGTTATATCGTATG 
                   
                 MAEAYSEIGMKGERRRGKGHD 
                   
               
               
                   
                 ATGGAAGTAATAAATACTATGCAGACTC 
                   
                 GLYQGLSTATKDTYDALHMQA 
                   
               
               
                   
                 CGTGAAGGGCCGATTCACCATCTCCAGA 
                   
                 LPPR 
                   
               
               
                   
                 GACAATTCCAAGAACACGCTGTATCTGC 
                   
                   
                   
               
               
                   
                 AAATGAACAGCCTGAGAGCCGAGGACAC 
                   
                   
                   
               
               
                   
                 GGCGGTGTACTACTGCGCCAGAGACGGT 
                   
                   
                   
               
               
                   
                 ACTTATCTAGGTGGTCTCTGGTACTTCG 
                   
                   
                   
               
               
                   
                 ACTTATGGGGGAGAGGTACCTTGGTCAC 
                   
                   
                   
               
               
                   
                 CGTCTCCTCAGCCGCTGCCCTTGATAAT 
                   
                   
                   
               
               
                   
                 GAAAAGTCAAACGGAACAATCATTCACG 
                   
                   
                   
               
               
                   
                 TGAAGGGCAAGCACCTCTGTCCGTCACC 
                   
                   
                   
               
               
                   
                 CTTGTTCCCTGGTCCATCCAAGCCATTC 
                   
                   
                   
               
               
                   
                 TGGGTGTTGGTCGTAGTGGGTGGAGTCC 
                   
                   
                   
               
               
                   
                 TCGCTTGTTACTCTCTGCTCGTCACCGT 
                   
                   
                   
               
               
                   
                 GGCTTTTATAATCTTCTGGGTTAGATCC 
                   
                   
                   
               
               
                   
                 AAAAGAAGCCGCCTGCTCCATAGCGATT 
                   
                   
                   
               
               
                   
                 ACATGAATATGACTCCACGCCGCCCTGG 
                   
                   
                   
               
               
                   
                 CCCCACAAGGAAACACTACCAGCCTTAC 
                   
                   
                   
               
               
                   
                 GCACCACCTAGAGATTTCGCTGCCTATC 
                   
                   
                   
               
               
                   
                 GGAGCAGGGTGAAGTTTTCCAGATCTGC 
                   
                   
                   
               
               
                   
                 AGATGCACCAGCGTATCAGCAGGGCCAG 
                   
                   
                   
               
               
                   
                 AACCAACTGTATAACGAGCTCAACCTGG 
                   
                   
                   
               
               
                   
                 GACGCAGGGAAGAGTATGACGTTTTGGA 
                   
                   
                   
               
               
                   
                 CAAGCGCAGAGGACGGGACCCTGAGATG 
                   
                   
                   
               
               
                   
                 GGTGGCAAACCAAGACGAAAAAACCCCC 
                   
                   
                   
               
               
                   
                 AGGAGGGTCTCTATAATGAGCTGCAGAA 
                   
                   
                   
               
               
                   
                 GGATAAGATGGCTGAAGCCTATTCTGAA 
                   
                   
                   
               
               
                   
                 ATAGGCATGAAAGGAGAGCGGAGAAGGG 
                   
                   
                   
               
               
                   
                 GAAAAGGGCACGACGGTTTGTACCAGGG 
                   
                   
                   
               
               
                   
                 ACTCAGCACTGCTACGAAGGATACTTAT 
                   
                   
                   
               
               
                   
                 GACGCTCTCCACATGCAAGCCCTGCCAC 
                   
                   
                   
               
               
                   
                 CTAGGTAA 
                   
                   
                   
               
               
                   
               
               
                 AJ- 
                 ATGGCACTCCCCGTAACTGCTCTGCTGC 
                 183 
                 MALPVTALLLPLALLLHAARP 
                 184 
               
               
                 21508CAR 
                 TGCCGTTGGCATTGCTCCTGCACGCCGC 
                   
                 QVQLVQSGAEVKKPGASVKVS 
                   
               
               
                 HxL 
                 ACGCCCGCAGGTGCAGCTGGTGCAGTCT 
                   
                 CKASGYTFTSYYMHWVRQAPG 
                   
               
               
                   
                 GGGGCTGAGGTGAAGAAGCCTGGGGCCT 
                   
                 QGLEWMGIINPGGGSTSYAQK 
                   
               
               
                   
                 CAGTGAAGGTTTCCTGCAAGGCATCTGG 
                   
                 FQGRVTMTRDTSTSTVYMELS 
                   
               
               
                   
                 ATACACCTTCACCAGCTACTATATGCAC 
                   
                 SLRSEDTAVYYCARESWPMDV 
                   
               
               
                   
                 TGGGTGCGACAGGCCCCTGGACAAGGGC 
                   
                 WGQGTTVTVSSGSTSGSGKPG 
                   
               
               
                   
                 TTGAGTGGATGGGAATAATCAACCCTGG 
                   
                 SGEGSTKGEIVMTQSPATLSV 
                   
               
               
                   
                 TGGTGGTAGCACAAGCTACGCACAGAAG 
                   
                 SPGERATLSCRASQSVSSNLA 
                   
               
               
                   
                 TTCCAGGGCAGAGTCACCATGACCAGGG 
                   
                 WYQQKPGQAPRLLIYGASTRA 
                   
               
               
                   
                 ACACGTCCACGAGCACAGTCTACATGGA 
                   
                 TGIPARFSGSGSGTEFTLTIS 
                   
               
               
                   
                 GCTGAGCAGCCTGAGATCTGAGGACACG 
                   
                 SLQSEDFAVYYCQQYAAYPTF 
                   
               
               
                   
                 GCGGTGTACTACTGCGCCAGAGAGAGTT 
                   
                 GGGTKVEIKRAAALDNEKSNG 
                   
               
               
                   
                 GGCCAATGGACGTATGGGGCCAGGGAAC 
                   
                 TIIHVKGKHLCPSPLFPGPSK 
                   
               
               
                   
                 AACTGTCACCGTCTCCTCAGGGTCTACA 
                   
                 PFWVLVVVGGVLACYSLLVTV 
                   
               
               
                   
                 TCCGGCTCCGGGAAGCCCGGAAGTGGCG 
                   
                 AFIIFWVRSKRSRLLHSDYMN 
                   
               
               
                   
                 AAGGTAGTACAAAGGGGGAAATAGTGAT 
                   
                 MTPRRPGPTRKHYQPYAPPRD 
                   
               
               
                   
                 GACGCAGTCTCCAGCCACCCTGTCTGTG 
                   
                 FAAYRSRVKFSRSADAPAYQQ 
                   
               
               
                   
                 TCTCCAGGGGAAAGAGCCACCCTCTCCT 
                   
                 GQNQLYNELNLGRREEYDVLD 
                   
               
               
                   
                 GCAGGGCCAGTCAGAGTGTTAGCAGCAA 
                   
                 KRRGRDPEMGGKPRRKNPQEG 
                   
               
               
                   
                 CTTAGCCTGGTACCAGCAGAAACCTGGC 
                   
                 LYNELQKDKMAEAYSEIGMKG 
                   
               
               
                   
                 CAGGCTCCCAGGCTCCTCATCTATGGTG 
                   
                 ERRRGKGHDGLYQGLSTATKD 
                   
               
               
                   
                 CATCCACCAGGGCCACTGGTATCCCAGC 
                   
                 TYDALHMQALPPR 
                   
               
               
                   
                 CAGGTTCAGTGGCAGTGGGTCTGGGACA 
                   
                   
                   
               
               
                   
                 GAGTTCACTCTCACCATCAGCAGCCTGC 
                   
                   
                   
               
               
                   
                 AGTCTGAAGATTTTGCAGTTTATTACTG 
                   
                   
                   
               
               
                   
                 TCAGCAGTACGCCGCCTACCCTACTTTT 
                   
                   
                   
               
               
                   
                 GGCGGAGGGACCAAGGTTGAGATCAAAC 
                   
                   
                   
               
               
                   
                 GGGCCGCTGCCCTTGATAATGAAAAGTC 
                   
                   
                   
               
               
                   
                 AAACGGAACAATCATTCACGTGAAGGGC 
                   
                   
                   
               
               
                   
                 AAGCACCTCTGTCCGTCACCCTTGTTCC 
                   
                   
                   
               
               
                   
                 CTGGTCCATCCAAGCCATTCTGGGTGTT 
                   
                   
                   
               
               
                   
                 GGTCGTAGTGGGTGGAGTCCTCGCTTGT 
                   
                   
                   
               
               
                   
                 TACTCTCTGCTCGTCACCGTGGCTTTTA 
                   
                   
                   
               
               
                   
                 TAATCTTCTGGGTTAGATCCAAAAGAAG 
                   
                   
                   
               
               
                   
                 CCGCCTGCTCCATAGCGATTACATGAAT 
                   
                   
                   
               
               
                   
                 ATGACTCCACGCCGCCCTGGCCCCACAA 
                   
                   
                   
               
               
                   
                 GGAAACACTACCAGCCTTACGCACCACC 
                   
                   
                   
               
               
                   
                 TAGAGATTTCGCTGCCTATCGGAGCAGG 
                   
                   
                   
               
               
                   
                 GTGAAGTTTTCCAGATCTGCAGATGCAC 
                   
                   
                   
               
               
                   
                 CAGCGTATCAGCAGGGCCAGAACCAACT 
                   
                   
                   
               
               
                   
                 GTATAACGAGCTCAACCTGGGACGCAGG 
                   
                   
                   
               
               
                   
                 GAAGAGTATGACGTTTTGGACAAGCGCA 
                   
                   
                   
               
               
                   
                 GAGGACGGGACCCTGAGATGGGTGGCAA 
                   
                   
                   
               
               
                   
                 ACCAAGACGAAAAAACCCCCAGGAGGGT 
                   
                   
                   
               
               
                   
                 CTCTATAATGAGCTGCAGAAGGATAAGA 
                   
                   
                   
               
               
                   
                 TGGCTGAAGCCTATTCTGAAATAGGCAT 
                   
                   
                   
               
               
                   
                 GAAAGGAGAGCGGAGAAGGGGAAAAGGG 
                   
                   
                   
               
               
                   
                 CACGACGGTTTGTACCAGGGACTCAGCA 
                   
                   
                   
               
               
                   
                 CTGCTACGAAGGATACTTATGACGCTCT 
                   
                   
                   
               
               
                   
                 CCACATGCAAGCCCTGCCACCTAGGTAA 
                   
                   
                   
               
               
                   
               
               
                 AJ- 
                 ATGGCACTCCCCGTAACTGCTCTGCTGC 
                 185 
                 MALPVTALLLPLALLLHAARP 
                 186 
               
               
                 21508CAR 
                 TGCCGTTGGCATTGCTCCTGCACGCCGC 
                   
                 EIVMTQSPATLSVSPGERATL 
                   
               
               
                 LxH 
                 ACGCCCGGAAATAGTGATGACGCAGTCT 
                   
                 SCRASQSVSSNLAWYQQKPGQ 
                   
               
               
                   
                 CCAGCCACCCTGTCTGTGTCTCCAGGGG 
                   
                 APRLLIYGASTRATGIPARFS 
                   
               
               
                   
                 AAAGAGCCACCCTCTCCTGCAGGGCCAG 
                   
                 GSGSGTEFTLTISSLQSEDFA 
                   
               
               
                   
                 TCAGAGTGTTAGCAGCAACTTAGCCTGG 
                   
                 VYYCQQYAAYPTFGGGTKVEI 
                   
               
               
                   
                 TACCAGCAGAAACCTGGCCAGGCTCCCA 
                   
                 KRGSTSGSGKPGSGEGSTKGQ 
                   
               
               
                   
                 GGCTCCTCATCTATGGTGCATCCACCAG 
                   
                 VQLVQSGAEVKKPGASVKVSC 
                   
               
               
                   
                 GGCCACTGGTATCCCAGCCAGGTTCAGT 
                   
                 KASGYTFTSYYMHWVRQAPGQ 
                   
               
               
                   
                 GGCAGTGGGTCTGGGACAGAGTTCACTC 
                   
                 GLEWMGIINPGGGSTSYAQKF 
                   
               
               
                   
                 TCACCATCAGCAGCCTGCAGTCTGAAGA 
                   
                 QGRVTMTRDTSTSTVYMELSS 
                   
               
               
                   
                 TTTTGCAGTTTATTACTGTCAGCAGTAC 
                   
                 LRSEDTAVYYCARESWPMDVW 
                   
               
               
                   
                 GCCGCCTACCCTACTTTTGGCGGAGGGA 
                   
                 GQGTTVTVSSAAALDNEKSNG 
                   
               
               
                   
                 CCAAGGTTGAGATCAAACGGGGGTCTAC 
                   
                 TIIHVKGKHLCPSPLFPGPSK 
                   
               
               
                   
                 ATCCGGCTCCGGGAAGCCCGGAAGTGGC 
                   
                 PFWVLVVVGGVLACYSLLVTV 
                   
               
               
                   
                 GAAGGTAGTACAAAGGGGCAGGTGCAGC 
                   
                 AFIIFWVRSKRSRLLHSDYMN 
                   
               
               
                   
                 TGGTGCAGTCTGGGGCTGAGGTGAAGAA 
                   
                 MTPRRPGPTRKHYQPYAPPRD 
                   
               
               
                   
                 GCCTGGGGCCTCAGTGAAGGTTTCCTGC 
                   
                 FAAYRSRVKFSRSADAPAYQQ 
                   
               
               
                   
                 AAGGCATCTGGATACACCTTCACCAGCT 
                   
                 GQNQLYNELNLGRREEYDVLD 
                   
               
               
                   
                 ACTATATGCACTGGGTGCGACAGGCCCC 
                   
                 KRRGRDPEMGGKPRRKNPQEG 
                   
               
               
                   
                 TGGACAAGGGCTTGAGTGGATGGGAATA 
                   
                 LYNELQKDKMAEAYSEIGMKG 
                   
               
               
                   
                 ATCAACCCTGGTGGTGGTAGCACAAGCT 
                   
                 ERRRGKGHDGLYQGLSTATKD 
                   
               
               
                   
                 ACGCACAGAAGTTCCAGGGCAGAGTCAC 
                   
                 TYDALHMQALPPR 
                   
               
               
                   
                 CATGACCAGGGACACGTCCACGAGCACA 
                   
                   
                   
               
               
                   
                 GTCTACATGGAGCTGAGCAGCCTGAGAT 
                   
                   
                   
               
               
                   
                 CTGAGGACACGGCGGTGTACTACTGCGC 
                   
                   
                   
               
               
                   
                 CAGAGAGAGTTGGCCAATGGACGTATGG 
                   
                   
                   
               
               
                   
                 GGCCAGGGAACAACTGTCACCGTCTCCT 
                   
                   
                   
               
               
                   
                 CAGCCGCTGCCCTTGATAATGAAAAGTC 
                   
                   
                   
               
               
                   
                 AAACGGAACAATCATTCACGTGAAGGGC 
                   
                   
                   
               
               
                   
                 AAGCACCTCTGTCCGTCACCCTTGTTCC 
                   
                   
                   
               
               
                   
                 CTGGTCCATCCAAGCCATTCTGGGTGTT 
                   
                   
                   
               
               
                   
                 GGTCGTAGTGGGTGGAGTCCTCGCTTGT 
                   
                   
                   
               
               
                   
                 TACTCTCTGCTCGTCACCGTGGCTTTTA 
                   
                   
                   
               
               
                   
                 TAATCTTCTGGGTTAGATCCAAAAGAAG 
                   
                   
                   
               
               
                   
                 CCGCCTGCTCCATAGCGATTACATGAAT 
                   
                   
                   
               
               
                   
                 ATGACTCCACGCCGCCCTGGCCCCACAA 
                   
                   
                   
               
               
                   
                 GGAAACACTACCAGCCTTACGCACCACC 
                   
                   
                   
               
               
                   
                 TAGAGATTTCGCTGCCTATCGGAGCAGG 
                   
                   
                   
               
               
                   
                 GTGAAGTTTTCCAGATCTGCAGATGCAC 
                   
                   
                   
               
               
                   
                 CAGCGTATCAGCAGGGCCAGAACCAACT 
                   
                   
                   
               
               
                   
                 GTATAACGAGCTCAACCTGGGACGCAGG 
                   
                   
                   
               
               
                   
                 GAAGAGTATGACGTTTTGGACAAGCGCA 
                   
                   
                   
               
               
                   
                 GAGGACGGGACCCTGAGATGGGTGGCAA 
                   
                   
                   
               
               
                   
                 ACCAAGACGAAAAAACCCCCAGGAGGGT 
                   
                   
                   
               
               
                   
                 CTCTATAATGAGCTGCAGAAGGATAAGA 
                   
                   
                   
               
               
                   
                 TGGCTGAAGCCTATTCTGAAATAGGCAT 
                   
                   
                   
               
               
                   
                 GAAAGGAGAGCGGAGAAGGGGAAAAGGG 
                   
                   
                   
               
               
                   
                 CACGACGGTTTGTACCAGGGACTCAGCA 
                   
                   
                   
               
               
                   
                 CTGCTACGAAGGATACTTATGACGCTCT 
                   
                   
                   
               
               
                   
                 CCACATGCAAGCCCTGCCACCTAGGTAA 
                   
                   
                   
               
               
                   
               
               
                 NM- 
                 ATGGCACTCCCCGTAACTGCTCTGCTGC 
                 187 
                 MALPVTALLLPLALLLHAARP 
                 188 
               
               
                 21517CAR 
                 TGCCGTTGGCATTGCTCCTGCACGCCGC 
                   
                 QLQLQESGPGLVKPSETLSLT 
                   
               
               
                 HxL 
                 ACGCCCGCAGCTGCAGCTGCAGGAGTCG 
                   
                 CTVSGGSISSSSYYWGWIRQP 
                   
               
               
                   
                 GGCCCAGGACTGGTGAAGCCTTCGGAGA 
                   
                 PGKGLEWIGSISYSGSTYYNP 
                   
               
               
                   
                 CCCTGTCCCTCACCTGCACTGTCTCTGG 
                   
                 SLKSRVTISVDTSKNQFSLKL 
                   
               
               
                   
                 TGGCTCCATCAGCAGTAGTAGTTACTAC 
                   
                 SSVTAADTAVYYCARGRGYAT 
                   
               
               
                   
                 TGGGGCTGGATCCGCCAGCCCCCAGGGA 
                   
                 SLAFDIWGQGTMVTVSSGSTS 
                   
               
               
                   
                 AGGGGCTGGAGTGGATTGGGAGTATCTC 
                   
                 GSGKPGSGEGSTKGEIVLTQS 
                   
               
               
                   
                 CTATAGTGGGAGCACCTACTACAACCCG 
                   
                 PATLSLSPGERATLSCRASQS 
                   
               
               
                   
                 TCCCTCAAGAGTCGAGTCACCATATCCG 
                   
                 VSSYLAWYQQKPGQAPRLLIY 
                   
               
               
                   
                 TAGACACGTCCAAGAACCAGTTCTCCCT 
                   
                 DASNRATGIPARFSGSGSGTD 
                   
               
               
                   
                 GAAGCTGAGTTCTGTGACCGCCGCAGAC 
                   
                 FTLTISSLEPEDFAVYYCQQR 
                   
               
               
                   
                 ACGGCGGTGTACTACTGCGCCAGAGGCA 
                   
                 HVWPPTFGGGTKVEIKRAAAL 
                   
               
               
                   
                 GGGGATATGCAACCAGCTTAGCCTTCGA 
                   
                 DNEKSNGTIIHVKGKHLCPSP 
                   
               
               
                   
                 TATCTGGGGTCAGGGTACAATGGTCACC 
                   
                 LFPGPSKPFWVLVVVGGVLAC 
                   
               
               
                   
                 GTCTCCTCAGGGTCTACATCCGGCTCCG 
                   
                 YSLLVTVAFIIFWVRSKRSRL 
                   
               
               
                   
                 GGAAGCCCGGAAGTGGCGAAGGTAGTAC 
                   
                 LHSDYMNMTPRRPGPTRKHYQ 
                   
               
               
                   
                 AAAGGGGGAAATTGTGTTGACACAGTCT 
                   
                 PYAPPRDFAAYRSRVKFSRSA 
                   
               
               
                   
                 CCAGCCACCCTGTCTTTGTCTCCAGGGG 
                   
                 DAPAYQQGQNQLYNELNLGRR 
                   
               
               
                   
                 AAAGAGCCACCCTCTCCTGCAGGGCCAG 
                   
                 EEYDVLDKRRGRDPEMGGKPR 
                   
               
               
                   
                 TCAGAGTGTTAGCAGCTACTTAGCCTGG 
                   
                 RKNPQEGLYNELQKDKMAEAY 
                   
               
               
                   
                 TACCAACAGAAACCTGGCCAGGCTCCCA 
                   
                 SEIGMKGERRRGKGHDGLYQG 
                   
               
               
                   
                 GGCTCCTCATCTATGATGCATCCAACAG 
                   
                 LSTATKDTYDALHMQALPPR 
                   
               
               
                   
                 GGCCACTGGCATCCCAGCCAGGTTCAGT 
                   
                   
                   
               
               
                   
                 GGCAGTGGGTCTGGGACAGACTTCACTC 
                   
                   
                   
               
               
                   
                 TCACCATCAGCAGCCTAGAGCCTGAAGA 
                   
                   
                   
               
               
                   
                 TTTTGCAGTTTATTACTGTCAGCAGAGA 
                   
                   
                   
               
               
                   
                 CACGTCTGGCCTCCTACTTTTGGCGGAG 
                   
                   
                   
               
               
                   
                 GGACCAAGGTTGAGATCAAACGGGCCGC 
                   
                   
                   
               
               
                   
                 TGCCCTTGATAATGAAAAGTCAAACGGA 
                   
                   
                   
               
               
                   
                 ACAATCATTCACGTGAAGGGCAAGCACC 
                   
                   
                   
               
               
                   
                 TCTGTCCGTCACCCTTGTTCCCTGGTCC 
                   
                   
                   
               
               
                   
                 ATCCAAGCCATTCTGGGTGTTGGTCGTA 
                   
                   
                   
               
               
                   
                 GTGGGTGGAGTCCTCGCTTGTTACTCTC 
                   
                   
                   
               
               
                   
                 TGCTCGTCACCGTGGCTTTTATAATCTT 
                   
                   
                   
               
               
                   
                 CTGGGTTAGATCCAAAAGAAGCCGCCTG 
                   
                   
                   
               
               
                   
                 CTCCATAGCGATTACATGAATATGACTC 
                   
                   
                   
               
               
                   
                 CACGCCGCCCTGGCCCCACAAGGAAACA 
                   
                   
                   
               
               
                   
                 CTACCAGCCTTACGCACCACCTAGAGAT 
                   
                   
                   
               
               
                   
                 TTCGCTGCCTATCGGAGCAGGGTGAAGT 
                   
                   
                   
               
               
                   
                 TTTCCAGATCTGCAGATGCACCAGCGTA 
                   
                   
                   
               
               
                   
                 TCAGCAGGGCCAGAACCAACTGTATAAC 
                   
                   
                   
               
               
                   
                 GAGCTCAACCTGGGACGCAGGGAAGAGT 
                   
                   
                   
               
               
                   
                 ATGACGTTTTGGACAAGCGCAGAGGACG 
                   
                   
                   
               
               
                   
                 GGACCCTGAGATGGGTGGCAAACCAAGA 
                   
                   
                   
               
               
                   
                 CGAAAAAACCCCCAGGAGGGTCTCTATA 
                   
                   
                   
               
               
                   
                 ATGAGCTGCAGAAGGATAAGATGGCTGA 
                   
                   
                   
               
               
                   
                 AGCCTATTCTGAAATAGGCATGAAAGGA 
                   
                   
                   
               
               
                   
                 GAGCGGAGAAGGGGAAAAGGGCACGACG 
                   
                   
                   
               
               
                   
                 GTTTGTACCAGGGACTCAGCACTGCTAC 
                   
                   
                   
               
               
                   
                 GAAGGATACTTATGACGCTCTCCACATG 
                   
                   
                   
               
               
                   
                 CAAGCCCTGCCACCTAGGTAA 
                   
                   
                   
               
               
                   
               
               
                 NM- 
                 ATGGCACTCCCCGTAACTGCTCTGCTGC 
                 189 
                 MALPVTALLLPLALLLHAARP 
                 190 
               
               
                 21517CAR 
                 TGCCGTTGGCATTGCTCCTGCACGCCGC 
                   
                 EIVLTQSPATLSLSPGERATL 
                   
               
               
                 LxH 
                 ACGCCCGGAAATTGTGTTGACACAGTCT 
                   
                 SCRASQSVSSYLAWYQQKPGQ 
                   
               
               
                   
                 CCAGCCACCCTGTCTTTGTCTCCAGGGG 
                   
                 APRLLIYDASNRATGIPARES 
                   
               
               
                   
                 AAAGAGCCACCCTCTCCTGCAGGGCCAG 
                   
                 GSGSGTDFTLTISSLEPEDFA 
                   
               
               
                   
                 TCAGAGTGTTAGCAGCTACTTAGCCTGG 
                   
                 VYYCQQRHVWPPTFGGGTKVE 
                   
               
               
                   
                 TACCAACAGAAACCTGGCCAGGCTCCCA 
                   
                 IKRGSTSGSGKPGSGEGSTKG 
                   
               
               
                   
                 GGCTCCTCATCTATGATGCATCCAACAG 
                   
                 QLQLQESGPGLVKPSETLSLT 
                   
               
               
                   
                 GGCCACTGGCATCCCAGCCAGGTTCAGT 
                   
                 CTVSGGSISSSSYYWGWIRQP 
                   
               
               
                   
                 GGCAGTGGGTCTGGGACAGACTTCACTC 
                   
                 PGKGLEWIGSISYSGSTYYNP 
                   
               
               
                   
                 TCACCATCAGCAGCCTAGAGCCTGAAGA 
                   
                 SLKSRVTISVDTSKNQFSLKL 
                   
               
               
                   
                 TTTTGCAGTTTATTACTGTCAGCAGAGA 
                   
                 SSVTAADTAVYYCARGRGYAT 
                   
               
               
                   
                 CACGTCTGGCCTCCTACTTTTGGCGGAG 
                   
                 SLAFDIWGQGTMVTVSSAAAL 
                   
               
               
                   
                 GGACCAAGGTTGAGATCAAACGGGGGTC 
                   
                 DNEKSNGTIIHVKGKHLCPSP 
                   
               
               
                   
                 TACATCCGGCTCCGGGAAGCCCGGAAGT 
                   
                 LFPGPSKPFWVLVVVGGVLAC 
                   
               
               
                   
                 GGCGAAGGTAGTACAAAGGGGCAGCTGC 
                   
                 YSLLVTVAFIIFWVRSKRSRL 
                   
               
               
                   
                 AGCTGCAGGAGTCGGGCCCAGGACTGGT 
                   
                 LHSDYMNMTPRRPGPTRKHYQ 
                   
               
               
                   
                 GAAGCCTTCGGAGACCCTGTCCCTCACC 
                   
                 PYAPPRDFAAYRSRVKFSRSA 
                   
               
               
                   
                 TGCACTGTCTCTGGTGGCTCCATCAGCA 
                   
                 DAPAYQQGQNQLYNELNLGRR 
                   
               
               
                   
                 GTAGTAGTTACTACTGGGGCTGGATCCG 
                   
                 EEYDVLDKRRGRDPEMGGKPR 
                   
               
               
                   
                 CCAGCCCCCAGGGAAGGGGCTGGAGTGG 
                   
                 RKNPQEGLYNELQKDKMAEAY 
                   
               
               
                   
                 ATTGGGAGTATCTCCTATAGTGGGAGCA 
                   
                 SEIGMKGERRRGKGHDGLYQG 
                   
               
               
                   
                 CCTACTACAACCCGTCCCTCAAGAGTCG 
                   
                 LSTATKDTYDALHMQALPPR 
                   
               
               
                   
                 AGTCACCATATCCGTAGACACGTCCAAG 
                   
                   
                   
               
               
                   
                 AACCAGTTCTCCCTGAAGCTGAGTTCTG 
                   
                   
                   
               
               
                   
                 TGACCGCCGCAGACACGGCGGTGTACTA 
                   
                   
                   
               
               
                   
                 CTGCGCCAGAGGCAGGGGATATGCAACC 
                   
                   
                   
               
               
                   
                 AGCTTAGCCTTCGATATCTGGGGTCAGG 
                   
                   
                   
               
               
                   
                 GTACAATGGTCACCGTCTCCTCAGCCGC 
                   
                   
                   
               
               
                   
                 TGCCCTTGATAATGAAAAGTCAAACGGA 
                   
                   
                   
               
               
                   
                 ACAATCATTCACGTGAAGGGCAAGCACC 
                   
                   
                   
               
               
                   
                 TCTGTCCGTCACCCTTGTTCCCTGGTCC 
                   
                   
                   
               
               
                   
                 ATCCAAGCCATTCTGGGTGTTGGTCGTA 
                   
                   
                   
               
               
                   
                 GTGGGTGGAGTCCTCGCTTGTTACTCTC 
                   
                   
                   
               
               
                   
                 TGCTCGTCACCGTGGCTTTTATAATCTT 
                   
                   
                   
               
               
                   
                 CTGGGTTAGATCCAAAAGAAGCCGCCTG 
                   
                   
                   
               
               
                   
                 CTCCATAGCGATTACATGAATATGACTC 
                   
                   
                   
               
               
                   
                 CACGCCGCCCTGGCCCCACAAGGAAACA 
                   
                   
                   
               
               
                   
                 CTACCAGCCTTACGCACCACCTAGAGAT 
                   
                   
                   
               
               
                   
                 TTCGCTGCCTATCGGAGCAGGGTGAAGT 
                   
                   
                   
               
               
                   
                 TTTCCAGATCTGCAGATGCACCAGCGTA 
                   
                   
                   
               
               
                   
                 TCAGCAGGGCCAGAACCAACTGTATAAC 
                   
                   
                   
               
               
                   
                 GAGCTCAACCTGGGACGCAGGGAAGAGT 
                   
                   
                   
               
               
                   
                 ATGACGTTTTGGACAAGCGCAGAGGACG 
                   
                   
                   
               
               
                   
                 GGACCCTGAGATGGGTGGCAAACCAAGA 
                   
                   
                   
               
               
                   
                 CGAAAAAACCCCCAGGAGGGTCTCTATA 
                   
                   
                   
               
               
                   
                 ATGAGCTGCAGAAGGATAAGATGGCTGA 
                   
                   
                   
               
               
                   
                 AGCCTATTCTGAAATAGGCATGAAAGGA 
                   
                   
                   
               
               
                   
                 GAGCGGAGAAGGGGAAAAGGGCACGACG 
                   
                   
                   
               
               
                   
                 GTTTGTACCAGGGACTCAGCACTGCTAC 
                   
                   
                   
               
               
                   
                 GAAGGATACTTATGACGCTCTCCACATG 
                   
                   
                   
               
               
                   
                 CAAGCCCTGCCACCTAGGTAA 
                   
                   
                   
               
               
                   
               
               
                 TS- 
                 ATGGCACTCCCCGTAACTGCTCTGCTGC 
                 191 
                 MALPVTALLLPLALLLHAARP 
                 192 
               
               
                 21522CAR 
                 TGCCGTTGGCATTGCTCCTGCACGCCGC 
                   
                 EVQLVESGGGLVQPGGSLRLS 
                   
               
               
                 HxL 
                 ACGCCCGGAGGTGCAGCTGGTGGAGTCT 
                   
                 CAASGFTFSSYSMNWVRQAPG 
                   
               
               
                   
                 GGGGGAGGCTTGGTACAGCCTGGGGGGT 
                   
                 KGLEWVSTISSSSSTIYYADS 
                   
               
               
                   
                 CCCTGAGACTCTCCTGTGCAGCCTCTGG 
                   
                 VKGRFTISRDNAKNSLYLQMN 
                   
               
               
                   
                 ATTCACCTTCAGTAGCTATAGCATGAAC 
                   
                 SLRAEDTAVYYCARGSQEHLI 
                   
               
               
                   
                 TGGGTCCGCCAGGCTCCAGGGAAGGGGC 
                   
                 FDYWGQGTLVTVSSGSTSGSG 
                   
               
               
                   
                 TGGAGTGGGTTTCAACCATTAGTAGTAG 
                   
                 KPGSGEGSTKGEIVLTQSPAT 
                   
               
               
                   
                 TAGTAGTACCATATACTACGCAGACTCT 
                   
                 LSLSPGERATLSCRASQSVSR 
                   
               
               
                   
                 GTGAAGGGCCGATTCACCATCTCCAGAG 
                   
                 YLAWYQQKPGQAPRLLIYDAS 
                   
               
               
                   
                 ACAATGCCAAGAACTCACTGTATCTGCA 
                   
                 NRATGIPARFSGSGSGTDFTL 
                   
               
               
                   
                 AATGAACAGCCTGAGAGCTGAGGACACG 
                   
                 TISSLEPEDFAVYYCQQRFYY 
                   
               
               
                   
                 GCGGTGTACTACTGCGCCAGAGGTTCTC 
                   
                 PWTFGGGTKVEIKRAAALDNE 
                   
               
               
                   
                 AGGAGCACCTGATTTTCGATTATTGGGG 
                   
                 KSNGTIIHVKGKHLCPSPLFP 
                   
               
               
                   
                 ACAGGGTACATTGGTCACCGTCTCCTCA 
                   
                 GPSKPFWVLVVVGGVLACYSL 
                   
               
               
                   
                 GGGTCTACATCCGGCTCCGGGAAGCCCG 
                   
                 LVTVAFIIFWVRSKRSRLLHS 
                   
               
               
                   
                 GAAGTGGCGAAGGTAGTACAAAGGGGGA 
                   
                 DYMNMTPRRPGPTRKHYQPYA 
                   
               
               
                   
                 AATTGTGTTGACACAGTCTCCAGCCACC 
                   
                 PPRDFAAYRSRVKFSRSADAP 
                   
               
               
                   
                 CTGTCTTTGTCTCCAGGGGAAAGAGCCA 
                   
                 AYQQGQNQLYNELNLGRREEY 
                   
               
               
                   
                 CCCTCTCCTGCAGGGCCAGTCAGAGTGT 
                   
                 DVLDKRRGRDPEMGGKPRRKN 
                   
               
               
                   
                 TAGCAGGTACTTAGCCTGGTACCAACAG 
                   
                 PQEGLYNELQKDKMAEAYSEI 
                   
               
               
                   
                 AAACCTGGCCAGGCTCCCAGGCTCCTCA 
                   
                 GMKGERRRGKGHDGLYQGLST 
                   
               
               
                   
                 TCTATGATGCATCCAACAGGGCCACTGG 
                   
                 ATKDTYDALHMQALPPR 
                   
               
               
                   
                 CATCCCAGCCAGGTTCAGTGGCAGTGGG 
                   
                   
                   
               
               
                   
                 TCTGGGACAGACTTCACTCTCACCATCA 
                   
                   
                   
               
               
                   
                 GCAGCCTAGAGCCTGAAGATTTTGCAGT 
                   
                   
                   
               
               
                   
                 TTATTACTGTCAGCAGAGATTCTACTAC 
                   
                   
                   
               
               
                   
                 CCTTGGACTTTTGGCGGAGGGACCAAGG 
                   
                   
                   
               
               
                   
                 TTGAGATCAAACGGGCCGCTGCCCTTGA 
                   
                   
                   
               
               
                   
                 TAATGAAAAGTCAAACGGAACAATCATT 
                   
                   
                   
               
               
                   
                 CACGTGAAGGGCAAGCACCTCTGTCCGT 
                   
                   
                   
               
               
                   
                 CACCCTTGTTCCCTGGTCCATCCAAGCC 
                   
                   
                   
               
               
                   
                 ATTCTGGGTGTTGGTCGTAGTGGGTGGA 
                   
                   
                   
               
               
                   
                 GTCCTCGCTTGTTACTCTCTGCTCGTCA 
                   
                   
                   
               
               
                   
                 CCGTGGCTTTTATAATCTTCTGGGTTAG 
                   
                   
                   
               
               
                   
                 ATCCAAAAGAAGCCGCCTGCTCCATAGC 
                   
                   
                   
               
               
                   
                 GATTACATGAATATGACTCCACGCCGCC 
                   
                   
                   
               
               
                   
                 CTGGCCCCACAAGGAAACACTACCAGCC 
                   
                   
                   
               
               
                   
                 TTACGCACCACCTAGAGATTTCGCTGCC 
                   
                   
                   
               
               
                   
                 TATCGGAGCAGGGTGAAGTTTTCCAGAT 
                   
                   
                   
               
               
                   
                 CTGCAGATGCACCAGCGTATCAGCAGGG 
                   
                   
                   
               
               
                   
                 CCAGAACCAACTGTATAACGAGCTCAAC 
                   
                   
                   
               
               
                   
                 CTGGGACGCAGGGAAGAGTATGACGTTT 
                   
                   
                   
               
               
                   
                 TGGACAAGCGCAGAGGACGGGACCCTGA 
                   
                   
                   
               
               
                   
                 GATGGGTGGCAAACCAAGACGAAAAAAC 
                   
                   
                   
               
               
                   
                 CCCCAGGAGGGTCTCTATAATGAGCTGC 
                   
                   
                   
               
               
                   
                 AGAAGGATAAGATGGCTGAAGCCTATTC 
                   
                   
                   
               
               
                   
                 TGAAATAGGCATGAAAGGAGAGCGGAGA 
                   
                   
                   
               
               
                   
                 AGGGGAAAAGGGCACGACGGTTTGTACC 
                   
                   
                   
               
               
                   
                 AGGGACTCAGCACTGCTACGAAGGATAC 
                   
                   
                   
               
               
                   
                 TTATGACGCTCTCCACATGCAAGCCCTG 
                   
                   
                   
               
               
                   
                 CCACCTAGGTAA 
                   
                   
                   
               
               
                   
               
               
                 TS- 
                 ATGGCACTCCCCGTAACTGCTCTGCTGC 
                 193 
                 MALPVTALLLPLALLLHAARP 
                 194 
               
               
                 21522CAR 
                 TGCCGTTGGCATTGCTCCTGCACGCCGC 
                   
                 EIVLTQSPATLSLSPGERATL 
                   
               
               
                 LxH 
                 ACGCCCGGAAATTGTGTTGACACAGTCT 
                   
                 SCRASQSVSRYLAWYQQKPGQ 
                   
               
               
                   
                 CCAGCCACCCTGTCTTTGTCTCCAGGGG 
                   
                 APRLLIYDASNRATGIPARES 
                   
               
               
                   
                 AAAGAGCCACCCTCTCCTGCAGGGCCAG 
                   
                 GSGSGTDFTLTISSLEPEDFA 
                   
               
               
                   
                 TCAGAGTGTTAGCAGGTACTTAGCCTGG 
                   
                 VYYCQQRFYYPWTFGGGTKVE 
                   
               
               
                   
                 TACCAACAGAAACCTGGCCAGGCTCCCA 
                   
                 IKRGSTSGSGKPGSGEGSTKG 
                   
               
               
                   
                 GGCTCCTCATCTATGATGCATCCAACAG 
                   
                 EVQLVESGGGLVQPGGSLRLS 
                   
               
               
                   
                 GGCCACTGGCATCCCAGCCAGGTTCAGT 
                   
                 CAASGFTFSSYSMNWVRQAPG 
                   
               
               
                   
                 GGCAGTGGGTCTGGGACAGACTTCACTC 
                   
                 KGLEWVSTISSSSSTIYYADS 
                   
               
               
                   
                 TCACCATCAGCAGCCTAGAGCCTGAAGA 
                   
                 VKGRFTISRDNAKNSLYLQMN 
                   
               
               
                   
                 TTTTGCAGTTTATTACTGTCAGCAGAGA 
                   
                 SLRAEDTAVYYCARGSQEHLI 
                   
               
               
                   
                 TTCTACTACCCTTGGACTTTTGGCGGAG 
                   
                 FDYWGQGTLVTVSSAAALDNE 
                   
               
               
                   
                 GGACCAAGGTTGAGATCAAACGGGGGTC 
                   
                 KSNGTIIHVKGKHLCPSPLFP 
                   
               
               
                   
                 TACATCCGGCTCCGGGAAGCCCGGAAGT 
                   
                 GPSKPFWVLVVVGGVLACYSL 
                   
               
               
                   
                 GGCGAAGGTAGTACAAAGGGGGAGGTGC 
                   
                 LVTVAFIIFWVRSKRSRLLHS 
                   
               
               
                   
                 AGCTGGTGGAGTCTGGGGGAGGCTTGGT 
                   
                 DYMNMTPRRPGPTRKHYQPYA 
                   
               
               
                   
                 ACAGCCTGGGGGGTCCCTGAGACTCTCC 
                   
                 PPRDFAAYRSRVKFSRSADAP 
                   
               
               
                   
                 TGTGCAGCCTCTGGATTCACCTTCAGTA 
                   
                 AYQQGQNQLYNELNLGRREEY 
                   
               
               
                   
                 GCTATAGCATGAACTGGGTCCGCCAGGC 
                   
                 DVLDKRRGRDPEMGGKPRRKN 
                   
               
               
                   
                 TCCAGGGAAGGGGCTGGAGTGGGTTTCA 
                   
                 PQEGLYNELQKDKMAEAYSEI 
                   
               
               
                   
                 ACCATTAGTAGTAGTAGTAGTACCATAT 
                   
                 GMKGERRRGKGHDGLYQGLST 
                   
               
               
                   
                 ACTACGCAGACTCTGTGAAGGGCCGATT 
                   
                 ATKDTYDALHMQALPPR 
                   
               
               
                   
                 CACCATCTCCAGAGACAATGCCAAGAAC 
                   
                   
                   
               
               
                   
                 TCACTGTATCTGCAAATGAACAGCCTGA 
                   
                   
                   
               
               
                   
                 GAGCTGAGGACACGGCGGTGTACTACTG 
                   
                   
                   
               
               
                   
                 CGCCAGAGGTTCTCAGGAGCACCTGATT 
                   
                   
                   
               
               
                   
                 TTCGATTATTGGGGACAGGGTACATTGG 
                   
                   
                   
               
               
                   
                 TCACCGTCTCCTCAGCCGCTGCCCTTGA 
                   
                   
                   
               
               
                   
                 TAATGAAAAGTCAAACGGAACAATCATT 
                   
                   
                   
               
               
                   
                 CACGTGAAGGGCAAGCACCTCTGTCCGT 
                   
                   
                   
               
               
                   
                 CACCCTTGTTCCCTGGTCCATCCAAGCC 
                   
                   
                   
               
               
                   
                 ATTCTGGGTGTTGGTCGTAGTGGGTGGA 
                   
                   
                   
               
               
                   
                 GTCCTCGCTTGTTACTCTCTGCTCGTCA 
                   
                   
                   
               
               
                   
                 CCGTGGCTTTTATAATCTTCTGGGTTAG 
                   
                   
                   
               
               
                   
                 ATCCAAAAGAAGCCGCCTGCTCCATAGC 
                   
                   
                   
               
               
                   
                 GATTACATGAATATGACTCCACGCCGCC 
                   
                   
                   
               
               
                   
                 CTGGCCCCACAAGGAAACACTACCAGCC 
                   
                   
                   
               
               
                   
                 TTACGCACCACCTAGAGATTTCGCTGCC 
                   
                   
                   
               
               
                   
                 TATCGGAGCAGGGTGAAGTTTTCCAGAT 
                   
                   
                   
               
               
                   
                 CTGCAGATGCACCAGCGTATCAGCAGGG 
                   
                   
                   
               
               
                   
                 CCAGAACCAACTGTATAACGAGCTCAAC 
                   
                   
                   
               
               
                   
                 CTGGGACGCAGGGAAGAGTATGACGTTT 
                   
                   
                   
               
               
                   
                 TGGACAAGCGCAGAGGACGGGACCCTGA 
                   
                   
                   
               
               
                   
                 GATGGGTGGCAAACCAAGACGAAAAAAC 
                   
                   
                   
               
               
                   
                 CCCCAGGAGGGTCTCTATAATGAGCTGC 
                   
                   
                   
               
               
                   
                 AGAAGGATAAGATGGCTGAAGCCTATTC 
                   
                   
                   
               
               
                   
                 TGAAATAGGCATGAAAGGAGAGCGGAGA 
                   
                   
                   
               
               
                   
                 AGGGGAAAAGGGCACGACGGTTTGTACC 
                   
                   
                   
               
               
                   
                 AGGGACTCAGCACTGCTACGAAGGATAC 
                   
                   
                   
               
               
                   
                 TTATGACGCTCTCCACATGCAAGCCCTG 
                   
                   
                   
               
               
                   
                 CCACCTAGGTAA 
                   
                   
                   
               
               
                   
               
               
                 RY- 
                 ATGGCACTCCCCGTAACTGCTCTGCTGC 
                 195 
                 MALPVTALLLPLALLLHAARP 
                 196 
               
               
                 21527CAR 
                 TGCCGTTGGCATTGCTCCTGCACGCCGC 
                   
                 QVQLVESGGGVVQPGRSLRLS 
                   
               
               
                 HxL 
                 ACGCCCGCAGGTGCAGCTGGTGGAGTCT 
                   
                 CAASGFTFSSYGMHWVRQAPG 
                   
               
               
                   
                 GGGGGAGGCGTGGTCCAGCCTGGGAGGT 
                   
                 KGLEWVAVISYDGSNKYYADS 
                   
               
               
                   
                 CCCTGAGACTCTCCTGTGCAGCGTCTGG 
                   
                 VKGRFTISRDNSKNTLYLQMN 
                   
               
               
                   
                 ATTCACCTTCAGTAGCTATGGCATGCAC 
                   
                 SLRAEDTAVYYCARTDFWSGS 
                   
               
               
                   
                 TGGGTCCGCCAGGCTCCAGGCAAGGGGC 
                   
                 PPGLDYWGQGTLVTVSSGSTS 
                   
               
               
                   
                 TGGAGTGGGTGGCAGTTATATCGTATGA 
                   
                 GSGKPGSGEGSTKGDIQLTQS 
                   
               
               
                   
                 TGGAAGTAATAAATACTATGCAGACTCC 
                   
                 PSSVSASVGDRVTITCRASQG 
                   
               
               
                   
                 GTGAAGGGCCGATTCACCATCTCCAGAG 
                   
                 ISSWLAWYQQKPGKAPKLLIY 
                   
               
               
                   
                 ACAATTCCAAGAACACGCTGTATCTGCA 
                   
                 GASSLQSGVPSRFSGSGSGTD 
                   
               
               
                   
                 AATGAACAGCCTGAGAGCCGAGGACACG 
                   
                 FTLTISSLQPEDFATYYCQQI 
                   
               
               
                   
                 GCGGTGTACTACTGCGCCAGAACTGACT 
                   
                 YTFPFTFGGGTKVEIKRAAAL 
                   
               
               
                   
                 TCTGGAGCGGATCCCCTCCAGGCTTAGA 
                   
                 DNEKSNGTIIHVKGKHLCPSP 
                   
               
               
                   
                 TTACTGGGGACAGGGTACATTGGTCACC 
                   
                 LFPGPSKPFWVLVVVGGVLAC 
                   
               
               
                   
                 GTCTCCTCAGGGTCTACATCCGGCTCCG 
                   
                 YSLLVTVAFIIFWVRSKRSRL 
                   
               
               
                   
                 GGAAGCCCGGAAGTGGCGAAGGTAGTAC 
                   
                 LHSDYMNMTPRRPGPTRKHYQ 
                   
               
               
                   
                 AAAGGGGGACATCCAGTTGACCCAGTCT 
                   
                 PYAPPRDFAAYRSRVKFSRSA 
                   
               
               
                   
                 CCATCTTCCGTGTCTGCATCTGTAGGAG 
                   
                 DAPAYQQGQNQLYNELNLGRR 
                   
               
               
                   
                 ACAGAGTCACCATCACTTGTCGGGCGAG 
                   
                 EEYDVLDKRRGRDPEMGGKPR 
                   
               
               
                   
                 TCAGGGTATTAGCAGCTGGTTAGCCTGG 
                   
                 RKNPQEGLYNELQKDKMAEAY 
                   
               
               
                   
                 TATCAGCAGAAACCAGGGAAAGCCCCTA 
                   
                 SEIGMKGERRRGKGHDGLYQG 
                   
               
               
                   
                 AGCTCCTGATCTATGGTGCATCCAGTTT 
                   
                 LSTATKDTYDALHMQALPPR 
                   
               
               
                   
                 GCAAAGTGGGGTCCCATCAAGGTTCAGC 
                   
                   
                   
               
               
                   
                 GGCAGTGGATCTGGGACAGATTTCACTC 
                   
                   
                   
               
               
                   
                 TCACCATCAGCAGCCTGCAGCCTGAAGA 
                   
                   
                   
               
               
                   
                 TTTTGCAACTTATTACTGTCAGCAGATA 
                   
                   
                   
               
               
                   
                 TACACCTTCCCTTTCACTTTTGGCGGAG 
                   
                   
                   
               
               
                   
                 GGACCAAGGTTGAGATCAAACGGGCCGC 
                   
                   
                   
               
               
                   
                 TGCCCTTGATAATGAAAAGTCAAACGGA 
                   
                   
                   
               
               
                   
                 ACAATCATTCACGTGAAGGGCAAGCACC 
                   
                   
                   
               
               
                   
                 TCTGTCCGTCACCCTTGTTCCCTGGTCC 
                   
                   
                   
               
               
                   
                 ATCCAAGCCATTCTGGGTGTTGGTCGTA 
                   
                   
                   
               
               
                   
                 GTGGGTGGAGTCCTCGCTTGTTACTCTC 
                   
                   
                   
               
               
                   
                 TGCTCGTCACCGTGGCTTTTATAATCTT 
                   
                   
                   
               
               
                   
                 CTGGGTTAGATCCAAAAGAAGCCGCCTG 
                   
                   
                   
               
               
                   
                 CTCCATAGCGATTACATGAATATGACTC 
                   
                   
                   
               
               
                   
                 CACGCCGCCCTGGCCCCACAAGGAAACA 
                   
                   
                   
               
               
                   
                 CTACCAGCCTTACGCACCACCTAGAGAT 
                   
                   
                   
               
               
                   
                 TTCGCTGCCTATCGGAGCAGGGTGAAGT 
                   
                   
                   
               
               
                   
                 TTTCCAGATCTGCAGATGCACCAGCGTA 
                   
                   
                   
               
               
                   
                 TCAGCAGGGCCAGAACCAACTGTATAAC 
                   
                   
                   
               
               
                   
                 GAGCTCAACCTGGGACGCAGGGAAGAGT 
                   
                   
                   
               
               
                   
                 ATGACGTTTTGGACAAGCGCAGAGGACG 
                   
                   
                   
               
               
                   
                 GGACCCTGAGATGGGTGGCAAACCAAGA 
                   
                   
                   
               
               
                   
                 CGAAAAAACCCCCAGGAGGGTCTCTATA 
                   
                   
                   
               
               
                   
                 ATGAGCTGCAGAAGGATAAGATGGCTGA 
                   
                   
                   
               
               
                   
                 AGCCTATTCTGAAATAGGCATGAAAGGA 
                   
                   
                   
               
               
                   
                 GAGCGGAGAAGGGGAAAAGGGCACGACG 
                   
                   
                   
               
               
                   
                 GTTTGTACCAGGGACTCAGCACTGCTAC 
                   
                   
                   
               
               
                   
                 GAAGGATACTTATGACGCTCTCCACATG 
                   
                   
                   
               
               
                   
                 CAAGCCCTGCCACCTAGGTAA 
                   
                   
                   
               
               
                   
               
               
                 RY- 
                 ATGGCACTCCCCGTAACTGCTCTGCTGC 
                 197 
                 MALPVTALLLPLALLLHAARP 
                 198 
               
               
                 21527CAR 
                 TGCCGTTGGCATTGCTCCTGCACGCCGC 
                   
                 DIQLTQSPSSVSASVGDRVTI 
                   
               
               
                 LxH 
                 ACGCCCGGACATCCAGTTGACCCAGTCT 
                   
                 TCRASQGISSWLAWYQQKPGK 
                   
               
               
                   
                 CCATCTTCCGTGTCTGCATCTGTAGGAG 
                   
                 APKLLIYGASSLQSGVPSRFS 
                   
               
               
                   
                 ACAGAGTCACCATCACTTGTCGGGCGAG 
                   
                 GSGSGTDFTLTISSLQPEDFA 
                   
               
               
                   
                 TCAGGGTATTAGCAGCTGGTTAGCCTGG 
                   
                 TYYCQQIYTFPFTFGGGTKVE 
                   
               
               
                   
                 TATCAGCAGAAACCAGGGAAAGCCCCTA 
                   
                 IKRGSTSGSGKPGSGEGSTKG 
                   
               
               
                   
                 AGCTCCTGATCTATGGTGCATCCAGTTT 
                   
                 QVQLVESGGGVVQPGRSLRLS 
                   
               
               
                   
                 GCAAAGTGGGGTCCCATCAAGGTTCAGC 
                   
                 CAASGFTFSSYGMHWVRQAPG 
                   
               
               
                   
                 GGCAGTGGATCTGGGACAGATTTCACTC 
                   
                 KGLEWVAVISYDGSNKYYADS 
                   
               
               
                   
                 TCACCATCAGCAGCCTGCAGCCTGAAGA 
                   
                 VKGRFTISRDNSKNTLYLQMN 
                   
               
               
                   
                 TTTTGCAACTTATTACTGTCAGCAGATA 
                   
                 SLRAEDTAVYYCARTDFWSGS 
                   
               
               
                   
                 TACACCTTCCCTTTCACTTTTGGCGGAG 
                   
                 PPGLDYWGQGTLVTVSSAAAL 
                   
               
               
                   
                 GGACCAAGGTTGAGATCAAACGGGGGTC 
                   
                 DNEKSNGTIIHVKGKHLCPSP 
                   
               
               
                   
                 TACATCCGGCTCCGGGAAGCCCGGAAGT 
                   
                 LFPGPSKPFWVLVVVGGVLAC 
                   
               
               
                   
                 GGCGAAGGTAGTACAAAGGGGCAGGTGC 
                   
                 YSLLVTVAFIIFWVRSKRSRL 
                   
               
               
                   
                 AGCTGGTGGAGTCTGGGGGAGGCGTGGT 
                   
                 LHSDYMNMTPRRPGPTRKHYQ 
                   
               
               
                   
                 CCAGCCTGGGAGGTCCCTGAGACTCTCC 
                   
                 PYAPPRDFAAYRSRVKFSRSA 
                   
               
               
                   
                 TGTGCAGCGTCTGGATTCACCTTCAGTA 
                   
                 DAPAYQQGQNQLYNELNLGRR 
                   
               
               
                   
                 GCTATGGCATGCACTGGGTCCGCCAGGC 
                   
                 EEYDVLDKRRGRDPEMGGKPR 
                   
               
               
                   
                 TCCAGGCAAGGGGCTGGAGTGGGTGGCA 
                   
                 RKNPQEGLYNELQKDKMAEAY 
                   
               
               
                   
                 GTTATATCGTATGATGGAAGTAATAAAT 
                   
                 SEIGMKGERRRGKGHDGLYQG 
                   
               
               
                   
                 ACTATGCAGACTCCGTGAAGGGCCGATT 
                   
                 LSTATKDTYDALHMQALPPR 
                   
               
               
                   
                 CACCATCTCCAGAGACAATTCCAAGAAC 
                   
                   
                   
               
               
                   
                 ACGCTGTATCTGCAAATGAACAGCCTGA 
                   
                   
                   
               
               
                   
                 GAGCCGAGGACACGGCGGTGTACTACTG 
                   
                   
                   
               
               
                   
                 CGCCAGAACTGACTTCTGGAGCGGATCC 
                   
                   
                   
               
               
                   
                 CCTCCAGGCTTAGATTACTGGGGACAGG 
                   
                   
                   
               
               
                   
                 GTACATTGGTCACCGTCTCCTCAGCCGC 
                   
                   
                   
               
               
                   
                 TGCCCTTGATAATGAAAAGTCAAACGGA 
                   
                   
                   
               
               
                   
                 ACAATCATTCACGTGAAGGGCAAGCACC 
                   
                   
                   
               
               
                   
                 TCTGTCCGTCACCCTTGTTCCCTGGTCC 
                   
                   
                   
               
               
                   
                 ATCCAAGCCATTCTGGGTGTTGGTCGTA 
                   
                   
                   
               
               
                   
                 GTGGGTGGAGTCCTCGCTTGTTACTCTC 
                   
                   
                   
               
               
                   
                 TGCTCGTCACCGTGGCTTTTATAATCTT 
                   
                   
                   
               
               
                   
                 CTGGGTTAGATCCAAAAGAAGCCGCCTG 
                   
                   
                   
               
               
                   
                 CTCCATAGCGATTACATGAATATGACTC 
                   
                   
                   
               
               
                   
                 CACGCCGCCCTGGCCCCACAAGGAAACA 
                   
                   
                   
               
               
                   
                 CTACCAGCCTTACGCACCACCTAGAGAT 
                   
                   
                   
               
               
                   
                 TTCGCTGCCTATCGGAGCAGGGTGAAGT 
                   
                   
                   
               
               
                   
                 TTTCCAGATCTGCAGATGCACCAGCGTA 
                   
                   
                   
               
               
                   
                 TCAGCAGGGCCAGAACCAACTGTATAAC 
                   
                   
                   
               
               
                   
                 GAGCTCAACCTGGGACGCAGGGAAGAGT 
                   
                   
                   
               
               
                   
                 ATGACGTTTTGGACAAGCGCAGAGGACG 
                   
                   
                   
               
               
                   
                 GGACCCTGAGATGGGTGGCAAACCAAGA 
                   
                   
                   
               
               
                   
                 CGAAAAAACCCCCAGGAGGGTCTCTATA 
                   
                   
                   
               
               
                   
                 ATGAGCTGCAGAAGGATAAGATGGCTGA 
                   
                   
                   
               
               
                   
                 AGCCTATTCTGAAATAGGCATGAAAGGA 
                   
                   
                   
               
               
                   
                 GAGCGGAGAAGGGGAAAAGGGCACGACG 
                   
                   
                   
               
               
                   
                 GTTTGTACCAGGGACTCAGCACTGCTAC 
                   
                   
                   
               
               
                   
                 GAAGGATACTTATGACGCTCTCCACATG 
                   
                   
                   
               
               
                   
                 CAAGCCCTGCCACCTAGGTAA 
                   
                   
                   
               
               
                   
               
               
                 PP- 
                 ATGGCACTCCCCGTAACTGCTCTGCTGC 
                 199 
                 MALPVTALLLPLALLLHAARP 
                 200 
               
               
                 21528CAR 
                 TGCCGTTGGCATTGCTCCTGCACGCCGC 
                   
                 QVQLVQSGAEVKKPGSSVKVS 
                   
               
               
                 HxL 
                 ACGCCCGCAGGTGCAGCTGGTGCAGTCT 
                   
                 CKASGGTFSSYAISWVRQAPG 
                   
               
               
                   
                 GGGGCTGAGGTGAAGAAGCCTGGGTCCT 
                   
                 QGLEWMGGIIPIFGTANYAQK 
                   
               
               
                   
                 CGGTGAAGGTCTCCTGCAAGGCTTCTGG 
                   
                 FQGRVTITADESTSTAYMELS 
                   
               
               
                   
                 AGGCACCTTCAGCAGCTATGCTATCAGC 
                   
                 SLRSEDTAVYYCARTPEYSSS 
                   
               
               
                   
                 TGGGTGCGACAGGCCCCTGGACAAGGGC 
                   
                 IWHYYYGMDVWGQGTTVTVSS 
                   
               
               
                   
                 TTGAGTGGATGGGAGGGATCATCCCTAT 
                   
                 GSTSGSGKPGSGEGSTKGDIV 
                   
               
               
                   
                 CTTTGGTACAGCAAACTACGCACAGAAG 
                   
                 MTQSPDSLAVSLGERATINCK 
                   
               
               
                   
                 TTCCAGGGCAGAGTCACGATTACCGCGG 
                   
                 SSQSVLYSSNNKNYLAWYQQK 
                   
               
               
                   
                 ACGAATCCACGAGCACAGCCTACATGGA 
                   
                 PGQPPKLLIYWASTRESGVPD 
                   
               
               
                   
                 GCTGAGCAGCCTGAGATCTGAGGACACG 
                   
                 RFSGSGSGTDFTLTISSLQAE 
                   
               
               
                   
                 GCGGTGTACTACTGCGCCAGAACTCCTG 
                   
                 DVAVYYCQQFAHTPFTFGGGT 
                   
               
               
                   
                 AATACTCCTCCAGCATATGGCACTATTA 
                   
                 KVEIKRAAALDNEKSNGTIIH 
                   
               
               
                   
                 CTACGGCATGGACGTATGGGGCCAGGGA 
                   
                 VKGKHLCPSPLFPGPSKPFWV 
                   
               
               
                   
                 ACAACTGTCACCGTCTCCTCAGGGTCTA 
                   
                 LVVVGGVLACYSLLVTVAFII 
                   
               
               
                   
                 CATCCGGCTCCGGGAAGCCCGGAAGTGG 
                   
                 FWVRSKRSRLLHSDYMNMTPR 
                   
               
               
                   
                 CGAAGGTAGTACAAAGGGGGACATCGTG 
                   
                 RPGPTRKHYQPYAPPRDFAAY 
                   
               
               
                   
                 ATGACCCAGTCTCCAGACTCCCTGGCTG 
                   
                 RSRVKFSRSADAPAYQQGQNQ 
                   
               
               
                   
                 TGTCTCTGGGCGAGAGGGCCACCATCAA 
                   
                 LYNELNLGRREEYDVLDKRRG 
                   
               
               
                   
                 CTGCAAGTCCAGCCAGAGTGTTTTATAC 
                   
                 RDPEMGGKPRRKNPQEGLYNE 
                   
               
               
                   
                 AGCTCCAACAATAAGAACTACTTAGCTT 
                   
                 LQKDKMAEAYSEIGMKGERRR 
                   
               
               
                   
                 GGTACCAGCAGAAACCAGGACAGCCTCC 
                   
                 GKGHDGLYQGLSTATKDTYDA 
                   
               
               
                   
                 TAAGCTGCTCATTTACTGGGCATCTACC 
                   
                 LHMQALPPR 
                   
               
               
                   
                 CGGGAATCCGGGGTCCCTGACCGATTCA 
                   
                   
                   
               
               
                   
                 GTGGCAGCGGGTCTGGGACAGATTTCAC 
                   
                   
                   
               
               
                   
                 TCTCACCATCAGCAGCCTGCAGGCTGAA 
                   
                   
                   
               
               
                   
                 GATGTGGCAGTTTATTACTGTCAGCAGT 
                   
                   
                   
               
               
                   
                 TCGCCCACACTCCTTTCACTTTTGGCGG 
                   
                   
                   
               
               
                   
                 AGGGACCAAGGTTGAGATCAAACGGGCC 
                   
                   
                   
               
               
                   
                 GCTGCCCTTGATAATGAAAAGTCAAACG 
                   
                   
                   
               
               
                   
                 GAACAATCATTCACGTGAAGGGCAAGCA 
                   
                   
                   
               
               
                   
                 CCTCTGTCCGTCACCCTTGTTCCCTGGT 
                   
                   
                   
               
               
                   
                 CCATCCAAGCCATTCTGGGTGTTGGTCG 
                   
                   
                   
               
               
                   
                 TAGTGGGTGGAGTCCTCGCTTGTTACTC 
                   
                   
                   
               
               
                   
                 TCTGCTCGTCACCGTGGCTTTTATAATC 
                   
                   
                   
               
               
                   
                 TTCTGGGTTAGATCCAAAAGAAGCCGCC 
                   
                   
                   
               
               
                   
                 TGCTCCATAGCGATTACATGAATATGAC 
                   
                   
                   
               
               
                   
                 TCCACGCCGCCCTGGCCCCACAAGGAAA 
                   
                   
                   
               
               
                   
                 CACTACCAGCCTTACGCACCACCTAGAG 
                   
                   
                   
               
               
                   
                 ATTTCGCTGCCTATCGGAGCAGGGTGAA 
                   
                   
                   
               
               
                   
                 GTTTTCCAGATCTGCAGATGCACCAGCG 
                   
                   
                   
               
               
                   
                 TATCAGCAGGGCCAGAACCAACTGTATA 
                   
                   
                   
               
               
                   
                 ACGAGCTCAACCTGGGACGCAGGGAAGA 
                   
                   
                   
               
               
                   
                 GTATGACGTTTTGGACAAGCGCAGAGGA 
                   
                   
                   
               
               
                   
                 CGGGACCCTGAGATGGGTGGCAAACCAA 
                   
                   
                   
               
               
                   
                 GACGAAAAAACCCCCAGGAGGGTCTCTA 
                   
                   
                   
               
               
                   
                 TAATGAGCTGCAGAAGGATAAGATGGCT 
                   
                   
                   
               
               
                   
                 GAAGCCTATTCTGAAATAGGCATGAAAG 
                   
                   
                   
               
               
                   
                 GAGAGCGGAGAAGGGGAAAAGGGCACGA 
                   
                   
                   
               
               
                   
                 CGGTTTGTACCAGGGACTCAGCACTGCT 
                   
                   
                   
               
               
                   
                 ACGAAGGATACTTATGACGCTCTCCACA 
                   
                   
                   
               
               
                   
                 TGCAAGCCCTGCCACCTAGGTAA 
                   
                   
                   
               
               
                   
               
               
                 PP- 
                 ATGGCACTCCCCGTAACTGCTCTGCTGC 
                 201 
                 MALPVTALLLPLALLLHAARP 
                 202 
               
               
                 21528CAR 
                 TGCCGTTGGCATTGCTCCTGCACGCCGC 
                   
                 DIVMTQSPDSLAVSLGERATI 
                   
               
               
                 LxH 
                 ACGCCCGGACATCGTGATGACCCAGTCT 
                   
                 NCKSSQSVLYSSNNKNYLAWY 
                   
               
               
                   
                 CCAGACTCCCTGGCTGTGTCTCTGGGCG 
                   
                 QQKPGQPPKLLIYWASTRESG 
                   
               
               
                   
                 AGAGGGCCACCATCAACTGCAAGTCCAG 
                   
                 VPDRFSGSGSGTDFTLTISSL 
                   
               
               
                   
                 CCAGAGTGTTTTATACAGCTCCAACAAT 
                   
                 QAEDVAVYYCQQFAHTPFTFG 
                   
               
               
                   
                 AAGAACTACTTAGCTTGGTACCAGCAGA 
                   
                 GGTKVEIKRGSTSGSGKPGSG 
                   
               
               
                   
                 AACCAGGACAGCCTCCTAAGCTGCTCAT 
                   
                 EGSTKGQVQLVQSGAEVKKPG 
                   
               
               
                   
                 TTACTGGGCATCTACCCGGGAATCCGGG 
                   
                 SSVKVSCKASGGTFSSYAISW 
                   
               
               
                   
                 GTCCCTGACCGATTCAGTGGCAGCGGGT 
                   
                 VRQAPGQGLEWMGGIIPIFGT 
                   
               
               
                   
                 CTGGGACAGATTTCACTCTCACCATCAG 
                   
                 ANYAQKFQGRVTITADESTST 
                   
               
               
                   
                 CAGCCTGCAGGCTGAAGATGTGGCAGTT 
                   
                 AYMELSSLRSEDTAVYYCART 
                   
               
               
                   
                 TATTACTGTCAGCAGTTCGCCCACACTC 
                   
                 PEYSSSIWHYYYGMDVWGQGT 
                   
               
               
                   
                 CTTTCACTTTTGGCGGAGGGACCAAGGT 
                   
                 TVTVSSAAALDNEKSNGTIIH 
                   
               
               
                   
                 TGAGATCAAACGGGGGTCTACATCCGGC 
                   
                 VKGKHLCPSPLFPGPSKPFWV 
                   
               
               
                   
                 TCCGGGAAGCCCGGAAGTGGCGAAGGTA 
                   
                 LVVVGGVLACYSLLVTVAFII 
                   
               
               
                   
                 GTACAAAGGGGCAGGTGCAGCTGGTGCA 
                   
                 FWVRSKRSRLLHSDYMNMTPR 
                   
               
               
                   
                 GTCTGGGGCTGAGGTGAAGAAGCCTGGG 
                   
                 RPGPTRKHYQPYAPPRDFAAY 
                   
               
               
                   
                 TCCTCGGTGAAGGTCTCCTGCAAGGCTT 
                   
                 RSRVKFSRSADAPAYQQGQNQ 
                   
               
               
                   
                 CTGGAGGCACCTTCAGCAGCTATGCTAT 
                   
                 LYNELNLGRREEYDVLDKRRG 
                   
               
               
                   
                 CAGCTGGGTGCGACAGGCCCCTGGACAA 
                   
                 RDPEMGGKPRRKNPQEGLYNE 
                   
               
               
                   
                 GGGCTTGAGTGGATGGGAGGGATCATCC 
                   
                 LQKDKMAEAYSEIGMKGERRR 
                   
               
               
                   
                 CTATCTTTGGTACAGCAAACTACGCACA 
                   
                 GKGHDGLYQGLSTATKDTYDA 
                   
               
               
                   
                 GAAGTTCCAGGGCAGAGTCACGATTACC 
                   
                 LHMQALPPR 
                   
               
               
                   
                 GCGGACGAATCCACGAGCACAGCCTACA 
                   
                   
                   
               
               
                   
                 TGGAGCTGAGCAGCCTGAGATCTGAGGA 
                   
                   
                   
               
               
                   
                 CACGGCGGTGTACTACTGCGCCAGAACT 
                   
                   
                   
               
               
                   
                 CCTGAATACTCCTCCAGCATATGGCACT 
                   
                   
                   
               
               
                   
                 ATTACTACGGCATGGACGTATGGGGCCA 
                   
                   
                   
               
               
                   
                 GGGAACAACTGTCACCGTCTCCTCAGCC 
                   
                   
                   
               
               
                   
                 GCTGCCCTTGATAATGAAAAGTCAAACG 
                   
                   
                   
               
               
                   
                 GAACAATCATTCACGTGAAGGGCAAGCA 
                   
                   
                   
               
               
                   
                 CCTCTGTCCGTCACCCTTGTTCCCTGGT 
                   
                   
                   
               
               
                   
                 CCATCCAAGCCATTCTGGGTGTTGGTCG 
                   
                   
                   
               
               
                   
                 TAGTGGGTGGAGTCCTCGCTTGTTACTC 
                   
                   
                   
               
               
                   
                 TCTGCTCGTCACCGTGGCTTTTATAATC 
                   
                   
                   
               
               
                   
                 TTCTGGGTTAGATCCAAAAGAAGCCGCC 
                   
                   
                   
               
               
                   
                 TGCTCCATAGCGATTACATGAATATGAC 
                   
                   
                   
               
               
                   
                 TCCACGCCGCCCTGGCCCCACAAGGAAA 
                   
                   
                   
               
               
                   
                 CACTACCAGCCTTACGCACCACCTAGAG 
                   
                   
                   
               
               
                   
                 ATTTCGCTGCCTATCGGAGCAGGGTGAA 
                   
                   
                   
               
               
                   
                 GTTTTCCAGATCTGCAGATGCACCAGCG 
                   
                   
                   
               
               
                   
                 TATCAGCAGGGCCAGAACCAACTGTATA 
                   
                   
                   
               
               
                   
                 ACGAGCTCAACCTGGGACGCAGGGAAGA 
                   
                   
                   
               
               
                   
                 GTATGACGTTTTGGACAAGCGCAGAGGA 
                   
                   
                   
               
               
                   
                 CGGGACCCTGAGATGGGTGGCAAACCAA 
                   
                   
                   
               
               
                   
                 GACGAAAAAACCCCCAGGAGGGTCTCTA 
                   
                   
                   
               
               
                   
                 TAATGAGCTGCAGAAGGATAAGATGGCT 
                   
                   
                   
               
               
                   
                 GAAGCCTATTCTGAAATAGGCATGAAAG 
                   
                   
                   
               
               
                   
                 GAGAGCGGAGAAGGGGAAAAGGGCACGA 
                   
                   
                   
               
               
                   
                 CGGTTTGTACCAGGGACTCAGCACTGCT 
                   
                   
                   
               
               
                   
                 ACGAAGGATACTTATGACGCTCTCCACA 
                   
                   
                   
               
               
                   
                 TGCAAGCCCTGCCACCTAGGTAA 
                   
                   
                   
               
               
                   
               
               
                 RD- 
                 ATGGCACTCCCCGTAACTGCTCTGCTGC 
                 203 
                 MALPVTALLLPLALLLHAARP 
                 204 
               
               
                 21530CAR 
                 TGCCGTTGGCATTGCTCCTGCACGCCGC 
                   
                 QVQLVESGGGVVQPGRSLRLS 
                   
               
               
                 HxL 
                 ACGCCCGCAGGTGCAGCTGGTGGAGTCT 
                   
                 CAASGFTFSSYGMHWVRQAPG 
                   
               
               
                   
                 GGGGGAGGCGTGGTCCAGCCTGGGAGGT 
                   
                 KGLEWVAVISYDGSNKYYADS 
                   
               
               
                   
                 CCCTGAGACTCTCCTGTGCAGCGTCTGG 
                   
                 VKGRFTISRDNSKNTLYLQMN 
                   
               
               
                   
                 ATTCACCTTCAGTAGCTATGGCATGCAC 
                   
                 SLRAEDTAVYYCVKGPLQEPP 
                   
               
               
                   
                 TGGGTCCGCCAGGCTCCAGGCAAGGGGC 
                   
                 YDYGMDVWGQGTTVTVSSGST 
                   
               
               
                   
                 TGGAGTGGGTGGCAGTTATATCGTATGA 
                   
                 SGSGKPGSGEGSTKGEIVMTQ 
                   
               
               
                   
                 TGGAAGTAATAAATACTATGCAGACTCC 
                   
                 SPATLSVSPGERATLSCRASQ 
                   
               
               
                   
                 GTGAAGGGCCGATTCACCATCTCCAGAG 
                   
                 SVSSNLAWYQQKPGQAPRLLI 
                   
               
               
                   
                 ACAATTCCAAGAACACGCTGTATCTGCA 
                   
                 YSASTRATGIPARFSGSGSGT 
                   
               
               
                   
                 AATGAACAGCCTGAGAGCCGAGGACACG 
                   
                 EFTLTISSLQSEDFAVYYCQQ 
                   
               
               
                   
                 GCGGTGTACTACTGCGTCAAGGGGCCGT 
                   
                 HHVWPLTFGGGTKVEIKRAAA 
                   
               
               
                   
                 TGCAGGAGCCGCCATACGATTATGGAAT 
                   
                 LDNEKSNGTIIHVKGKHLCPS 
                   
               
               
                   
                 GGACGTATGGGGCCAGGGAACAACTGTC 
                   
                 PLFPGPSKPFWVLVVVGGVLA 
                   
               
               
                   
                 ACCGTCTCCTCAGGGTCTACATCCGGCT 
                   
                 CYSLLVTVAFIIFWVRSKRSR 
                   
               
               
                   
                 CCGGGAAGCCCGGAAGTGGCGAAGGTAG 
                   
                 LLHSDYMNMTPRRPGPTRKHY 
                   
               
               
                   
                 TACAAAGGGGGAAATAGTGATGACGCAG 
                   
                 QPYAPPRDFAAYRSRVKFSRS 
                   
               
               
                   
                 TCTCCAGCCACCCTGTCTGTGTCTCCAG 
                   
                 ADAPAYQQGQNQLYNELNLGR 
                   
               
               
                   
                 GGGAAAGAGCCACCCTCTCCTGCAGGGC 
                   
                 REEYDVLDKRRGRDPEMGGKP 
                   
               
               
                   
                 CAGTCAGAGTGTTAGCAGCAACTTAGCC 
                   
                 RRKNPQEGLYNELQKDKMAEA 
                   
               
               
                   
                 TGGTACCAGCAGAAACCTGGCCAGGCTC 
                   
                 YSEIGMKGERRRGKGHDGLYQ 
                   
               
               
                   
                 CCAGGCTCCTCATCTATAGCGCATCCAC 
                   
                 GLSTATKDTYDALHMQALPPR 
                   
               
               
                   
                 CAGGGCCACTGGTATCCCAGCCAGGTTC 
                   
                   
                   
               
               
                   
                 AGTGGCAGTGGGTCTGGGACAGAGTTCA 
                   
                   
                   
               
               
                   
                 CTCTCACCATCAGCAGCCTGCAGTCTGA 
                   
                   
                   
               
               
                   
                 AGATTTTGCAGTTTATTACTGTCAGCAG 
                   
                   
                   
               
               
                   
                 CACCACGTCTGGCCTCTCACTTTTGGCG 
                   
                   
                   
               
               
                   
                 GAGGGACCAAGGTTGAGATCAAACGGGC 
                   
                   
                   
               
               
                   
                 CGCTGCCCTTGATAATGAAAAGTCAAAC 
                   
                   
                   
               
               
                   
                 GGAACAATCATTCACGTGAAGGGCAAGC 
                   
                   
                   
               
               
                   
                 ACCTCTGTCCGTCACCCTTGTTCCCTGG 
                   
                   
                   
               
               
                   
                 TCCATCCAAGCCATTCTGGGTGTTGGTC 
                   
                   
                   
               
               
                   
                 GTAGTGGGTGGAGTCCTCGCTTGTTACT 
                   
                   
                   
               
               
                   
                 CTCTGCTCGTCACCGTGGCTTTTATAAT 
                   
                   
                   
               
               
                   
                 CTTCTGGGTTAGATCCAAAAGAAGCCGC 
                   
                   
                   
               
               
                   
                 CTGCTCCATAGCGATTACATGAATATGA 
                   
                   
                   
               
               
                   
                 CTCCACGCCGCCCTGGCCCCACAAGGAA 
                   
                   
                   
               
               
                   
                 ACACTACCAGCCTTACGCACCACCTAGA 
                   
                   
                   
               
               
                   
                 GATTTCGCTGCCTATCGGAGCAGGGTGA 
                   
                   
                   
               
               
                   
                 AGTTTTCCAGATCTGCAGATGCACCAGC 
                   
                   
                   
               
               
                   
                 GTATCAGCAGGGCCAGAACCAACTGTAT 
                   
                   
                   
               
               
                   
                 AACGAGCTCAACCTGGGACGCAGGGAAG 
                   
                   
                   
               
               
                   
                 AGTATGACGTTTTGGACAAGCGCAGAGG 
                   
                   
                   
               
               
                   
                 ACGGGACCCTGAGATGGGTGGCAAACCA 
                   
                   
                   
               
               
                   
                 AGACGAAAAAACCCCCAGGAGGGTCTCT 
                   
                   
                   
               
               
                   
                 ATAATGAGCTGCAGAAGGATAAGATGGC 
                   
                   
                   
               
               
                   
                 TGAAGCCTATTCTGAAATAGGCATGAAA 
                   
                   
                   
               
               
                   
                 GGAGAGCGGAGAAGGGGAAAAGGGCACG 
                   
                   
                   
               
               
                   
                 ACGGTTTGTACCAGGGACTCAGCACTGC 
                   
                   
                   
               
               
                   
                 TACGAAGGATACTTATGACGCTCTCCAC 
                   
                   
                   
               
               
                   
                 ATGCAAGCCCTGCCACCTAGGTAA 
                   
                   
                   
               
               
                   
               
               
                 RD- 
                 ATGGCACTCCCCGTAACTGCTCTGCTGC 
                 205 
                 MALPVTALLLPLALLLHAARP 
                 206 
               
               
                 21530CAR 
                 TGCCGTTGGCATTGCTCCTGCACGCCGC 
                   
                 EIVMTQSPATLSVSPGERATL 
                   
               
               
                 LxH 
                 ACGCCCGGAAATAGTGATGACGCAGTCT 
                   
                 SCRASQSVSSNLAWYQQKPGQ 
                   
               
               
                   
                 CCAGCCACCCTGTCTGTGTCTCCAGGGG 
                   
                 APRLLIYSASTRATGIPARFS 
                   
               
               
                   
                 AAAGAGCCACCCTCTCCTGCAGGGCCAG 
                   
                 GSGSGTEFTLTISSLQSEDFA 
                   
               
               
                   
                 TCAGAGTGTTAGCAGCAACTTAGCCTGG 
                   
                 VYYCQQHHVWPLTFGGGTKVE 
                   
               
               
                   
                 TACCAGCAGAAACCTGGCCAGGCTCCCA 
                   
                 IKRGSTSGSGKPGSGEGSTKG 
                   
               
               
                   
                 GGCTCCTCATCTATAGCGCATCCACCAG 
                   
                 QVQLVESGGGVVQPGRSLRLS 
                   
               
               
                   
                 GGCCACTGGTATCCCAGCCAGGTTCAGT 
                   
                 CAASGFTFSSYGMHWVRQAPG 
                   
               
               
                   
                 GGCAGTGGGTCTGGGACAGAGTTCACTC 
                   
                 KGLEWVAVISYDGSNKYYADS 
                   
               
               
                   
                 TCACCATCAGCAGCCTGCAGTCTGAAGA 
                   
                 VKGRFTISRDNSKNTLYLQMN 
                   
               
               
                   
                 TTTTGCAGTTTATTACTGTCAGCAGCAC 
                   
                 SLRAEDTAVYYCVKGPLQEPP 
                   
               
               
                   
                 CACGTCTGGCCTCTCACTTTTGGCGGAG 
                   
                 YDYGMDVWGQGTTVTVSSAAA 
                   
               
               
                   
                 GGACCAAGGTTGAGATCAAACGGGGGTC 
                   
                 LDNEKSNGTIIHVKGKHLCPS 
                   
               
               
                   
                 TACATCCGGCTCCGGGAAGCCCGGAAGT 
                   
                 PLFPGPSKPFWVLVVVGGVLA 
                   
               
               
                   
                 GGCGAAGGTAGTACAAAGGGGCAGGTGC 
                   
                 CYSLLVTVAFIIFWVRSKRSR 
                   
               
               
                   
                 AGCTGGTGGAGTCTGGGGGAGGCGTGGT 
                   
                 LLHSDYMNMTPRRPGPTRKHY 
                   
               
               
                   
                 CCAGCCTGGGAGGTCCCTGAGACTCTCC 
                   
                 QPYAPPRDFAAYRSRVKFSRS 
                   
               
               
                   
                 TGTGCAGCGTCTGGATTCACCTTCAGTA 
                   
                 ADAPAYQQGQNQLYNELNLGR 
                   
               
               
                   
                 GCTATGGCATGCACTGGGTCCGCCAGGC 
                   
                 REEYDVLDKRRGRDPEMGGKP 
                   
               
               
                   
                 TCCAGGCAAGGGGCTGGAGTGGGTGGCA 
                   
                 RRKNPQEGLYNELQKDKMAEA 
                   
               
               
                   
                 GTTATATCGTATGATGGAAGTAATAAAT 
                   
                 YSEIGMKGERRRGKGHDGLYQ 
                   
               
               
                   
                 ACTATGCAGACTCCGTGAAGGGCCGATT 
                   
                 GLSTATKDTYDALHMQALPPR 
                   
               
               
                   
                 CACCATCTCCAGAGACAATTCCAAGAAC 
                   
                   
                   
               
               
                   
                 ACGCTGTATCTGCAAATGAACAGCCTGA 
                   
                   
                   
               
               
                   
                 GAGCCGAGGACACGGCGGTGTACTACTG 
                   
                   
                   
               
               
                   
                 CGTCAAGGGGCCGTTGCAGGAGCCGCCA 
                   
                   
                   
               
               
                   
                 TACGATTATGGAATGGACGTATGGGGCC 
                   
                   
                   
               
               
                   
                 AGGGAACAACTGTCACCGTCTCCTCAGC 
                   
                   
                   
               
               
                   
                 CGCTGCCCTTGATAATGAAAAGTCAAAC 
                   
                   
                   
               
               
                   
                 GGAACAATCATTCACGTGAAGGGCAAGC 
                   
                   
                   
               
               
                   
                 ACCTCTGTCCGTCACCCTTGTTCCCTGG 
                   
                   
                   
               
               
                   
                 TCCATCCAAGCCATTCTGGGTGTTGGTC 
                   
                   
                   
               
               
                   
                 GTAGTGGGTGGAGTCCTCGCTTGTTACT 
                   
                   
                   
               
               
                   
                 CTCTGCTCGTCACCGTGGCTTTTATAAT 
                   
                   
                   
               
               
                   
                 CTTCTGGGTTAGATCCAAAAGAAGCCGC 
                   
                   
                   
               
               
                   
                 CTGCTCCATAGCGATTACATGAATATGA 
                   
                   
                   
               
               
                   
                 CTCCACGCCGCCCTGGCCCCACAAGGAA 
                   
                   
                   
               
               
                   
                 ACACTACCAGCCTTACGCACCACCTAGA 
                   
                   
                   
               
               
                   
                 GATTTCGCTGCCTATCGGAGCAGGGTGA 
                   
                   
                   
               
               
                   
                 AGTTTTCCAGATCTGCAGATGCACCAGC 
                   
                   
                   
               
               
                   
                 GTATCAGCAGGGCCAGAACCAACTGTAT 
                   
                   
                   
               
               
                   
                 AACGAGCTCAACCTGGGACGCAGGGAAG 
                   
                   
                   
               
               
                   
                 AGTATGACGTTTTGGACAAGCGCAGAGG 
                   
                   
                   
               
               
                   
                 ACGGGACCCTGAGATGGGTGGCAAACCA 
                   
                   
                   
               
               
                   
                 AGACGAAAAAACCCCCAGGAGGGTCTCT 
                   
                   
                   
               
               
                   
                 ATAATGAGCTGCAGAAGGATAAGATGGC 
                   
                   
                   
               
               
                   
                 TGAAGCCTATTCTGAAATAGGCATGAAA 
                   
                   
                   
               
               
                   
                 GGAGAGCGGAGAAGGGGAAAAGGGCACG 
                   
                   
                   
               
               
                   
                 ACGGTTTGTACCAGGGACTCAGCACTGC 
                   
                   
                   
               
               
                   
                 TACGAAGGATACTTATGACGCTCTCCAC 
                   
                   
                   
               
               
                   
                 ATGCAAGCCCTGCCACCTAGGTAA 
               
               
                   
               
            
           
         
       
     
     In some embodiments, the polynucleotide of the present invention encodes a CAR, wherein the CAR comprises an amino acid sequence at least about 75%, at least about 85%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, and 206. In certain embodiments, the CAR comprises an amino acid sequence selected from the group consisting of SEQ ID NOs: 176, 178, 180, 182, 184, 186, 188, 190, 192, 194, 196, 198, 200, 202, 204, and 206. In one embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 176. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 178. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 180. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 182. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 184. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 186. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 188. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 190. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 192. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 194. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 196. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 198. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 200. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 202. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 204. In another embodiment, the CAR comprises the amino acid sequence of SEQ ID NO: 206. 
     In some embodiments, the polynucleotide of the present invention comprises an nucleotide sequence at least about 50%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 85%, at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, at least about 99%, or 100% identical to an amino acid sequence selected from the group consisting of SEQ ID NOs: 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, and 205. In certain embodiments, the polynucleotide comprises a nucleotide sequence selected from the group consisting of SEQ ID NOs: 175, 177, 179, 181, 183, 185, 187, 189, 191, 193, 195, 197, 199, 201, 203, and 205. In one embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 175. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 177. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 179. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 181. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 183. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 185. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 187. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 189. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 191. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 193. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 195. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 197. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 199. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 201. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 203. In another embodiment, the polynucleotide comprises the nucleotide sequence of SEQ ID NO: 205. 
     In further embodiments, the invention relates to Clone FS-26528 HC DNA (SEQ ID NO: 271) as follows: 
     
       
         
           
               
            
               
                 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGT 
               
               
                   
               
               
                 CCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGACGACTATGC 
               
               
                   
               
               
                 CATGGCATGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCA 
               
               
                   
               
               
                 GCTATTAGTGATGCAGGTGACAGAACATACTACGCAGACTCCGTGAGGG 
               
               
                   
               
               
                 GCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCA 
               
               
                   
               
               
                 AATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCAAGA 
               
               
                   
               
               
                 GCCGAGATGGGAGCCGTATTCGACATATGGGGTCAGGGTACAATGGTCA 
               
               
                   
               
               
                 CCGTCTCCTCA. 
               
            
           
         
       
     
     In further embodiments, the invention relates to the Clone FS-26528 HC amino acid sequence (SEQ ID NO: 272): 
     
       
         
           
               
               
            
               
                   
                 EVQLLESGGG LVQPGGSLRL  SCAASGFTFD   DYAMA WVRQA 
               
               
                   
                 PGKGLEWVS A   ISDAGDRTYY   ADSVRG RFTI SRDNSKNTLY 
               
               
                   
                 LQMNSLRAED TAVYYC ARAE   MGAVFDI WGQ GTMVTVSS. 
               
            
           
         
       
     
     In further embodiments, the invention relates to HC CDR1 thereof: SCAASGFTFDDYAMA (SEQ ID NO: 273). In further embodiments, the invention relates to HC CDR2 thereof: AISDAGDRTYYADSVRG (SEQ ID NO: 274). In further embodiments, the invention relates to HC CDR3 thereof: ARAEMGAVFDI (SEQ ID NO: 275) [HC CDR3] 
     In further embodiments, the invention relates to Clone FS-26528 LC DNA (SEQ ID NO: 276): 
     
       
         
           
               
            
               
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGG 
               
               
                   
               
               
                 AAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGGTACTT 
               
               
                   
               
               
                 AGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
               
               
                 GATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTG 
               
               
                   
               
               
                 GGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGA 
               
               
                   
               
               
                 TTTTGCAGTTTATTACTGTCAGCAGAGAATCTCCTGGCCTTTCACTTTT 
               
               
                   
               
               
                 GGCGGAGGGACCAAGGTTGAGATCAAACGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone FS-26528 LC AA sequence (SEQ ID NO: 277): 
     
       
         
           
               
               
            
               
                   
                 EIVLTQSPAT LSLSPGERAT LSC RASQSVS   RYLA WYQQKP 
               
               
                   
                 GQAPRLLIY D   ASNRAT GIPA RFSGSGSGTD FTLTISSLEP 
               
               
                   
                 EDFAVYYC QQ   RISWPFT FGG GTKVEIKR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to LC CDR1 thereof: RASQSVSRYLA (SEQ ID NO: 278). In further embodiments, the invention relates to LC CDR2 thereof: DASNRAT (SEQ ID NO: 279). In further embodiments, the invention relates to the LC CDR3 thereof: QQRISWPFT (SEQ ID NO: 280). 
     In further embodiments, the invention relates to Clone FS-26528 CAR DNA H×L (SEQ ID NO: 281): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC 
               
               
                   
               
               
                 ACGCCGCACGCCCGGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGT 
               
               
                   
               
               
                 ACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACC 
               
               
                   
               
               
                 TTTGACGACTATGCCATGGCATGGGTCCGCCAGGCTCCAGGGAAGGGGC 
               
               
                   
               
               
                 TGGAGTGGGTCTCAGCTATTAGTGATGCAGGTGACAGAACATACTACGC 
               
               
                   
               
               
                 AGACTCCGTGAGGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAAC 
               
               
                   
               
               
                 ACACTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGT 
               
               
                   
               
               
                 ACTACTGCGCAAGAGCCGAGATGGGAGCCGTATTCGACATATGGGGTCA 
               
               
                   
               
               
                 GGGTACAATGGTCACCGTCTCCTCAGGGTCTACATCCGGCTCCGGGAAG 
               
               
                   
               
               
                 CCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATTGTGTTGACACAGT 
               
               
                   
               
               
                 CTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTG 
               
               
                   
               
               
                 CAGGGCCAGTCAGAGTGTTAGCAGGTACTTAGCCTGGTACCAACAGAAA 
               
               
                   
               
               
                 CCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCA 
               
               
                   
               
               
                 CTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTCAC 
               
               
                   
               
               
                 TCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGT 
               
               
                   
               
               
                 CAGCAGAGAATCTCCTGGCCTTTCACTTTTGGCGGAGGGACCAAGGTTG 
               
               
                   
               
               
                 AGATCAAACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAAT 
               
               
                   
               
               
                 CATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGT 
               
               
                   
               
               
                 CCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTT 
               
               
                   
               
               
                 GTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATC 
               
               
                   
               
               
                 CAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGC 
               
               
                   
               
               
                 CGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAG 
               
               
                   
               
               
                 ATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGC 
               
               
                   
               
               
                 ACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTG 
               
               
                   
               
               
                 GGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACC 
               
               
                   
               
               
                 CTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTA 
               
               
                   
               
               
                 TAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGC 
               
               
                   
               
               
                 ATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGG 
               
               
                   
               
               
                 GACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGC 
               
               
                   
               
               
                 CCTGCCACCTAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone FS-26528 CAR H×L AA sequence (SEQ ID NO: 282): 
     
       
         
           
               
               
            
               
                   
                 MALPVTALLL PLALLLHAAR PEVQLLESGG GLVQPGGSLR 
               
               
                   
                   
               
               
                   
                 LSCAASGFTF DDYAMAWVRQ APGKGLEWVS AISDAGDRTY 
               
               
                   
                   
               
               
                   
                 YADSVRGRFT ISRDNSKNTL YLQMNSLRAE DTAVYYCARA 
               
               
                   
                   
               
               
                   
                 EMGAVFDIWG QGTMVTVSSG STSGSGKPGS GEGSTKGEIV 
               
               
                   
                   
               
               
                   
                 LTQSPATLSL SPGERATLSC RASQSVSRYL AWYQQKPGQA 
               
               
                   
                   
               
               
                   
                 PRLLIYDASN RATGIPARFS GSGSGTDFTL TISSLEPEDF 
               
               
                   
                   
               
               
                   
                 AVYYCQQRIS WPFTFGGGTK VEIKRAAALD NEKSNGTIIH 
               
               
                   
                   
               
               
                   
                 VKGKHLCPSP LFPGPSKPFW VLVVVGGVLA CYSLLVTVAF 
               
               
                   
                   
               
               
                   
                 IIFWVRSKRS RLLHSDYMNM TPRRPGPTRK HYQPYAPPRD 
               
               
                   
                   
               
               
                   
                 FAAYRSRVKF SRSADAPAYQ QGQNQLYNEL NLGRREEYDV 
               
               
                   
                   
               
               
                   
                 LDKRRGRDPE MGGKPRRKNP QEGLYNELQK DKMAEAYSEI 
               
               
                   
                   
               
               
                   
                 GMKGERRRGK GHDGLYQGLS TATKDTYDAL HMQALPPR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone FS-26528 CAR DNA L×H (SEQ ID NO: 283): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC 
               
               
                   
               
               
                 ACGCCGCACGCCCGGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTC 
               
               
                   
               
               
                 TTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGT 
               
               
                   
               
               
                 GTTAGCAGGTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCA 
               
               
                   
               
               
                 GGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAG 
               
               
                   
               
               
                 GTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGC 
               
               
                   
               
               
                 CTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGAGAATCTCCT 
               
               
                   
               
               
                 GGCCTTTCACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTC 
               
               
                   
               
               
                 TACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGG 
               
               
                   
               
               
                 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGT 
               
               
                   
               
               
                 CCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTTGACGACTATGC 
               
               
                   
               
               
                 CATGGCATGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCA 
               
               
                   
               
               
                 GCTATTAGTGATGCAGGTGACAGAACATACTACGCAGACTCCGTGAGGG 
               
               
                   
               
               
                 GCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCA 
               
               
                   
               
               
                 AATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCAAGA 
               
               
                   
               
               
                 GCCGAGATGGGAGCCGTATTCGACATATGGGGTCAGGGTACAATGGTCA 
               
               
                   
               
               
                 CCGTCTCCTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAAT 
               
               
                   
               
               
                 CATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGT 
               
               
                   
               
               
                 CCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTT 
               
               
                   
               
               
                 GTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATC 
               
               
                   
               
               
                 CAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGC 
               
               
                   
               
               
                 CGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAG 
               
               
                   
               
               
                 ATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGC 
               
               
                   
               
               
                 ACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTG 
               
               
                   
               
               
                 GGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACC 
               
               
                   
               
               
                 CTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTA 
               
               
                   
               
               
                 TAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGC 
               
               
                   
               
               
                 ATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGG 
               
               
                   
               
               
                 GACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGC 
               
               
                   
               
               
                 CCTGCCACCTAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to the Clone FS-26528 CAR L×H AA sequence (SEQ ID NO: 284): 
     
       
         
           
               
               
            
               
                   
                 MALPVTALLL PLALLLHAAR PEIVLTQSPA TLSLSPGERA 
               
               
                   
                   
               
               
                   
                 TLSCRASQSV SRYLAWYQQK PGQAPRLLIY DASNRATGIP 
               
               
                   
                   
               
               
                   
                 ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ QRISWPFTFG 
               
               
                   
                   
               
               
                   
                 GGTKVEIKRG STSGSGKPGS GEGSTKGEVQ LLESGGGLVQ 
               
               
                   
                   
               
               
                   
                 PGGSLRLSCA ASGFTFDDYA MAWVRQAPGK GLEWVSAISD 
               
               
                   
                   
               
               
                   
                 AGDRTYYADS VRGRFTISRD NSKNTLYLQM NSLRAEDTAV 
               
               
                   
                   
               
               
                   
                 YYCARAEMGA VFDIWGQGTM VTVSSAAALD NEKSNGTIIH 
               
               
                   
                   
               
               
                   
                 VKGKHLCPSP LFPGPSKPFW VLVVVGGVLA CYSLLVTVAF 
               
               
                   
                   
               
               
                   
                 IIFWVRSKRS RLLHSDYMNM TPRRPGPTRK HYQPYAPPRD 
               
               
                   
                   
               
               
                   
                 FAAYRSRVKF SRSADAPAYQ QGQNQLYNEL NLGRREEYDV 
               
               
                   
                   
               
               
                   
                 LDKRRGRDPE MGGKPRRKNP QEGLYNELQK DKMAEAYSEI 
               
               
                   
                   
               
               
                   
                 GMKGERRRGK GHDGLYQGLS TATKDTYDAL HMQALPPR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone PC-26534 HC DNA (SEQ ID NO: 285) as follows: 
     
       
         
           
               
            
               
                 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGT 
               
               
                   
               
               
                 CCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTGAGCATGG 
               
               
                   
               
               
                 CATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCA 
               
               
                   
               
               
                 GCTATATCTTATGATGGAAGGAATAAACACTATGCAGACTCCGTGAAGG 
               
               
                   
               
               
                 GCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCA 
               
               
                   
               
               
                 AATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCCAGA 
               
               
                   
               
               
                 GACGGTACTTATCTAGGTGGTCTCTGGTACTTCGACTTATGGGGGAGAG 
               
               
                   
               
               
                 GTACCTTGGTCACCGTCTCCTCA. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone PC-26534 HC (SEQ ID NO: 286): 
     
       
         
           
               
            
               
                 QVQLVESGGG VVQPGRSLRL SCAASG FTFS   EHGMH WVRQA 
               
               
                 PGKGLEWVA A   ISYDGRNKHY   ADSVKG RFTI SRDNSKNTLY 
               
               
                 LQMNSLRAED TAVYYC ARDG   TYLGGLWYFD   L WGRGTLVTV SS. 
               
            
           
         
       
     
     In further embodiments, the invention relates to HC CDR1 thereof: FTFSEHGMH (SEQ ID NO: 287). In further embodiments, the invention relates to HC CDR2 thereof: AISYDGRNKHYADSVKG (SEQ ID NO: 288). In further embodiments, the invention relates to HC CDR3 thereof: ARDGTYLGGLWYFDL (SEQ ID NO: 289). 
     In further embodiments, the invention relates to Clone PC-26534 LC DNA (SEQ ID NO: 290) as follows: 
     
       
         
           
               
            
               
                 GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAG 
               
               
                   
               
               
                 AGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAA 
               
               
                   
               
               
                 TGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCA 
               
               
                   
               
               
                 CAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACA 
               
               
                   
               
               
                 GGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAG 
               
               
                   
               
               
                 AGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAGGGACTCGGC 
               
               
                   
               
               
                 CTCCCTCTCACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone PC-26534 LC AA sequence (SEQ ID NO: 291): 
     
       
         
           
               
               
            
               
                   
                 DIVMTQSPLS LPVTPGEPAS ISC RSSQSLL   HSNGYNYLD W 
               
               
                   
                 YLQKPGQSPQ LLIY LGSNRA   S GVPDRFSGS GSGTDFTLKI 
               
               
                   
                 SRVEAEDVGV YYC MQGLGLP   LT FGGGTKVE IKR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to LC CDR1 AA sequence thereof: RSSQSLLHSNGYNYLD (SEQ ID NO: 292). In further embodiments, the invention relates to LC CDR2 thereof: LGSNRAS (SEQ ID NO: 293). In further embodiments, the invention relates to LC CDR3 thereof: MQGLGLPLT (SEQ ID NO: 294). 
     In further embodiments, the invention relates to Clone PC-26534 CAR DNA H×L (SEQ ID NO: 295) as follows: 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC 
               
               
                   
               
               
                 ACGCCGCACGCCCGCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGT 
               
               
                   
               
               
                 CCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACC 
               
               
                   
               
               
                 TTCAGTGAGCATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGC 
               
               
                   
               
               
                 TGGAGTGGGTGGCAGCTATATCTTATGATGGAAGGAATAAACACTATGC 
               
               
                   
               
               
                 AGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAAC 
               
               
                   
               
               
                 ACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGT 
               
               
                   
               
               
                 ACTACTGCGCCAGAGACGGTACTTATCTAGGTGGTCTCTGGTACTTCGA 
               
               
                   
               
               
                 CTTATGGGGGAGAGGTACCTTGGTCACCGTCTCCTCAGGGTCTACATCC 
               
               
                   
               
               
                 GGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGATATTG 
               
               
                   
               
               
                 TGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGC 
               
               
                   
               
               
                 CTCCATCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATAC 
               
               
                   
               
               
                 AACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCTCCACAGCTCC 
               
               
                   
               
               
                 TGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAG 
               
               
                   
               
               
                 TGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAG 
               
               
                   
               
               
                 GCTGAGGATGTTGGGGTTTATTACTGCATGCAGGGACTCGGCCTCCCTC 
               
               
                   
               
               
                 TCACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGCCGCTGCCCT 
               
               
                   
               
               
                 TGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCAC 
               
               
                   
               
               
                 CTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGT 
               
               
                   
               
               
                 TGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGT 
               
               
                   
               
               
                 GGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCAT 
               
               
                   
               
               
                 AGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAAC 
               
               
                   
               
               
                 ACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAG 
               
               
                   
               
               
                 GGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAG 
               
               
                   
               
               
                 AACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACG 
               
               
                   
               
               
                 TTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAG 
               
               
                   
               
               
                 ACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAG 
               
               
                   
               
               
                 ATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGG 
               
               
                   
               
               
                 GAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGA 
               
               
                   
               
               
                 TACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone PC-26534 CAR H×L AA sequence (SEQ ID NO: 296): 
     
       
         
           
               
               
            
               
                   
                 MALPVTALLL PLALLLHAAR PQVQLVESGG GVVQPGRSLR 
               
               
                   
                   
               
               
                   
                 LSCAASGFTF SEHGMHWVRQ APGKGLEWVA AISYDGRNKH 
               
               
                   
                   
               
               
                   
                 YADSVKGRFT ISRDNSKNTL YLQMNSLRAE DTAVYYCARD 
               
               
                   
                   
               
               
                   
                 GTYLGGLWYF DLWGRGTLVT VSSGSTSGSG KPGSGEGSTK 
               
               
                   
                   
               
               
                   
                 GDIVMTQSPL SLPVTPGEPA SISCRSSQSL LHSNGYNYLD 
               
               
                   
                   
               
               
                   
                 WYLQKPGQSP QLLIYLGSNR ASGVPDRFSG SGSGTDFTLK 
               
               
                   
                   
               
               
                   
                 ISRVEAEDVG VYYCMQGLGL PLTFGGGTKV EIKRAAALDN 
               
               
                   
                   
               
               
                   
                 EKSNGTIIHV KGKHLCPSPL FPGPSKPFWV LVVVGGVLAC 
               
               
                   
                   
               
               
                   
                 YSLLVTVAFI IFWVRSKRSR LLHSDYMNMT PRRPGPTRKH 
               
               
                   
                   
               
               
                   
                 YQPYAPPRDF AAYRSRVKFS RSADAPAYQQ GQNQLYNELN 
               
               
                   
                   
               
               
                   
                 LGRREEYDVL DKRRGRDPEM GGKPRRKNPQ EGLYNELQKD  
               
               
                   
                   
               
               
                   
                 KMAEAYSEIG MKGERRRGKG HDGLYQGLST ATKDTYDALH 
               
               
                   
                   
               
               
                   
                 MQALPPR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone PC-26534 CAR DNA L×H (SEQ ID NO: 297): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC 
               
               
                   
               
               
                 ACGCCGCACGCCCGGATATTGTGATGACTCAGTCTCCACTCTCCCTGCC 
               
               
                   
               
               
                 CGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCTAGTCAGAGC 
               
               
                   
               
               
                 CTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACCTGCAGAAGC 
               
               
                   
               
               
                 CAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTC 
               
               
                   
               
               
                 CGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACA 
               
               
                   
               
               
                 CTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCA 
               
               
                   
               
               
                 TGCAGGGACTCGGCCTCCCTCTCACTTTTGGCGGAGGGACCAAGGTTGA 
               
               
                   
               
               
                 GATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAA 
               
               
                   
               
               
                 GGTAGTACAAAGGGGCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGG 
               
               
                   
               
               
                 TCCAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCAC 
               
               
                   
               
               
                 CTTCAGTGAGCATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGG 
               
               
                   
               
               
                 CTGGAGTGGGTGGCAGCTATATCTTATGATGGAAGGAATAAACACTATG 
               
               
                   
               
               
                 CAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAA 
               
               
                   
               
               
                 CACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTG 
               
               
                   
               
               
                 TACTACTGCGCCAGAGACGGTACTTATCTAGGTGGTCTCTGGTACTTCG 
               
               
                   
               
               
                 ACTTATGGGGGAGAGGTACCTTGGTCACCGTCTCCTCAGCCGCTGCCCT 
               
               
                   
               
               
                 TGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCAC 
               
               
                   
               
               
                 CTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGT 
               
               
                   
               
               
                 TGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGT 
               
               
                   
               
               
                 GGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCAT 
               
               
                   
               
               
                 AGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAAC 
               
               
                   
               
               
                 ACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAG 
               
               
                   
               
               
                 GGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAG 
               
               
                   
               
               
                 AACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACG 
               
               
                   
               
               
                 TTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAG 
               
               
                   
               
               
                 ACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAG 
               
               
                   
               
               
                 ATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGG 
               
               
                   
               
               
                 GAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGA 
               
               
                   
               
               
                 TACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone PC-26534 CAR L×H chain sequences (SEQ ID NO: 298): 
     
       
         
           
               
               
            
               
                   
                 MALPVTALLL PLALLLHAAR PDIVMTQSPL SLPVTPGEPA 
               
               
                   
                   
               
               
                   
                 SISCRSSQSL LHSNGYNYLD WYLQKPGQSP QLLIYLGSNR 
               
               
                   
                   
               
               
                   
                 ASGVPDRFSG SGSGTDFTLK ISRVEAEDVG VYYCMQGLGL 
               
               
                   
                   
               
               
                   
                 PLTFGGGTKV EIKRGSTSGS GKPGSGEGST KGQVQLVESG 
               
               
                   
                   
               
               
                   
                 GGVVQPGRSL RLSCAASGFT FSEHGMHWVR QAPGKGLEWV 
               
               
                   
                   
               
               
                   
                 AAISYDGRNK HYADSVKGRF TISRDNSKNT LYLQMNSLRA 
               
               
                   
                   
               
               
                   
                 EDTAVYYCAR DGTYLGGLWY FDLWGRGTLV TVSSAAALDN 
               
               
                   
                   
               
               
                   
                 EKSNGTIIHV KGKHLCPSPL FPGPSKPFWV LVVVGGVLAC 
               
               
                   
                   
               
               
                   
                 YSLLVTVAFI IFWVRSKRSR LLHSDYMNMT PRRPGPTRKH 
               
               
                   
                   
               
               
                   
                 YQPYAPPRDF AAYRSRVKFS RSADAPAYQQ GQNQLYNELN 
               
               
                   
                   
               
               
                   
                 LGRREEYDVL DKRRGRDPEM GGKPRRKNPQ EGLYNELQKD 
               
               
                   
                   
               
               
                   
                 KMAEAYSEIG MKGERRRGKG HDGLYQGLST ATKDTYDALH 
               
               
                   
                   
               
               
                   
                 MQALPPR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone AJ-26545 HC DNA (SEQ ID NO: 299): 
     
       
         
           
               
            
               
                 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCT 
               
               
                   
               
               
                 CAGTGAAGGTTTCCTGCAGGGCATCTGGATACACCTTCATGGAGCACTA 
               
               
                   
               
               
                 TATGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGA 
               
               
                   
               
               
                 GTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGCACAGAAGTTCCAGG 
               
               
                   
               
               
                 GCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGA 
               
               
                   
               
               
                 GCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGA 
               
               
                   
               
               
                 GAGAATTGGCCAATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCT 
               
               
                   
               
               
                 CCTCA. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone AJ-26545 HC AA sequence (SEQ ID NO: 300): 
     
       
         
           
               
               
            
               
                   
                 QVQLVQSGAE VKKPGASVKV SCRASG YTFM   EHYMH WVRQA 
               
               
                   
                 PGQGLEWMG V   IGPSGGKTSY   AQKFQG RVTM TRDTSTSTVY 
               
               
                   
                 MELSSLRSED TAVYYC ARES   WPMDV WGQGT TVTVSS. 
               
            
           
         
       
     
     In further embodiments, the invention relates to HC CDR1 thereof: YTFMEHYMH (SEQ ID NO: 301). In further embodiments, the invention relates to HC CDR2 thereof: VIGPSGGKTSYAQKFQG (SEQ ID NO: 302). In further embodiments, the invention relates to HC CDR3 thereof: ARESWPMDV (SEQ ID NO: 303). 
     In further embodiments, the invention relates to Clone AJ-26545 LC DNA (SEQ ID NO: 304): 
     
       
         
           
               
            
               
                 GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGG 
               
               
                   
               
               
                 AAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTT 
               
               
                   
               
               
                 AGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
               
               
                 GGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTG 
               
               
                   
               
               
                 GGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGA 
               
               
                   
               
               
                 TTTTGCAGTTTATTACTGTCAGCAGTACGCCGCCTACCCTACTTTTGGC 
               
               
                   
               
               
                 GGAGGGACCAAGGTTGAGATCAAACGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone AJ-26545 LC AA sequence (SEQ ID NO: 305): 
     
       
         
           
               
               
            
               
                   
                 EIVMTQSPAT LSVSPGERAT LSC RASQSVS   SNLA WYQQKP 
               
               
                   
                 GQAPRLLIY G   ASTRAT GIPA RFSGSGSGTE FTLTISSLQS 
               
               
                   
                 EDFAVYYC QQ   YAAYPT FGGG TKVEIKR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to LC CDR1 thereof: RASQSVSSNLA (SEQ ID NO: 306). In further embodiments, the invention relates to LC CDR2 thereof: GASTRAT (SEQ ID NO: 307). In further embodiments, the invention relates to the LC CDR3 thereof: QQYAAYPT (SEQ ID NO: 308). 
     In further embodiments, the invention relates to Clone AJ-26545 CAR DNA H×L (SEQ ID NO: 309): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC 
               
               
                   
               
               
                 ACGCCGCACGCCCGCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAA 
               
               
                   
               
               
                 GAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAGGGCATCTGGATACACC 
               
               
                   
               
               
                 TTCATGGAGCACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGGC 
               
               
                   
               
               
                 TTGAGTGGATGGGAGTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGC 
               
               
                   
               
               
                 ACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGC 
               
               
                   
               
               
                 ACAGTCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGT 
               
               
                   
               
               
                 ACTACTGCGCCAGAGAGAATTGGCCAATGGACGTATGGGGCCAGGGAAC 
               
               
                   
               
               
                 AACTGTCACCGTCTCCTCAGGGTCTACATCCGGCTCCGGGAAGCCCGGA 
               
               
                   
               
               
                 AGTGGCGAAGGTAGTACAAAGGGGGAAATAGTGATGACGCAGTCTCCAG 
               
               
                   
               
               
                 CCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGC 
               
               
                   
               
               
                 CAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC 
               
               
                   
               
               
                 CAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTA 
               
               
                   
               
               
                 TCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCAC 
               
               
                   
               
               
                 CATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAG 
               
               
                   
               
               
                 TACGCCGCCTACCCTACTTTTGGCGGAGGGACCAAGGTTGAGATCAAAC 
               
               
                   
               
               
                 GGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGT 
               
               
                   
               
               
                 GAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAG 
               
               
                   
               
               
                 CCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTC 
               
               
                   
               
               
                 TGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAG 
               
               
                   
               
               
                 CCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGC 
               
               
                   
               
               
                 CCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTG 
               
               
                   
               
               
                 CCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTA 
               
               
                   
               
               
                 TCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGG 
               
               
                   
               
               
                 GAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGG 
               
               
                   
               
               
                 GTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCT 
               
               
                   
               
               
                 GCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGA 
               
               
                   
               
               
                 GAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCA 
               
               
                   
               
               
                 CTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACC 
               
               
                   
               
               
                 TAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone AJ-26545 CAR H×L AA sequence (SEQ ID NO: 310): 
     
       
         
           
               
               
            
               
                   
                 MALPVTALLL PLALLLHAAR PQVQLVQSGA EVKKPGASVK 
               
               
                   
                   
               
               
                   
                 VSCRASGYTF MEHYMHWVRQ APGQGLEWMG VIGPSGGKTS 
               
               
                   
                   
               
               
                   
                 YAQKFQGRVT MTRDTSTSTV YMELSSLRSE DTAVYYCARE 
               
               
                   
                   
               
               
                   
                 SWPMDVWGQG TTVTVSSGST SGSGKPGSGE GSTKGEIVMT 
               
               
                   
                   
               
               
                   
                 QSPATLSVSP GERATLSCRA SQSVSSNLAW YQQKPGQAPR 
               
               
                   
                   
               
               
                   
                 LLIYGASTRA TGIPARFSGS GSGTEFTLTI SSLQSEDFAV 
               
               
                   
                   
               
               
                   
                 YYCQQYAAYP TFGGGTKVEI KRAAALDNEK SNGTIIHVKG 
               
               
                   
                   
               
               
                   
                 KHLCPSPLFP GPSKPFWVLV VVGGVLACYS LLVTVAFIIF 
               
               
                   
                   
               
               
                   
                 WVRSKRSRLL HSDYMNMTPR RPGPTRKHYQ PYAPPRDFAA 
               
               
                   
                   
               
               
                   
                 YRSRVKFSRS ADAPAYQQGQ NQLYNELNLG RREEYDVLDK 
               
               
                   
                   
               
               
                   
                 RRGRDPEMGG KPRRKNPQEG LYNELQKDKM AEAYSEIGMK 
               
               
                   
                   
               
               
                   
                 GERRRGKGHD GLYQGLSTAT KDTYDALHMQ ALPPR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone AJ-26545 CAR DNA L×H (SEQ ID NO: 311): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC 
               
               
                   
               
               
                 ACGCCGCACGCCCGGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTC 
               
               
                   
               
               
                 TGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGT 
               
               
                   
               
               
                 GTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCA 
               
               
                   
               
               
                 GGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAG 
               
               
                   
               
               
                 GTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGC 
               
               
                   
               
               
                 CTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTACGCCGCCT 
               
               
                   
               
               
                 ACCCTACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTCTAC 
               
               
                   
               
               
                 ATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGCAG 
               
               
                   
               
               
                 GTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAG 
               
               
                   
               
               
                 TGAAGGTTTCCTGCAGGGCATCTGGATACACCTTCATGGAGCACTATAT 
               
               
                   
               
               
                 GCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGTA 
               
               
                   
               
               
                 ATCGGGCCTAGTGGTGGTAAGACAAGCTACGCACAGAAGTTCCAGGGCA 
               
               
                   
               
               
                 GAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCT 
               
               
                   
               
               
                 GAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGAG 
               
               
                   
               
               
                 AATTGGCCAATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCT 
               
               
                   
               
               
                 CAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGT 
               
               
                   
               
               
                 GAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAG 
               
               
                   
               
               
                 CCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTC 
               
               
                   
               
               
                 TGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAG 
               
               
                   
               
               
                 CCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGC 
               
               
                   
               
               
                 CCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTG 
               
               
                   
               
               
                 CCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTA 
               
               
                   
               
               
                 TCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGG 
               
               
                   
               
               
                 GAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGG 
               
               
                   
               
               
                 GTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCT 
               
               
                   
               
               
                 GCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGA 
               
               
                   
               
               
                 GAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCA 
               
               
                   
               
               
                 CTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACC 
               
               
                   
               
               
                 TAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone AJ-26545 CAR L×H AA sequence (SEQ ID NO: 312): 
     
       
         
           
               
               
            
               
                   
                 MALPVTALLL PLALLLHAAR PEIVMTQSPA TLSVSPGERA 
               
               
                   
                   
               
               
                   
                 TLSCRASQSV SSNLAWYQQK PGQAPRLLIY GASTRATGIP 
               
               
                   
                   
               
               
                   
                 ARFSGSGSGT EFTLTISSLQ SEDFAVYYCQ QYAAYPTFGG 
               
               
                   
                   
               
               
                   
                 GTKVEIKRGS TSGSGKPGSG EGSTKGQVQL VQSGAEVKKP 
               
               
                   
                   
               
               
                   
                 GASVKVSCRA SGYTFMEHYM HWVRQAPGQG LEWMGVIGPS 
               
               
                   
                   
               
               
                   
                 GGKTSYAQKF QGRVTMTRDT STSTVYMELS SLRSEDTAVY 
               
               
                   
                   
               
               
                   
                 YCARESWPMD VWGQGTTVTV SSAAALDNEK SNGTIIHVKG 
               
               
                   
                   
               
               
                   
                 KHLCPSPLFP GPSKPFWVLV VVGGVLACYS LLVTVAFIIF 
               
               
                   
                   
               
               
                   
                 WVRSKRSRLL HSDYMNMTPR RPGPTRKHYQ PYAPPRDFAA 
               
               
                   
                   
               
               
                   
                 YRSRVKFSRS ADAPAYQQGQ NQLYNELNLG RREEYDVLDK 
               
               
                   
                   
               
               
                   
                 RRGRDPEMGG KPRRKNPQEG LYNELQKDKM AEAYSEIGMK 
               
               
                   
                   
               
               
                   
                 GERRRGKGHD GLYQGLSTAT KDTYDALHMQ ALPPR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone AJ-26554 HC DNA (SEQ ID NO: 313): 
     
       
         
           
               
            
               
                 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCT 
               
               
                   
               
               
                 CAGTGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACGGAGCACTA 
               
               
                   
               
               
                 TATGCACTGGGTGCGACAGGCCCCTGGACAAAGGCTTGAGTGGATGGGA 
               
               
                   
               
               
                 GTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGCACAGAAGTTCCAGG 
               
               
                   
               
               
                 GCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGA 
               
               
                   
               
               
                 GCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGA 
               
               
                   
               
               
                 GAGAGTTGGCCAATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCT 
               
               
                   
               
               
                 CCTCA. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone AJ-26554 HC (SEQ ID NO: 314): 
     
       
         
           
               
               
            
               
                   
                 QVQLVQSGAE VKKPGASVKV SCKASG YTFT   EHYMH WVRQA 
               
               
                   
                 PGQRLEWMG V   IGPSGGKTSY   AQKFQG RVTM TRDTSTSTVY 
               
               
                   
                 MELSSLRSED TAVYYC ARES   WPMDV WGOGT TVTVSS. 
               
            
           
         
       
     
     In further embodiments, the invention relates to HC CDR1 thereof: YTFTEHYMH (SEQ ID NO: 315). In further embodiments, the invention relates to HC CDR2 thereof: VIGPSGGKTSYAQKFQG (SEQ ID NO: 316). In further embodiments, the invention relates to HC CDR3 thereof: ARESWPMDV (SEQ ID NO: 317). 
     In further embodiments, the invention relates to Clone AJ-26554 LC DNA (SEQ ID NO: 318): 
     
       
         
           
               
            
               
                 GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGG 
               
               
                   
               
               
                 AAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTT 
               
               
                   
               
               
                 AGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
               
               
                 GGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTG 
               
               
                   
               
               
                 GGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGA 
               
               
                   
               
               
                 TTTTGCAGTTTATTACTGTCAGCAGTACGCCGCCTACCCTACTTTTGGC 
               
               
                   
               
               
                 GGAGGGACCAAGGTTGAGATCAAACGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone AJ-26554 LC AA sequence (SEQ ID NO: 319): 
     
       
         
           
               
               
            
               
                   
                 EIVMTQSPAT LSVSPGERAT LSC RASQSVS   SNLA WYQQKP 
               
               
                   
                 GQAPRLLIY G   ASTRAT GIPA RFSGSGSGTE FTLTISSLQS 
               
               
                   
                 EDFAVYYC QQ   YAAYPT FGGG TKVEIKR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to the LC CDR1 thereof: RASQSVSSNLA (SEQ ID NO: 320). In further embodiments, the invention relates to the LC CDR2 thereof: GASTRAT (SEQ ID NO: 321). In further embodiments, the invention relates to LC CDR3 thereof: QQYAAYPT (SEQ ID NO: 322). 
     In further embodiments, the invention relates to Clone AJ-26554 CAR DNA H×L (SEQ ID NO: 323): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC 
               
               
                   
               
               
                 ACGCCGCACGCCCGCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAA 
               
               
                   
               
               
                 GAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCATCTGGATACACC 
               
               
                   
               
               
                 TTCACGGAGCACTATATGCACTGGGTGCGACAGGCCCCTGGACAAAGGC 
               
               
                   
               
               
                 TTGAGTGGATGGGAGTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGC 
               
               
                   
               
               
                 ACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGC 
               
               
                   
               
               
                 ACAGTCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGT 
               
               
                   
               
               
                 ACTACTGCGCCAGAGAGAGTTGGCCAATGGACGTATGGGGCCAGGGAAC 
               
               
                   
               
               
                 AACTGTCACCGTCTCCTCAGGGTCTACATCCGGCTCCGGGAAGCCCGGA 
               
               
                   
               
               
                 AGTGGCGAAGGTAGTACAAAGGGGGAAATAGTGATGACGCAGTCTCCAG 
               
               
                   
               
               
                 CCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGC 
               
               
                   
               
               
                 CAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC 
               
               
                   
               
               
                 CAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTA 
               
               
                   
               
               
                 TCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCAC 
               
               
                   
               
               
                 CATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAG 
               
               
                   
               
               
                 TACGCCGCCTACCCTACTTTTGGCGGAGGGACCAAGGTTGAGATCAAAC 
               
               
                   
               
               
                 GGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGT 
               
               
                   
               
               
                 GAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAG 
               
               
                   
               
               
                 CCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTC 
               
               
                   
               
               
                 TGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAG 
               
               
                   
               
               
                 CCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGC 
               
               
                   
               
               
                 CCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTG 
               
               
                   
               
               
                 CCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTA 
               
               
                   
               
               
                 TCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGG 
               
               
                   
               
               
                 GAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGG 
               
               
                   
               
               
                 GTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCT 
               
               
                   
               
               
                 GCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGA 
               
               
                   
               
               
                 GAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCA 
               
               
                   
               
               
                 CTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACC 
               
               
                   
               
               
                 TAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone AJ-26554 CAR H×L AA sequence (SEQ ID NO: 324): 
     
       
         
           
               
               
            
               
                   
                 MALPVTALLL PLALLLHAAR PQVQLVQSGA EVKKPGASVK 
               
               
                   
                   
               
               
                   
                 VSCKASGYTF TEHYMHWVRQ APGQRLEWMG VIGPSGGKTS 
               
               
                   
                   
               
               
                   
                 YAQKFQGRVT MTRDTSTSTV YMELSSLRSE DTAVYYCARE 
               
               
                   
                   
               
               
                   
                 SWPMDVWGQG TTVTVSSGST SGSGKPGSGE GSTKGEIVMT 
               
               
                   
                   
               
               
                   
                 QSPATLSVSP GERATLSCRA SQSVSSNLAW YQQKPGQAPR 
               
               
                   
                   
               
               
                   
                 LLIYGASTRA TGIPARFSGS GSGTEFTLTI SSLQSEDFAV 
               
               
                   
                   
               
               
                   
                 YYCQQYAAYP TFGGGTKVEI KRAAALDNEK SNGTIIHVKG 
               
               
                   
                   
               
               
                   
                 KHLCPSPLFP GPSKPFWVLV VVGGVLACYS LLVTVAFIIF 
               
               
                   
                   
               
               
                   
                 WVRSKRSRLL HSDYMNMTPR RPGPTRKHYQ PYAPPRDFAA 
               
               
                   
                   
               
               
                   
                 YRSRVKFSRS ADAPAYQQGQ NQLYNELNLG RREEYDVLDK 
               
               
                   
                   
               
               
                   
                 RRGRDPEMGG KPRRKNPQEG LYNELQKDKM AEAYSEIGMK 
               
               
                   
                   
               
               
                   
                 GERRRGKGHD LYQGLSTAT KDTYDALHMQ ALPPR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone AJ-26554 CAR DNA L×H (SEQ ID NO: 325): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC 
               
               
                   
               
               
                 ACGCCGCACGCCCGGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTC 
               
               
                   
               
               
                 TGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGT 
               
               
                   
               
               
                 GTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCA 
               
               
                   
               
               
                 GGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAG 
               
               
                   
               
               
                 GTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGC 
               
               
                   
               
               
                 CTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTACGCCGCCT 
               
               
                   
               
               
                 ACCCTACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTCTAC 
               
               
                   
               
               
                 ATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGCAG 
               
               
                   
               
               
                 GTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAG 
               
               
                   
               
               
                 TGAAGGTTTCCTGCAAGGCATCTGGATACACCTTCACGGAGCACTATAT 
               
               
                   
               
               
                 GCACTGGGTGCGACAGGCCCCTGGACAAAGGCTTGAGTGGATGGGAGTA 
               
               
                   
               
               
                 ATCGGGCCTAGTGGTGGTAAGACAAGCTACGCACAGAAGTTCCAGGGCA 
               
               
                   
               
               
                 GAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCT 
               
               
                   
               
               
                 GAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGAG 
               
               
                   
               
               
                 AGTTGGCCAATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCT 
               
               
                   
               
               
                 CAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGT 
               
               
                   
               
               
                 GAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAG 
               
               
                   
               
               
                 CCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTC 
               
               
                   
               
               
                 TGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAG 
               
               
                   
               
               
                 CCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGC 
               
               
                   
               
               
                 CCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTG 
               
               
                   
               
               
                 CCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTA 
               
               
                   
               
               
                 TCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGG 
               
               
                   
               
               
                 GAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGG 
               
               
                   
               
               
                 GTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCT 
               
               
                   
               
               
                 GCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGA 
               
               
                   
               
               
                 GAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCA 
               
               
                   
               
               
                 CTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACC 
               
               
                   
               
               
                 TAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone AJ-26554 CAR L×H AA sequence (SEQ ID NO: 326): 
     
       
         
           
               
               
            
               
                   
                 MALPVTALLL PLALLLHAAR PEIVMTQSPA TLSVSPGERA 
               
               
                   
                   
               
               
                   
                 TLSCRASQSV SSNLAWYQQK PGQAPRLLIY GASTRATGIP 
               
               
                   
                   
               
               
                   
                 ARFSGSGSGT EFTLTISSLQ SEDFAVYYCQ QYAAYPTFGG 
               
               
                   
                   
               
               
                   
                 GTKVEIKRGS TSGSGKPGSG EGSTKGQVQL VQSGAEVKKP 
               
               
                   
                   
               
               
                   
                 GASVKVSCKA SGYTFTEHYM HWVRQAPGQR LEWMGVIGPS 
               
               
                   
                   
               
               
                   
                 GGKTSYAQKF QGRVTMTRDT STSTVYMELS SLRSEDTAVY 
               
               
                   
                   
               
               
                   
                 YCARESWPMD VWGQGTTVTV SSAAALDNEK SNGTIIHVKG 
               
               
                   
                   
               
               
                   
                 KHLCPSPLFP GPSKPFWVLV VVGGVLACYS LLVTVAFIIF 
               
               
                   
                   
               
               
                   
                 WVRSKRSRLL HSDYMNMTPR RPGPTRKHYQ PYAPPRDFAA 
               
               
                   
                   
               
               
                   
                 YRSRVKFSRS ADAPAYQQGQ NQLYNELNLG RREEYDVLDK 
               
               
                   
                   
               
               
                   
                 RRGRDPEMGG KPRRKNPQEG LYNELQKDKM AEAYSEIGMK 
               
               
                   
                   
               
               
                   
                 GERRRGKGH DGLYQGLSTAT KDTYDALHMQ ALPPR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone NM-26562 HC DNA (SEQ ID NO: 327): 
     
       
         
           
               
            
               
                 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGAC 
               
               
                   
               
               
                 CCTGTCCCTCACCTGTACTGTCTCTGGTGGCTCCATCGGGAGTGGTGGTA 
               
               
                   
               
               
                 GTTACTGGAGCTGGATCCGCCAGCACCCAGGGAAGGGCCTGGAGTGGATT 
               
               
                   
               
               
                 GGGTTGATCTATTACGATGGGAGCACCTACTACAACCCGTCCCTCAAGAG 
               
               
                   
               
               
                 TCGAGTTACCATATCAGTAGACACGTCTAAGAACCAGTTCTCCCTGAAGC 
               
               
                   
               
               
                 TGAGTTCTGTGACCGCCGCAGACACGGCGGTGTACTACTGCGCCAGAGGC 
               
               
                   
               
               
                 AGGGGATATGAGACTTCTTTAGCCTTCGATATCTGGGGTCAGGGTACAAT 
               
               
                   
               
               
                 GGTCACCGTCTCCTCA. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone NM-26562 HC AA sequence (SEQ ID NO: 328): 
     
       
         
           
               
            
               
                 QVQLQESGPG LVKPSQTLSL TCTVSG GSIG   SGGSYWS WIR 
               
               
                 QHPGKGLEWI G LIYYDGSTY   YNPSLKS RVT ISVDTSKNQF 
               
               
                 SLKLSSVTAA DTAVYYC ARG   RGYETSLAFD   I WGQGTMVTV SS. 
               
            
           
         
       
     
     In further embodiments, the invention relates to HC CDR1 thereof: GSIGSGGSYWS (SEQ ID NO: 329). In further embodiments, the invention relates to HC CDR2 thereof: LIYYDGSTYYNPSLKS (SEQ ID NO: 330). In further embodiments, the invention relates to HC CDR3 thereof: ARGRGYETSLAFDI (SEQ ID NO: 331). 
     In further embodiments, the invention relates to Clone NM-26562 LC DNA (SEQ ID NO: 332): 
     
       
         
           
               
            
               
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGG 
               
               
                   
               
               
                 AAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTT 
               
               
                   
               
               
                 AGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
               
               
                 GATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTG 
               
               
                   
               
               
                 GGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGA 
               
               
                   
               
               
                 TTTTGCAGTTTATTACTGTCAGCAGAGACACGTCTGGCCTCCTACTTTT 
               
               
                   
               
               
                 GGCGGAGGGACCAAGGTTGAGATCAAACGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone NM-26562 LC AA sequence (SEQ ID NO: 333): 
     
       
         
           
               
               
            
               
                   
                 EIVLTQSPAT LSLSPGERAT LSC RASQSVS   SYLA WYQQKP 
               
               
                   
                 GQAPRLLIY D   ASNRAT GIPA RFSGSGSGTD FTLTISSLEP 
               
               
                   
                 EDFAVYYC QQ   RHVWPPT FGG GTKVEIKR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to LC CDR1 AA sequence thereof: RASQSVSSYLA (SEQ ID NO: 334) In further embodiments, the invention relates to LC CDR2 AA sequence thereof: DASNRAT (SEQ ID NO: 335). In further embodiments, the invention relates to LC CDR3 AA sequence thereof: QQRHVWPPT (SEQ ID NO: 336) (LC CDR3). 
     In further embodiments, the invention relates to Clone NM-26562 CAR DNA H×L (SEQ ID NO: 337): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC 
               
               
                   
               
               
                 ACGCCGCACGCCCGCAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGT 
               
               
                   
               
               
                 GAAGCCTTCACAGACCCTGTCCCTCACCTGTACTGTCTCTGGTGGCTCC 
               
               
                   
               
               
                 ATCGGGAGTGGTGGTAGTTACTGGAGCTGGATCCGCCAGCACCCAGGGA 
               
               
                   
               
               
                 AGGGCCTGGAGTGGATTGGGTTGATCTATTACGATGGGAGCACCTACTA 
               
               
                   
               
               
                 CAACCCGTCCCTCAAGAGTCGAGTTACCATATCAGTAGACACGTCTAAG 
               
               
                   
               
               
                 AACCAGTTCTCCCTGAAGCTGAGTTCTGTGACCGCCGCAGACACGGCGG 
               
               
                   
               
               
                 TGTACTACTGCGCCAGAGGCAGGGGATATGAGACTTCTTTAGCCTTCGA 
               
               
                   
               
               
                 TATCTGGGGTCAGGGTACAATGGTCACCGTCTCCTCAGGGTCTACATCC 
               
               
                   
               
               
                 GGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATTG 
               
               
                   
               
               
                 TGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGC 
               
               
                   
               
               
                 CACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGG 
               
               
                   
               
               
                 TACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCAT 
               
               
                   
               
               
                 CCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGG 
               
               
                   
               
               
                 GACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCA 
               
               
                   
               
               
                 GTTTATTACTGTCAGCAGAGACACGTCTGGCCTCCTACTTTTGGCGGAG 
               
               
                   
               
               
                 GGACCAAGGTTGAGATCAAACGGGCCGCTGCCCTTGATAATGAAAAGTC 
               
               
                   
               
               
                 AAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCC 
               
               
                   
               
               
                 TTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTG 
               
               
                   
               
               
                 GAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTT 
               
               
                   
               
               
                 CTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAAT 
               
               
                   
               
               
                 ATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACG 
               
               
                   
               
               
                 CACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAG 
               
               
                   
               
               
                 ATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAAC 
               
               
                   
               
               
                 GAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCA 
               
               
                   
               
               
                 GAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCA 
               
               
                   
               
               
                 GGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTAT 
               
               
                   
               
               
                 TCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACG 
               
               
                   
               
               
                 GTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCT 
               
               
                   
               
               
                 CCACATGCAAGCCCTGCCACCTAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone NM-26562 CAR H×L (SEQ ID NO: 338): 
     
       
         
           
               
            
               
                 MALPVTALLL PLALLLHAAR PQVQLQESGP GLVKPSQTLS 
               
               
                   
               
               
                 LTCTVSGGSI GSGGSYWSWI RQHPGKGLEW IGLIYYDGST 
               
               
                   
               
               
                 YYNPSLKSRV TISVDTSKNQ FSLKLSSVTA ADTAVYYCAR 
               
               
                   
               
               
                 GRGYETSLAF DIWGQGTMVT VSSGSTSGSG KPGSGEGSTK 
               
               
                   
               
               
                 GEIVLTQSPA TLSLSPGERA TLSCRASQSV SSYLAWYQQK 
               
               
                   
               
               
                 PGQAPRLLIY DASNRATGIP ARFSGSGSGT DFTLTISSLE 
               
               
                   
               
               
                 PEDFAVYYCQ QRHVWPPTFG GGTKVEIKRA AALDNEKSNG 
               
               
                   
               
               
                 TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV 
               
               
                   
               
               
                 TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG PTRKHYQPYA 
               
               
                   
               
               
                 PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE 
               
               
                   
               
               
                 EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA 
               
               
                   
               
               
                 YSEIGMKGER RRGKGHDGLY QGLSTATKDT YDALHMQALP PR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone NM-26562 CAR DNA L×H (SEQ ID NO: 339): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCAC 
               
               
                   
               
               
                 GCCGCACGCCCGGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTG 
               
               
                   
               
               
                 TCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGC 
               
               
                   
               
               
                 AGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTC 
               
               
                   
               
               
                 ATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGC 
               
               
                   
               
               
                 AGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAA 
               
               
                   
               
               
                 GATTTTGCAGTTTATTACTGTCAGCAGAGACACGTCTGGCCTCCTACTTTT 
               
               
                   
               
               
                 GGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTCTACATCCGGCTCCGGG 
               
               
                   
               
               
                 AAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGCAGGTGCAGCTGCAGGAG 
               
               
                   
               
               
                 TCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCACCTGTACT 
               
               
                   
               
               
                 GTCTCTGGTGGCTCCATCGGGAGTGGTGGTAGTTACTGGAGCTGGATCCGC 
               
               
                   
               
               
                 CAGCACCCAGGGAAGGGCCTGGAGTGGATTGGGTTGATCTATTACGATGGG 
               
               
                   
               
               
                 AGCACCTACTACAACCCGTCCCTCAAGAGTCGAGTTACCATATCAGTAGAC 
               
               
                   
               
               
                 ACGTCTAAGAACCAGTTCTCCCTGAAGCTGAGTTCTGTGACCGCCGCAGAC 
               
               
                   
               
               
                 ACGGCGGTGTACTACTGCGCCAGAGGCAGGGGATATGAGACTTCTTTAGCC 
               
               
                   
               
               
                 TTCGATATCTGGGGTCAGGGTACAATGGTCACCGTCTCCTCAGCCGCTGCC 
               
               
                   
               
               
                 CTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCAC 
               
               
                   
               
               
                 CTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTG 
               
               
                   
               
               
                 GTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCT 
               
               
                   
               
               
                 TTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGAT 
               
               
                   
               
               
                 TACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAG 
               
               
                   
               
               
                 CCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTT 
               
               
                   
               
               
                 TCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTAT 
               
               
                   
               
               
                 AACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGC 
               
               
                   
               
               
                 AGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAG 
               
               
                   
               
               
                 GAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCT 
               
               
                   
               
               
                 GAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTG 
               
               
                   
               
               
                 TACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATG 
               
               
                   
               
               
                 CAAGCCCTGCCACCTAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone NM-26562 CAR L×H (SEQ ID NO: 340): 
     
       
         
           
               
            
               
                 MALPVTALLL PLALLLHAAR PEIVLTQSPA TLSLSPGERA 
               
               
                   
               
               
                 TLSCRASQSV SSYLAWYQQK PGQAPRLLIY DASNRATGIP 
               
               
                   
               
               
                 ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ QRHVWPPTFG 
               
               
                   
               
               
                 GGTKVEIKRG STSGSGKPGS GEGSTKGQVQ LQESGPGLVK 
               
               
                   
               
               
                 PSQTLSLTCT VSGGSIGSGG SYWSWIRQHP GKGLEWIGLI 
               
               
                   
               
               
                 YYDGSTYYNP SLKSRVTISV DTSKNQFSLK LSSVTAADTA 
               
               
                   
               
               
                 VYYCARGRGY ETSLAFDIWG QGTMVTVSSA AALDNEKSNG 
               
               
                   
               
               
                 TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV 
               
               
                   
               
               
                 TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG PTRKHYQPYA 
               
               
                   
               
               
                 PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE 
               
               
                   
               
               
                 EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA 
               
               
                   
               
               
                 YSEIGMKGER RRGKGHDGLY QGLSTATKDT YDALHMQALP PR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone TS-26564 HC DNA sequence (SEQ ID NO: 341): 
     
       
         
           
               
            
               
                 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGT 
               
               
                   
               
               
                 CCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAG 
               
               
                   
               
               
                 CATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTTCA 
               
               
                   
               
               
                 ACCATTAGTAGTAGTAGTAGTATCATATACTACGCAGACTCTGTGAAGG 
               
               
                   
               
               
                 GCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTGCA 
               
               
                   
               
               
                 AATGAACAGCCTGAGAGCTGAGGACACGGCGGTGTACTACTGCGCCAGA 
               
               
                   
               
               
                 GGTTCTCAGGAGCACCTGATTTTCGATTATTGGGGACAGGGTACATTGG 
               
               
                   
               
               
                 TCACCGTCTCCTCA. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone TS-26564 HC AA sequence (SEQ ID NO: 342): 
     
       
         
           
               
               
            
               
                   
                 EVQLVESGGG LVQPGGSLRL SCAASG FTFS   SYSMN WVRQA 
               
               
                   
                 PGKGLEWVS T   ISSSSSIIYY   ADSVKG RFTI SRDNAKNSLY 
               
               
                   
                 LQMNSLRAED TAVYYC ARGS   QEHLIFDY WG QGTLVTVSS. 
               
            
           
         
       
     
     In further embodiments, the invention relates to HC CDR1 AA sequence thereof: FTFSSYSMN (SEQ ID NO: 343). In further embodiments, the invention relates to HC CDR2 AA sequence thereof: TISSSSSIIYYADSVKG (SEQ ID NO: 344). In further embodiments, the invention relates to HC CDR3 AA sequence thereof: ARGSQEHLIFDY (SEQ ID NO: 345). 
     In further embodiments, the invention relates to Clone TS-26564 LC DNA (SEQ ID NO: 346): 
     
       
         
           
               
            
               
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGG 
               
               
                   
               
               
                 AAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGGTACTT 
               
               
                   
               
               
                 AGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTAT 
               
               
                   
               
               
                 GATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTG 
               
               
                   
               
               
                 GGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGA 
               
               
                   
               
               
                 TTTTGCAGTTTATTACTGTCAGCAGAGATTCTACTACCCTTGGACTTTT 
               
               
                   
               
               
                 GGCGGAGGGACCAAGGTTGAGATCAAACGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone TS-26564 LC AA sequence (SEQ ID NO: 347): 
     
       
         
           
               
               
            
               
                   
                 EIVLTQSPAT LSLSPGERAT LSC RASQSVS   RYLA WYQQKP 
               
               
                   
                 GQAPRLLIY D   ASNRAT GIPA RFSGSGSGTD FTLTISSLEP 
               
               
                   
                 EDFAVYYC QQ   RFYYPWT FGG GTKVEIKR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to LC CDR1 AA sequence thereof: RASQSVSRYLA (SEQ ID NO: 348). In further embodiments, the invention relates to LC CDR2 AA sequence thereof: DASNRAT (SEQ ID NO: 349). In further embodiments, the invention relates to LC CDR3 AA sequence thereof: QQRFYYPWT (SEQ ID NO: 350). 
     In further embodiments, the invention relates to Clone TS-26564 CAR DNA H×L (SEQ ID NO: 351): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC 
               
               
                   
               
               
                 ACGCCGCACGCCCGGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGT 
               
               
                   
               
               
                 ACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACC 
               
               
                   
               
               
                 TTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGC 
               
               
                   
               
               
                 TGGAGTGGGTTTCAACCATTAGTAGTAGTAGTAGTATCATATACTACGC 
               
               
                   
               
               
                 AGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAAC 
               
               
                   
               
               
                 TCACTGTATCTGCAAATGAACAGCCTGAGAGCTGAGGACACGGCGGTGT 
               
               
                   
               
               
                 ACTACTGCGCCAGAGGTTCTCAGGAGCACCTGATTTTCGATTATTGGGG 
               
               
                   
               
               
                 ACAGGGTACATTGGTCACCGTCTCCTCAGGGTCTACATCCGGCTCCGGG 
               
               
                   
               
               
                 AAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATTGTGTTGACAC 
               
               
                   
               
               
                 AGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTC 
               
               
                   
               
               
                 CTGCAGGGCCAGTCAGAGTGTTAGCAGGTACTTAGCCTGGTACCAACAG 
               
               
                   
               
               
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGG 
               
               
                   
               
               
                 CCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTT 
               
               
                   
               
               
                 CACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTAC 
               
               
                   
               
               
                 TGTCAGCAGAGATTCTACTACCCTTGGACTTTTGGCGGAGGGACCAAGG 
               
               
                   
               
               
                 TTGAGATCAAACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAAC 
               
               
                   
               
               
                 AATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCT 
               
               
                   
               
               
                 GGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCG 
               
               
                   
               
               
                 CTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAG 
               
               
                   
               
               
                 ATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCA 
               
               
                   
               
               
                 CGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTA 
               
               
                   
               
               
                 GAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGA 
               
               
                   
               
               
                 TGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAAC 
               
               
                   
               
               
                 CTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGG 
               
               
                   
               
               
                 ACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCT 
               
               
                   
               
               
                 CTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATA 
               
               
                   
               
               
                 GGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACC 
               
               
                   
               
               
                 AGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCA 
               
               
                   
               
               
                 AGCCCTGCCACCTAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone TS-26564 CAR H×L AA sequence (SEQ ID NO: 352): 
     
       
         
           
               
               
            
               
                   
                 MALPVTALLL PLALLLHAAR PEVQLVESGG GLVQPGGSLR 
               
               
                   
                   
               
               
                   
                 LSCAASGFTF SSYSMNWVRQ APGKGLEWVS TISSSSSIIY 
               
               
                   
                   
               
               
                   
                 YADSVKGRFT ISRDNAKNSL YLQMNSLRAE DTAVYYCARG 
               
               
                   
                   
               
               
                   
                 SQEHLIFDYW GQGTLVTVSS GSTSGSGKPG SGEGSTKGEI 
               
               
                   
                   
               
               
                   
                 VLTQSPATLS LSPGERATLS CRASQSVSRY LAWYQQKPGQ 
               
               
                   
                   
               
               
                   
                 APRLLIYDAS NRATGIPARF SGSGSGTDFT LTISSLEPED 
               
               
                   
                   
               
               
                   
                 FAVYYCQQRF YYPWTFGGGT KVEIKRAAAL DNEKSNGTII 
               
               
                   
                   
               
               
                   
                 HVKGKHLCPS PLFPGPSKPF WVLVVVGGVL ACYSLLVTVA 
               
               
                   
                   
               
               
                   
                 FIIFWVRSKR SRLLHSDYMN MTPRRPGPTR KHYQPYAPPR 
               
               
                   
                   
               
               
                   
                 DFAAYRSRVK FSRSADAPAY QQGQNQLYNE LNLGRREEYD 
               
               
                   
                   
               
               
                   
                 VLDKRRGRDP EMGGKPRRKN PQEGLYNELQ KDKMAEAYSE 
               
               
                   
                   
               
               
                   
                 IGMKGERRRG KGHDGLYQGL STATKDTYDA LHMQALPPR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone TS-26564 CAR DNA L×H (SEQ ID NO: 353): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGC 
               
               
                   
               
               
                 ACGCCGCACGCCCGGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTC 
               
               
                   
               
               
                 TTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGT 
               
               
                   
               
               
                 GTTAGCAGGTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCA 
               
               
                   
               
               
                 GGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAG 
               
               
                   
               
               
                 GTTCAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGC 
               
               
                   
               
               
                 CTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGAGATTCTACT 
               
               
                   
               
               
                 ACCCTTGGACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTC 
               
               
                   
               
               
                 TACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGG 
               
               
                   
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGT 
               
               
                   
               
               
                 CCCTGAGACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAG 
               
               
                   
               
               
                 CATGAACTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTTTCA 
               
               
                   
               
               
                 ACCATTAGTAGTAGTAGTAGTATCATATACTACGCAGACTCTGTGAAGG 
               
               
                   
               
               
                 GCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTGCA 
               
               
                   
               
               
                 AATGAACAGCCTGAGAGCTGAGGACACGGCGGTGTACTACTGCGCCAGA 
               
               
                   
               
               
                 GGTTCTCAGGAGCACCTGATTTTCGATTATTGGGGACAGGGTACATTGG 
               
               
                   
               
               
                 TCACCGTCTCCTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAAC 
               
               
                   
               
               
                 AATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCT 
               
               
                   
               
               
                 GGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCG 
               
               
                   
               
               
                 CTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAG 
               
               
                   
               
               
                 ATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCA 
               
               
                   
               
               
                 CGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTA 
               
               
                   
               
               
                 GAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGA 
               
               
                   
               
               
                 TGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAAC 
               
               
                   
               
               
                 CTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGG 
               
               
                   
               
               
                 ACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCT 
               
               
                   
               
               
                 CTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATA 
               
               
                   
               
               
                 GGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACC 
               
               
                   
               
               
                 AGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCA 
               
               
                   
               
               
                 AGCCCTGCCACCTAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone TS-26564 CAR L×H AA sequence (SEQ ID NO: 354): 
     
       
         
           
               
               
            
               
                   
                 MALPVTALLL PLALLLHAAR PEIVLTQSPA TLSLSPGERA 
               
               
                   
                   
               
               
                   
                 TLSCRASQSV SRYLAWYQQK PGQAPRLLIY DASNRATGIP 
               
               
                   
                   
               
               
                   
                 ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ QRFYYPWTFG 
               
               
                   
                   
               
               
                   
                 GGTKVEIKRG STSGSGKPGS GEGSTKGEVQ LVESGGGLVQ 
               
               
                   
                   
               
               
                   
                 PGGSLRLSCA ASGFTFSSYS MNWVRQAPGK GLEWVSTISS 
               
               
                   
                   
               
               
                   
                 SSSIIYYADS VKGRFTISRD NAKNSLYLQM NSLRAEDTAV 
               
               
                   
                   
               
               
                   
                 YYCARGSQEH LIFDYWGQGT LVTVSSAAAL DNEKSNGTII 
               
               
                   
                   
               
               
                   
                 HVKGKHLCPS PLFPGPSKPF WVLVVVGGVL ACYSLLVTVA 
               
               
                   
                   
               
               
                   
                 FIIFWVRSKR SRLLHSDYMN MTPRRPGPTR KHYQPYAPPR 
               
               
                   
                   
               
               
                   
                 DFAAYRSRVK FSRSADAPAY QQGQNQLYNE LNLGRREEYD 
               
               
                   
                   
               
               
                   
                 VLDKRRGRDP EMGGKPRRKN PQEGLYNELQ KDKMAEAYSE 
               
               
                   
                   
               
               
                   
                 IGMKGERRRG KGHDGLYQGL STATKDTYDA LHMQALPPR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone RY-26568 HC DNA (SEQ ID NO: 355): 
     
       
         
           
               
            
               
                 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGT 
               
               
                   
               
               
                 CCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCGGGAGCTATGG 
               
               
                   
               
               
                 CATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCA 
               
               
                   
               
               
                 GTTATACATTATGATGGAAGTGTTGAATACTATGCAGACTCCGTGAAGG 
               
               
                   
               
               
                 GCCGATTCACCATCTCCAGAGACAATTCCAAGGACACGCTGTATCTGCA 
               
               
                   
               
               
                 AATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCCAGA 
               
               
                   
               
               
                 ACTGACTTCTGGAGCGGATCCCCTCCAAGCTTAGATTACTGGGGACAGG 
               
               
                   
               
               
                 GTACATTGGTCACCGTCTCCTCA. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone RY-26568 HC AA sequence (SEQ ID NO: 356): 
     
       
         
           
               
            
               
                 QVQLVESGGG VVQPGRSLRL SCAASG FTFG   SYGMH WVRQA 
               
               
                 PGKGLEWVA V  I HYDGSVEYY   ADSVKG RFTI SRDNSKDTLY 
               
               
                 LQMNSLRAED TAVYYC ARTD   FWSGSPPSLD   Y WGQGTLVTV SS. 
               
            
           
         
       
     
     In further embodiments, the invention relates to HC CDR1 thereof: FTFGSYGMH (SEQ ID NO: 357). In further embodiments, the invention relates to HC CDR2 thereof: VIHYDGSVEYYADSVKG (SEQ ID NO: 358). In further embodiments, the invention relates to HC CDR3 thereof: ARTDFWSGSPPSLDY (SEQ ID NO: 359). 
     In further embodiments, the invention relates to Clone RY-26568 LC DNA (SEQ ID NO: 360): 
     
       
         
           
               
            
               
                 GACATCCAGTTGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGA 
               
               
                   
               
               
                 CAGAGTCACCATCACTTGTCGGGCGAGTCGGGGTATTAGCAGCTGGTTAG 
               
               
                   
               
               
                 CCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCTCCTGATCTATGGT 
               
               
                   
               
               
                 GCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGATC 
               
               
                   
               
               
                 TGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTG 
               
               
                   
               
               
                 CAACTTATTACTGTCAGCAGATATACACCTTCCCTTTCACTTTTGGCGGA 
               
               
                   
               
               
                 GGGACCAAGGTTGAGATCAAACGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone RY-26568 LC AA sequence (SEQ ID NO: 361): 
     
       
         
           
               
               
            
               
                   
                 DIQLTQSPSS VSASVGDRVT ITC RASRGIS   SWLA WYQQKP 
               
               
                   
                 GKAPKLLIY G   ASSLQS GVPS RFSGSGSGTD FTLTISSLQP 
               
               
                   
                 EDFATYYC QQ   IYTFPFT FGG GTKVEIKR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to LC CDR1 AA sequence thereof: RASRGISSWLA (SEQ ID NO: 362). In further embodiments, the invention relates to LC CDR2 AA sequence thereof: GASSLQS (SEQ ID NO: 363). In further embodiments, the invention relates to LC CDR3 AA sequence thereof: QQIYTFPFT (SEQ ID NO: 364) (LC CDR3). 
     In further embodiments, the invention relates to Clone RY-26568 CAR DNA H×L (SEQ ID NO: 365): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCA 
               
               
                   
               
               
                 CGCCGCACGCCCGCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCC 
               
               
                   
               
               
                 AGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTC 
               
               
                   
               
               
                 GGGAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGA 
               
               
                   
               
               
                 GTGGGTGGCAGTTATACATTATGATGGAAGTGTTGAATACTATGCAGACT 
               
               
                   
               
               
                 CCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGGACACGCTG 
               
               
                   
               
               
                 TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTG 
               
               
                   
               
               
                 CGCCAGAACTGACTTCTGGAGCGGATCCCCTCCAAGCTTAGATTACTGGG 
               
               
                   
               
               
                 GACAGGGTACATTGGTCACCGTCTCCTCAGGGTCTACATCCGGCTCCGGG 
               
               
                   
               
               
                 AAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGACATCCAGTTGACCCA 
               
               
                   
               
               
                 GTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTT 
               
               
                   
               
               
                 GTCGGGCGAGTCGGGGTATTAGCAGCTGGTTAGCCTGGTATCAGCAGAAA 
               
               
                   
               
               
                 CCAGGGAAAGCCCCTAAGCTCCTGATCTATGGTGCATCCAGTTTGCAAAG 
               
               
                   
               
               
                 TGGGGTCCCATCAAGGTTCAGCGGCAGTGGATCTGGGACAGATTTCACTC 
               
               
                   
               
               
                 TCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTACTGTCAG 
               
               
                   
               
               
                 CAGATATACACCTTCCCTTTCACTTTTGGCGGAGGGACCAAGGTTGAGAT 
               
               
                   
               
               
                 CAAACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTC 
               
               
                   
               
               
                 ACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCC 
               
               
                   
               
               
                 AAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTC 
               
               
                   
               
               
                 TCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAA 
               
               
                   
               
               
                 GCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGC 
               
               
                   
               
               
                 CCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGC 
               
               
                   
               
               
                 CTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATC 
               
               
                   
               
               
                 AGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAA 
               
               
                   
               
               
                 GAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGG 
               
               
                   
               
               
                 CAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGA 
               
               
                   
               
               
                 AGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGG 
               
               
                   
               
               
                 AGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTAC 
               
               
                   
               
               
                 GAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone RY-26568 CAR H×L AA sequence (SEQ ID NO: 366): 
     
       
         
           
               
            
               
                 MALPVTALLL PLALLLHAAR PQVQLVESGG GVVQPGRSLR 
               
               
                   
               
               
                 LSCAASGFTF GSYGMHWVRQ APGKGLEWVA VIHYDGSVEY 
               
               
                   
               
               
                 YADSVKGRFT ISRDNSKDTL YLQMNSLRAE DTAVYYCART 
               
               
                   
               
               
                 DFWSGSPPSL DYWGQGTLVT VSSGSTSGSG KPGSGEGSTK 
               
               
                   
               
               
                 GDIQLTQSPS SVSASVGDRV TITCRASRGI SSWLAWYQQK 
               
               
                   
               
               
                 PGKAPKLLIY GASSLQSGVP SRFSGSGSGT DFTLTISSLQ 
               
               
                   
               
               
                 PEDFATYYCQ QIYTFPFTFG GGTKVEIKRA AALDNEKSNG 
               
               
                   
               
               
                 TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV 
               
               
                   
               
               
                 TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG PTRKHYQPYA 
               
               
                   
               
               
                 PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE 
               
               
                   
               
               
                 EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA 
               
               
                   
               
               
                 YSEIGMKGER RRGKGHDGLY QGLSTATKDT YDALHMQALP PR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone RY-26568 CAR DNA L×H (SEQ ID NO: 367): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCA 
               
               
                   
               
               
                 CGCCGCACGCCCGGACATCCAGTTGACCCAGTCTCCATCTTCCGTGTCTG 
               
               
                   
               
               
                 CATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCGAGTCGGGGTATT 
               
               
                   
               
               
                 AGCAGCTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCT 
               
               
                   
               
               
                 CCTGATCTATGGTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCA 
               
               
                   
               
               
                 GCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAG 
               
               
                   
               
               
                 CCTGAAGATTTTGCAACTTATTACTGTCAGCAGATATACACCTTCCCTTT 
               
               
                   
               
               
                 CACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTCTACATCCG 
               
               
                   
               
               
                 GCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGCAGGTGCAG 
               
               
                   
               
               
                 CTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT 
               
               
                   
               
               
                 CTCCTGTGCAGCGTCTGGATTCACCTTCGGGAGCTATGGCATGCACTGGG 
               
               
                   
               
               
                 TCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATACATTAT 
               
               
                   
               
               
                 GATGGAAGTGTTGAATACTATGCAGACTCCGTGAAGGGCCGATTCACCAT 
               
               
                   
               
               
                 CTCCAGAGACAATTCCAAGGACACGCTGTATCTGCAAATGAACAGCCTGA 
               
               
                   
               
               
                 GAGCCGAGGACACGGCGGTGTACTACTGCGCCAGAACTGACTTCTGGAGC 
               
               
                   
               
               
                 GGATCCCCTCCAAGCTTAGATTACTGGGGACAGGGTACATTGGTCACCGT 
               
               
                   
               
               
                 CTCCTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTC 
               
               
                   
               
               
                 ACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCC 
               
               
                   
               
               
                 AAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTC 
               
               
                   
               
               
                 TCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAA 
               
               
                   
               
               
                 GCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGC 
               
               
                   
               
               
                 CCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGC 
               
               
                   
               
               
                 CTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATC 
               
               
                   
               
               
                 AGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAA 
               
               
                   
               
               
                 GAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGG 
               
               
                   
               
               
                 CAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGA 
               
               
                   
               
               
                 AGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGG 
               
               
                   
               
               
                 AGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTAC 
               
               
                   
               
               
                 GAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone RY-26568 CAR L×H AA sequence (SEQ ID NO: 368): 
     
       
         
           
               
            
               
                 MALPVTALLL PLALLLHAAR PDIQLTQSPS SVSASVGDRV 
               
               
                   
               
               
                 TITCRASRGI SSWLAWYQQK PGKAPKLLIY GASSLQSGVP 
               
               
                   
               
               
                 SRFSGSGSGT DFTLTISSLQ PEDFATYYCQ QIYTFPFTFG 
               
               
                   
               
               
                 GGTKVEIKRG STSGSGKPGS GEGSTKGQVQ LVESGGGVVQ 
               
               
                   
               
               
                 PGRSLRLSCA ASGFTFGSYG MHWVRQAPGK GLEWVAVIHY 
               
               
                   
               
               
                 DGSVEYYADS VKGRFTISRD NSKDTLYLQM NSLRAEDTAV 
               
               
                   
               
               
                 YYCARTDFWS GSPPSLDYWG QGTLVTVSSA AALDNEKSNG 
               
               
                   
               
               
                 TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLV 
               
               
                   
               
               
                 TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG PTRKHYQPYA 
               
               
                   
               
               
                 PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE 
               
               
                   
               
               
                 EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA 
               
               
                   
               
               
                 YSEIGMKGER RRGKGHDGLY QGLSTATKDT YDALHMQALP PR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone PP-26575 HC DNA (SEQ ID NO: 369): 
     
       
         
           
               
            
               
                 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTC 
               
               
                   
               
               
                 GGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCCTCAGCAGCCTGGCTA 
               
               
                   
               
               
                 TCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGG 
               
               
                   
               
               
                 GTCATCCCTATCTTGGGTCGGGCAAACTACGCACAGAAGTTCCAGGGCAG 
               
               
                   
               
               
                 AGTCACGATTACCGCGGACGAGTCCACGAGCACAGCCTACATGGAGCTGA 
               
               
                   
               
               
                 GCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAACTCCT 
               
               
                   
               
               
                 GAATACTCCTCCAGCATATGGCACTATTACTACGGCATGGACGTATGGGG 
               
               
                   
               
               
                 CCAGGGAACAACTGTCACCGTCTCCTCA. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone PP-26575 HC AA sequence (SEQ ID NO: 370): 
     
       
         
           
               
               
            
               
                   
                 QVQLVQSGAE VKKPGSSVKV SCKASG GTLS   SLAIS WVRQA 
               
               
                   
                   
               
               
                   
                 PGQGLEWMG G   VIPILGRANY   AQKFQG RVTI TADESTSTAY 
               
               
                   
                   
               
               
                   
                 MELSSLRSED TAVYYC ARTP   EYSSSIWHYY   YGMDV WGQGT 
               
               
                   
                   
               
               
                   
                 TVTVSS. 
               
            
           
         
       
     
     In further embodiments, the invention relates to HC CDR1 AA sequence thereof: GILSSLAIS (SEQ ID NO: 371). In further embodiments, the invention relates to HC CDR2 AA sequence thereof: GVIPILGRANYAQKFQG (SEQ ID NO: 372). In further embodiments, the invention relates to HC CDR3 thereof: ARTPEYSSSIWHYYYGMDV (SEQ ID NO: 373). 
     In further embodiments, the invention relates to Clone PP-26575 LC DNA (SEQ ID NO: 374): 
     
       
         
           
               
            
               
                 GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGA 
               
               
                   
               
               
                 GAGGGCCACCATCAACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCA 
               
               
                   
               
               
                 ACAATAAGAACTACTTAGCTTGGTACCAGCAGAAACCAGGACAGCCTCCT 
               
               
                   
               
               
                 AAGCTGCTCATTTACTGGGCATCTACCCGGGAATCCGGGGTCCCTGACCG 
               
               
                   
               
               
                 ATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCC 
               
               
                   
               
               
                 TGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAGTTCGCCCACACT 
               
               
                   
               
               
                 CCTTTCACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone PP-26575 LC AA sequence (SEQ ID NO: 375): 
     
       
         
           
               
               
            
               
                   
                 DIVMTQSPDS LAVSLGERAT INC KSSQSVL   YSSNNKNYLA   
               
               
                   
                   
               
               
                   
                 WYQQKPGQPP KLLIY WASTR   ES GVPDRFSG SGSGTDFTLT 
               
               
                   
                   
               
               
                   
                 ISSLQAEDVA VYYCQ QFAHT   PFT FGGGTKV EIKR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to LC CDR 1 AA sequence thereof: KSSQSVLYSSNNKNYLA (SEQ ID NO: 376). In further embodiments, the invention relates to LC CDR2 AA sequence thereof: WASTRES (SEQ ID NO: 377). In further embodiments, the invention relates to LC CDR3 AA sequence thereof: QQFAHTPFT (SEQ ID NO: 378). 
     In further embodiments, the invention relates to Clone PP-26575 CAR DNA H×L (SEQ ID NO: 379): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCA 
               
               
                   
               
               
                 CGCCGCACGCCCGCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGA 
               
               
                   
               
               
                 AGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCCTC 
               
               
                   
               
               
                 AGCAGCCTGGCTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGA 
               
               
                   
               
               
                 GTGGATGGGAGGGGTCATCCCTATCTTGGGTCGGGCAAACTACGCACAGA 
               
               
                   
               
               
                 AGTTCCAGGGCAGAGTCACGATTACCGCGGACGAGTCCACGAGCACAGCC 
               
               
                   
               
               
                 TACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTG 
               
               
                   
               
               
                 CGCCAGAACTCCTGAATACTCCTCCAGCATATGGCACTATTACTACGGCA 
               
               
                   
               
               
                 TGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCAGGGTCTACA 
               
               
                   
               
               
                 TCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGACAT 
               
               
                   
               
               
                 CGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGG 
               
               
                   
               
               
                 CCACCATCAACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCAACAAT 
               
               
                   
               
               
                 AAGAACTACTTAGCTTGGTACCAGCAGAAACCAGGACAGCCTCCTAAGCT 
               
               
                   
               
               
                 GCTCATTTACTGGGCATCTACCCGGGAATCCGGGGTCCCTGACCGATTCA 
               
               
                   
               
               
                 GTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAG 
               
               
                   
               
               
                 GCTGAAGATGTGGCAGTTTATTACTGTCAGCAGTTCGCCCACACTCCTTT 
               
               
                   
               
               
                 CACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGCCGCTGCCCTTG 
               
               
                   
               
               
                 ATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTC 
               
               
                   
               
               
                 TGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGT 
               
               
                   
               
               
                 CGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTT 
               
               
                   
               
               
                 TTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGAT 
               
               
                   
               
               
                 TACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCA 
               
               
                   
               
               
                 GCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGT 
               
               
                   
               
               
                 TTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTG 
               
               
                   
               
               
                 TATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAA 
               
               
                   
               
               
                 GCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACC 
               
               
                   
               
               
                 CCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCC 
               
               
                   
               
               
                 TATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGA 
               
               
                   
               
               
                 CGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTC 
               
               
                   
               
               
                 TCCACATGCAAGCCCTGCCACCTAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone PP-26575 CAR H×L AA sequence (SEO TD NO: 3801: 
     
       
         
           
               
               
            
               
                   
                 MALPVTALLL PLALLLHAAR PQVQLVQSGA EVKKPGSSVK 
               
               
                   
                   
               
               
                   
                 VSCKASGGTL SSLAISWVRQ APGQGLEWMG GVIPILGRAN 
               
               
                   
                   
               
               
                   
                 YAQKFQGRVT ITADESTSTA YMELSSLRSE DTAVYYCART 
               
               
                   
                   
               
               
                   
                 PEYSSSIWHY YYGMDVWGOG TTVTVSSGST SGSGKPGSGE 
               
               
                   
                   
               
               
                   
                 GSTKGDIVMT QSPDSLAVSL GERATINCKS SQSVLYSSNN 
               
               
                   
                   
               
               
                   
                 KNYLAWYQQK PGQPPKLLIY WASTRESGVP DRFSGSGSGT 
               
               
                   
                   
               
               
                   
                 DFTLTISSLQ AEDVAVYYCQ QFAHTPFTFG GGTKVEIKRA 
               
               
                   
                   
               
               
                   
                 AALDNEKSNG TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG 
               
               
                   
                   
               
               
                   
                 GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG 
               
               
                   
                   
               
               
                   
                 PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL 
               
               
                   
                   
               
               
                   
                 YNELNLGRRE EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN 
               
               
                   
                   
               
               
                   
                 ELQKDKMAEA YSEIGMKGER RRGKGHDGLY QGLSTATKDT 
               
               
                   
                   
               
               
                   
                 YDALHMQALP PR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone PP-26575 CAR DNA L×H (SEQ ID NO: 381): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCA 
               
               
                   
               
               
                 CGCCGCACGCCCGGACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTG 
               
               
                   
               
               
                 TGTCTCTGGGCGAGAGGGCCACCATCAACTGCAAGTCCAGCCAGAGTGTT 
               
               
                   
               
               
                 TTATACAGCTCCAACAATAAGAACTACTTAGCTTGGTACCAGCAGAAACC 
               
               
                   
               
               
                 AGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGAATCCG 
               
               
                   
               
               
                 GGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTC 
               
               
                   
               
               
                 ACCATCAGCAGCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCA 
               
               
                   
               
               
                 GTTCGCCCACACTCCTTTCACTTTTGGCGGAGGGACCAAGGTTGAGATCA 
               
               
                   
               
               
                 AACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGT 
               
               
                   
               
               
                 ACAAAGGGGCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCC 
               
               
                   
               
               
                 TGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCCTCAGCA 
               
               
                   
               
               
                 GCCTGGCTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGG 
               
               
                   
               
               
                 ATGGGAGGGGTCATCCCTATCTTGGGTCGGGCAAACTACGCACAGAAGTT 
               
               
                   
               
               
                 CCAGGGCAGAGTCACGATTACCGCGGACGAGTCCACGAGCACAGCCTACA 
               
               
                   
               
               
                 TGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCC 
               
               
                   
               
               
                 AGAACTCCTGAATACTCCTCCAGCATATGGCACTATTACTACGGCATGGA 
               
               
                   
               
               
                 CGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCAGCCGCTGCCCTTG 
               
               
                   
               
               
                 ATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTC 
               
               
                   
               
               
                 TGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGT 
               
               
                   
               
               
                 CGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTT 
               
               
                   
               
               
                 TTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGAT 
               
               
                   
               
               
                 TACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCA 
               
               
                   
               
               
                 GCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGT 
               
               
                   
               
               
                 TTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTG 
               
               
                   
               
               
                 TATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAA 
               
               
                   
               
               
                 GCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACC 
               
               
                   
               
               
                 CCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCC 
               
               
                   
               
               
                 TATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGA 
               
               
                   
               
               
                 CGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTC 
               
               
                   
               
               
                 TCCACATGCAAGCCCTGCCACCTAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone PP-26575 CAR L×H AA sequence (SEQ ID NO: 382): 
     
       
         
           
               
               
            
               
                   
                 MALPVTALLL PLALLLHAAR PDIVMTQSPD SLAVSLGERA 
               
               
                   
                   
               
               
                   
                 TINCKSSQSV LYSSNNKNYL AWYQQKPGQP PKLLIYWAST 
               
               
                   
                   
               
               
                   
                 RESGVPDRFS GSGSGTDFTL TISSLQAEDV AVYYCQQFAH 
               
               
                   
                   
               
               
                   
                 TPFTFGGGTK VEIKRGSTSG SGKPGSGEGS TKGQVQLVQS 
               
               
                   
                   
               
               
                   
                 GAEVKKPGSS VKVSCKASGG TLSSLAISWV RQAPGQGLEW 
               
               
                   
                   
               
               
                   
                 MGGVIPILGR ANYAQKFQGR VTITADESTS TAYMELSSLR 
               
               
                   
                   
               
               
                   
                 SEDTAVYYCA RTPEYSSSIW HYYYGMDVWG QGTTVTVSSA 
               
               
                   
                   
               
               
                   
                 AALDNEKSNG TIIHVKGKHL CPSPLFPGPS KPFWVLVVVG 
               
               
                   
                   
               
               
                   
                 GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG 
               
               
                   
                   
               
               
                   
                 PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL 
               
               
                   
                   
               
               
                   
                 YNELNLGRRE EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN 
               
               
                   
                   
               
               
                   
                 ELQKDKMAEA YSEIGMKGER RRGKGHDGLY QGLSTATKDT 
               
               
                   
                   
               
               
                   
                 YDALHMQALP PR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone RD-26576 HC DNA (SEQ ID NO: 383): 
     
       
         
           
               
            
               
                 CAGGTGCGGCTGGTGGAGTCTGGGGGGGGCGTGGTCCAGCCTGGGAGGTC 
               
               
                   
               
               
                 CCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCA 
               
               
                   
               
               
                 TACACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTT 
               
               
                   
               
               
                 ATAGGGTATGATGGACAGGAGAAATACTATGCAGACTCCGTGAAGGGCCG 
               
               
                   
               
               
                 ATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGA 
               
               
                   
               
               
                 ACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCG 
               
               
                   
               
               
                 TTGCAGGAGCCGCCATACGCTTTTGGGATGGACGTATGGGGCCAGGGAAC 
               
               
                   
               
               
                 AACTGTCACCGTCTCCTCA. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone RD-26576 HC AA sequence (SEQ ID NO: 384): 
     
       
         
           
               
            
               
                 QVRLVESGGG VVQPGRSLRL SCAASG FTFS   SYGIH WVRQA 
               
               
                   
               
               
                 PGKGLEWVA V   IGYDGQEKYY   ADSVKG RFTI SRDNSKNTLY 
               
               
                   
               
               
                 LQMNSLRAED TAVYYC VKGP   LQEPPYAFGM   DV WGQGTTVT VSS. 
               
            
           
         
       
     
     In further embodiments, the invention relates to HC CDR1 AA sequence thereof: FTFSSYGIH (SEQ ID NO: 385). In further embodiments, the invention relates to HC CDR2 AA sequence thereof: VIGYDGQEKYYADSVKG (SEQ ID NO: 386). In further embodiments, the invention relates to the HC CDR3 AA sequence thereof: VKGPLQEPPYAFGMDV (SEQ ID NO: 387). 
     In further embodiments, the invention relates to Clone RD-26576 LC DNA (SEQ ID NO: 388): 
     
       
         
           
               
            
               
                 GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGA 
               
               
                   
               
               
                 AAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAG 
               
               
                   
               
               
                 CCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATAGC 
               
               
                   
               
               
                 GCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTC 
               
               
                   
               
               
                 TGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTG 
               
               
                   
               
               
                 CAGTTTATTACTGTCAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGA 
               
               
                   
               
               
                 GGGACCAAGGTTGAGATCAAACGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone RD-26576 LC AA sequence (SEQ ID NO: 389): 
     
       
         
           
               
               
            
               
                   
                 EIVMTQSPAT LSVSPGERAT LSC RASQSVS   SNLA WYQQKP 
               
               
                   
                   
               
               
                   
                 GQAPRLLIY S   ASTRAT GIPA RFSGSGSGTE FTLTISSLQS 
               
               
                   
                   
               
               
                   
                 EDFAVYYC QQ   HHVWPLT FGG GTKVEIKR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to LC CDR1 AA sequence thereof: RASQSVSSNLA (SEQ ID NO: 390). In further embodiments, the invention relates to LC CDR2 AA sequence thereof: SASTRAT (SEQ ID NO: 391). In further embodiments, the invention relates to LC CDR3 AA sequence thereof: QQHHVWPLT (SEQ ID NO: 392). 
     In further embodiments, the invention relates to Clone RD-26576 CAR DNA H×L (SEQ ID NO: 393): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCA 
               
               
                   
               
               
                 CGCCGCACGCCCGCAGGTGCGGCTGGTGGAGTCTGGGGGGGGCGTGGTCC 
               
               
                   
               
               
                 AGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTC 
               
               
                   
               
               
                 AGTAGCTATGGCATACACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGA 
               
               
                   
               
               
                 GTGGGTGGCAGTTATAGGGTATGATGGACAGGAGAAATACTATGCAGACT 
               
               
                   
               
               
                 CCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG 
               
               
                   
               
               
                 TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTG 
               
               
                   
               
               
                 CGTCAAGGGGCCGTTGCAGGAGCCGCCATACGCTTTTGGGATGGACGTAT 
               
               
                   
               
               
                 GGGGCCAGGGAACAACTGTCACCGTCTCCTCAGGGTCTACATCCGGCTCC 
               
               
                   
               
               
                 GGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATAGTGATGAC 
               
               
                   
               
               
                 GCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCT 
               
               
                   
               
               
                 CCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAG 
               
               
                   
               
               
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTATAGCGCATCCACCAGGGC 
               
               
                   
               
               
                 CACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCA 
               
               
                   
               
               
                 CTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGT 
               
               
                   
               
               
                 CAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGAGGGACCAAGGTTGA 
               
               
                   
               
               
                 GATCAAACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCA 
               
               
                   
               
               
                 TTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCA 
               
               
                   
               
               
                 TCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTA 
               
               
                   
               
               
                 CTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAA 
               
               
                   
               
               
                 GAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCT 
               
               
                   
               
               
                 GGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGC 
               
               
                   
               
               
                 TGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGT 
               
               
                   
               
               
                 ATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGG 
               
               
                   
               
               
                 GAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGG 
               
               
                   
               
               
                 TGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGC 
               
               
                   
               
               
                 AGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAG 
               
               
                   
               
               
                 CGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGC 
               
               
                   
               
               
                 TACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone RD-26576 CAR H×L AA sequence (SEQ ID NO: 394): 
     
       
         
           
               
            
               
                 MALPVTALLL PLALLLHAAR PQVRLVESGG GVVQPGRSLR 
               
               
                   
               
               
                 LSCAASGFTF SSYGIHWVRQ APGKGLEWVA VIGYDGQEKY 
               
               
                   
               
               
                 YADSVKGRFT ISRDNSKNTL YLQMNSLRAE DTAVYYCVKG 
               
               
                   
               
               
                 PLQEPPYAFG MDVWGQGTTV TVSSGSTSGS GKPGSGEGST 
               
               
                   
               
               
                 KGEIVMTQSP ATLSVSPGER ATLSCRASQS VSSNLAWYQQ 
               
               
                   
               
               
                 KPGQAPRLLI YSASTRATGI PARFSGSGSG TEFTLTISSL 
               
               
                   
               
               
                 QSEDFAVYYC QQHHVWPLTF GGGTKVEIKR AAALDNEKSN 
               
               
                   
               
               
                 GTIIHVKGKH LCPSPLFPGP SKPFWVLVVV GGVLACYSLL 
               
               
                   
               
               
                 VTVAFIIFWV RSKRSRLLHS DYMNMTPRRP GPTRKHYQPY 
               
               
                   
               
               
                 APPRDFAAYR SRVKFSRSAD APAYQQGQNQ LYNELNLGRR 
               
               
                   
               
               
                 EEYDVLDKRR GRDPEMGGKP RRKNPQEGLY NELQKDKMAE 
               
               
                   
               
               
                 AYSEIGMKGE RRRGKGHDGL YQGLSTATKD TYDALHMQAL PPR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone RD-26576 CAR DNA L×H (SEQ ID NO: 395): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCA 
               
               
                   
               
               
                 CGCCGCACGCCCGGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTG 
               
               
                   
               
               
                 TGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTT 
               
               
                   
               
               
                 AGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCT 
               
               
                   
               
               
                 CCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCA 
               
               
                   
               
               
                 GTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAG 
               
               
                   
               
               
                 TCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCACCACGTCTGGCCTCT 
               
               
                   
               
               
                 CACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTCTACATCCG 
               
               
                   
               
               
                 GCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGCAGGTGCGG 
               
               
                   
               
               
                 CTGGTGGAGTCTGGGGGGGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT 
               
               
                   
               
               
                 TCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATACACTGGGT 
               
               
                   
               
               
                 CCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATAGGGTATG 
               
               
                   
               
               
                 ATGGACAGGAGAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCATC 
               
               
                   
               
               
                 TCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGAG 
               
               
                   
               
               
                 AGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCGTTGCAGGAGC 
               
               
                   
               
               
                 CGCCATACGCTTTTGGGATGGACGTATGGGGCCAGGGAACAACTGTCACC 
               
               
                   
               
               
                 GTCTCCTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCAT 
               
               
                   
               
               
                 TCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCAT 
               
               
                   
               
               
                 CCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTAC 
               
               
                   
               
               
                 TCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAG 
               
               
                   
               
               
                 AAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTG 
               
               
                   
               
               
                 GCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCT 
               
               
                   
               
               
                 GCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTA 
               
               
                   
               
               
                 TCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGG 
               
               
                   
               
               
                 AAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGT 
               
               
                   
               
               
                 GGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCA 
               
               
                   
               
               
                 GAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGC 
               
               
                   
               
               
                 GGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCT 
               
               
                   
               
               
                 ACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone RD-26576 CAR L×H AA sequence (SEQ ID NO: 396): 
     
       
         
           
               
            
               
                 MALPVTALLL PLALLLHAAR PEIVMTQSPA TLSVSPGERA 
               
               
                   
               
               
                 TLSCRASQSV SSNLAWYQQK PGQAPRLLIY SASTRATGIP 
               
               
                   
               
               
                 ARFSGSGSGT EFTLTISSLQ SEDFAVYYCQ QHHVWPLTFG 
               
               
                   
               
               
                 GGTKVEIKRG STSGSGKPGS GEGSTKGQVR LVESGGGVVQ 
               
               
                   
               
               
                 PGRSLRLSCA ASGFTFSSYG IHWVRQAPGK GLEWVAVIGY 
               
               
                   
               
               
                 DGQEKYYADS VKGRFTISRD NSKNTLYLQM NSLRAEDTAV 
               
               
                   
               
               
                 YYCVKGPLQE PPYAFGMDVW GQGTTVTVSS AAALDNEKSN 
               
               
                   
               
               
                 GTIIHVKGKH LCPSPLFPGP SKPFWVLVVV GGVLACYSLL 
               
               
                   
               
               
                 VTVAFIIFWV RSKRSRLLHS DYMNMTPRRP GPTRKHYQPY 
               
               
                   
               
               
                 APPRDFAAYR SRVKFSRSAD APAYQQGQNQ LYNELNLGRR 
               
               
                   
               
               
                 EEYDVLDKRR GRDPEMGGKP RRKNPQEGLY NELQKDKMAE 
               
               
                   
               
               
                 AYSEIGMKGE RRRGKGHDGL YQGLSTATKD TYDALHMQAL PPR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone RD-26578 HC DNA (SEQ ID NO: 397): 
     
       
         
           
               
            
               
                 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTC 
               
               
                   
               
               
                 CCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCCGTGGCA 
               
               
                   
               
               
                 TGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTT 
               
               
                   
               
               
                 ATAGGGTATGATGGACAGGAGAAATACTATGCAGACTCCGTGAAGGGCCG 
               
               
                   
               
               
                 ATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGA 
               
               
                   
               
               
                 ACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCG 
               
               
                   
               
               
                 TTGCAGGAGCCGCCATACGATTATGGAATGGACGTATGGGGCCAGGGAAC 
               
               
                   
               
               
                 AACTGTCACCGTCTCCTCA. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone RD-26578 HC AA sequence (SEQ ID NO: 398): 
     
       
         
           
               
            
               
                 QVQLVESGGG VVQPGRSLRL SCAASG FTFS   SRGMH WVRQA 
               
               
                   
               
               
                 PGKGLEWVA V   IGYDGQEKYY   ADSVKG RFTI SRDNSKNTLY 
               
               
                   
               
               
                 LQMNSLRAED TAVYYC VKGP   LQEPPYDYGM   DV WGQGTTVT VSS. 
               
            
           
         
       
     
     In further embodiments, the invention relates to HC CDR1 AA sequence thereof: FTFSSRGMH (SEQ ID NO: 399). In further embodiments, the invention relates to HC CDR2 AA sequence thereof: VIGYDGQEKYYADSVKG (SEQ ID NO: 400). In further embodiments, the invention relates to HC CDR3 thereof: VKGPLQEPPYDYGMDV (SEQ ID NO: 401). 
     In further embodiments, the invention relates to Clone RD-26578 LC DNA (SEQ ID NO: 402): 
     
       
         
           
               
            
               
                 GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGA 
               
               
                   
               
               
                 AAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAG 
               
               
                   
               
               
                 CCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATAGC 
               
               
                   
               
               
                 GCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTC 
               
               
                   
               
               
                 TGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTG 
               
               
                   
               
               
                 CAGTTTATTACTGTCAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGA 
               
               
                   
               
               
                 GGGACCAAGGTTGAGATCAAACGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone RD-26578 LC AA sequence (SEQ ID NO: 403): 
     
       
         
           
               
               
            
               
                   
                 EIVMTQSPAT LSVSPGERAT LSC RASQSVS   SNLA WYQQKP 
               
               
                   
                   
               
               
                   
                 GQAPRLLIY S   ASTRAT GIPA RFSGSGSGTE FTLTISSLQS 
               
               
                   
                   
               
               
                   
                 EDFAVYYC QQ   HHVWPLT FGG GTKVEIKR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to LC CDR1 AA sequence: RASQSVSSNLA (SEQ ID NO: 404). In further embodiments, the invention relates to LC CDR2 AA sequence thereof: SASTRAT (SEQ ID NO: 405). In further embodiments, the invention relates to LC CDR3 AA sequence thereof: QQHHVWPLT (SEQ ID NO: 406). 
     In further embodiments, the invention relates to Clone RD-26578 CAR DNA H×L (SEQ ID NO: 407): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCA 
               
               
                   
               
               
                 CGCCGCACGCCCGCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCC 
               
               
                   
               
               
                 AGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTC 
               
               
                   
               
               
                 AGTAGCCGTGGCATGCACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGA 
               
               
                   
               
               
                 GTGGGTGGCAGTTATAGGGTATGATGGACAGGAGAAATACTATGCAGACT 
               
               
                   
               
               
                 CCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTG 
               
               
                   
               
               
                 TATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTG 
               
               
                   
               
               
                 CGTCAAGGGGCCGTTGCAGGAGCCGCCATACGATTATGGAATGGACGTAT 
               
               
                   
               
               
                 GGGGCCAGGGAACAACTGTCACCGTCTCCTCAGGGTCTACATCCGGCTCC 
               
               
                   
               
               
                 GGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATAGTGATGAC 
               
               
                   
               
               
                 GCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCT 
               
               
                   
               
               
                 CCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAG 
               
               
                   
               
               
                 AAACCTGGCCAGGCTCCCAGGCTCCTCATCTATAGCGCATCCACCAGGGC 
               
               
                   
               
               
                 CACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCA 
               
               
                   
               
               
                 CTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGT 
               
               
                   
               
               
                 CAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGAGGGACCAAGGTTGA 
               
               
                   
               
               
                 GATCAAACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCA 
               
               
                   
               
               
                 TTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCA 
               
               
                   
               
               
                 TCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTA 
               
               
                   
               
               
                 CTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAA 
               
               
                   
               
               
                 GAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCT 
               
               
                   
               
               
                 GGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGC 
               
               
                   
               
               
                 TGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGT 
               
               
                   
               
               
                 ATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGG 
               
               
                   
               
               
                 GAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGG 
               
               
                   
               
               
                 TGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGC 
               
               
                   
               
               
                 AGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAG 
               
               
                   
               
               
                 CGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGC 
               
               
                   
               
               
                 TACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone RD-26578 CAR H×L AA sequence (SEQ ID NO: 408): 
     
       
         
           
               
            
               
                 MALPVTALLL PLALLLHAAR PQVQLVESGG GVVQPGRSLR 
               
               
                   
               
               
                 LSCAASGFTF SSRGMHWVRQ APGKGLEWVA VIGYDGQEKY 
               
               
                   
               
               
                 YADSVKGRFT ISRDNSKNTL YLQMNSLRAE DTAVYYCVKG 
               
               
                   
               
               
                 PLQEPPYDYG MDVWGQGTTV TVSSGSTSGS GKPGSGEGST 
               
               
                   
               
               
                 KGEIVMTQSP ATLSVSPGER ATLSCRASQS VSSNLAWYQQ 
               
               
                   
               
               
                 KPGQAPRLLI YSASTRATGI PARFSGSGSG TEFTLTISSL 
               
               
                   
               
               
                 QSEDFAVYYC QQHHVWPLTF GGGTKVEIKR AAALDNEKSN 
               
               
                   
               
               
                 GTIIHVKGKH LCPSPLFPGP SKPFWVLVVV GGVLACYSLL 
               
               
                   
               
               
                 VTVAFIIFWV RSKRSRLLHS DYMNMTPRRP GPTRKHYQPY 
               
               
                   
               
               
                 APPRDFAAYR SRVKFSRSAD APAYQQGQNQ LYNELNLGRR 
               
               
                   
               
               
                 EEYDVLDKRR GRDPEMGGKP RRKNPQEGLY NELQKDKMAE 
               
               
                   
               
               
                 AYSEIGMKGE RRRGKGHDGL YQGLSTATKD TYDALHMQAL PPR. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone RD-26578 CAR DNA L×H (SEQ ID NO: 409): 
     
       
         
           
               
            
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCA 
               
               
                   
               
               
                 CGCCGCACGCCCGGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTG 
               
               
                   
               
               
                 TGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTT 
               
               
                   
               
               
                 AGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCT 
               
               
                   
               
               
                 CCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCA 
               
               
                   
               
               
                 GTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAG 
               
               
                   
               
               
                 TCTGAAGATTTTGCAGTTTATTACTGTCAGCAGCACCACGTCTGGCCTCT 
               
               
                   
               
               
                 CACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTCTACATCCG 
               
               
                   
               
               
                 GCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGCAGGTGCAG 
               
               
                   
               
               
                 CTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACT 
               
               
                   
               
               
                 CTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCCGTGGCATGCACTGGG 
               
               
                   
               
               
                 TCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATAGGGTAT 
               
               
                   
               
               
                 GATGGACAGGAGAAATACTATGCAGACTCCGTGAAGGGCCGATTCACCAT 
               
               
                   
               
               
                 CTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAATGAACAGCCTGA 
               
               
                   
               
               
                 GAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCGTTGCAGGAG 
               
               
                   
               
               
                 CCGCCATACGATTATGGAATGGACGTATGGGGCCAGGGAACAACTGTCAC 
               
               
                   
               
               
                 CGTCTCCTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCA 
               
               
                   
               
               
                 TTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCA 
               
               
                   
               
               
                 TCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTA 
               
               
                   
               
               
                 CTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAA 
               
               
                   
               
               
                 GAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCT 
               
               
                   
               
               
                 GGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGC 
               
               
                   
               
               
                 TGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGT 
               
               
                   
               
               
                 ATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGG 
               
               
                   
               
               
                 GAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGG 
               
               
                   
               
               
                 TGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGC 
               
               
                   
               
               
                 AGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAG 
               
               
                   
               
               
                 CGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGC 
               
               
                   
               
               
                 TACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG. 
               
            
           
         
       
     
     In further embodiments, the invention relates to Clone RD-26578 CAR L×H AA sequence (SEQ ID NO: 410): 
     
       
         
           
               
            
               
                 MALPVTALLL PLALLLHAAR PEIVMTQSPA TLSVSPGERA 
               
               
                   
               
               
                 TLSCRASQSV SSNLAWYQQK PGQAPRLLIY SASTRATGIP 
               
               
                   
               
               
                 ARFSGSGSGT EFTLTISSLQ SEDFAVYYCQ QHHVWPLTFG 
               
               
                   
               
               
                 GGTKVEIKRG STSGSGKPGS GEGSTKGQVQ LVESGGGVVQ 
               
               
                   
               
               
                 PGRSLRLSCA ASGFTFSSRG MHWVRQAPGK GLEWVAVIGY 
               
               
                   
               
               
                 DGQEKYYADS VKGRFTISRD NSKNTLYLQM NSLRAEDTAV 
               
               
                   
               
               
                 YYCVKGPLQE PPYDYGMDVW GQGTTVTVSS AAALDNEKSN 
               
               
                   
               
               
                 GTIIHVKGKH LCPSPLFPGP SKPFWVLVVV GGVLACYSLL 
               
               
                   
               
               
                 VTVAFIIFWV RSKRSRLLHS DYMNMTPRRP GPTRKHYQPY 
               
               
                   
               
               
                 APPRDFAAYR SRVKFSRSAD APAYQQGQNQ LYNELNLGRR 
               
               
                   
               
               
                 EEYDVLDKRR GRDPEMGGKP RRKNPQEGLY NELQKDKMAE 
               
               
                   
               
               
                 AYSEIGMKGE RRRGKGHDGL YQGLSTATKD TYDALHMQAL PPR. 
               
            
           
         
       
     
     It will be appreciated that the sequences recited herein can be useful by themselves, in combination with one or more sequences recited herein, and/or incorporated into cells (such as CAR or TCR-based T cells) for use in immune- or other therapies. It will be further appreciated that these sequences can be used in accordance with the invention incorporated in vectors for transduction, transfection, and the like, into cells. 
     It will be appreciated that adverse events may be minimized by transducing the immune cells (containing one or more CARs or TCRs) with a suicide gene. It may also be desired to incorporate an inducible “on” or “accelerator” switch into the immune cells. Suitable techniques include use of inducible caspase-9 (U.S. Appl. 2011/0286980) or a thymidine kinase, before, after or at the same time, as the cells are transduced with the CAR construct of the present invention. Additional methods for introducing suicide genes and/or “on” switches include TALENS, zinc fingers, RNAi, siRNA, shRNA, antisense technology, and other techniques known in the art. 
     In accordance with the invention, additional on-off or other types of control switch techniques may be incorporated herein. These techniques may employ the use of dimerization domains and optional activators of such domain dimerization. These techniques include, e.g., those described by Wu et al., Science 2014 350 (6258) utilizing FKBP/Rapalog dimerization systems in certain cells, the contents of which are incorporated by reference herein in their entirety. Additional dimerization technology is described in, e.g., Fegan et al. Chem. Rev. 2010, 110, 3315-3336 as well as U.S. Pat. Nos. 5,830,462; 5,834,266; 5,869,337; and 6,165,787, the contents of which are also incorporated by reference herein in their entirety. Additional dimerization pairs may include cyclosporine-A/cyclophilin, receptor, estrogen/estrogen receptor (optionally using tamoxifen), glucocorticoids/glucocorticoid receptor, tetracycline/tetracycline receptor, vitamin D/vitamin D receptor. Further examples of dimerization technology can be found in e.g., WO2014/127261, WO2015/090229, US2014/0286987, US2015/0266973, US2016/0046700, U.S. Pat. No. 8,486,693, US2014/0171649, and US2012/0130076, the contents of which are further incorporated by reference herein in their entirety. 
     IV. Vectors, Cells, and Pharmaceutical Compositions 
     In certain aspects, provided herein are vectors comprising a polynucleotide of the present invention. In some embodiments, the present invention is directed to a vector or a set of vectors comprising a polynucleotide encoding a CAR or a TCR, as described herein. In other embodiments, the present invention is directed to a vector or a set of vectors comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein. 
     Any vector known in the art can be suitable for the present invention. In some embodiments, the vector is a viral vector. In some embodiments, the vector is a retroviral vector (such as pMSVG1), a DNA vector, a murine leukemia virus vector, an SFG vector, a plasmid, a RNA vector, an adenoviral vector, a baculoviral vector, an Epstein Barr viral vector, a papovaviral vector, a vaccinia viral vector, a herpes simplex viral vector, an adenovirus associated vector (AAV), a lentiviral vector (such as pGAR), or any combination thereof. 
     The pGAR sequence (SEQ ID NO: 413) is as follows: 
     
       
         
           
               
               
            
               
                 CTGACGCGCCCTGTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGT 
                   
               
               
                   
               
               
                 GACCGCTACACTTGCCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTTCCTTT 
               
               
                   
               
               
                 CTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGGGCTCCCTTTAGGGT 
               
               
                   
               
               
                 TCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTAGGGTGATGGTTC 
               
               
                   
               
               
                 ACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACG 
               
               
                   
               
               
                 TTCTTTAATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGTCT 
               
               
                   
               
               
                 ATTCTTTTGATTTATAAGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCT 
               
               
                   
               
               
                 GATTTAACAAAAATTTAACGCGAATTTTAACAAAATATTAACGCTTACAATTTGCCAT 
               
               
                   
               
               
                 TCGCCATTCAGGCTGCGCAACTGTTGGGAAGGGCGATCGGTGCGGGCCTCTTCGCTAT 
               
               
                   
               
               
                 TACGCCAGCTGGCGAAAGGGGGATGTGCTGCAAGGCGATTAAGTTGGGTAACGCCAGG 
               
               
                   
               
               
                 GTTTTCCCAGTCACGACGTTGTAAAACGACGGCCAGTGAATTGTAATACGACTCACTA 
               
               
                   
               
               
                 TAGGGCGACCCGGGGATGGCGCGCCAGTAATCAATTACGGGGTCATTAGTTCATAGCC 
               
               
                   
               
               
                 CATATATGGAGTTCCGCGTTACATAACTTACGGTAAATGGCCCGCCTGGCTGACCGCC 
               
               
                   
               
               
                 CAACGACCCCCGCCCATTGACGTCAATAATGACGTATGTTCCCATAGTAACGCCAATA 
               
               
                   
               
               
                 GGGACTTTCCATTGACGTCAATGGGTGGAGTATTTACGGTAAACTGCCCACTTGGCAG 
               
               
                   
               
               
                 TACATCAAGTGTATCATATGCCAAGTACGCCCCCTATTGACGTCAATGACGGTAAATG 
               
               
                   
               
               
                 GCCCGCCTGGCATTATGCCCAGTACATGACCTTATGGGACTTTCCTACTTGGCAGTAC 
               
               
                   
               
               
                 ATCTACGTATTAGTCATCGCTATTACCATGCTGATGCGGTTTTGGCAGTACATCAATG 
               
               
                   
               
               
                 GGCGTGGATAGCGGTTTGACTCACGGGGATTTCCAAGTCTCCACCCCATTGACGTCAA 
               
               
                   
               
               
                 TGGGAGTTTGTTTTGGCACCAAAATCAACGGGACTTTCCAAAATGTCGTAACAACTCC 
               
               
                   
               
               
                 GCCCCATTGACGCAAATGGGCGGTAGGCGTGTACGGTGGGAGGTCTATATAAGCAGAG 
               
               
                   
               
               
                 CTGGTTTAGTGAACCGGGGTCTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCT 
               
               
                   
               
               
                 GGCTAACTAGGGAACCCACTGCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAG 
               
               
                   
               
               
                 TAGTGTGTGCCCGTCTGTTGTGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTA 
               
               
                   
               
               
                 GTCAGTGTGGAAAATCTCTAGCAGTGGCGCCCGAACAGGGACTTGAAAGCGAAAGGGA 
               
               
                   
               
               
                 AACCAGAGGAGCTCTCTCGACGCAGGACTCGGCTTGCTGAAGCGCGCACGGCAAGAGG 
               
               
                   
               
               
                 CGAGGGGCGGCGACTGGTGAGTACGCCAAAAATTTTGACTAGCGGAGGCTAGAAGGAG 
               
               
                   
               
               
                 AGAGATGGGTGCGAGAGCGTCAGTATTAAGCGGGGGAGAATTAGATCGCGATGGGAAA 
               
               
                   
               
               
                 AAATTCGGTTAAGGCCAGGGGGAAAGAAAAAATATAAATTAAAACATATAGTATGGGC 
               
               
                   
               
               
                 AAGCAGGGAGCTAGAACGATTCGCAGTTAATCCTGGCCTGTTAGAAACATCAGAAGGC 
               
               
                   
               
               
                 TGTAGACAAATACTGGGACAGCTACAACCATCCCTTCAGACAGGATCAGAAGAACTTA 
               
               
                   
               
               
                 GATCATTATATAATACAGTAGCAACCCTCTATTGTGTGCATCAAAGGATAGAGATAAA 
               
               
                   
               
               
                 AGACACCAAGGAAGCTTTAGACAAGATAGAGGAAGAGCAAAACAAAAGTAAGACCACC 
               
               
                   
               
               
                 GCACAGCAAGCCGCCGCTGATCTTCAGACCTGGAGGAGGAGATATGAGGGACAATTGG 
               
               
                   
               
               
                 AGAAGTGAATTATATAAATATAAAGTAGTAAAAATTGAACCATTAGGAGTAGCACCCA 
               
               
                   
               
               
                 CCAAGGCAAAGAGAAGAGTGGTGCAGAGAGAAAAAAGAGCAGTGGGAATAGGAGCTTT 
               
               
                   
               
               
                 GTTCCTTGGGTTCTTGGGAGCAGCAGGAAGCACTATGGGCGCAGCGTCAATGACGCTG 
               
               
                   
               
               
                 ACGGTACAGGCCAGACAATTATTGTCTGGTATAGTGCAGCAGCAGAACAATTTGCTGA 
               
               
                   
               
               
                 GGGCTATTGAGGCGCAACAGCATCTGTTGCAACTCACAGTCTGGGGCATCAAGCAGCT 
               
               
                   
               
               
                 CCAGGCAAGAATCCTGGCTGTGGAAAGATACCTAAAGGATCAACAGCTCCTGGGGATT 
               
               
                   
               
               
                 TGGGGTTGCTCTGGAAAACTCATTTGCACCACTGCTGTGCCTTGGAATGCTAGTTGGA 
               
               
                   
               
               
                 GTAATAAATCTCTGGAACAGATTTGGAATCACACGACCTGGATGGAGTGGGACAGAGA 
               
               
                   
               
               
                 AATTAACAATTACACAAGCTTAATACACTCCTTAATTGAAGAATCGCAAAACCAGCAA 
               
               
                   
               
               
                 GAAAAGAATGAACAAGAATTATTGGAATTAGATAAATGGGCAAGTTTGTGGAATTGGT 
               
               
                   
               
               
                 TTAACATAACAAATTGGCTGTGGTATATAAAATTATTCATAATGATAGTAGGAGGCTT 
               
               
                   
               
               
                 GGTAGGTTTAAGAATAGTTTTTGCTGTACTTTCTATAGTGAATAGAGTTAGGCAGGGA 
               
               
                   
               
               
                 TATTCACCATTATCGTTTCAGACCCACCTCCCAACCCCGAGGGGACCCGACAGGCCCG 
               
               
                   
               
               
                 AAGGAATAGAAGAAGAAGGTGGAGAGAGAGACAGAGACAGATCCATTCGATTAGTGAA 
               
               
                   
               
               
                 CGGATCTCGACGGTATCGGTTAACTTTTAAAAGAAAAGGGGGGATTGGGGGGTACAGT 
               
               
                   
               
               
                 GCAGGGGAAAGAATAGTAGACATAATAGCAACAGACATACAAACTAAAGAATTACAAA 
               
               
                   
               
               
                 AACAAATTACAAAATTCAAAATTTTATCGCGATCGCGGAATGAAAGACCCCACCTGTA 
               
               
                   
               
               
                 GGTTTGGCAAGCTAGCTTAAGTAACGCCATTTTGCAAGGCATGGAAAATACATAACTG 
               
               
                   
               
               
                 AGAATAGAGAAGTTCAGATCAAGGTTAGGAACAGAGAGACAGCAGAATATGGGCCAAA 
               
               
                   
               
               
                 CAGGATATCTGTGGTAAGCAGTTCCTGCCCCGGCTCAGGGCCAAGAACAGATGGTCCC 
               
               
                   
               
               
                 CAGATGCGGTCCCGCCCTCAGCAGTTTCTAGAGAACCATCAGATGTTTCCAGGGTGCC 
               
               
                   
               
               
                 CCAAGGACCTGAAAATGACCCTGTGCCTTATTTGAACTAACCAATCAGTTCGCTTCTC 
               
               
                   
               
               
                 GCTTCTGTTCGCGCGCTTCTGCTCCCCGAGCTCAATAAAAGAGCCCACAACCCCTCAC 
               
               
                   
               
               
                 TCGGCGCGCCAGTCCTTCGAAGTAGATCTTTGTCGATCCTACCATCCACTCGACACAC 
               
               
                   
               
               
                 CCGCCAGCGGCCGCTGCCAAGCTTCCGAGCTCTCGAATTAATTCACGGTACCCACCAT 
               
               
                   
               
               
                 GGCCTAGGGAGACTAGTCGAATCGATATCAACCTCTGGATTACAAAATTTGTGAAAGA 
               
               
                   
               
               
                 TTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAA 
               
               
                   
               
               
                 TGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAA 
               
               
                   
               
               
                 ATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTG 
               
               
                   
               
               
                 GTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTC 
               
               
                   
               
               
                 AGCTCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGC 
               
               
                   
               
               
                 CGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTG 
               
               
                   
               
               
                 GTGTTGTCGGGGAAGCTGACGTCCTTTTCATGGCTGCTCGCCTGTGTTGCCACCTGGA 
               
               
                   
               
               
                 TTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCC 
               
               
                   
               
               
                 TTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAG 
               
               
                   
               
               
                 ACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCCTGGTTAATTAAAGTACCTTTAAG 
               
               
                   
               
               
                 ACCAATGACTTACAAGGCAGCTGTAGATCTTAGCCACTTTTTAAAAGAAAAGGGGGGA 
               
               
                   
               
               
                 CTGGAAGGGCGAATTCACTCCCAACGAAGACAAGATCTGCTTTTTGCTTGTACTGGGT 
               
               
                   
               
               
                 CTCTCTGGTTAGACCAGATCTGAGCCTGGGAGCTCTCTGGCTAACTAGGGAACCCACT 
               
               
                   
               
               
                 GCTTAAGCCTCAATAAAGCTTGCCTTGAGTGCTTCAAGTAGTGTGTGCCCGTCTGTTG 
               
               
                   
               
               
                 TGTGACTCTGGTAACTAGAGATCCCTCAGACCCTTTTAGTCAGTGTGGAAAATCTCTA 
               
               
                   
               
               
                 GCAGGCATGCCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGAA 
               
               
                   
               
               
                 TGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAAC 
               
               
                   
               
               
                 CATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAG 
               
               
                   
               
               
                 GTTCAGGGGGAGGTGTGGGAGGTTTTTTGGCGCGCCATCGTCGAGGTTCCCTTTAGTG 
               
               
                   
               
               
                 AGGGTTAATTGCGAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTGTGTGAAATTGT 
               
               
                   
               
               
                 TATCCGCTCACAATTCCACACAACATACGAGCCGGAAGCATAAAGTGTAAAGCCTGGG 
               
               
                   
               
               
                 GTGCCTAATGAGTGAGCTAACTCACATTAATTGCGTTGCGCTCACTGCCCGCTTTCCA 
               
               
                   
               
               
                 GTCGGGAAACCTGTCGTGCCAGCTGCATTAATGAATCGGCCAACGCGCGGGGAGAGGC 
               
               
                   
               
               
                 GGTTTGCGTATTGGGCGCTCTTCCGCTTCCTCGCTCACTGACTCGCTGCGCTCGGTCG 
               
               
                   
               
               
                 TTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAGGCGGTAATACGGTTATCCACAGA 
               
               
                   
               
               
                 ATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAGGCCAGCAAAAGGCCAGGAAC 
               
               
                   
               
               
                 CGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGCTCCGCCCCCCTGACGAGCATC 
               
               
                   
               
               
                 ACAAAAATCGACGCTCAAGTCAGAGGTGGCGAAACCCGACAGGACTATAAAGATACCA 
               
               
                   
               
               
                 GGCGTTTCCCCCTGGAAGCTCCCTCGTGCGCTCTCCTGTTCCGACCCTGCCGCTTACC 
               
               
                   
               
               
                 GGATACCTGTCCGCCTTTCTCCCTTCGGGAAGCGTGGCGCTTTCTCATAGCTCACGCT 
               
               
                   
               
               
                 GTAGGTATCTCAGTTCGGTGTAGGTCGTTCGCTCCAAGCTGGGCTGTGTGCACGAACC 
               
               
                   
               
               
                 CCCCGTTCAGCCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCG 
               
               
                   
               
               
                 GTAAGACACGACTTATCGCCACTGGCAGCAGCCACTGGTAACAGGATTAGCAGAGCGA 
               
               
                   
               
               
                 GGTATGTAGGCGGTGCTACAGAGTTCTTGAAGTGGTGGCCTAACTACGGCTACACTAG 
               
               
                   
               
               
                 AAGAACAGTATTTGGTATCTGCGCTCTGCTGAAGCCAGTTACCTTCGGAAAAAGAGTT 
               
               
                   
               
               
                 GGTAGCTCTTGATCCGGCAAACAAACCACCGCTGGTAGCGGTGGTTTTTTTGTTTGCA 
               
               
                   
               
               
                 AGCAGCAGATTACGCGCAGAAAAAAAGGATCTCAAGAAGATCCTTTGATCTTTTCTAC 
               
               
                   
               
               
                 GGGGTCTGACGCTCAGTGGAACGAAAACTCACGTTAAGGGATTTTGGTCATGAGATTA 
               
               
                   
               
               
                 TCAAAAAGGATCTTCACCTAGATCCTTTTAAATTAAAAATGAAGTTTTAAATCAATCT 
               
               
                   
               
               
                 AAAGTATATATGAGTAAACTTGGTCTGACAGTTACCAATGCTTAATCAGTGAGGCACC 
               
               
                   
               
               
                 TATCTCAGCGATCTGTCTATTTCGTTCATCCATAGTTGCCTGACTCCCCGTCGTGTAG 
               
               
                   
               
               
                 ATAACTACGATACGGGAGGGCTTACCATCTGGCCCCAGTGCTGCAATGATACCGCGAG 
               
               
                   
               
               
                 ACCCACGCTCACCGGCTCCAGATTTATCAGCAATAAACCAGCCAGCCGGAAGGGCCGA 
               
               
                   
               
               
                 GCGCAGAAGTGGTCCTGCAACTTTATCCGCCTCCATCCAGTCTATTAATTGTTGCCGG 
               
               
                   
               
               
                 GAAGCTAGAGTAAGTAGTTCGCCAGTTAATAGTTTGCGCAACGTTGTTGCCATTGCTA 
               
               
                   
               
               
                 CAGGCATCGTGGTGTCACGCTCGTCGTTTGGTATGGCTTCATTCAGCTCCGGTTCCCA 
               
               
                   
               
               
                 ACGATCAAGGCGAGTTACATGATCCCCCATGTTGTGCAAAAAAGCGGTTAGCTCCTTC 
               
               
                   
               
               
                 GGTCCTCCGATCGTTGTCAGAAGTAAGTTGGCCGCAGTGTTATCACTCATGGTTATGG 
               
               
                   
               
               
                 CAGCACTGCATAATTCTCTTACTGTCATGCCATCCGTAAGATGCTTTTCTGTGACTGG 
               
               
                   
               
               
                 TGAGTACTCAACCAAGTCATTCTGAGAATAGTGTATGCGGCGACCGAGTTGCTCTTGC 
               
               
                   
               
               
                 CCGGCGTCAATACGGGATAATACCGCGCCACATAGCAGAACTTTAAAAGTGCTCATCA 
               
               
                   
               
               
                 TTGGAAAACGTTCTTCGGGGCGAAAACTCTCAAGGATCTTACCGCTGTTGAGATCCAG 
               
               
                   
               
               
                 TTCGATGTAACCCACTCGTGCACCCAACTGATCTTCAGCATCTTTTACTTTCACCAGC 
               
               
                   
               
               
                 GTTTCTGGGTGAGCAAAAACAGGAAGGCAAAATGCCGCAAAAAAGGGAATAAGGGCGA 
               
               
                   
               
               
                 CACGGAAATGTTGAATACTCATACTCTTCCTTTTTCAATATTATTGAAGCATTTATCA 
               
               
                   
               
               
                 GGGTTATTGTCTCATGAGCGGATACATATTTGAATGTATTTAGAAAAATAAACAAATA 
               
               
                   
               
               
                 GGGGTTCCGCGCACATTTCCCCGAAAAGTGCCAC. 
               
            
           
         
       
     
     The pGAR vector map is set forth in  FIG.  19   . 
     Suitable additional exemplary vectors include e.g., pBABE-puro, pBABE-neo largeTcDNA, pBABE-hygro-hTERT, pMKO.1 GFP, MSCV-IRES-GFP, pMSCV PIG (Puro IRES GFP empty plasmid), pMSCV-loxp-dsRed-loxp-eGFP-Puro-WPRE, MSCV IRES Luciferase, pMIG, MDH1-PGK-GFP_2.0, TtRMPVIR, pMSCV-IRES-mCherry FP, pRetroX GFP T2A Cre, pRXTN, pLncEXP, and pLXIN-Luc. 
     In other aspects, provided herein are cells comprising a polynucleotide or a vector of the present invention. In some embodiments, the present invention is directed to cells, in vitro cells, comprising a polynucleotide encoding a CAR or a TCR, as described herein. In some embodiments, the present invention is directed to cells, e.g., in vitro cells, comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein. In other embodiments, the present invention is directed to in vitro cells comprising a polypeptide encoded by a polynucleotide encoding a CAR or a TCR, as disclosed herein. In other embodiments, the present invention is directed to cells, in vitro cells, comprising a polypeptide encoded by a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein. 
     Any cell may be used as a host cell for the polynucleotides, the vectors, or the polypeptides of the present invention. In some embodiments, the cell can be a prokaryotic cell, fungal cell, yeast cell, or higher eukaryotic cells such as a mammalian cell. Suitable prokaryotic cells include, without limitation, eubacteria, such as Gram-negative or Gram-positive organisms, for example, Enterobactehaceae such as  Escherichia , e.g.,  E. coli; Enterobacter; Erwinia; Klebsiella; Proteus; Salmonella , e.g.,  Salmonella typhimurium; Serratia , e.g.,  Serratia marcescans , and  Shigella ; Bacilli such as  B. subtilis  and  B. licheniformis; Pseudomonas  such as  P. aeruginosa ; and  Streptomyces . In some embodiments, the cell is a human cell. In some embodiments, the cell is an immune cell. In some embodiments, the immune cell is selected from the group consisting of a T cell, a B cell, a tumor infiltrating lymphocyte (TIL), a TCR expressing cell, a natural killer (NK) cell, a dendritic cell, a granulocyte, an innate lymphoid cell, a megakaryocyte, a monocyte, a macrophage, a platelet, a thymocyte, and a myeloid cell. In one embodiment, the immune cell is a T cell. In another embodiment, the immune cell is an NK cell. In certain embodiments, the T cell is a tumor-infiltrating lymphocyte (TIL), autologous T cell, engineered autologous T cell (eACT™), an allogeneic T cell, a heterologous T cell, or any combination thereof. 
     The cell of the present invention can be obtained through any source known in the art. For example, T cells can be differentiated in vitro from a hematopoietic stem cell population, or T cells can be obtained from a subject. T cells can be obtained from, e.g., peripheral blood mononuclear cells, bone marrow, lymph node tissue, cord blood, thymus tissue, tissue from a site of infection, ascites, pleural effusion, spleen tissue, and tumors. In addition, the T cells can be derived from one or more T cell lines available in the art. T cells can also be obtained from a unit of blood collected from a subject using any number of techniques known to the skilled artisan, such as FICOLL™ separation and/or apheresis. In certain embodiments, the cells collected by apheresis are washed to remove the plasma fraction, and placed in an appropriate buffer or media for subsequent processing. In some embodiments, the cells are washed with PBS. As will be appreciated, a washing step can be used, such as by using a semiautomated flowthrough centrifuge, e.g., the COBE™ 2991 cell processor, the Baxter CYTOMATE™, or the like. In some embodiments, the washed cells are resuspended in one or more biocompatible buffers, or other saline solution with or without buffer. In certain embodiments, the undesired components of the apheresis sample are removed. Additional methods of isolating T cells for a T cell therapy are disclosed in U.S. Patent Publication No. 2013/0287748, which is herein incorporated by references in its entirety. 
     In certain embodiments, T cells are isolated from PBMCs by lysing the red blood cells and depleting the monocytes, e.g., by using centrifugation through a PERCOLL™ gradient. In some embodiments, a specific subpopulation of T cells, such as CD28 + , CD4 + , CD8 + , CD45RA + , and CD45RO +  T cells is further isolated by positive or negative selection techniques known in the art. For example, enrichment of a T cell population by negative selection can be accomplished with a combination of antibodies directed to surface markers unique to the negatively selected cells. In some embodiments, cell sorting and/or selection via negative magnetic immunoadherence or flow cytometry that uses a cocktail of monoclonal antibodies directed to cell surface markers present on the cells negatively selected can be used. For example, to enrich for CD4 +  cells by negative selection, a monoclonal antibody cocktail typically includes antibodies to CD14, CD20, CD11b, CD16, HLA-DR, and CD8. In certain embodiments, flow cytometry and cell sorting are used to isolate cell populations of interest for use in the present invention. 
     In some embodiments, PBMCs are used directly for genetic modification with the immune cells (such as CARs or TCRs) using methods as described herein. In certain embodiments, after isolating the PBMCs, T lymphocytes are further isolated, and both cytotoxic and helper T lymphocytes are sorted into naive, memory, and effector T cell subpopulations either before or after genetic modification and/or expansion. 
     In some embodiments, CD8 +  cells are further sorted into naive, central memory, and effector cells by identifying cell surface antigens that are associated with each of these types of CD8 +  cells. In some embodiments, the expression of phenotypic markers of central memory T cells includes CD45RO, CD62L, CCR7, CD28, CD3, and CD127 and are negative for granzyme B. In some embodiments, central memory T cells are CD45RO + , CD62L + , CD8 +  T cells. In some embodiments, effector T cells are negative for CD62L, CCR7, CD28, and CD127 and positive for granzyme B and perforin. In certain embodiments, CD4 +  T cells are further sorted into subpopulations. For example, CD4 +  T helper cells can be sorted into naive, central memory, and effector cells by identifying cell populations that have cell surface antigens. 
     In some embodiments, the immune cells, e.g., T cells, are genetically modified following isolation using known methods, or the immune cells are activated and expanded (or differentiated in the case of progenitors) in vitro prior to being genetically modified. In another embodiment, the immune cells, e.g., T cells, are genetically modified with the chimeric antigen receptors described herein (e.g., transduced with a viral vector comprising one or more nucleotide sequences encoding a CAR) and then are activated and/or expanded in vitro. Methods for activating and expanding T cells are known in the art and are described, e.g., in U.S. Pat. Nos. 6,905,874; 6,867,041; and 6,797,514; and PCT Publication No. WO 2012/079000, the contents of which are hereby incorporated by reference in their entirety. Generally, such methods include contacting PBMC or isolated T cells with a stimulatory agent and costimulatory agent, such as anti-CD3 and anti-CD28 antibodies, generally attached to a bead or other surface, in a culture medium with appropriate cytokines, such as IL-2. Anti-CD3 and anti-CD28 antibodies attached to the same bead serve as a “surrogate” antigen presenting cell (APC). One example is The Dynabeads® system, a CD3 CD28 activator/stimulator system for physiological activation of human T cells. In other embodiments, the T cells are activated and stimulated to proliferate with feeder cells and appropriate antibodies and cytokines using methods such as those described in U.S. Pat. Nos. 6,040,177 and 5,827,642 and PCT Publication No. WO 2012/129514, the contents of which are hereby incorporated by reference in their entirety. 
     In certain embodiments, the T cells are obtained from a donor subject. In some embodiments, the donor subject is human patient afflicted with a cancer or a tumor. In other embodiments, the donor subject is a human patient not afflicted with a cancer or a tumor. 
     Other aspects of the present invention are directed to compositions comprising a polynucleotide described herein, a vector described herein, a polypeptide described herein, or an in vitro cell described herein. In some embodiments, the composition comprises a pharmaceutically acceptable carrier, diluent, solubilizer, emulsifier, preservative and/or adjuvant. In some embodiments, the composition comprises an excipient. In one embodiment, the composition comprises a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA. In another embodiment, the composition comprises a CAR or a TCR encoded by a polynucleotide of the present invention, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA. In another embodiment, the composition comprises a T cell comprising a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA. In another embodiment, the composition comprises an antibody or an antigen binding molecule thereof encoded by a polynucleotide of the present invention. In another embodiment, the composition comprises an in vitro cell comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof encoded by a polynucleotide of the present invention. 
     In some embodiments, the composition includes more than one different antigen binding molecule to BMCA. In some embodiments, the composition included more than one antigen binding molecule to BCMA, wherein the antigen binding molecules to BCMA bind more than one epitope. In some embodiments, the antigen binding molecules will not compete with one another for binding to BCMA. In some embodiments, any of the antigen binding molecules provided herein are combined together in a pharmaceutical composition. 
     In other embodiments, the composition is selected for parenteral delivery, for inhalation, or for delivery through the digestive tract, such as orally. The preparation of such pharmaceutically acceptable compositions is within the ability of one skilled in the art. In certain embodiments, buffers are used to maintain the composition at physiological pH or at a slightly lower pH, typically within a pH range of from about 5 to about 8. In certain embodiments, when parenteral administration is contemplated, the composition is in the form of a pyrogen-free, parenterally acceptable aqueous solution comprising a desired antigen binding molecule to BCMA, with or without additional therapeutic agents, in a pharmaceutically acceptable vehicle. In certain embodiments, the vehicle for parenteral injection is sterile distilled water in which an antigen binding molecule to BCMA, with or without at least one additional therapeutic agent, is formulated as a sterile, isotonic solution, properly preserved. In certain embodiments, the preparation involves the formulation of the desired molecule with polymeric compounds (such as polylactic acid or polyglycolic acid), beads or liposomes, that provide for the controlled or sustained release of the product, which are then be delivered via a depot injection. In certain embodiments, implantable drug delivery devices are used to introduce the desired molecule. 
     V. Methods of the Invention 
     Another aspect of the invention is directed to a method of making a cell expressing a CAR or a TCR comprising transducing a cell with a polynucleotide disclosed herein under suitable conditions. In some embodiments, the method comprises transducing a cell with a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, as disclosed herein. In some embodiments, the method comprises transducing a cell with a vector comprising the polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA. In other embodiments, the method comprises transducing a cell with a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein. In some embodiments, the method comprises transducing a cell with a vector comprising the polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as described herein. In some embodiments, the method further comprises isolating the cell. 
     Another aspect of the present invention is directed to a method of inducing an immunity against a tumor comprising administering to a subject an effective amount of a cell comprising a polynucleotide described herein, a vector described herein, or a CAR or a TCR described herein. In one embodiment, the method comprises administering to a subject an effective amount of a cell comprising a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, as disclosed herein. In another embodiment, the method comprises administering to a subject an effective amount of a cell comprising a vector comprising a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, as disclosed herein. In another embodiment, the method comprises administering to a subject an effective amount of a cell comprising a CAR or a TCR encoded by a polynucleotide disclosed herein, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA. In other embodiments, the method comprises administering to a subject an effective amount of a cell comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein. In another embodiment, the method comprises administering to a subject an effective amount of a cell comprising a vector comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein. In another embodiment, the method comprises administering to a subject an effective amount of a cell comprising an antibody or antigen binding molecule thereof encoded by a polynucleotide disclosed herein, wherein the antibody or antigen binding molecule thereof specifically binds to BCMA. 
     Another aspect of the present invention is directed to a method of inducing an immune response in a subject comprising administering an effective amount of the engineered immune cells of the present application. In some embodiments, the immune response is a T cell-mediated immune response. In some embodiments, the T cell-mediated immune response is directed against one or more target cells. In some embodiments, the engineered immune cell comprises a CAR or a TCR. In some embodiments, the target cell is a tumor cell. 
     Another aspect of the present invention is directed to a method for treating or preventing a malignancy, said method comprising administering to a subject in need thereof an effective amount of at least one isolated antigen binding molecule described herein or at least one immune cell, wherein the immune cell comprises at least one CAR, TCR, and/or an isolated antigen binding molecule as described herein. 
     Another aspect of the present invention is directed to a method of treating a hyperproliferative disorder or an inflammatory disease in a subject in need thereof comprising administering to the subject a polynucleotide disclosed herein, a vector disclosed herein, a CAR or a TCR disclosed herein, a cell disclosed herein, or a composition disclosed herein. In some embodiments, the inflammatory disease is selected from the group consisting of rheumatoid arthritis, psoriasis, allergies, asthma, autoimmune diseases such as Crohn&#39;s, IBD, fibromyalga, mastocytosis, Celiac disease, and any combination thereof. Additionally, the present invention may be useful to treat diabetes, particularly Type 1 diabetes. 
     Another aspect of the present invention is directed to a method of treating a cancer in a subject in need thereof comprising administering to the subject a polynucleotide disclosed herein, a vector disclosed herein, a CAR or a TCR disclosed herein, a cell disclosed herein, or a composition disclosed herein. In one embodiment, the method comprises administering a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, as disclosed herein. In another embodiment, the method comprises administering a vector comprising a polynucleotide encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, as disclosed herein. In another embodiment, the method comprises administering a CAR or a TCR encoded by a polynucleotide disclosed herein, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA. In another embodiment, the method comprises administering a cell comprising the polynucleotide, or a vector comprising the polynucleotide, encoding a CAR or a TCR, wherein the CAR or the TCR comprises an antigen binding molecule that specifically binds to BCMA, as disclosed herein. In other embodiments, the method comprises administering a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein. In another embodiment, the method comprises administering a vector comprising a polynucleotide encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein. In another embodiment, the method comprises administering an antibody or an antigen binding molecule thereof encoded by a polynucleotide disclosed herein, wherein the antibody or the antigen binding molecule thereof specifically binds to BCMA. In another embodiment, the method comprises administering a cell comprising the polynucleotide, or a vector comprising the polynucleotide, encoding an antibody or an antigen binding molecule thereof that specifically binds to BCMA, as disclosed herein. 
     In some embodiments, an antigen binding molecule to BCMA is administered alone. In certain embodiments, an antigen binding molecule to BCMA is administered as part of a CAR, TCR, or other immune cell. In such immune cells, the antigen binding molecule to BCMA can be under the control of the same promoter region, or a separate promoter. In certain embodiments, the genes encoding protein agents and/or an antigen binding molecule to BCMA can be in separate vectors. 
     In some embodiments, the methods of treating a cancer in a subject in need thereof comprise a T cell therapy. In one embodiment, the T cell therapy of the present invention is engineered Autologous Cell Therapy (eACT™). According to this embodiment, the method can include collecting blood cells from the patient. The isolated blood cells (e.g., T cells) can then be engineered to express an anti-BCMA CAR of the present invention (“anti-BCMA CAR T cells”). In a particular embodiment, the anti-BCMA CAR T cells are administered to the patient. In some embodiments, the anti-BCMA CAR T cells treat a tumor or a cancer in the patient. In one embodiment the anti-BCMA CAR T cells reduce the size of a tumor or a cancer. 
     In some embodiments, the donor T cells for use in the T cell therapy are obtained from the patient (e.g., for an autologous T cell therapy). In other embodiments, the donor T cells for use in the T cell therapy are obtained from a subject that is not the patient. 
     The T cells can be administered at a therapeutically effective amount. For example, a therapeutically effective amount of the T cells can be at least about 10 4  cells, at least about 10 5  cells, at least about 10 6  cells, at least about 10 7  cells, at least about 10 8  cells, at least about 10 9  cells, at least about 10 10  cells, or at least about 10 11  cells. In another embodiment, the therapeutically effective amount of the T cells is about 10 4  cells, about 10 5  cells, about 10 6  cells, about 10 7  cells, or about 10 8  cells. In one particular embodiment, the therapeutically effective amount of the anti-BCMA CAR T cells is about 2×10 6  cells/kg, about 3×10 6  cells/kg, about 4×10 6  cells/kg, about 5×10 6  cells/kg, about 6×10 6  cells/kg, about 7×10 6  cells/kg, about 8×10 6  cells/kg, about 9×10 6  cells/kg, about 1×10 7  cells/kg, about 2×10 7  cells/kg, about 3×10 7  cells/kg, about 4×10 7  cells/kg, about 5×10 7  cells/kg, about 6×10 7  cells/kg, about 7×10 7  cells/kg, about 8×10 7  cells/kg, or about 9×10 7  cells/kg. 
     Another aspect of the present invention is directed to methods of diagnosis, detection, or validation. In some embodiments, the antigen binding molecule is used as a diagnostic or validation tool. In certain embodiments, the antigen binding molecules disclosed herein are used to assay the amount of BCMA present in a sample and/or subject. In some embodiments, the diagnostic antigen binding molecule is not neutralizing. In some embodiments, the antigen binding molecules disclosed herein are used or provided in an assay kit and/or method for the detection of BCMA in mammalian tissues or cells in order to screen/diagnose for a disease or disorder associated with changes in levels of BCMA. In some embodiments, the kit comprises an antigen binding molecule that binds BCMA, along with means for indicating the binding of the antigen binding molecule with BCMA, if present, and optionally BCMA protein levels. Various means for indicating the presence of an antigen binding molecule can be used. For example, fluorophores, other molecular probes, or enzymes can be linked to the antigen binding molecule and the presence of the antigen binding molecule can be observed in a variety of ways. As will be appreciated by one of skill in the art, the degree of antigen binding molecule binding can be used to determine how much BCMA is in a sample. 
     V.A. Cancer Treatment 
     The methods of the invention can be used to treat a cancer in a subject, reduce the size of a tumor, kill tumor cells, prevent tumor cell proliferation, prevent growth of a tumor, eliminate a tumor from a patient, prevent relapse of a tumor, prevent tumor metastasis, induce remission in a patient, or any combination thereof. In certain embodiments, the methods induce a complete response. In other embodiments, the methods induce a partial response. 
     Cancers that may be treated include tumors that are not vascularized, not yet substantially vascularized, or vascularized. The cancer may also include solid or non-solid tumors. In some embodiments, the cancer is a hematologic cancer. In some embodiments, the cancer is of the white blood cells. In other embodiments, the cancer is of the plasma cells. In some embodiments, the cancer is leukemia, lymphoma, or myeloma. In certain embodiments, the cancer is multiple myeloma, Hodgkin&#39;s Disease, non-Hodgkin&#39;s lymphoma (NHL), primary mediastinal large B cell lymphoma (PMBC), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL), transformed follicular lymphoma, splenic marginal zone lymphoma (SMZL), chronic or acute leukemia, myeloid diseases including but not limited to acute myeloid leukemia (AML), chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) (including non T cell ALL), chronic lymphocytic leukemia (CLL), T-cell lymphoma, one or more of B-cell acute lymphoid leukemia (“BALL”), T-cell acute lymphoid leukemia (“TALL”), acute lymphoid leukemia (ALL), chronic myelogenous leukemia (CML), B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt&#39;s lymphoma, diffuse large B cell lymphoma, follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma, mantle cell lymphoma, Marginal zone lymphoma, myelodysplasia and myelodysplastic syndrome (MDS), hemophagocytic syndrome (Macrophage Activating Syndrome (MAS), and hemophagocytic lymphohistocytosis (HLH)), chronic or acute granulomatous disease, large cell granuloma, leukocyte adhesion deficiency, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, plasma cell proliferative disorders (e.g., asymptomatic myeloma (smoldering multiple myeloma or indolent myeloma), monoclonal gammapathy of undetermined significance (MGUS), plasmacytomas (e.g., plasma cell dyscrasia, solitary myeloma, solitary plasmacytoma, extramedullary plasmacytoma, and multiple plasmacytoma), systemic amyloid light chain amyloidosis, POEMS syndrome (Crow-Fukase syndrome, Takatsuki disease, PEP syndrome), or combinations thereof. In one embodiment, the cancer is a myeloma. In one particular embodiment, the cancer is multiple myeloma. 
     In some embodiments, the methods further comprise administering a chemotherapeutic. In certain embodiments, the chemotherapeutic selected is a lymphodepleting (preconditioning) chemotherapeutic. Beneficial preconditioning treatment regimens, along with correlative beneficial biomarkers are described in U.S. Provisional Patent Applications 62/262,143 and 62/167,750 which are hereby incorporated by reference in their entirety herein. These describe, e.g., methods of conditioning a patient in need of a T cell therapy comprising administering to the patient specified beneficial doses of cyclophosphamide (between 200 mg/m 2 /day and 2000 mg/m 2 /day) and specified doses of fludarabine (between 20 mg/m 2 /day and 900 mg/m 2 /day). A preferred dose regimen involves treating a patient comprising administering daily to the patient about 500 mg/m 2 /day of cyclophosphamide and about 60 mg/m 2 /day of fludarabine for three days prior to administration of a therapeutically effective amount of engineered T cells to the patient. 
     In other embodiments, the antigen binding molecule, transduced (or otherwise engineered) cells (such as CARs or TCRs), and the chemotherapeutic agent are administered each in an amount effective to treat the disease or condition in the subject. 
     In certain embodiments, compositions comprising CAR- and/or TCR-expressing immune effector cells disclosed herein may be administered in conjunction with any number of chemotherapeutic agents. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN™); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and uredopa; ethylenimines and methylamelamines including altretamine, triethylenemelamine, trietylenephosphoramide, triethylenethiophosphaoramide and trimethylolomelamine resume; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosureas such as carmustine, chlorozotocin, fotemustine, lomustine, nimustine, ranimustine; antibiotics such as aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, calicheamicin, carabicin, carminomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin, epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as denopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogs such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine, 5-FU; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replenisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; amsacrine; bestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformithine; elliptinium acetate; etoglucid; gallium nitrate; hydroxyurea; lentinan; lonidamine; mitoguazone; mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK®; razoxane; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2′,2″-trichlorotriethylamine; urethan; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside (“Ara-C”); cyclophosphamide; thiotepa; taxoids, e.g. paclitaxel (TAXOL™, Bristol-Myers Squibb) and doxetaxel (TAXOTERE®, Rhone-Poulenc Rorer); chlorambucil; gemcitabine; 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitomycin C; mitoxantrone; vincristine; vinorelbine; navelbine; novantrone; teniposide; daunomycin; aminopterin; xeloda; ibandronate; CPT-11; topoisomerase inhibitor RFS2000; difluoromethylomithine (DMFO); retinoic acid derivatives such as Targretin™ (bexarotene), Panretin™, (alitretinoin); ONTAK™ (denileukin diftitox); esperamicins; capecitabine; and pharmaceutically acceptable salts, acids or derivatives of any of the above. In some embodiments, compositions comprising CAR- and/or TCR-expressing immune effector cells disclosed herein may be administered in conjunction with an anti-hormonal agent that acts to regulate or inhibit hormone action on tumors such as anti-estrogens including for example tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above. Combinations of chemotherapeutic agents are also administered where appropriate, including, but not limited to CHOP, i.e., Cyclophosphamide (Cytoxan®), Doxorubicin (hydroxydoxorubicin), Vincristine (Oncovin®), and Prednisone. 
     In some embodiments, the chemotherapeutic agent is administered at the same time or within one week after the administration of the engineered cell or nucleic acid. In other embodiments, the chemotherapeutic agent is administered from 1 to 4 weeks or from 1 week to 1 month, 1 week to 2 months, 1 week to 3 months, 1 week to 6 months, 1 week to 9 months, or 1 week to 12 months after the administration of the engineered cell or nucleic acid. In some embodiments, the chemotherapeutic agent is administered at least 1 month before administering the cell or nucleic acid. In some embodiments, the methods further comprise administering two or more chemotherapeutic agents. 
     A variety of additional therapeutic agents may be used in conjunction with the compositions described herein. For example, potentially useful additional therapeutic agents include PD-1 inhibitors such as nivolumab (Opdivo®), pembrolizumab (Keytruda®), pembrolizumab, pidilizumab (CureTech), and atezolizumab (Roche). 
     Additional therapeutic agents suitable for use in combination with the invention include, but are not limited to, ibrutinib (Imbruvica®), ofatumumab (Arzerra®), rituximab (Rituxan®), bevacizumab (Avastin®), trastuzumab (Herceptin®), trastuzumab emtansine (KADCYLA®), imatinib (Gleevec®), cetuximab (Erbitux®), panitumumab (Vectibix®), catumaxomab, ibritumomab, ofatumumab, tositumomab, brentuximab, alemtuzumab, gemtuzumab, erlotinib, gefitinib, vandetanib, afatinib, lapatinib, neratinib, axitinib, masitinib, pazopanib, sunitinib, sorafenib, toceranib, lestaurtinib, axitinib, cediranib, lenvatinib, nintedanib, pazopanib, regorafenib, semaxanib, sorafenib, sunitinib, tivozanib, toceranib, vandetanib, entrectinib, cabozantinib, imatinib, dasatinib, nilotinib, ponatinib, radotinib, bosutinib, lestaurtinib, ruxolitinib, pacritinib, cobimetinib, selumetinib, trametinib, binimetinib, alectinib, ceritinib, crizotinib, aflibercept, adipotide, denileukin diftitox, mTOR inhibitors such as Everolimus and Temsirolimus, hedgehog inhibitors such as sonidegib and vismodegib, CDK inhibitors such as CDK inhibitor (palbociclib). 
     In additional embodiments, the composition comprising CAR- and/or TCR-containing immune are administered with an anti-inflammatory agent. Anti-inflammatory agents or drugs can include, but are not limited to, steroids and glucocorticoids (including betamethasone, budesonide, dexamethasone, hydrocortisone acetate, hydrocortisone, hydrocortisone, methylprednisolone, prednisolone, prednisone, triamcinolone), nonsteroidal anti-inflammatory drugs (NSAIDS) including aspirin, ibuprofen, naproxen, methotrexate, sulfasalazine, leflunomide, anti-TNF medications, cyclophosphamide and mycophenolate. Exemplary NSAIDs include ibuprofen, naproxen, naproxen sodium, Cox-2 inhibitors, and sialylates. Exemplary analgesics include acetaminophen, oxycodone, tramadol of proporxyphene hydrochloride. Exemplary glucocorticoids include cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, or prednisone. Exemplary biological response modifiers include molecules directed against cell surface markers (e.g., CD4, CD5, etc.), cytokine inhibitors, such as the TNF antagonists, (e.g., etanercept (ENBREL®), adalimumab (HUMIRA®) and infliximab (REMICADE®), chemokine inhibitors and adhesion molecule inhibitors. The biological response modifiers include monoclonal antibodies as well as recombinant forms of molecules. Exemplary DMARDs include azathioprine, cyclophosphamide, cyclosporine, methotrexate, penicillamine, leflunomide, sulfasalazine, hydroxychloroquine, Gold (oral (auranofin) and intramuscular), and minocycline. 
     In certain embodiments, the compositions described herein are administered in conjunction with a cytokine. “Cytokine” as used herein is meant to refer to proteins released by one cell population that act on another cell as intercellular mediators. Examples of cytokines are lymphokines, monokines, and traditional polypeptide hormones. Included among the cytokines are growth hormones such as human growth hormone, N-methionyl human growth hormone, and bovine growth hormone; parathyroid hormone; thyroxine; insulin; proinsulin; relaxin; prorelaxin; glycoprotein hormones such as follicle stimulating hormone (FSH), thyroid stimulating hormone (TSH), and luteinizing hormone (LH); hepatic growth factor (HGF); fibroblast growth factor (FGF); prolactin; placental lactogen; mullerian-inhibiting substance; mouse gonadotropin-associated peptide; inhibin; activin; vascular endothelial growth factor; integrin; thrombopoietin (TPO); nerve growth factors (NGFs) such as NGF-beta; platelet-growth factor; transforming growth factors (TGFs) such as TGF-alpha and TGF-beta; insulin-like growth factor-I and -II; erythropoietin (EPO); osteoinductive factors; interferons such as interferon-alpha, beta, and -gamma; colony stimulating factors (CSFs) such as macrophage-CSF (M-CSF); granulocyte-macrophage-CSF (GM-CSF); and granulocyte-CSF (G-CSF); interleukins (ILs) such as IL-1, IL-1 alpha, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12; IL-15, a tumor necrosis factor such as TNF-alpha or TNF-beta; and other polypeptide factors including LIF and kit ligand (KL). As used herein, the term cytokine includes proteins from natural sources or from recombinant cell culture, and biologically active equivalents of the native sequence cytokines. 
     All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference. However, the citation of a reference herein should not be construed as an acknowledgement that such reference is prior art to the present invention. To the extent that any of the definitions or terms provided in the references incorporated by reference differ from the terms and discussion provided herein, the present terms and definitions control. 
     The present invention is further illustrated by the following examples which should not be construed as further limiting. The contents of all references cited throughout this application are expressly incorporated herein by reference. 
     EXAMPLES 
     Example 1 
     BCMA expression was measured in various cell lines. BCMA was found to be expressed, with a fragments/kilobase of exon/million reads mapped (FPKM) greater than 35, in 99% of multiple myeloma tumor cell lines tested ( FIG.  2 A ). BCMA expression was greater than that of CD70, CS-1, CLL-1, DLL-1 and FLT3 ( FIG.  2 A ). To further characterize the expression of BCMA, EoL-1 (Sigma), NCI-H929 (Molecular Imaging), and MM1S (Molecular Imaging) cells were stained with an anti-BCMA antibody conjugated to PE (Biolegend, San Diego, Calif.) in stain buffer (BD Pharmingen, San Jose, Calif.) for 30 minutes at 4° C. Cells were then washed and resuspended in stain buffer with propidium iodide (BD Pharmingen) prior to data acquisition. Samples were then acquired by flow cytometry and data analyzed ( FIGS.  2 B- 2 C ). BCMA expression was observed in the myeloma cell lines MM1S ( FIG.  2 C ) and NCI-H929 ( FIG.  2 D ), but not in the human eosinophil cell line EoL-1 ( FIG.  2 B ). In addition, little to no BCMA expression was observed in normal immune cells ( FIG.  2 E ). 
     Example 2 
     A third generation lentiviral transfer vector containing the BCMA CAR constructs was used along with the ViraPower Lentiviral Packaging Mix (Life Technologies, FIX′) to generate the lentiviral supernatants. Briefly, a transfection mix was generated by mixing 15 μg of DNA and 22.5 μl of polyethileneimine (Polysciences, 1 mg/ml) in 600 μl of OptiMEM media. The transfection mix was incubated for 5 minutes at room temperature. Simultaneously, 293T cells (ATCC) were trypsinized and counted. A total of 10×10 6  total 293T cells were then plated in a T75 flask with the transfection mix. Following culture for three days, supernatants were collected and filtered through a 0.45 μm filter and stored at −80° C. 
     Peripheral blood mononuclear cells (PBMCs) were isolated from two different healthy donor leukopaks (Hemacare) using ficoll-paque density centrifugation according to the manufacturer&#39;s instructions. PBMCs were stimulated using OKT3 (Muromonab-CD3, 50 ng/ml, Miltenyi Biotec) in R10 media supplemented with IL-2 (300 IU/ml, Proleukin®, Prometheus® Therapeutics and Diagnostics). Forty-eight hours post-stimulation, cells were transduced using lentivirus containing the different BCMA CAR constructs at a multiplicity of infection (MOI) of 10. Cells were maintained at 0.5×10 6 -2.0×10 6  cells/ml prior to use in activity assays. 
     At day 12 post-stimulation, transduced T cells were stained with recombinant BCMA-Fc (R&amp;D Systems) in stain buffer (BD Pharmingen) for 30 minutes at 4° C. Cells were then washed and stained with goat anti-human IgG Fc PE (Jackson ImmunoResearch, West Grove, Pa.) in stain buffer for 30 minutes at 4° C. Cells were then washed and resuspended in stain buffer with propidium iodide (BD Pharmingen) prior to data acquisition. All experiments were performed in two different donors. BCMA CAR expression was observed for each of the constructs in both Donor 1 ( FIG.  3 A ) and Donor 2 ( FIG.  3 B ) transduced cells. 
     Effector cells, e.g., anti-BCMA CAR T cells, were cultured with target cells at a 1:1 effector cell to target cell (E:T) ratio in R10 media 12 days after T cell stimulation. Cell lines tested included EoL-1, NCI-H929 and MM1S. Sixteen hours post-co-culture, supernatants were analyzed by Luminex (EMD Millipore), according to the manufacturer&#39;s instructions, for production of the cytokines IFNγ ( FIGS.  4 A- 4 B ), TNFα ( FIGS.  4 C- 4 D ), and IL-2 ( FIGS.  4 E- 4 F ). IFNγ ( FIGS.  4 A- 4 B ), TNFα ( FIGS.  4 C- 4 D ), and IL-2 ( FIGS.  4 E- 4 F ) were observed in the supernatant of NCI-H929 and MM1S target cell co-cultures for each anti-BCMA CAR T cell tested in both donors ( FIGS.  4 A- 4 B ); however, IFNγ ( FIGS.  4 A- 4 B ), TNFα ( FIGS.  4 C- 4 D ), and IL-2 ( FIGS.  4 E- 4 F ) were only observed in the supernatant of EoL-1 target cell co-cultures above background for the IR negative control T cells ( FIG.  4 A ). 
     Target cell viability was assessed by flow cytometric analysis of propidium iodide (PI) uptake of CD3 negative cells. The anti-BCMA CAR T cells were co-cultured with EoL1 ( FIGS.  5 A- 5 B ), NCI-H929 ( FIGS.  5 C- 5 D ), or MM1S ( FIGS.  5 E- 5 F ) target cells for 16 hours, 40 hours, 64 hours, 88 hours, or 112 hours. Little cytolytic activity was observed in the EoL-1 co-cultures at any time period for the anti-BCMA CAR T cells ( FIG.  5 A- 5 B ). However, co-culture of the anti-BCMA CAR T cells and the NCI-H929 or MM1S target cells resulted in a decrease in the percentage of viable target cells at each time point measured for each of the anti-BCMA CAR T cells. 
     To examine proliferation, anti-BCMA CAR T cells were labeled with carboxyfluorescein succinimidyl ester (CFSE) prior to co-culture with EoL-1, NCI-H929, or MM1S target cells at a 1:1 E:T ratio in R10 media. Five days later, T cell proliferation was assessed by flow cytometric analysis of CFSE dilution. Data was analyzed and plotted as histogram using FlowJo™ ( FIGS.  6 A- 6 B ). All experiments were performed in two different donors. 
     Example 3 
     Antigens were biotinylated using the EZ-Link Sulfo-NHS-Biotinylation Kit from Pierce/ThermoFisher (Waltham, Mass.). Goat anti-human F(ab′)2 kappa-FITC (LC-FITC), Extravidin-PE (EA-PE) and streptavidin-633 (SA-633) were obtained from Southern Biotech (Birmingham, Ala.), Sigma (St. Louis, Mo.) and Molecular Probes/Invitrogen (Waltham, Mass.), respectively. Streptavidin MicroBeads and MACS LC separation columns were purchased from Miltenyi Biotec (Gladbachn, Germany). 
     Naïve Discovery 
     Eight naïve human synthetic yeast libraries each of ˜109 diversity were propagated as described herein (see WO2009036379, WO2010105256, and WO2012009568 to Xu et al.). For the first two rounds of selection, a magnetic bead sorting technique utilizing the Miltenyi MACs system was performed, as described (Siegel et al., 2004). Briefly, yeast cells (˜1010 cells/library) were incubated with 3 ml of 100 nM biotinylated monomeric antigen or 10 nM biotinylated Fc fusion antigen for 15 minutes at room temperature in FACS wash buffer (phosphate-buffered saline (PBS)/0.1% bovine serum albumin (BSA)). After washing once with 50 ml ice-cold wash buffer, the cell pellet was resuspended in 40 mL wash buffer, and Streptavidin MicroBeads (500 μl) were added to the yeast and incubated for 15 minutes at 4° C. Next, the yeast were pelleted, resuspended in 5 mL wash buffer, and loaded onto a Miltenyi LS column. After the 5 mL was loaded, the column was washed 3 times with 3 ml FACS wash buffer. The column was then removed from the magnetic field, and the yeast were eluted with 5 mL of growth media and then grown overnight. The following rounds of sorting were performed using flow cytometry. Approximately 1×108 yeast were pelleted, washed three times with wash buffer, and incubated with decreasing concentrations of biotinylated monomeric or Fc fusion antigen (100 to 1 nM) under equilibrium conditions at room temperature. Yeast were then washed twice and stained with LC-FITC (diluted 1:100) and either SA-633 (diluted 1:500) or EA-PE (diluted 1:50) secondary reagents for 15 minutes at 4° C. After washing twice with ice-cold wash buffer, the cell pellets were resuspended in 0.4 mL wash buffer and transferred to strainer-capped sort tubes. Sorting was performed using a FACS ARIA sorter (BD Biosciences, San Jose, Calif.) and sort gates were assigned to select for specific binders relative to a background control. Subsequent rounds of selection were focused on reduction of non-specific reagent binders (utilizing soluble membrane proteins from CHO cell), as well as pressuring for affinity to BCMA. After the final round of sorting, yeast were plated and individual colonies were picked for characterization. 
     Affinity Maturation 
     Binding optimization of naïve clones was carried out using three maturation strategies: light chain diversification, diversification of VH CDRH1/CDRH2, and performing VHmut/VKmut selections. 
     Light Chain Diversification: Heavy chain plasmids were extracted and transformed into a light chain library with a diversity of 1×10 6 . Selections were performed as described above with one round of MACS sorting and two rounds of FACS sorting using 10 nM or 1 nM biotinylated antigen for respective rounds. 
     CDRH1 and CDRH2 Selection: A selected donor CDRH3 was recombined into a premade library with CDRH1 and CDRH2 variants of a diversity of 1×10 8  and selections were performed as described above. Affinity pressures were applied by incubating the biotinylated antigen-antibody yeast complex with unbiotinylated antigen for varying amounts of time to select for the highest affinity antibodies. 
     VHmut/VKmut Selection: This round of affinity maturation included error prone PCR-based mutagenesis of the heavy chain and/or light chain. Selections were performed similar to previous cycles, but employing FACS sorting for all selection rounds. Antigen concentration was reduced and cold antigen competition times were increased to pressure further for optimal affinity. 
     Antibody Production and Purification 
     Yeast clones were grown to saturation and then induced for 48 h at 30° C. with shaking. After induction, yeast cells were pelleted and the supernatants were harvested for purification. IgGs were purified using a Protein A column and eluted with acetic acid, pH 2.0. Fab fragments were generated by papain digestion and purified over KappaSelect (GE Healthcare LifeSciences, Pittsburgh, Pa.). 
     ForteBio KD Measurements 
     ForteBio affinity measurements were performed generally as previously described (Estep et al., 2013). Briefly, ForteBio affinity measurements were performed by loading IgGs on-line onto AHQ sensors. Sensors were equilibrated off-line in assay buffer for 30 minutes and then monitored on-line for 60 seconds for baseline establishment. Sensors with loaded IgGs were exposed to 100 nM antigen for 5 minutes, afterwards they were transferred to assay buffer for 5 minutes for off-rate measurement. Kinetics were analyzed using the 1:1 binding model. 
     MSD-SET KD Measurements 
     Equilibrium affinity measurements performed generally as previously described (Estep et al., 2013). Briefly, solution equilibrium titrations (SET) were performed in PBS+0.1% IgG-Free BSA (PBSF) with antigen (BCMA monomer) held constant at 10-100 pM and incubated with 3- to 5-fold serial dilutions of Fab or mAbs starting at 10 pM-10 nM (experimental condition is sample dependent). Antibodies (20 nM in PBS) were coated onto standard bind MSD-ECL plates overnight at 4° C. or at room temperature for 30 minutes. Plates were then blocked by BSA for 30 minutes with shaking at 700 rpm, followed by three washes with wash buffer (PBSF+0.05% Tween 20). SET samples were applied and incubated on the plates for 150 seconds with shaking at 700 rpm followed by one wash. Antigen captured on a plate was detected with 250 ng/mL Sulfotag™-labeled streptavidin in PBSF by incubation on the plate for 3 minutes. The plates were washed three times with wash buffer and then read on the MSD Sector Imager 2400™ instrument using 1× Read Buffer T with surfactant. The percent free antigen was plotted as a function of titrated antibody in Prism™ and fit to a quadratic equation to extract the KD. To improve throughput, liquid handling robots were used throughout MSD-SET experiments, including SET sample preparation. 
     Octet Red384 Epitope Binning/Ligand Blocking 
     Epitope binning/ligand blocking was performed using a standard sandwich format cross-blocking assay. Control anti-target IgG was loaded onto AHQ sensors and unoccupied Fc-binding sites on the sensor were blocked with an irrelevant human IgG1 antibody. The sensors were then exposed to 100 nM target antigen followed by a second anti-target antibody or ligand. Data was processed using ForteBio&#39;s Data Analysis Software 7.0. Additional binding by the second antibody or ligand after antigen association indicates an unoccupied epitope (non-competitor), while no binding indicates epitope blocking (competitor or ligand blocking). 
     Size Exclusion Chromatography 
     A TSKgel SuperSW mAb HTP column (22855) was used for fast SEC analysis of yeast produced mAbs at 0.4 mL/minute with a cycle time of 6 minutes/run. 200 mM Sodium Phosphate and 250 mM Sodium Chloride was used as the mobile phase. 
     Dynamic Scanning Fluorimetry 
     10 uL of 20× Sypro Orange™ is added to 20 uL of 0.2-1 mg/mL mAb or Fab solution. A RT-PCR instrument (BioRad CFX96 RT PCR) is used to ramp the sample plate temperature from 40° to 95° C. at 0.5C increment, with 2 minutes to equilibrate at each temperature. The negative of first derivative for the raw data is used to extract Tm. 
     
       
         
           
               
               
            
               
                 Clone FS-26528 HC DNA 
                   
               
               
                 (SEQ ID NO: 271) 
                   
               
               
                 GAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTC 
                   
               
               
                   
               
               
                 CTGTGCAGCCTCTGGATTCACCTTTGACGACTATGCCATGGCATGGGTCCGCCAGGCTCCAG 
               
               
                   
               
               
                 GGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGATGCAGGTGACAGAACATACTACGCAGAC 
               
               
                   
               
               
                 TCCGTGAGGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAAT 
               
               
                   
               
               
                 GAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCAAGAGCCGAGATGGGAGCCG 
               
               
                   
               
               
                 TATTCGACATATGGGGTCAGGGTACAATGGTCACCGTCTCCTCA 
               
               
                   
               
               
                 Clone FS-26528 HC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 272) 
                   
               
               
                 EVQLLESGGGLVQPGGSLRL SCAASGFTFDDYAMA WVRQAPGKGLEWVS AISDAGDRTYY   
                   
               
               
                   
               
               
                   ADSVRG RFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARAEMGAVFDI WGQGTMVTVSS 
               
               
                   
               
               
                 (SEQ ID NO: 273) 
                   
               
               
                 SCAASGFTFDDYAMA [HC CDR1] 
                   
               
               
                   
               
               
                 (SEQ ID NO: 274) 
                   
               
               
                 AISDAGDRTYYADSVRG [HC CDR2] 
                   
               
               
                   
               
               
                 (SEQ ID NO: 275) 
                   
               
               
                 ARAEMGAVFDI [HC CDR3] 
                   
               
               
                   
               
               
                 Clone FS-26528 LC DNA 
               
               
                 (SEQ ID NO: 276) 
                   
               
               
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT 
                   
               
               
                   
               
               
                 CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGGTACTTAGCCTGGTACCAACAGAAACCTGGCC 
               
               
                   
               
               
                 AGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTC 
               
               
                   
               
               
                 AGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTT 
               
               
                   
               
               
                 TGCAGTTTATTACTGTCAGCAGAGAATCTCCTGGCCTTTCACTTTTGGCGGAGGGACCAAGG 
               
               
                   
               
               
                 TTGAGATCAAACGG 
               
               
                   
               
               
                 Clone FS-26528 LC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 277) 
                   
               
               
                 EIVLTQSPATLSLSPGERATLSC RASQSVSRYLA WYQQKPGQAPRLLIY DASNRAT GIPARF 
                   
               
               
                   
               
               
                 SGSGSGTDFTLTISSLEPEDFAVYYC QQ   RISWPFT FGGGTKVEIKR 
               
               
                   
               
               
                 (SEQ ID NO: 278) 
                   
               
               
                 RASQSVSRYLA [LC CDR1] 
                   
               
               
                   
               
               
                 (SEQ ID NO: 279) 
                   
               
               
                 DASNRAT [LC CDR2] 
                   
               
               
                   
               
               
                 (SEQ ID NO: 280) 
                   
               
               
                 QQRISWPFT [LC CDR3] 
                   
               
               
                   
               
               
                 Clone FS-26528 CAR DNA HxL 
               
               
                 (SEQ ID NO: 281) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCT 
               
               
                   
               
               
                 CCTGTGCAGCCTCTGGATTCACCTTTGACGACTATGCCATGGCATGGGTCCGCCAGGCTCCA 
               
               
                   
               
               
                 GGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGATGCAGGTGACAGAACATACTACGCAGA 
               
               
                   
               
               
                 CTCCGTGAGGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATCTGCAAA 
               
               
                   
               
               
                 TGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCAAGAGCCGAGATGGGAGCC 
               
               
                   
               
               
                 GTATTCGACATATGGGGTCAGGGTACAATGGTCACCGTCTCCTCAGGGTCTACATCCGGCTC 
               
               
                   
               
               
                 CGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATTGTGTTGACACAGTCTCCAG 
               
               
                   
               
               
                 CCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTT 
               
               
                   
               
               
                 AGCAGGTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGA 
               
               
                   
               
               
                 TGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACT 
               
               
                   
               
               
                 TCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAGAGA 
               
               
                   
               
               
                 ATCTCCTGGCCTTTCACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGCCGCTGCCCT 
               
               
                   
               
               
                 TGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCAC 
               
               
                   
               
               
                 CCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCT 
               
               
                   
               
               
                 TGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCG 
               
               
                   
               
               
                 CCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACT 
               
               
                   
               
               
                 ACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGA 
               
               
                   
               
               
                 TCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGG 
               
               
                   
               
               
                 ACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCA 
               
               
                   
               
               
                 AACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCT 
               
               
                   
               
               
                 GAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTT 
               
               
                   
               
               
                 GTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGC 
               
               
                   
               
               
                 CACCTAGG 
               
               
                   
               
               
                 Clone FS-26528 CAR HxL 
               
               
                 (SEQ ID NO: 282) 
                   
               
               
                 MALPVTALLLPLALLLHAARPEVQLLESGGGLVQPGGSLRLSCAASGFTFDDYAMAWVRQAP 
                   
               
               
                   
               
               
                 GKGLEWVSAISDAGDRTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAEMGA 
               
               
                   
               
               
                 VFDIWGQGTMVTVSSGSTSGSGKPGSGEGSTKGEIVLTQSPATLSLSPGERATLSCRASQSV 
               
               
                   
               
               
                 SRYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQR 
               
               
                   
               
               
                 ISWPFTFGGGTKVEIKRAAALDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLA 
               
               
                   
               
               
                 CYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSR 
               
               
                   
               
               
                 SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMA 
               
               
                   
               
               
                 EAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 
               
               
                   
               
               
                 Clone FS-26528 CAR DNA LxH 
               
               
                 (SEQ ID NO: 283) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC 
               
               
                   
               
               
                 TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGGTACTTAGCCTGGTACCAACAGAAACCTGGC 
               
               
                   
               
               
                 CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT 
               
               
                   
               
               
                 CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATT 
               
               
                   
               
               
                 TTGCAGTTTATTACTGTCAGCAGAGAATCTCCTGGCCTTTCACTTTTGGCGGAGGGACCAAG 
               
               
                   
               
               
                 GTTGAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTAC 
               
               
                   
               
               
                 AAAGGGGGAGGTGCAGCTGTTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGA 
               
               
                   
               
               
                 GACTCTCCTGTGCAGCCTCTGGATTCACCTTTGACGACTATGCCATGGCATGGGTCCGCCAG 
               
               
                   
               
               
                 GCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATTAGTGATGCAGGTGACAGAACATACTA 
               
               
                   
               
               
                 CGCAGACTCCGTGAGGGGCCGGTTCACCATCTCCAGAGACAATTCCAAGAACACACTGTATC 
               
               
                   
               
               
                 TGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCAAGAGCCGAGATG 
               
               
                   
               
               
                 GGAGCCGTATTCGACATATGGGGTCAGGGTACAATGGTCACCGTCTCCTCAGCCGCTGCCCT 
               
               
                   
               
               
                 TGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCAC 
               
               
                   
               
               
                 CCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCT 
               
               
                   
               
               
                 TGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCG 
               
               
                   
               
               
                 CCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACT 
               
               
                   
               
               
                 ACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGA 
               
               
                   
               
               
                 TCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGG 
               
               
                   
               
               
                 ACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCA 
               
               
                   
               
               
                 AACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCT 
               
               
                   
               
               
                 GAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTT 
               
               
                   
               
               
                 GTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGC 
               
               
                   
               
               
                 CACCTAGG 
               
               
                   
               
               
                 Clone FS-26528 CAR LxH 
               
               
                 (SEQ ID NO: 284) 
                   
               
               
                 MALPVTALLLPLALLLHAARPEIVLTQSPATLSLSPGERATLSCRASQSVSRYLAWYQQKPG 
                   
               
               
                   
               
               
                 QAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRISWPFTFGGGTK 
               
               
                   
               
               
                 VEIKRGSTSGSGKPGSGEGSTKGEVQLLESGGGLVQPGGSLRLSCAASGFTFDDYAMAWVRQ 
               
               
                   
               
               
                 APGKGLEWVSAISDAGDRTYYADSVRGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARAEM 
               
               
                   
               
               
                 GAVFDIWGQGTMVTVSSAAALDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWVLVVVGGVLA 
               
               
                   
               
               
                 CYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRSRVKFSR 
               
               
                   
               
               
                 SADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMA 
               
               
                   
               
               
                 EAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 
               
               
                   
               
               
                 Clone PC-26534 HC DNA 
               
               
                 (SEQ ID NO: 285) 
                   
               
               
                 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTC 
                   
               
               
                   
               
               
                 CTGTGCAGCGTCTGGATTCACCTTCAGTGAGCATGGCATGCACTGGGTCCGCCAGGCTCCAG 
               
               
                   
               
               
                 GCAAGGGGCTGGAGTGGGTGGCAGCTATATCTTATGATGGAAGGAATAAACACTATGCAGAC 
               
               
                   
               
               
                 TCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAAT 
               
               
                   
               
               
                 GAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCCAGAGACGGTACTTATCTAG 
               
               
                   
               
               
                 GTGGTCTCTGGTACTTCGACTTATGGGGGAGAGGTACCTTGGTCACCGTCTCCTCA 
               
               
                   
               
               
                 Clone PC-26534 HC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 286) 
                   
               
               
                 QVQLVESGGGVVQPGRSLRLSCAASG FTFSEHGMH WVRQAPGKGLEWVA AISYDGRNKHY   
                   
               
               
                   
               
               
                   ADSVKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARDGTYLGGLWYFDL WGRGTLVTVSS 
               
               
                   
               
               
                 (SEQ ID NO: 287) 
                   
               
               
                 FTFSEHGMH [HC CDR1] 
                   
               
               
                   
               
               
                 (SEQ ID NO: 288) 
                   
               
               
                 AISYDGRNKHYADSVKG [HC CDR2] 
                   
               
               
                   
               
               
                 (SEQ ID NO: 289) 
                   
               
               
                 ARDGTYLGGLWYFDL [HC CDR3] 
                   
               
               
                   
               
               
                 Clone PC-26534 LC DNA 
               
               
                 (SEQ ID NO: 290) 
                   
               
               
                 GATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCAT 
                   
               
               
                   
               
               
                 CTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACC 
               
               
                   
               
               
                 TGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGG 
               
               
                   
               
               
                 GTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGT 
               
               
                   
               
               
                 GGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAGGGACTCGGCCTCCCTCTCACTTTTG 
               
               
                   
               
               
                 GCGGAGGGACCAAGGTTGAGATCAAACGG 
               
               
                   
               
               
                 Clone PC-26534 LC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 291) 
                   
               
               
                 DIVMTQSPLSLPVTPGEPASISC RSSQSLL H SNGYNYLD WYLQKPGQSPQLLIY LGSNRA   
                   
               
               
                   
               
               
                   S GVPDRFSGSGSGTDFTLKISRVEAEDVGVYYC MQGLGLPLT FGGGTKVEIKR 
               
               
                   
               
               
                 (SEQ ID NO: 292) 
                   
               
               
                   
               
               
                 RSSQSLLHSNGYNYLD [LC CDR1] 
                   
               
               
                   
               
               
                 (SEQ ID NO: 293) 
                   
               
               
                 LGSNRAS [LC CDR2] 
                   
               
               
                   
               
               
                 (SEQ ID NO: 294) 
                   
               
               
                 MQGLGLPLT [LC CDR3] 
                   
               
               
                   
               
               
                 Clone PC-26534 CAR DNA HxL 
               
               
                 (SEQ ID NO: 295) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCT 
               
               
                   
               
               
                 CCTGTGCAGCGTCTGGATTCACCTTCAGTGAGCATGGCATGCACTGGGTCCGCCAGGCTCCA 
               
               
                   
               
               
                 GGCAAGGGGCTGGAGTGGGTGGCAGCTATATCTTATGATGGAAGGAATAAACACTATGCAGA 
               
               
                   
               
               
                 CTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAA 
               
               
                   
               
               
                 TGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCCAGAGACGGTACTTATCTA 
               
               
                   
               
               
                 GGTGGTCTCTGGTACTTCGACTTATGGGGGAGAGGTACCTTGGTCACCGTCTCCTCAGGGTC 
               
               
                   
               
               
                 TACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGATATTGTGATGA 
               
               
                   
               
               
                 CTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGGTCT 
               
               
                   
               
               
                 AGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGG 
               
               
                   
               
               
                 GCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGT 
               
               
                   
               
               
                 TCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGAT 
               
               
                   
               
               
                 GTTGGGGTTTATTACTGCATGCAGGGACTCGGCCTCCCTCTCACTTTTGGCGGAGGGACCAA 
               
               
                   
               
               
                 GGTTGAGATCAAACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACG 
               
               
                   
               
               
                 TGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTG 
               
               
                   
               
               
                 TTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAAT 
               
               
                   
               
               
                 CTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCAC 
               
               
                   
               
               
                 GCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCC 
               
               
                   
               
               
                 TATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAA 
               
               
                   
               
               
                 CCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCA 
               
               
                   
               
               
                 GAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTAT 
               
               
                   
               
               
                 AATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCG 
               
               
                   
               
               
                 GAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTT 
               
               
                   
               
               
                 ATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG 
               
               
                   
               
               
                 Clone PC-26534 CAR HxL 
               
               
                 (SEQ ID NO: 296) 
                   
               
               
                 MALPVTALLLPLALLLHAARPQVQLVESGGGVVQPGRSLRLSCAASGFTFSEHGMHWVRQAP 
                   
               
               
                   
               
               
                 GKGLEWVAAISYDGRNKHYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARDGTYL 
               
               
                   
               
               
                 GGLWYFDLWGRGTLVTVSSGSTSGSGKPGSGEGSTKGDIVMTQSPLSLPVTPGEPASISCRS 
               
               
                   
               
               
                 SQSLLHSNGYNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGSGTDFTLKISRVEAED 
               
               
                   
               
               
                 VGVYYCMQGLGLPLTFGGGTKVEIKRAAALDNEKSNGTIIHVKGKHLCPSPLFPGPSKPFWV 
               
               
                   
               
               
                 LVVVGGVLACYSLLVTVAFIIFWVRSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAA 
               
               
                   
               
               
                 YRSRVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLY 
               
               
                   
               
               
                 NELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR 
               
               
                   
               
               
                 Clone PC-26534 CAR DNA LxH 
               
               
                 (SEQ ID NO: 297) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GGATATTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCA 
               
               
                   
               
               
                 TCTCCTGCAGGTCTAGTCAGAGCCTCCTGCATAGTAATGGATACAACTATTTGGATTGGTAC 
               
               
                   
               
               
                 CTGCAGAAGCCAGGGCAGTCTCCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGG 
               
               
                   
               
               
                 GGTCCCTGACAGGTTCAGTGGCAGTGGATCAGGCACAGATTTTACACTGAAAATCAGCAGAG 
               
               
                   
               
               
                 TGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAGGGACTCGGCCTCCCTCTCACTTTT 
               
               
                   
               
               
                 GGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAG 
               
               
                   
               
               
                 TGGCGAAGGTAGTACAAAGGGGCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGC 
               
               
                   
               
               
                 CTGGGAGGTCCCTGAGACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTGAGCATGGCATG 
               
               
                   
               
               
                 CACTGGGTCCGCCAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGCTATATCTTATGATGG 
               
               
                   
               
               
                 AAGGAATAAACACTATGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCA 
               
               
                   
               
               
                 AGAACACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGC 
               
               
                   
               
               
                 GCCAGAGACGGTACTTATCTAGGTGGTCTCTGGTACTTCGACTTATGGGGGAGAGGTACCTT 
               
               
                   
               
               
                 GGTCACCGTCTCCTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACG 
               
               
                   
               
               
                 TGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTG 
               
               
                   
               
               
                 TTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAAT 
               
               
                   
               
               
                 CTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCAC 
               
               
                   
               
               
                 GCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCC 
               
               
                   
               
               
                 TATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAA 
               
               
                   
               
               
                 CCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCA 
               
               
                   
               
               
                 GAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTAT 
               
               
                   
               
               
                 AATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCG 
               
               
                   
               
               
                 GAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTT 
               
               
                   
               
               
                 ATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG 
               
               
                   
               
               
                 Clone PC-26534 CAR LxH 
               
               
                 (SEQ ID NO: 298) 
                   
               
               
                 MALPVTALLL PLALLLHAAR PDIVMTQSPL SLPVTPGEPA SISCRSSQSL 
                   
               
               
                   
               
               
                 LHSNGYNYLD WYLQKPGQSP QLLIYLGSNR ASGVPDRFSG SGSGTDFTLK 
               
               
                   
               
               
                 ISRVEAEDVG VYYCMQGLGL PLTFGGGTKV EIKRGSTSGS GKPGSGEGST 
               
               
                   
               
               
                 KGQVQLVESG GGVVQPGRSL RLSCAASGFT FSEHGMHWVR QAPGKGLEWV 
               
               
                   
               
               
                 AAISYDGRNK HYADSVKGRF TISRDNSKNT LYLQMNSLRA EDTAVYYCAR 
               
               
                   
               
               
                 DGTYLGGLWY FDLWGRGTLV TVSSAAALDN EKSNGTIIHV KGKHLCPSPL 
               
               
                   
               
               
                 FPGPSKPFWV LVVVGGVLAC YSLLVTVAFI IFWVRSKRSR LLHSDYMNMT 
               
               
                   
               
               
                 PRRPGPTRKH YQPYAPPRDF AAYRSRVKFS RSADAPAYQQ GQNQLYNELN 
               
               
                   
               
               
                 LGRREEYDVL DKRRGRDPEM GGKPRRKNPQ EGLYNELQKD KMAEAYSEIG 
               
               
                   
               
               
                 MKGERRRGKG HDGLYQGLST ATKDTYDALH MQALPPR 
               
               
                   
               
               
                 Clone AJ-26545 HC DNA 
               
               
                 (SEQ ID NO: 299) 
                   
               
               
                 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTC 
                   
               
               
                   
               
               
                 CTGCAGGGCATCTGGATACACCTTCATGGAGCACTATATGCACTGGGTGCGACAGGCCCCTG 
               
               
                   
               
               
                 GACAAGGGCTTGAGTGGATGGGAGTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGCACAG 
               
               
                   
               
               
                 AAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCT 
               
               
                   
               
               
                 GAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGAGAATTGGCCAATGG 
               
               
                   
               
               
                 ACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCA 
               
               
                   
               
               
                 Clone AJ-26545 HC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 300) 
                   
               
               
                 QVQLVQSGAEVKKPGASVKVSCRASG YTFMEHYMH WVRQAPGQGLEWMG VIGPSGGKTSY   
                   
               
               
                   
               
               
                   AQKFQG RVTMTRDTSTSTVYMELSSLRSEDTAVYYC ARESWPMDV WGQGTTVTVSS 
               
               
                   
               
               
                 (SEQ ID NO: 301) 
                   
               
               
                 YTFMEHYMH (HC CDR1) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 302) 
                   
               
               
                 VIGPSGGKTSYAQKFQG (HC CDR2) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 303) 
                   
               
               
                 ARESWPMDV (HC CDR3) 
                   
               
               
                   
               
               
                 Clone AJ-26545 LC DNA 
               
               
                 (SEQ ID NO: 304) 
                   
               
               
                 GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT 
                   
               
               
                   
               
               
                 CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCC 
               
               
                   
               
               
                 AGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTC 
               
               
                   
               
               
                 AGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTT 
               
               
                   
               
               
                 TGCAGTTTATTACTGTCAGCAGTACGCCGCCTACCCTACTTTTGGCGGAGGGACCAAGGTTG 
               
               
                   
               
               
                 AGATCAAACGG 
               
               
                   
               
               
                 Clone AJ-26545 LC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 305) 
                   
               
               
                 EIVMTQSPATLSVSPGERATLSC RASQSVSSNLA WYQQKPGQAPRLLIY GASTRAT GIPARF 
                   
               
               
                   
               
               
                 SGSGSGTEFTLTISSLQSEDFAVYYC QQYAAYPT FGGGTKVEIKR 
               
               
                   
               
               
                 (SEQ ID NO: 306) 
                   
               
               
                 RASQSVSSNLA (LC CDR1) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 307) 
                   
               
               
                 GASTRAT (LC CDR2) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 308) 
                   
               
               
                 QQYAAYPT (LC CDR3) 
                   
               
               
                   
               
               
                 Clone AJ-26545 CAR DNA HxL 
               
               
                 (SEQ ID NO: 309) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTT 
               
               
                   
               
               
                 CCTGCAGGGCATCTGGATACACCTTCATGGAGCACTATATGCACTGGGTGCGACAGGCCCCT 
               
               
                   
               
               
                 GGACAAGGGCTTGAGTGGATGGGAGTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGCACA 
               
               
                   
               
               
                 GAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGC 
               
               
                   
               
               
                 TGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGAGAATTGGCCAATG 
               
               
                   
               
               
                 GACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCAGGGTCTACATCCGGCTCCGGGAA 
               
               
                   
               
               
                 GCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATAGTGATGACGCAGTCTCCAGCCACCC 
               
               
                   
               
               
                 TGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGC 
               
               
                   
               
               
                 AACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATC 
               
               
                   
               
               
                 CACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTC 
               
               
                   
               
               
                 TCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTACGCCGCC 
               
               
                   
               
               
                 TACCCTACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGCCGCTGCCCTTGATAATGA 
               
               
                   
               
               
                 AAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCC 
               
               
                   
               
               
                 CTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCT 
               
               
                   
               
               
                 CTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCA 
               
               
                   
               
               
                 TAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTT 
               
               
                   
               
               
                 ACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGAT 
               
               
                   
               
               
                 GCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGA 
               
               
                   
               
               
                 AGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGAC 
               
               
                   
               
               
                 GAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTAT 
               
               
                   
               
               
                 TCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGG 
               
               
                   
               
               
                 ACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG 
               
               
                   
               
               
                 Clone AJ-26545 CAR HxL 
               
               
                 (SEQ ID NO: 310) 
                   
               
               
                 MALPVTALLL PLALLLHAAR PQVQLVQSGA EVKKPGASVK VSCRASGYTF 
                   
               
               
                   
               
               
                 MEHYMHWVRQ APGQGLEWMG VIGPSGGKTS YAQKFQGRVT MTRDTSTSTV 
               
               
                   
               
               
                 YMELSSLRSE DTAVYYCARE SWPMDVWGQG TTVTVSSGST SGSGKPGSGE 
               
               
                   
               
               
                 GSTKGEIVMT QSPATLSVSP GERATLSCRA SQSVSSNLAW YQQKPGQAPR 
               
               
                   
               
               
                 LLIYGASTRA TGIPARFSGS GSGTEFTLTI SSLQSEDFAV YYCQQYAAYP 
               
               
                   
               
               
                 TFGGGTKVEI KRAAALDNEK SNGTIIHVKG KHLCPSPLFP GPSKPFWVLV 
               
               
                   
               
               
                 VVGGVLACYS LLVTVAFIIF WVRSKRSRLL HSDYMNMTPR RPGPTRKHYQ 
               
               
                   
               
               
                 PYAPPRDFAA YRSRVKFSRS ADAPAYQQGQ NQLYNELNLG RREEYDVLDK 
               
               
                   
               
               
                 RRGRDPEMGG KPRRKNPQEG LYNELQKDKM AEAYSEIGMK GERRRGKGHD 
               
               
                   
               
               
                 GLYQGLSTAT KDTYDALHMQ ALPPR 
               
               
                   
               
               
                 Clone AJ-26545 CAR DNA LxH 
               
               
                 (SEQ ID NO: 311) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC 
               
               
                   
               
               
                 TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC 
               
               
                   
               
               
                 CAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTT 
               
               
                   
               
               
                 CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATT 
               
               
                   
               
               
                 TTGCAGTTTATTACTGTCAGCAGTACGCCGCCTACCCTACTTTTGGCGGAGGGACCAAGGTT 
               
               
                   
               
               
                 GAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAA 
               
               
                   
               
               
                 GGGGCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGG 
               
               
                   
               
               
                 TTTCCTGCAGGGCATCTGGATACACCTTCATGGAGCACTATATGCACTGGGTGCGACAGGCC 
               
               
                   
               
               
                 CCTGGACAAGGGCTTGAGTGGATGGGAGTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGC 
               
               
                   
               
               
                 ACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGG 
               
               
                   
               
               
                 AGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGAGAATTGGCCA 
               
               
                   
               
               
                 ATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCAGCCGCTGCCCTTGATAATGA 
               
               
                   
               
               
                 AAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCC 
               
               
                   
               
               
                 CTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCT 
               
               
                   
               
               
                 CTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCA 
               
               
                   
               
               
                 TAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTT 
               
               
                   
               
               
                 ACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGAT 
               
               
                   
               
               
                 GCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGA 
               
               
                   
               
               
                 AGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGAC 
               
               
                   
               
               
                 GAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTAT 
               
               
                   
               
               
                 TCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGG 
               
               
                   
               
               
                 ACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG 
               
               
                   
               
               
                 Clone AJ-26545 CAR LxH 
               
               
                 (SEQ ID NO: 312) 
                   
               
               
                 MALPVTALLL PLALLLHAAR PEIVMTQSPA TLSVSPGERA TLSCRASQSV 
                   
               
               
                   
               
               
                 SSNLAWYQQK PGQAPRLLIY GASTRATGIP ARFSGSGSGT EFTLTISSLQ 
               
               
                   
               
               
                 SEDFAVYYCQ QYAAYPTFGG GTKVEIKRGS TSGSGKPGSG EGSTKGQVQL 
               
               
                   
               
               
                 VQSGAEVKKP GASVKVSCRA SGYTFMEHYM HWVRQAPGQG LEWMGVIGPS 
               
               
                   
               
               
                 GGKTSYAQKF QGRVTMTRDT STSTVYMELS SLRSEDTAVY YCARESWPMD 
               
               
                   
               
               
                 VWGQGTTVTV SSAAALDNEK SNGTIIHVKG KHLCPSPLFP GPSKPFWVLV 
               
               
                   
               
               
                 VVGGVLACYS LLVTVAFIIF WVRSKRSRLL HSDYMNMTPR RPGPTRKHYQ 
               
               
                   
               
               
                 PYAPPRDFAA YRSRVKFSRS ADAPAYQQGQ NQLYNELNLG RREEYDVLDK 
               
               
                   
               
               
                 RRGRDPEMGG KPRRKNPQEG LYNELQKDKM AEAYSEIGMK GERRRGKGHD 
               
               
                   
               
               
                 GLYQGLSTAT KDTYDALHMQ ALPPR 
               
               
                   
               
               
                 Clone AJ-26554 HC DNA 
               
               
                 (SEQ ID NO: 313) 
                   
               
               
                 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTC 
                   
               
               
                   
               
               
                 CTGCAAGGCATCTGGATACACCTTCACGGAGCACTATATGCACTGGGTGCGACAGGCCCCTG 
               
               
                   
               
               
                 GACAAAGGCTTGAGTGGATGGGAGTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGCACAG 
               
               
                   
               
               
                 AAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGCT 
               
               
                   
               
               
                 GAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGAGAGTTGGCCAATGG 
               
               
                   
               
               
                 ACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCA 
               
               
                   
               
               
                 Clone AJ-26554 HC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 314) 
                   
               
               
                 QVQLVQSGAE VKKPGASVKV SCKASG YTFT   EHYMH WVRQA PGQRLEWMG V   
                   
               
               
                   
               
               
                   IGPSGGKTSY   AQKFQG RVTM TRDTSTSTVY MELSSLRSED TAVYYC ARES   
               
               
                   
               
               
                   WPMDV WGQGT TVTVSS 
               
               
                   
               
               
                 (SEQ ID NO: 315) 
                   
               
               
                 YTFTEHYMH (HC CDR1) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 316) 
                   
               
               
                 VIGPSGGKTSYAQKFQG (HC CDR2) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 317) 
                   
               
               
                 ARESWPMDV (HC CDR3) 
                   
               
               
                   
               
               
                 Clone AJ-26554 LC DNA 
               
               
                 (SEQ ID NO: 318) 
                   
               
               
                 GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT 
                   
               
               
                   
               
               
                 CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCC 
               
               
                   
               
               
                 AGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTC 
               
               
                   
               
               
                 AGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTT 
               
               
                   
               
               
                 TGCAGTTTATTACTGTCAGCAGTACGCCGCCTACCCTACTTTTGGCGGAGGGACCAAGGTTG 
               
               
                   
               
               
                 AGATCAAACGG 
               
               
                   
               
               
                 Clone AJ-26554 LC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 319) 
                   
               
               
                 EIVMTQSPATLSVSPGERATLSC RASQSVSSNLA WYQQKPGQAPRLLIY GASTRAT GIPA 
                   
               
               
                   
               
               
                 RFSGSGSGTEFTLTISSLQSEDFAVYYC QQYAAYPT FGGGTKVEIKR 
               
               
                   
               
               
                 (SEQ ID NO: 320) 
                   
               
               
                 RASQSVSSNLA (LC CDR1) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 321) 
                   
               
               
                 GASTRAT (LC CDR2) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 322) 
                   
               
               
                 QQYAAYPT (LC CDR3) 
                   
               
               
                   
               
               
                 Clone AJ-26554 CAR DNA HxL 
               
               
                 (SEQ ID NO: 323) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTT 
               
               
                   
               
               
                 CCTGCAAGGCATCTGGATACACCTTCACGGAGCACTATATGCACTGGGTGCGACAGGCCCCT 
               
               
                   
               
               
                 GGACAAAGGCTTGAGTGGATGGGAGTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGCACA 
               
               
                   
               
               
                 GAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGGAGC 
               
               
                   
               
               
                 TGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGAGAGTTGGCCAATG 
               
               
                   
               
               
                 GACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCAGGGTCTACATCCGGCTCCGGGAA 
               
               
                   
               
               
                 GCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATAGTGATGACGCAGTCTCCAGCCACCC 
               
               
                   
               
               
                 TGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGC 
               
               
                   
               
               
                 AACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTATGGTGCATC 
               
               
                   
               
               
                 CACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGAGTTCACTC 
               
               
                   
               
               
                 TCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTATTACTGTCAGCAGTACGCCGCC 
               
               
                   
               
               
                 TACCCTACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGCCGCTGCCCTTGATAATGA 
               
               
                   
               
               
                 AAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCC 
               
               
                   
               
               
                 CTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCT 
               
               
                   
               
               
                 CTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCA 
               
               
                   
               
               
                 TAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTT 
               
               
                   
               
               
                 ACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGAT 
               
               
                   
               
               
                 GCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGA 
               
               
                   
               
               
                 AGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGAC 
               
               
                   
               
               
                 GAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTAT 
               
               
                   
               
               
                 TCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGG 
               
               
                   
               
               
                 ACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG 
               
               
                   
               
               
                 Clone AJ-26554 CAR HxL 
               
               
                 (SEQ ID NO: 324) 
                   
               
               
                 MALPVTALLL PLALLLHAAR PQVQLVQSGA EVKKPGASVK VSCKASGYTF 
                   
               
               
                   
               
               
                 TEHYMHWVRQ APGQRLEWMG VIGPSGGKTS YAQKFQGRVT MTRDTSTSTV 
               
               
                   
               
               
                 YMELSSLRSE DTAVYYCARE SWPMDVWGQG TTVTVSSGST SGSGKPGSGE 
               
               
                   
               
               
                 GSTKGEIVMT QSPATLSVSP GERATLSCRA SQSVSSNLAW YQQKPGQAPR 
               
               
                   
               
               
                 LLIYGASTRA TGIPARFSGS GSGTEFTLTI SSLQSEDFAV YYCQQYAAYP 
               
               
                   
               
               
                 TFGGGTKVEI KRAAALDNEK SNGTIIHVKG KHLCPSPLFP GPSKPFWVLV 
               
               
                   
               
               
                 VVGGVLACYS LLVTVAFIIF WVRSKRSRLL HSDYMNMTPR RPGPTRKHYQ 
               
               
                   
               
               
                 PYAPPRDFAA YRSRVKFSRS ADAPAYQQGQ NQLYNELNLG RREEYDVLDK 
               
               
                   
               
               
                 RRGRDPEMGG KPRRKNPQEG LYNELQKDKM AEAYSEIGMK GERRRGKGHD 
               
               
                   
               
               
                 GLYQGLSTAT KDTYDALHMQ ALPPR 
               
               
                   
               
               
                 Clone AJ-26554 CAR DNA LxH 
               
               
                 (SEQ ID NO: 325) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC 
               
               
                   
               
               
                 TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC 
               
               
                   
               
               
                 CAGGCTCCCAGGCTCCTCATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTT 
               
               
                   
               
               
                 CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATT 
               
               
                   
               
               
                 TTGCAGTTTATTACTGTCAGCAGTACGCCGCCTACCCTACTTTTGGCGGAGGGACCAAGGTT 
               
               
                   
               
               
                 GAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAA 
               
               
                   
               
               
                 GGGGCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGG 
               
               
                   
               
               
                 TTTCCTGCAAGGCATCTGGATACACCTTCACGGAGCACTATATGCACTGGGTGCGACAGGCC 
               
               
                   
               
               
                 CCTGGACAAAGGCTTGAGTGGATGGGAGTAATCGGGCCTAGTGGTGGTAAGACAAGCTACGC 
               
               
                   
               
               
                 ACAGAAGTTCCAGGGCAGAGTCACCATGACCAGGGACACGTCCACGAGCACAGTCTACATGG 
               
               
                   
               
               
                 AGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAGAGAGTTGGCCA 
               
               
                   
               
               
                 ATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCAGCCGCTGCCCTTGATAATGA 
               
               
                   
               
               
                 AAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCC 
               
               
                   
               
               
                 CTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCT 
               
               
                   
               
               
                 CTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCA 
               
               
                   
               
               
                 TAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTT 
               
               
                   
               
               
                 ACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGAT 
               
               
                   
               
               
                 GCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGA 
               
               
                   
               
               
                 AGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGAC 
               
               
                   
               
               
                 GAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTAT 
               
               
                   
               
               
                 TCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGG 
               
               
                   
               
               
                 ACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG 
               
               
                   
               
               
                 Clone AJ-26554 CAR LxH 
               
               
                 (SEQ ID NO: 326) 
                   
               
               
                 MALPVTALLL PLALLLHAAR PEIVMTQSPA TLSVSPGERA TLSCRASQSV 
                   
               
               
                   
               
               
                 SSNLAWYQQK PGQAPRLLIY GASTRATGIP ARFSGSGSGT EFTLTISSLQ 
               
               
                   
               
               
                 SEDFAVYYCQ QYAAYPTFGG GTKVEIKRGS TSGSGKPGSG EGSTKGQVQL 
               
               
                   
               
               
                 VQSGAEVKKP GASVKVSCKA SGYTFTEHYM HWVRQAPGQR LEWMGVIGPS 
               
               
                   
               
               
                 GGKTSYAQKF QGRVTMTRDT STSTVYMELS SLRSEDTAVY YCARESWPMD 
               
               
                   
               
               
                 VWGQGTTVTV SSAAALDNEK SNGTIIHVKG KHLCPSPLFP GPSKPFWVLV 
               
               
                   
               
               
                 VVGGVLACYS LLVTVAFIIF WVRSKRSRLL HSDYMNMTPR RPGPTRKHYQ 
               
               
                   
               
               
                 PYAPPRDFAA YRSRVKFSRS ADAPAYQQGQ NQLYNELNLG RREEYDVLDK 
               
               
                   
               
               
                 RRGRDPEMGG KPRRKNPQEG LYNELQKDKM AEAYSEIGMK GERRRGKGHD 
               
               
                   
               
               
                 GLYQGLSTAT KDTYDALHMQ ALPPR 
               
               
                   
               
               
                 Clone NM-26562 HC DNA 
               
               
                 (SEQ ID NO: 327) 
                   
               
               
                 CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCAC 
                   
               
               
                   
               
               
                 CTGTACTGTCTCTGGTGGCTCCATCGGGAGTGGTGGTAGTTACTGGAGCTGGATCCGCCAGC 
               
               
                   
               
               
                 ACCCAGGGAAGGGCCTGGAGTGGATTGGGTTGATCTATTACGATGGGAGCACCTACTACAAC 
               
               
                   
               
               
                 CCGTCCCTCAAGAGTCGAGTTACCATATCAGTAGACACGTCTAAGAACCAGTTCTCCCTGAA 
               
               
                   
               
               
                 GCTGAGTTCTGTGACCGCCGCAGACACGGCGGTGTACTACTGCGCCAGAGGCAGGGGATATG 
               
               
                   
               
               
                 AGACTTCTTTAGCCTTCGATATCTGGGGTCAGGGTACAATGGTCACCGTCTCCTCA 
               
               
                   
               
               
                 Clone NM-26562 HC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 328) 
                   
               
               
                 QVQLQESGPGLVKPSQTLSLTCTVSG GSIGSGGSYWS WIRQHPGKGLEWIG LIYYDGSTY   
                   
               
               
                   
               
               
                   YNPSLKS RVTISVDTSKNQFSLKLSSVTAADTAVYYC ARGRGYETSLAFDI WGQGTMVTVSS 
               
               
                   
               
               
                 (SEQ ID NO: 329) 
                   
               
               
                 GSIGSGGSYWS (HC CDR1) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 330) 
                   
               
               
                 LIYYDGSTYYNPSLKS (HC CDR2) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 331) 
                   
               
               
                 ARGRGYETSLAFDI (HC CDR3) 
                   
               
               
                   
               
               
                 Clone NM-26562 LC DNA 
               
               
                 (SEQ ID NO: 332) 
                   
               
               
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT 
                   
               
               
                   
               
               
                 CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGCC 
               
               
                   
               
               
                 AGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTC 
               
               
                   
               
               
                 AGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTT 
               
               
                   
               
               
                 TGCAGTTTATTACTGTCAGCAGAGACACGTCTGGCCTCCTACTTTTGGCGGAGGGACCAAGG 
               
               
                   
               
               
                 TTGAGATCAAACGG 
               
               
                   
               
               
                 Clone NM-26562 LC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 333) 
                   
               
               
                 EIVLTQSPATLSLSPGERATLSC RASQSVSSYLA WYQQKPGQAPRLLIY DASNRAT GIPA 
                   
               
               
                   
               
               
                 RFSGSGSGTDFTLTISSLEPEDFAVYYC QQRHVWPPT FGGGTKVEIKR 
               
               
                   
               
               
                 (SEQ ID NO: 334) 
                   
               
               
                 RASQSVSSYLA (LC CDR1) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 335) 
                   
               
               
                 DASNRAT (LC CDR2) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 336) 
                   
               
               
                 QQRHVWPPT (LC CDR3) 
                   
               
               
                   
               
               
                 Clone NM-26562 CAR DNA HxL 
               
               
                 (SEQ ID NO: 337) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GCAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGTCCCTCA 
               
               
                   
               
               
                 CCTGTACTGTCTCTGGTGGCTCCATCGGGAGTGGTGGTAGTTACTGGAGCTGGATCCGCCAG 
               
               
                   
               
               
                 CACCCAGGGAAGGGCCTGGAGTGGATTGGGTTGATCTATTACGATGGGAGCACCTACTACAA 
               
               
                   
               
               
                 CCCGTCCCTCAAGAGTCGAGTTACCATATCAGTAGACACGTCTAAGAACCAGTTCTCCCTGA 
               
               
                   
               
               
                 AGCTGAGTTCTGTGACCGCCGCAGACACGGCGGTGTACTACTGCGCCAGAGGCAGGGGATAT 
               
               
                   
               
               
                 GAGACTTCTTTAGCCTTCGATATCTGGGGTCAGGGTACAATGGTCACCGTCTCCTCAGGGTC 
               
               
                   
               
               
                 TACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATTGTGTTGA 
               
               
                   
               
               
                 CACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCC 
               
               
                   
               
               
                 AGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCT 
               
               
                   
               
               
                 CCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGT 
               
               
                   
               
               
                 CTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTAC 
               
               
                   
               
               
                 TGTCAGCAGAGACACGTCTGGCCTCCTACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACG 
               
               
                   
               
               
                 GGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACC 
               
               
                   
               
               
                 TCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGT 
               
               
                   
               
               
                 GGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATC 
               
               
                   
               
               
                 CAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCA 
               
               
                   
               
               
                 CAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTG 
               
               
                   
               
               
                 AAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGA 
               
               
                   
               
               
                 GCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTG 
               
               
                   
               
               
                 AGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAG 
               
               
                   
               
               
                 GATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGG 
               
               
                   
               
               
                 GCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACA 
               
               
                   
               
               
                 TGCAAGCCCTGCCACCTAGG 
               
               
                   
               
               
                 Clone NM-26562 CAR HxL 
               
               
                 (SEQ ID NO: 338) 
                   
               
               
                 MALPVTALLL PLALLLHAAR PQVQLQESGP GLVKPSQTLS LTCTVSGGSI 
                   
               
               
                   
               
               
                 GSGGSYWSWI RQHPGKGLEW IGLIYYDGST YYNPSLKSRV TISVDTSKNQ 
               
               
                   
               
               
                 FSLKLSSVTA ADTAVYYCAR GRGYETSLAF DIWGQGTMVT VSSGSTSGSG 
               
               
                   
               
               
                 KPGSGEGSTK GEIVLTQSPA TLSLSPGERA TLSCRASQSV SSYLAWYQQK 
               
               
                   
               
               
                 PGQAPRLLIY DASNRATGIP ARFSGSGSGT DFTLTISSLE PEDFAVYYCQ 
               
               
                   
               
               
                 QRHVWPPTFG GGTKVEIKRA AALDNEKSNG TIIHVKGKHL CPSPLFPGPS 
               
               
                   
               
               
                 KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG 
               
               
                   
               
               
                 PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE 
               
               
                   
               
               
                 EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA YSEIGMKGER 
               
               
                   
               
               
                 RRGKGHDGLY QGLSTATKDT YDALHMQALP PR 
               
               
                   
               
               
                 Clone NM-26562 CAR DNA LxH 
               
               
                 (SEQ ID NO: 339) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC 
               
               
                   
               
               
                 TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCTACTTAGCCTGGTACCAACAGAAACCTGGC 
               
               
                   
               
               
                 CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT 
               
               
                   
               
               
                 CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATT 
               
               
                   
               
               
                 TTGCAGTTTATTACTGTCAGCAGAGACACGTCTGGCCTCCTACTTTTGGCGGAGGGACCAAG 
               
               
                   
               
               
                 GTTGAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTAC 
               
               
                   
               
               
                 AAAGGGGCAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCACAGACCCTGT 
               
               
                   
               
               
                 CCCTCACCTGTACTGTCTCTGGTGGCTCCATCGGGAGTGGTGGTAGTTACTGGAGCTGGATC 
               
               
                   
               
               
                 CGCCAGCACCCAGGGAAGGGCCTGGAGTGGATTGGGTTGATCTATTACGATGGGAGCACCTA 
               
               
                   
               
               
                 CTACAACCCGTCCCTCAAGAGTCGAGTTACCATATCAGTAGACACGTCTAAGAACCAGTTCT 
               
               
                   
               
               
                 CCCTGAAGCTGAGTTCTGTGACCGCCGCAGACACGGCGGTGTACTACTGCGCCAGAGGCAGG 
               
               
                   
               
               
                 GGATATGAGACTTCTTTAGCCTTCGATATCTGGGGTCAGGGTACAATGGTCACCGTCTCCTC 
               
               
                   
               
               
                 AGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACC 
               
               
                   
               
               
                 TCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGT 
               
               
                   
               
               
                 GGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATC 
               
               
                   
               
               
                 CAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCA 
               
               
                   
               
               
                 CAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTG 
               
               
                   
               
               
                 AAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGA 
               
               
                   
               
               
                 GCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTG 
               
               
                   
               
               
                 AGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAG 
               
               
                   
               
               
                 GATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGG 
               
               
                   
               
               
                 GCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACA 
               
               
                   
               
               
                 TGCAAGCCCTGCCACCTAGG 
               
               
                   
               
               
                 Clone NM-26562 CAR LxH 
               
               
                 (SEQ ID NO: 340) 
                   
               
               
                 MALPVTALLL PLALLLHAAR PEIVLTQSPA TLSLSPGERA TLSCRASQSV 
                   
               
               
                   
               
               
                 SSYLAWYQQK PGQAPRLLIY DASNRATGIP ARFSGSGSGT DFTLTISSLE 
               
               
                   
               
               
                 PEDFAVYYCQ QRHVWPPTFG GGTKVEIKRG STSGSGKPGS GEGSTKGQVQ 
               
               
                   
               
               
                 LQESGPGLVK PSQTLSLTCT VSGGSIGSGG SYWSWIRQHP GKGLEWIGLI 
               
               
                   
               
               
                 YYDGSTYYNP SLKSRVTISV DTSKNQFSLK LSSVTAADTA VYYCARGRGY 
               
               
                   
               
               
                 ETSLAFDIWG QGTMVTVSSA AALDNEKSNG TIIHVKGKHL CPSPLFPGPS 
               
               
                   
               
               
                 KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG 
               
               
                   
               
               
                 PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE 
               
               
                   
               
               
                 EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA YSEIGMKGER 
               
               
                   
               
               
                 RRGKGHDGLY QGLSTATKDT YDALHMQALP PR 
               
               
                   
               
               
                 Clone TS-26564 HC DNA 
               
               
                 (SEQ ID NO: 341) 
                   
               
               
                 GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTC 
                   
               
               
                   
               
               
                 CTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGCTCCAG 
               
               
                   
               
               
                 GGAAGGGGCTGGAGTGGGTTTCAACCATTAGTAGTAGTAGTAGTATCATATACTACGCAGAC 
               
               
                   
               
               
                 TCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTGCAAAT 
               
               
                   
               
               
                 GAACAGCCTGAGAGCTGAGGACACGGCGGTGTACTACTGCGCCAGAGGTTCTCAGGAGCACC 
               
               
                   
               
               
                 TGATTTTCGATTATTGGGGACAGGGTACATTGGTCACCGTCTCCTCA 
               
               
                   
               
               
                 Clone TS-26564 HC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 342) 
                   
               
               
                 EVQLVESGGGLVQPGGSLRLSCAASG FTFSSYSMN WVRQAPGKGLEWVS TISSSSSIIYY   
                   
               
               
                   
               
               
                   ADSVKG RFTISRDNAKNSLYLQMNSLRAEDTAVYYC ARGSQEHLIFDY WGQGTLVTVSS 
               
               
                   
               
               
                 (SEQ ID NO: 343) 
                   
               
               
                 FTFSSYSMN (HC CDR1) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 344) 
                   
               
               
                 TISSSSSIIYYADSVKG (HC CDR2) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 345) 
                   
               
               
                 ARGSQEHLIFDY (HC CDR3) 
                   
               
               
                   
               
               
                 Clone TS-26564 LC DNA 
               
               
                 (SEQ ID NO: 346) 
                   
               
               
                 GAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCT 
                   
               
               
                   
               
               
                 CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGGTACTTAGCCTGGTACCAACAGAAACCTGGCC 
               
               
                   
               
               
                 AGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTC 
               
               
                   
               
               
                 AGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTT 
               
               
                   
               
               
                 TGCAGTTTATTACTGTCAGCAGAGATTCTACTACCCTTGGACTTTTGGCGGAGGGACCAAGG 
               
               
                   
               
               
                 TTGAGATCAAACGG 
               
               
                   
               
               
                 Clone TS-26564 LC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 347) 
                   
               
               
                 EIVLTQSPATLSLSPGERATLSC RASQSVSRYLA WYQQKPGQAPRLLIY DASNRAT GIPA 
                   
               
               
                   
               
               
                 RFSGSGSGTDFTLTISSLEPEDFAVYYC QQRFYYPWT FGGGTKVEIKR 
               
               
                   
               
               
                 (SEQ ID NO: 348) 
                   
               
               
                 RASQSVSRYLA (LC CDR1) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 349) 
                   
               
               
                 DASNRAT (LC CDR2) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 350) 
                   
               
               
                 QQRFYYPWT (LC CDR3) 
                   
               
               
                   
               
               
                 Clone TS-26564 CAR DNA HxL 
               
               
                 (SEQ ID NO: 351) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCT 
               
               
                   
               
               
                 CCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAGGCTCCA 
               
               
                   
               
               
                 GGGAAGGGGCTGGAGTGGGTTTCAACCATTAGTAGTAGTAGTAGTATCATATACTACGCAGA 
               
               
                   
               
               
                 CTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATCTGCAAA 
               
               
                   
               
               
                 TGAACAGCCTGAGAGCTGAGGACACGGCGGTGTACTACTGCGCCAGAGGTTCTCAGGAGCAC 
               
               
                   
               
               
                 CTGATTTTCGATTATTGGGGACAGGGTACATTGGTCACCGTCTCCTCAGGGTCTACATCCGG 
               
               
                   
               
               
                 CTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATTGTGTTGACACAGTCTC 
               
               
                   
               
               
                 CAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGGGCCAGTCAGAGT 
               
               
                   
               
               
                 GTTAGCAGGTACTTAGCCTGGTACCAACAGAAACCTGGCCAGGCTCCCAGGCTCCTCATCTA 
               
               
                   
               
               
                 TGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAG 
               
               
                   
               
               
                 ACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATTTTGCAGTTTATTACTGTCAGCAG 
               
               
                   
               
               
                 AGATTCTACTACCCTTGGACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGCCGCTGC 
               
               
                   
               
               
                 CCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGT 
               
               
                   
               
               
                 CACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTC 
               
               
                   
               
               
                 GCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAG 
               
               
                   
               
               
                 CCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAAC 
               
               
                   
               
               
                 ACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCC 
               
               
                   
               
               
                 AGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCT 
               
               
                   
               
               
                 GGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTG 
               
               
                   
               
               
                 GCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATG 
               
               
                   
               
               
                 GCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGG 
               
               
                   
               
               
                 TTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCC 
               
               
                   
               
               
                 TGCCACCTAGG 
               
               
                   
               
               
                 Clone TS-26564 CAR HxL 
               
               
                 (SEQ ID NO: 352) 
                   
               
               
                 MALPVTALLL PLALLLHAAR PEVQLVESGG GLVQPGGSLR LSCAASGFTF 
                   
               
               
                   
               
               
                 SSYSMNWVRQ APGKGLEWVS TISSSSSIIY YADSVKGRFT ISRDNAKNSL 
               
               
                   
               
               
                 YLQMNSLRAE DTAVYYCARG SQEHLIFDYW GQGTLVTVSS GSTSGSGKPG 
               
               
                   
               
               
                 SGEGSTKGEI VLTQSPATLS LSPGERATLS CRASQSVSRY LAWYQQKPGQ 
               
               
                   
               
               
                 APRLLIYDAS NRATGIPARF SGSGSGTDFT LTISSLEPED FAVYYCQQRF 
               
               
                   
               
               
                 YYPWTFGGGT KVEIKRAAAL DNEKSNGTII HVKGKHLCPS PLFPGPSKPF 
               
               
                   
               
               
                 WVLVVVGGVL ACYSLLVTVA FIIFWVRSKR SRLLHSDYMN MTPRRPGPTR 
               
               
                   
               
               
                 KHYQPYAPPR DFAAYRSRVK FSRSADAPAY QQGQNQLYNE LNLGRREEYD 
               
               
                   
               
               
                 VLDKRRGRDP EMGGKPRRKN PQEGLYNELQ KDKMAEAYSE IGMKGERRRG 
               
               
                   
               
               
                 KGHDGLYQGL STATKDTYDA LHMQALPPR 
               
               
                   
               
               
                 Clone TS-26564 CAR DNA LxH 
               
               
                 (SEQ ID NO: 353) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GGAAATTGTGTTGACACAGTCTCCAGCCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCC 
               
               
                   
               
               
                 TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGGTACTTAGCCTGGTACCAACAGAAACCTGGC 
               
               
                   
               
               
                 CAGGCTCCCAGGCTCCTCATCTATGATGCATCCAACAGGGCCACTGGCATCCCAGCCAGGTT 
               
               
                   
               
               
                 CAGTGGCAGTGGGTCTGGGACAGACTTCACTCTCACCATCAGCAGCCTAGAGCCTGAAGATT 
               
               
                   
               
               
                 TTGCAGTTTATTACTGTCAGCAGAGATTCTACTACCCTTGGACTTTTGGCGGAGGGACCAAG 
               
               
                   
               
               
                 GTTGAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTAC 
               
               
                   
               
               
                 AAAGGGGGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGA 
               
               
                   
               
               
                 GACTCTCCTGTGCAGCCTCTGGATTCACCTTCAGTAGCTATAGCATGAACTGGGTCCGCCAG 
               
               
                   
               
               
                 GCTCCAGGGAAGGGGCTGGAGTGGGTTTCAACCATTAGTAGTAGTAGTAGTATCATATACTA 
               
               
                   
               
               
                 CGCAGACTCTGTGAAGGGCCGATTCACCATCTCCAGAGACAATGCCAAGAACTCACTGTATC 
               
               
                   
               
               
                 TGCAAATGAACAGCCTGAGAGCTGAGGACACGGCGGTGTACTACTGCGCCAGAGGTTCTCAG 
               
               
                   
               
               
                 GAGCACCTGATTTTCGATTATTGGGGACAGGGTACATTGGTCACCGTCTCCTCAGCCGCTGC 
               
               
                   
               
               
                 CCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGT 
               
               
                   
               
               
                 CACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTC 
               
               
                   
               
               
                 GCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAG 
               
               
                   
               
               
                 CCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAAC 
               
               
                   
               
               
                 ACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCC 
               
               
                   
               
               
                 AGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCT 
               
               
                   
               
               
                 GGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTG 
               
               
                   
               
               
                 GCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATG 
               
               
                   
               
               
                 GCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGG 
               
               
                   
               
               
                 TTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCC 
               
               
                   
               
               
                 TGCCACCTAGG 
               
               
                   
               
               
                 Clone TS-26564 CAR LxH 
               
               
                 (SEQ ID NO: 354) 
                   
               
               
                 MALPVTALLL PLALLLHAAR PEIVLTQSPA TLSLSPGERA TLSCRASQSV 
                   
               
               
                   
               
               
                 SRYLAWYQQK PGQAPRLLIY DASNRATGIP ARFSGSGSGT DFTLTISSLE 
               
               
                   
               
               
                 PEDFAVYYCQ QRFYYPWTFG GGTKVEIKRG STSGSGKPGS GEGSTKGEVQ 
               
               
                   
               
               
                 LVESGGGLVQ PGGSLRLSCA ASGFTFSSYS MNWVRQAPGK GLEWVSTISS 
               
               
                   
               
               
                 SSSIIYYADS VKGRFTISRD NAKNSLYLQM NSLRAEDTAV YYCARGSQEH 
               
               
                   
               
               
                 LIFDYWGQGT LVTVSSAAAL DNEKSNGTII HVKGKHLCPS PLFPGPSKPF 
               
               
                   
               
               
                 WVLVVVGGVL ACYSLLVTVA FIIFWVRSKR SRLLHSDYMN MTPRRPGPTR 
               
               
                   
               
               
                 KHYQPYAPPR DFAAYRSRVK FSRSADAPAY QQGQNQLYNE LNLGRREEYD 
               
               
                   
               
               
                 VLDKRRGRDP EMGGKPRRKN PQEGLYNELQ KDKMAEAYSE IGMKGERRRG 
               
               
                   
               
               
                 KGHDGLYQGL STATKDTYDA LHMQALPPR 
               
               
                   
               
               
                 Clone RY-26568 HC DNA 
               
               
                 (SEQ ID NO: 355) 
                   
               
               
                 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTC 
                   
               
               
                   
               
               
                 CTGTGCAGCGTCTGGATTCACCTTCGGGAGCTATGGCATGCACTGGGTCCGCCAGGCTCCAG 
               
               
                   
               
               
                 GCAAGGGGCTGGAGTGGGTGGCAGTTATACATTATGATGGAAGTGTTGAATACTATGCAGAC 
               
               
                   
               
               
                 TCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGGACACGCTGTATCTGCAAAT 
               
               
                   
               
               
                 GAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCCAGAACTGACTTCTGGAGCG 
               
               
                   
               
               
                 GATCCCCTCCAAGCTTAGATTACTGGGGACAGGGTACATTGGTCACCGTCTCCTCA 
               
               
                   
               
               
                 Clone RY-26568 HC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 356) 
                   
               
               
                 QVQLVESGGG VVQPGRSLRL SCAASG FTFG   SYGMH WVRQA PGKGLEWVAV 
                   
               
               
                   
               
               
                 I HYDGSVEYY   ADSVKG RFTI SRDNSKDTLY LQMNSLRAED TAVYYC ARTD   
               
               
                   
               
               
                   FWSGSPPSLD   Y WGQGTLVTV SS 
               
               
                   
               
               
                 (SEQ ID NO: 357) 
                   
               
               
                 FTFGSYGMH (HC CDR1) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 358) 
                   
               
               
                 VIHYDGSVEYYADSVKG (HC CDR2) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 359) 
                   
               
               
                 ARTDFWSGSPPSLDY (HC CDR3) 
                   
               
               
                   
               
               
                 Clone RY-26568 LC DNA 
               
               
                 (SEQ ID NO: 360) 
                   
               
               
                 GACATCCAGTTGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCAT 
                   
               
               
                   
               
               
                 CACTTGTCGGGCGAGTCGGGGTATTAGCAGCTGGTTAGCCTGGTATCAGCAGAAACCAGGGA 
               
               
                   
               
               
                 AAGCCCCTAAGCTCCTGATCTATGGTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTC 
               
               
                   
               
               
                 AGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTT 
               
               
                   
               
               
                 TGCAACTTATTACTGTCAGCAGATATACACCTTCCCTTTCACTTTTGGCGGAGGGACCAAGG 
               
               
                   
               
               
                 TTGAGATCAAACGG 
               
               
                   
               
               
                 Clone RY-26568 LC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 361) 
                   
               
               
                 DIQLTQSPSSVSASVGDRVTITC RASRGISSWLA WYQQKPGKAPKLLIY GASSLQS GVPSRF 
                   
               
               
                   
               
               
                 SGSGSGTDFTLTISSLQPEDFATYYC QQIYTFPFT FGGGTKVEIKR 
               
               
                   
               
               
                 (SEQ ID NO: 362) 
                   
               
               
                 RASRGISSWLA (LC CDR1) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 363) 
                   
               
               
                 GASSLQS (LC CDR2) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 364) 
                   
               
               
                 QQIYTFPFT (LC CDR3) 
                   
               
               
                   
               
               
                 Clone RY-26568 CAR DNA HxL 
               
               
                 (SEQ ID NO: 365) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCT 
               
               
                   
               
               
                 CCTGTGCAGCGTCTGGATTCACCTTCGGGAGCTATGGCATGCACTGGGTCCGCCAGGCTCCA 
               
               
                   
               
               
                 GGCAAGGGGCTGGAGTGGGTGGCAGTTATACATTATGATGGAAGTGTTGAATACTATGCAGA 
               
               
                   
               
               
                 CTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGGACACGCTGTATCTGCAAA 
               
               
                   
               
               
                 TGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCCAGAACTGACTTCTGGAGC 
               
               
                   
               
               
                 GGATCCCCTCCAAGCTTAGATTACTGGGGACAGGGTACATTGGTCACCGTCTCCTCAGGGTC 
               
               
                   
               
               
                 TACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGACATCCAGTTGA 
               
               
                   
               
               
                 CCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCATCACTTGTCGGGCG 
               
               
                   
               
               
                 AGTCGGGGTATTAGCAGCTGGTTAGCCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCT 
               
               
                   
               
               
                 CCTGATCTATGGTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGCGGCAGTGGAT 
               
               
                   
               
               
                 CTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATTTTGCAACTTATTAC 
               
               
                   
               
               
                 TGTCAGCAGATATACACCTTCCCTTTCACTTTTGGCGGAGGGACCAAGGTTGAGATCAAACG 
               
               
                   
               
               
                 GGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACC 
               
               
                   
               
               
                 TCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGT 
               
               
                   
               
               
                 GGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATC 
               
               
                   
               
               
                 CAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCA 
               
               
                   
               
               
                 CAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTG 
               
               
                   
               
               
                 AAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGA 
               
               
                   
               
               
                 GCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTG 
               
               
                   
               
               
                 AGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAG 
               
               
                   
               
               
                 GATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGG 
               
               
                   
               
               
                 GCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACA 
               
               
                   
               
               
                 TGCAAGCCCTGCCACCTAGG 
               
               
                   
               
               
                 Clone RY-26568 CAR HxL  
               
               
                 SEQ ID NO: 366) 
                   
               
               
                 MALPVTALLL PLALLLHAAR PQVQLVESGG GVVQPGRSLR LSCAASGFTF 
                   
               
               
                   
               
               
                 GSYGMHWVRQ APGKGLEWVA VIHYDGSVEY YADSVKGRET ISRDNSKDTL 
               
               
                   
               
               
                 YLQMNSLRAE DTAVYYCART DFWSGSPPSL DYWGQGTLVT VSSGSTSGSG 
               
               
                   
               
               
                 KPGSGEGSTK GDIQLTQSPS SVSASVGDRV TITCRASRGI SSWLAWYQQK 
               
               
                   
               
               
                 PGKAPKLLIY GASSLQSGVP SRFSGSGSGT DFTLTISSLQ PEDFATYYCQ 
               
               
                   
               
               
                 QIYTFPFTFG GGTKVEIKRA AALDNEKSNG TIIHVKGKHL CPSPLFPGPS 
               
               
                   
               
               
                 KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG 
               
               
                   
               
               
                 PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE 
               
               
                   
               
               
                 EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA YSEIGMKGER 
               
               
                   
               
               
                 RRGKGHDGLY QGLSTATKDT YDALHMQALP PR 
               
               
                   
               
               
                 Clone RY-26568 CAR DNA LxH 
               
               
                 (SEQ ID NO: 367) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GGACATCCAGTTGACCCAGTCTCCATCTTCCGTGTCTGCATCTGTAGGAGACAGAGTCACCA 
               
               
                   
               
               
                 TCACTTGTCGGGCGAGTCGGGGTATTAGCAGCTGGTTAGCCTGGTATCAGCAGAAACCAGGG 
               
               
                   
               
               
                 AAAGCCCCTAAGCTCCTGATCTATGGTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTT 
               
               
                   
               
               
                 CAGCGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGCAGCCTGCAGCCTGAAGATT 
               
               
                   
               
               
                 TTGCAACTTATTACTGTCAGCAGATATACACCTTCCCTTTCACTTTTGGCGGAGGGACCAAG 
               
               
                   
               
               
                 GTTGAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTAC 
               
               
                   
               
               
                 AAAGGGGCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGA 
               
               
                   
               
               
                 GACTCTCCTGTGCAGCGTCTGGATTCACCTTCGGGAGCTATGGCATGCACTGGGTCCGCCAG 
               
               
                   
               
               
                 GCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATACATTATGATGGAAGTGTTGAATACTA 
               
               
                   
               
               
                 TGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGGACACGCTGTATC 
               
               
                   
               
               
                 TGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGCCAGAACTGACTTC 
               
               
                   
               
               
                 TGGAGCGGATCCCCTCCAAGCTTAGATTACTGGGGACAGGGTACATTGGTCACCGTCTCCTC 
               
               
                   
               
               
                 AGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGCACC 
               
               
                   
               
               
                 TCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTGGGT 
               
               
                   
               
               
                 GGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAGATC 
               
               
                   
               
               
                 CAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCCCCA 
               
               
                   
               
               
                 CAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGGGTG 
               
               
                   
               
               
                 AAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAACGA 
               
               
                   
               
               
                 GCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACCCTG 
               
               
                   
               
               
                 AGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAGAAG 
               
               
                   
               
               
                 GATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAAAGG 
               
               
                   
               
               
                 GCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCCACA 
               
               
                   
               
               
                 TGCAAGCCCTGCCACCTAGG 
               
               
                   
               
               
                 Clone RY-26568 CAR LxH 
               
               
                 (SEQ ID NO: 368) 
                   
               
               
                 MALPVTALLL PLALLLHAAR PDIQLTQSPS SVSASVGDRV TITCRASRGI 
                   
               
               
                   
               
               
                 SSWLAWYQQK PGKAPKLLIY GASSLQSGVP SRFSGSGSGT DFTLTISSLQ 
               
               
                   
               
               
                 PEDFATYYCQ QIYTFPFTFG GGTKVEIKRG STSGSGKPGS GEGSTKGQVQ 
               
               
                   
               
               
                 LVESGGGVVQ PGRSLRLSCA ASGFTFGSYG MHWVRQAPGK GLEWVAVIHY 
               
               
                   
               
               
                 DGSVEYYADS VKGRFTISRD NSKDTLYLQM NSLRAEDTAV YYCARTDFWS 
               
               
                   
               
               
                 GSPPSLDYWG QGTLVTVSSA AALDNEKSNG TIIHVKGKHL CPSPLFPGPS 
               
               
                   
               
               
                 KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD YMNMTPRRPG 
               
               
                   
               
               
                 PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL YNELNLGRRE 
               
               
                   
               
               
                 EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA YSEIGMKGER 
               
               
                   
               
               
                 RRGKGHDGLY QGLSTATKDT YDALHMQALP PR 
               
               
                   
               
               
                 Clone PP-26575 HC DNA 
               
               
                 (SEQ ID NO: 369) 
                   
               
               
                 CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTC 
                   
               
               
                   
               
               
                 CTGCAAGGCTTCTGGAGGCACCCTCAGCAGCCTGGCTATCAGCTGGGTGCGACAGGCCCCTG 
               
               
                   
               
               
                 GACAAGGGCTTGAGTGGATGGGAGGGGTCATCCCTATCTTGGGTCGGGCAAACTACGCACAG 
               
               
                   
               
               
                 AAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAGTCCACGAGCACAGCCTACATGGAGCT 
               
               
                   
               
               
                 GAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAACTCCTGAATACTCCT 
               
               
                   
               
               
                 CCAGCATATGGCACTATTACTACGGCATGGACGTATGGGGCCAGGGAACAACTGTCACCGTC 
               
               
                   
               
               
                 TCCTCA 
               
               
                   
               
               
                 Clone PP-26575 HC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 370) 
                   
               
               
                 QVQLVQSGAEVKKPGSSVKVSCKASG GTLSSLAIS WVRQAPGQGLEWMG GVIPILGRANYAQ   
                   
               
               
                   
               
               
                   KFQG RVTITADESTSTAYMELSSLRSEDTAVYYC ARTPEYSSSIWHYYYGMDV WGQGTTVTV 
               
               
                   
               
               
                 SS 
               
               
                   
               
               
                 (SEQ ID NO: 371) 
                   
               
               
                 GTLSSLAIS (HC CDR1) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 372) 
                   
               
               
                 GVIPILGRANYAQKFQG (HC CDR2) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 373) 
                   
               
               
                 ARTPEYSSSIWHYYYGMDV (HC CDR3) 
                   
               
               
                   
               
               
                 Clone PP-26575 LC DNA 
               
               
                 (SEQ ID NO: 374) 
                   
               
               
                 GACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCAT 
                   
               
               
                   
               
               
                 CAACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTTGGT 
               
               
                   
               
               
                 ACCAGCAGAAACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGAATCC 
               
               
                   
               
               
                 GGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAG 
               
               
                   
               
               
                 CCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAGTTCGCCCACACTCCTTTCACTT 
               
               
                   
               
               
                 TTGGCGGAGGGACCAAGGTTGAGATCAAACGG 
               
               
                   
               
               
                 Clone PP-26575 LC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 375) 
                   
               
               
                 DIVMTQSPDSLAVSLGERATINC KSSQSVLYSSNNKNYLA WYQQKPGQPPKLLIY WASTR   
                   
               
               
                   
               
               
                   ES GVPDRFSGSGSGTDFTLTISSLQAEDVAVYYC QQFAHTPFT FGGGTKVEIKR 
               
               
                   
               
               
                 (SEQ ID NO: 376) 
                   
               
               
                 KSSQSVLYSSNNKNYLA (LC CDR1) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 377) 
                   
               
               
                 WASTRES (LC CDR2) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 378) 
                   
               
               
                 QQFAHTPFT (LC CDR3) 
                   
               
               
                   
               
               
                 Clone PP-26575 CAR DNA HxL 
               
               
                 (SEQ ID NO: 379) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCT 
               
               
                   
               
               
                 CCTGCAAGGCTTCTGGAGGCACCCTCAGCAGCCTGGCTATCAGCTGGGTGCGACAGGCCCCT 
               
               
                   
               
               
                 GGACAAGGGCTTGAGTGGATGGGAGGGGTCATCCCTATCTTGGGTCGGGCAAACTACGCACA 
               
               
                   
               
               
                 GAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAGTCCACGAGCACAGCCTACATGGAGC 
               
               
                   
               
               
                 TGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTACTGCGCCAGAACTCCTGAATACTCC 
               
               
                   
               
               
                 TCCAGCATATGGCACTATTACTACGGCATGGACGTATGGGGCCAGGGAACAACTGTCACCGT 
               
               
                   
               
               
                 CTCCTCAGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGG 
               
               
                   
               
               
                 ACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCATC 
               
               
                   
               
               
                 AACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTTGGTA 
               
               
                   
               
               
                 CCAGCAGAAACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGAATCCG 
               
               
                   
               
               
                 GGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGC 
               
               
                   
               
               
                 CTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAGTTCGCCCACACTCCTTTCACTTT 
               
               
                   
               
               
                 TGGCGGAGGGACCAAGGTTGAGATCAAACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACG 
               
               
                   
               
               
                 GAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCC 
               
               
                   
               
               
                 AAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCAC 
               
               
                   
               
               
                 CGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACA 
               
               
                   
               
               
                 TGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCT 
               
               
                   
               
               
                 AGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTA 
               
               
                   
               
               
                 TCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACG 
               
               
                   
               
               
                 TTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCC 
               
               
                   
               
               
                 CAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGG 
               
               
                   
               
               
                 CATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTG 
               
               
                   
               
               
                 CTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG 
               
               
                   
               
               
                 Clone PP-26575 CAR HxL 
               
               
                 (SEQ ID NO: 380) 
                   
               
               
                 MALPVTALLL PLALLLHAAR PQVQLVQSGA EVKKPGSSVK VSCKASGGTL 
                   
               
               
                   
               
               
                 SSLAISWVRQ APGQGLEWMG GVIPILGRAN YAQKFQGRVT ITADESTSTA 
               
               
                   
               
               
                 YMELSSLRSE DTAVYYCART PEYSSSIWHY YYGMDVWGQG TTVTVSSGST 
               
               
                   
               
               
                 SGSGKPGSGE GSTKGDIVMT QSPDSLAVSL GERATINCKS SQSVLYSSNN 
               
               
                   
               
               
                 KNYLAWYQQK PGQPPKLLIY WASTRESGVP DRFSGSGSGT DFTLTISSLQ 
               
               
                   
               
               
                 AEDVAVYYCQ QFAHTPFTFG GGTKVEIKRA AALDNEKSNG TIIHVKGKHL 
               
               
                   
               
               
                 CPSPLFPGPS KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD 
               
               
                   
               
               
                 YMNMTPRRPG PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL 
               
               
                   
               
               
                 YNELNLGRRE EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA 
               
               
                   
               
               
                 YSEIGMKGER RRGKGHDGLY QGLSTATKDT YDALHMQALP PR 
               
               
                   
               
               
                 Clone PP-26575 CAR DNA LxH 
               
               
                 (SEQ ID NO: 381) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GGACATCGTGATGACCCAGTCTCCAGACTCCCTGGCTGTGTCTCTGGGCGAGAGGGCCACCA 
               
               
                   
               
               
                 TCAACTGCAAGTCCAGCCAGAGTGTTTTATACAGCTCCAACAATAAGAACTACTTAGCTTGG 
               
               
                   
               
               
                 TACCAGCAGAAACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCATCTACCCGGGAATC 
               
               
                   
               
               
                 CGGGGTCCCTGACCGATTCAGTGGCAGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCA 
               
               
                   
               
               
                 GCCTGCAGGCTGAAGATGTGGCAGTTTATTACTGTCAGCAGTTCGCCCACACTCCTTTCACT 
               
               
                   
               
               
                 TTTGGCGGAGGGACCAAGGTTGAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGG 
               
               
                   
               
               
                 AAGTGGCGAAGGTAGTACAAAGGGGCAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGA 
               
               
                   
               
               
                 AGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGGCTTCTGGAGGCACCCTCAGCAGCCTGGCT 
               
               
                   
               
               
                 ATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATGGGAGGGGTCATCCCTAT 
               
               
                   
               
               
                 CTTGGGTCGGGCAAACTACGCACAGAAGTTCCAGGGCAGAGTCACGATTACCGCGGACGAGT 
               
               
                   
               
               
                 CCACGAGCACAGCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCGGTGTACTAC 
               
               
                   
               
               
                 TGCGCCAGAACTCCTGAATACTCCTCCAGCATATGGCACTATTACTACGGCATGGACGTATG 
               
               
                   
               
               
                 GGGCCAGGGAACAACTGTCACCGTCTCCTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACG 
               
               
                   
               
               
                 GAACAATCATTCACGTGAAGGGCAAGCACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCC 
               
               
                   
               
               
                 AAGCCATTCTGGGTGTTGGTCGTAGTGGGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCAC 
               
               
                   
               
               
                 CGTGGCTTTTATAATCTTCTGGGTTAGATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACA 
               
               
                   
               
               
                 TGAATATGACTCCACGCCGCCCTGGCCCCACAAGGAAACACTACCAGCCTTACGCACCACCT 
               
               
                   
               
               
                 AGAGATTTCGCTGCCTATCGGAGCAGGGTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTA 
               
               
                   
               
               
                 TCAGCAGGGCCAGAACCAACTGTATAACGAGCTCAACCTGGGACGCAGGGAAGAGTATGACG 
               
               
                   
               
               
                 TTTTGGACAAGCGCAGAGGACGGGACCCTGAGATGGGTGGCAAACCAAGACGAAAAAACCCC 
               
               
                   
               
               
                 CAGGAGGGTCTCTATAATGAGCTGCAGAAGGATAAGATGGCTGAAGCCTATTCTGAAATAGG 
               
               
                   
               
               
                 CATGAAAGGAGAGCGGAGAAGGGGAAAAGGGCACGACGGTTTGTACCAGGGACTCAGCACTG 
               
               
                   
               
               
                 CTACGAAGGATACTTATGACGCTCTCCACATGCAAGCCCTGCCACCTAGG 
               
               
                   
               
               
                 Clone PP-26575 CAR LxH 
               
               
                 (SEQ ID NO: 382) 
                   
               
               
                 MALPVTALLL PLALLLHAAR PDIVMTQSPD SLAVSLGERA TINCKSSQSV 
                   
               
               
                   
               
               
                 LYSSNNKNYL AWYQQKPGQP PKLLIYWAST RESGVPDRFS GSGSGTDFTL 
               
               
                   
               
               
                 TISSLQAEDV AVYYCQQFAH TPFTFGGGTK VEIKRGSTSG SGKPGSGEGS 
               
               
                   
               
               
                 TKGQVQLVQS GAEVKKPGSS VKVSCKASGG TLSSLAISWV RQAPGQGLEW 
               
               
                   
               
               
                 MGGVIPILGR ANYAQKFQGR VTITADESTS TAYMELSSLR SEDTAVYYCA 
               
               
                   
               
               
                 RTPEYSSSIW HYYYGMDVWG QGTTVTVSSA AALDNEKSNG TIIHVKGKHL 
               
               
                   
               
               
                 CPSPLFPGPS KPFWVLVVVG GVLACYSLLV TVAFIIFWVR SKRSRLLHSD 
               
               
                   
               
               
                 YMNMTPRRPG PTRKHYQPYA PPRDFAAYRS RVKFSRSADA PAYQQGQNQL 
               
               
                   
               
               
                 YNELNLGRRE EYDVLDKRRG RDPEMGGKPR RKNPQEGLYN ELQKDKMAEA 
               
               
                   
               
               
                 YSEIGMKGER RRGKGHDGLY QGLSTATKDT YDALHMQALP PR 
               
               
                   
               
               
                 Clone RD-26576 HC DNA 
               
               
                 (SEQ ID NO: 383) 
                   
               
               
                 CAGGTGCGGCTGGTGGAGTCTGGGGGGGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTC 
                   
               
               
                   
               
               
                 CTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATACACTGGGTCCGCCAGGCTCCAG 
               
               
                   
               
               
                 GCAAGGGGCTGGAGTGGGTGGCAGTTATAGGGTATGATGGACAGGAGAAATACTATGCAGAC 
               
               
                   
               
               
                 TCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAAT 
               
               
                   
               
               
                 GAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCGTTGCAGGAGC 
               
               
                   
               
               
                 CGCCATACGCTTTTGGGATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCA 
               
               
                   
               
               
                 Clone RD-26576 HC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 384) 
                   
               
               
                 QVRLVESGGGVVQPGRSLRLSCAASG FTFSSYGIH WVRQAPGKGLEWVA VIGYDGQEKYYAD   
                   
               
               
                   
               
               
                   SVKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYC VKGPLQEPPYAFGMDV WGQGTTVTVSS 
               
               
                   
               
               
                 (SEQ ID NO: 385) 
                   
               
               
                 FTFSSYGIH (HC CDR1) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 386) 
                   
               
               
                 VIGYDGQEKYYADSVKG (HC CDR2) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 387) 
                   
               
               
                 VKGPLQEPPYAFGMDV (HC CDR3) 
                   
               
               
                   
               
               
                 Clone RD-26576 LC DNA 
               
               
                 (SEQ ID NO: 388) 
                   
               
               
                 GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT 
                   
               
               
                   
               
               
                 CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCC 
               
               
                   
               
               
                 AGGCTCCCAGGCTCCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTC 
               
               
                   
               
               
                 AGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTT 
               
               
                   
               
               
                 TGCAGTTTATTACTGTCAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGAGGGACCAAGG 
               
               
                   
               
               
                 TTGAGATCAAACGG 
               
               
                   
               
               
                 Clone RD-26576 LC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 389) 
                   
               
               
                 EIVMTQSPATLSVSPGERATLSC RASQSVSSNLA WYQQKPGQAPRLLIY SASTRAT GIPA 
                   
               
               
                   
               
               
                 RFSGSGSGTEFTLTISSLQSEDFAVYYC QQHHVWPLT FGGGTKVEIKR 
               
               
                   
               
               
                 (SEQ ID NO: 390) 
                   
               
               
                 RASQSVSSNLA (LC CDR1) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 391) 
                   
               
               
                 SASTRAT (LC CDR2) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 392) 
                   
               
               
                 QQHHVWPLT (LC CDR3) 
                   
               
               
                   
               
               
                 Clone RD-26576 CAR DNA HxL 
               
               
                 (SEQ ID NO: 393) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GCAGGTGCGGCTGGTGGAGTCTGGGGGGGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCT 
               
               
                   
               
               
                 CCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATACACTGGGTCCGCCAGGCTCCA 
               
               
                   
               
               
                 GGCAAGGGGCTGGAGTGGGTGGCAGTTATAGGGTATGATGGACAGGAGAAATACTATGCAGA 
               
               
                   
               
               
                 CTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAA 
               
               
                   
               
               
                 TGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCGTTGCAGGAG 
               
               
                   
               
               
                 CCGCCATACGCTTTTGGGATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCAGG 
               
               
                   
               
               
                 GTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATAGTGA 
               
               
                   
               
               
                 TGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG 
               
               
                   
               
               
                 GCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAG 
               
               
                   
               
               
                 GCTCCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTG 
               
               
                   
               
               
                 GGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTAT 
               
               
                   
               
               
                 TACTGTCAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGAGGGACCAAGGTTGAGATCAA 
               
               
                   
               
               
                 ACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGC 
               
               
                   
               
               
                 ACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTG 
               
               
                   
               
               
                 GGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAG 
               
               
                   
               
               
                 ATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCC 
               
               
                   
               
               
                 CCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGG 
               
               
                   
               
               
                 GTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAA 
               
               
                   
               
               
                 CGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACC 
               
               
                   
               
               
                 CTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAG 
               
               
                   
               
               
                 AAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAA 
               
               
                   
               
               
                 AGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCC 
               
               
                   
               
               
                 ACATGCAAGCCCTGCCACCTAGG 
               
               
                   
               
               
                 Clone RD-26576 CAR HxL 
               
               
                 (SEQ ID NO: 394) 
                   
               
               
                 MALPVTALLL PLALLLHAAR PQVRLVESGG GVVQPGRSLR LSCAASGFTF 
                   
               
               
                   
               
               
                 SSYGIHWVRQ APGKGLEWVA VIGYDGQEKY YADSVKGRET ISRDNSKNTL 
               
               
                   
               
               
                 YLQMNSLRAE DTAVYYCVKG PLQEPPYAFG MDVWGQGTTV TVSSGSTSGS 
               
               
                   
               
               
                 GKPGSGEGST KGEIVMTQSP ATLSVSPGER ATLSCRASQS VSSNLAWYQQ 
               
               
                   
               
               
                 KPGQAPRLLI YSASTRATGI PARFSGSGSG TEFTLTISSL QSEDFAVYYC 
               
               
                   
               
               
                 QQHHVWPLTF GGGTKVEIKR AAALDNEKSN GTIIHVKGKH LCPSPLFPGP 
               
               
                   
               
               
                 SKPFWVLVVV GGVLACYSLL VTVAFIIFWV RSKRSRLLHS DYMNMTPRRP 
               
               
                   
               
               
                 GPTRKHYQPY APPRDFAAYR SRVKFSRSAD APAYQQGQNQ LYNELNLGRR 
               
               
                   
               
               
                 EEYDVLDKRR GRDPEMGGKP RRKNPQEGLY NELQKDKMAE AYSEIGMKGE 
               
               
                   
               
               
                 RRRGKGHDGL YQGLSTATKD TYDALHMQAL PPR 
               
               
                   
               
               
                 Clone RD-26576 CAR DNA LxH 
               
               
                 (SEQ ID NO: 395) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC 
               
               
                   
               
               
                 TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC 
               
               
                   
               
               
                 CAGGCTCCCAGGCTCCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTT 
               
               
                   
               
               
                 CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATT 
               
               
                   
               
               
                 TTGCAGTTTATTACTGTCAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGAGGGACCAAG 
               
               
                   
               
               
                 GTTGAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTAC 
               
               
                   
               
               
                 AAAGGGGCAGGTGCGGCTGGTGGAGTCTGGGGGGGGCGTGGTCCAGCCTGGGAGGTCCCTGA 
               
               
                   
               
               
                 GACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCTATGGCATACACTGGGTCCGCCAG 
               
               
                   
               
               
                 GCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATAGGGTATGATGGACAGGAGAAATACTA 
               
               
                   
               
               
                 TGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATC 
               
               
                   
               
               
                 TGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCGTTG 
               
               
                   
               
               
                 CAGGAGCCGCCATACGCTTTTGGGATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTC 
               
               
                   
               
               
                 CTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGC 
               
               
                   
               
               
                 ACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTG 
               
               
                   
               
               
                 GGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAG 
               
               
                   
               
               
                 ATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCC 
               
               
                   
               
               
                 CCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGG 
               
               
                   
               
               
                 GTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAA 
               
               
                   
               
               
                 CGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACC 
               
               
                   
               
               
                 CTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAG 
               
               
                   
               
               
                 AAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAA 
               
               
                   
               
               
                 AGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCC 
               
               
                   
               
               
                 ACATGCAAGCCCTGCCACCTAGG 
               
               
                   
               
               
                 Clone RD-26576 CAR LxH 
               
               
                 (SEQ ID NO: 396) 
                   
               
               
                 MALPVTALLL PLALLLHAAR PEIVMTQSPA TLSVSPGERA TLSCRASQSV 
                   
               
               
                   
               
               
                 SSNLAWYQQK PGQAPRLLIY SASTRATGIP ARFSGSGSGT EFTLTISSLQ 
               
               
                   
               
               
                 SEDFAVYYCQ QHHVWPLTFG GGTKVEIKRG STSGSGKPGS GEGSTKGQVR 
               
               
                   
               
               
                 LVESGGGVVQ PGRSLRLSCA ASGFTFSSYG IHWVRQAPGK GLEWVAVIGY 
               
               
                   
               
               
                 DGQEKYYADS VKGRFTISRD NSKNTLYLQM NSLRAEDTAV YYCVKGPLQE 
               
               
                   
               
               
                 PPYAFGMDVW GQGTTVTVSS AAALDNEKSN GTIIHVKGKH LCPSPLFPGP 
               
               
                   
               
               
                 SKPFWVLVVV GGVLACYSLL VTVAFIIFWV RSKRSRLLHS DYMNMTPRRP 
               
               
                   
               
               
                 GPTRKHYQPY APPRDFAAYR SRVKFSRSAD APAYQQGQNQ LYNELNLGRR 
               
               
                   
               
               
                 EEYDVLDKRR GRDPEMGGKP RRKNPQEGLY NELQKDKMAE AYSEIGMKGE 
               
               
                   
               
               
                 RRRGKGHDGL YQGLSTATKD TYDALHMQAL PPR 
               
               
                   
               
               
                 Clone RD-26578 HC DNA 
               
               
                 (SEQ ID NO: 397) 
                   
               
               
                 CAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCTC 
                   
               
               
                   
               
               
                 CTGTGCAGCGTCTGGATTCACCTTCAGTAGCCGTGGCATGCACTGGGTCCGCCAGGCTCCAG 
               
               
                   
               
               
                 GCAAGGGGCTGGAGTGGGTGGCAGTTATAGGGTATGATGGACAGGAGAAATACTATGCAGAC 
               
               
                   
               
               
                 TCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAAT 
               
               
                   
               
               
                 GAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCGTTGCAGGAGC 
               
               
                   
               
               
                 CGCCATACGATTATGGAATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCA 
               
               
                   
               
               
                 Clone RD-26578 HC CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 398) 
                   
               
               
                 QVQLVESGGGVVQPGRSLRLSCAASG FTFSSRGMH WVRQAPGKGLEWVA VIGYDGQEKYYAD   
                   
               
               
                   
               
               
                   SVKG RFTISRDNSKNTLYLQMNSLRAEDTAVYYC VKGPLQEPPYDYGMDV WGQGTTVTVSS 
               
               
                   
               
               
                 (SEQ ID NO: 399)  
                   
               
               
                 FTFSSRGMH (HC CDR1) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 400) 
                   
               
               
                 VIGYDGQEKYYADSVKG (HC CDR2) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 401) 
                   
               
               
                 VKGPLQEPPYDYGMDV (HC CDR3) 
                   
               
               
                   
               
               
                 Clone RD-26578 LC DNA 
               
               
                 (SEQ ID NO: 402) 
                   
               
               
                 GAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCT 
                   
               
               
                   
               
               
                 CTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCC 
               
               
                   
               
               
                 AGGCTCCCAGGCTCCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTC 
               
               
                   
               
               
                 AGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTT 
               
               
                   
               
               
                 TGCAGTTTATTACTGTCAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGAGGGACCAAGG 
               
               
                   
               
               
                 TTGAGATCAAACGG 
               
               
                   
               
               
                 Clone RD-26578 LC. CDRs 1, 2, and 3 are 
               
               
                 underlined. 
               
               
                 (SEQ ID NO: 403) 
                   
               
               
                 EIVMTQSPATLSVSPGERATLSC RASQSVSSNLA WYQQKPGQAPRLLIY S   
                   
               
               
                   
               
               
                   ASTRAT GIPARFSGSGSGTEFTLTISSLQSEDFAVYYC QQHHVWPLT FGGGTKVEIKR 
               
               
                   
               
               
                 (SEQ ID NO: 404) 
                   
               
               
                 RASQSVSSNLA (LC CDR1) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 405) 
                   
               
               
                 SASTRAT (LC CDR2) 
                   
               
               
                   
               
               
                 (SEQ ID NO: 406) 
                   
               
               
                 QQHHVWPLT (LC CDR3) 
                   
               
               
                   
               
               
                 Clone RD-26578 CAR DNA HxL 
               
               
                 (SEQ ID NO: 407) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGAGACTCT 
               
               
                   
               
               
                 CCTGTGCAGCGTCTGGATTCACCTTCAGTAGCCGTGGCATGCACTGGGTCCGCCAGGCTCCA 
               
               
                   
               
               
                 GGCAAGGGGCTGGAGTGGGTGGCAGTTATAGGGTATGATGGACAGGAGAAATACTATGCAGA 
               
               
                   
               
               
                 CTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATCTGCAAA 
               
               
                   
               
               
                 TGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCGTTGCAGGAG 
               
               
                   
               
               
                 CCGCCATACGATTATGGAATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTCCTCAGG 
               
               
                   
               
               
                 GTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTACAAAGGGGGAAATAGTGA 
               
               
                   
               
               
                 TGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG 
               
               
                   
               
               
                 GCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAG 
               
               
                   
               
               
                 GCTCCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTG 
               
               
                   
               
               
                 GGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATTTTGCAGTTTAT 
               
               
                   
               
               
                 TACTGTCAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGAGGGACCAAGGTTGAGATCAA 
               
               
                   
               
               
                 ACGGGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGC 
               
               
                   
               
               
                 ACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTG 
               
               
                   
               
               
                 GGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAG 
               
               
                   
               
               
                 ATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCC 
               
               
                   
               
               
                 CCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGG 
               
               
                   
               
               
                 GTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAA 
               
               
                   
               
               
                 CGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACC 
               
               
                   
               
               
                 CTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAG 
               
               
                   
               
               
                 AAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAA 
               
               
                   
               
               
                 AGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCC 
               
               
                   
               
               
                 ACATGCAAGCCCTGCCACCTAGG 
               
               
                   
               
               
                 Clone RD-26578 CAR HxL 
               
               
                 (SEQ ID NO: 408) 
                   
               
               
                 MALPVTALLL PLALLLHAAR PQVQLVESGG GVVQPGRSLR LSCAASGFTF 
                   
               
               
                   
               
               
                 SSRGMHWVRQ APGKGLEWVA VIGYDGQEKY YADSVKGRFT ISRDNSKNTL 
               
               
                   
               
               
                 YLQMNSLRAE DTAVYYCVKG PLQEPPYDYG MDVWGQGTTV TVSSGSTSGS 
               
               
                   
               
               
                 GKPGSGEGST KGEIVMTQSP ATLSVSPGER ATLSCRASQS VSSNLAWYQQ 
               
               
                   
               
               
                 KPGQAPRLLI YSASTRATGI PARFSGSGSG TEFTLTISSL QSEDFAVYYC 
               
               
                   
               
               
                 QQHHVWPLTF GGGTKVEIKR AAALDNEKSN GTIIHVKGKH LCPSPLFPGP 
               
               
                   
               
               
                 SKPFWVLVVV GGVLACYSLL VTVAFIIFWV RSKRSRLLHS DYMNMTPRRP 
               
               
                   
               
               
                 GPTRKHYQPY APPRDFAAYR SRVKFSRSAD APAYQQGQNQ LYNELNLGRR 
               
               
                   
               
               
                 EEYDVLDKRR GRDPEMGGKP RRKNPQEGLY NELQKDKMAE AYSEIGMKGE 
               
               
                   
               
               
                 RRRGKGHDGL YQGLSTATKD TYDALHMQAL PPR 
               
               
                   
               
               
                 Clone RD-26578 CAR DNA LxH 
               
               
                 (SEQ ID NO: 409) 
                   
               
               
                 ATGGCACTCCCCGTAACTGCTCTGCTGCTGCCGTTGGCATTGCTCCTGCACGCCGCACGCCC 
                   
               
               
                   
               
               
                 GGAAATAGTGATGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCC 
               
               
                   
               
               
                 TCTCCTGCAGGGCCAGTCAGAGTGTTAGCAGCAACTTAGCCTGGTACCAGCAGAAACCTGGC 
               
               
                   
               
               
                 CAGGCTCCCAGGCTCCTCATCTATAGCGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTT 
               
               
                   
               
               
                 CAGTGGCAGTGGGTCTGGGACAGAGTTCACTCTCACCATCAGCAGCCTGCAGTCTGAAGATT 
               
               
                   
               
               
                 TTGCAGTTTATTACTGTCAGCAGCACCACGTCTGGCCTCTCACTTTTGGCGGAGGGACCAAG 
               
               
                   
               
               
                 GTTGAGATCAAACGGGGGTCTACATCCGGCTCCGGGAAGCCCGGAAGTGGCGAAGGTAGTAC 
               
               
                   
               
               
                 AAAGGGGCAGGTGCAGCTGGTGGAGTCTGGGGGAGGCGTGGTCCAGCCTGGGAGGTCCCTGA 
               
               
                   
               
               
                 GACTCTCCTGTGCAGCGTCTGGATTCACCTTCAGTAGCCGTGGCATGCACTGGGTCCGCCAG 
               
               
                   
               
               
                 GCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATAGGGTATGATGGACAGGAGAAATACTA 
               
               
                   
               
               
                 TGCAGACTCCGTGAAGGGCCGATTCACCATCTCCAGAGACAATTCCAAGAACACGCTGTATC 
               
               
                   
               
               
                 TGCAAATGAACAGCCTGAGAGCCGAGGACACGGCGGTGTACTACTGCGTCAAGGGGCCGTTG 
               
               
                   
               
               
                 CAGGAGCCGCCATACGATTATGGAATGGACGTATGGGGCCAGGGAACAACTGTCACCGTCTC 
               
               
                   
               
               
                 CTCAGCCGCTGCCCTTGATAATGAAAAGTCAAACGGAACAATCATTCACGTGAAGGGCAAGC 
               
               
                   
               
               
                 ACCTCTGTCCGTCACCCTTGTTCCCTGGTCCATCCAAGCCATTCTGGGTGTTGGTCGTAGTG 
               
               
                   
               
               
                 GGTGGAGTCCTCGCTTGTTACTCTCTGCTCGTCACCGTGGCTTTTATAATCTTCTGGGTTAG 
               
               
                   
               
               
                 ATCCAAAAGAAGCCGCCTGCTCCATAGCGATTACATGAATATGACTCCACGCCGCCCTGGCC 
               
               
                   
               
               
                 CCACAAGGAAACACTACCAGCCTTACGCACCACCTAGAGATTTCGCTGCCTATCGGAGCAGG 
               
               
                   
               
               
                 GTGAAGTTTTCCAGATCTGCAGATGCACCAGCGTATCAGCAGGGCCAGAACCAACTGTATAA 
               
               
                   
               
               
                 CGAGCTCAACCTGGGACGCAGGGAAGAGTATGACGTTTTGGACAAGCGCAGAGGACGGGACC 
               
               
                   
               
               
                 CTGAGATGGGTGGCAAACCAAGACGAAAAAACCCCCAGGAGGGTCTCTATAATGAGCTGCAG 
               
               
                   
               
               
                 AAGGATAAGATGGCTGAAGCCTATTCTGAAATAGGCATGAAAGGAGAGCGGAGAAGGGGAAA 
               
               
                   
               
               
                 AGGGCACGACGGTTTGTACCAGGGACTCAGCACTGCTACGAAGGATACTTATGACGCTCTCC 
               
               
                   
               
               
                 ACATGCAAGCCCTGCCACCTAGG 
               
               
                   
               
               
                 Clone RD-26578 CAR LxH 
               
               
                 (SEQ ID NO: 410) 
                   
               
               
                 MALPVTALLL PLALLLHAAR PEIVMTQSPA TLSVSPGERA TLSCRASQSV 
                   
               
               
                   
               
               
                 SSNLAWYQQK PGQAPRLLIY SASTRATGIP ARFSGSGSGT EFTLTISSLQ 
               
               
                   
               
               
                 SEDFAVYYCQ QHHVWPLTFG GGTKVEIKRG STSGSGKPGS GEGSTKGQVQ 
               
               
                   
               
               
                 LVESGGGVVQ PGRSLRLSCA ASGFTFSSRG MHWVRQAPGK GLEWVAVIGY 
               
               
                   
               
               
                 DGQEKYYADS VKGRFTISRD NSKNTLYLQM NSLRAEDTAV YYCVKGPLQE 
               
               
                   
               
               
                 PPYDYGMDVW GQGTTVTVSS AAALDNEKSN GTIIHVKGKH LCPSPLFPGP 
               
               
                   
               
               
                 SKPFWVLVVV GGVLACYSLL VTVAFIIFWV RSKRSRLLHS DYMNMTPRRP 
               
               
                   
               
               
                 GPTRKHYQPY APPRDFAAYR SRVKFSRSAD APAYQQGQNQ LYNELNLGRR 
               
               
                   
               
               
                 EEYDVLDKRR GRDPEMGGKP RRKNPQEGLY NELQKDKMAE AYSEIGMKGE 
               
               
                   
               
               
                 RRRGKGHDGL YQGLSTATKD TYDALHMQAL PPR